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ABSTRACT OF DISSERTATION 
 
 
 
MOLECULAR AND GENOMIC APPROACHES TO UNDERSTANDING HOST-
VIRUS INTERACTIONS IN SHAPING THE OUTCOME OF EQUINE ARTERITIS 
VIRUS INFECTION 
 
Equine arteritis virus (EAV) is the causal agent of equine viral arteritis, a disease of 
equids.  During natural outbreaks of the disease, EAV can cause abortion in pregnant mares and 
persistent infection in stallions.  Understanding how host cellular proteins interact with viral RNA 
and viral proteins, as well as their role in viral infection, will enable better characterization of the 
pathogenesis of EAV and establishment of persistent infection in stallions.  Accordingly, we 
hypothesized that both viral factors and host genetically related factors could influence the 
outcome of EAV infection in horses.  To test this hypothesis, we first combined contemporary 
molecular biology techniques with dual color flow cytometric analysis to characterize the 
interactions of viral structural proteins and the equine peripheral blood mononuclear cells in vitro.  
Results from this study demonstrated that interactions between GP2, GP3, GP4, GP5 and M 
envelope proteins of EAV play a major role in determining the CD14+ monocyte tropism while 
the tropism of CD3+ T lymphocytes is determined by GP2, GP4, GP5 and M envelope proteins 
but not the GP3 protein.  Secondly, a genome wide association study using SNP genotyping 
identified a common haplotype associated with the in vitro CD3+ T lymphocyte/resistance to 
EAV infection among four breeds of horses.  Subsequently, these studies were extended to 
establish a possible correlation between the in vitro susceptibility of CD3+ T lymphocytes to EAV 
and establishment of persistent infection in stallions.  Interestingly, carrier stallions with 
susceptible CD3+ T lymphocyte phenotype to EAV may represent those at higher risk of 
becoming persistently infected.  Finally, the precise effect of EAV on the immune system of 
horses, innate and humoral immunity, was studied.  Horses were shown to mount a strong 
humoral antibody response to nonstructural proteins (nsps) 2, 4, 5 and 12 of EAV, whereas nsps 1, 
2 and 11 suppressed the type I interferon production.  The data presented in this dissertation 
suggest new directions for future EAV research using genomic and proteomic approaches to 
study host cell factors involved in EAV attachment and entry and establishment of persistent 
infection in the stallions.   
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Humoral immunity, Innate immunity 
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CHAPTER ONE 
 
Literature Review 
 
 
1.1.  INTRODUCTION 
Positive-stranded RNA viruses constitute the largest virus group and comprise a 
wide variety of pathogens of plants and animals.  Positive-stranded RNA viruses that 
consist of linear, single-stranded genomes of mRNA polarity can initiate viral gene 
expression immediately after genome uncoating in infected cells.  These viruses replicate 
in the cytoplasm of infected cells.  RNA viruses have evolved having extremely diverse 
genomes and replicative mechanisms due to presumably low fidelity of their RNA 
synthesis [1,2]. Among RNA viruses, nidoviruses are considered the most genetically 
complex group with relatively large genomes.  The complex feature of nidoviral RNA 
replication and transcription involving numerous virus-encoded proteins with enzymatic 
activities is a unique feature of the members of the order Nidovirales [3,4,5,6].  In 
particular, generation of a nested set of subgenomic (sg) mRNAs is the hallmark of their 
genome expression from which the name Nidovirales (the Latin word nidus means “nest”) 
is derived.  Nidovirus infections are often associated with severe diseases such as human 
severe acute respiratory syndrome (SARS), feline infectious peritonitis, infectious 
bronchitis of chickens, porcine reproductive and respiratory syndrome (PRRS) and 
yellow head disease of prawns.  Recently, efforts to understand nidovirus replication and 
transcription have been facilitated by development of reverse genetic systems for many 
coronaviruses and arteriviruses.  Another important goal is to understand the mechanisms 
of virus entry, assembly and egress from infected cells which involves studies 
concentrated on interactions between viral and host cellular proteins. Most recently, the 
host-virus interaction has become one of the most focused areas of nidovirus research.  
The host’s innate immune response is critical in controlling infections and effectively 
inhibiting spread of the virus in the early phase of infection.  Thus, viruses have evolved 
mechanisms to counteract the innate immune response in order to survive in the host.  
  2 
Nidoviruses have also developed mechanisms to suppress type I interferon induction and 
signaling, the details of which are still to be determined.  Unraveling such mechanisms 
will enable development of antiviral drugs and therapeutics to combat devastating 
diseases caused by some nidoviruses.   
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Table 1.1.  Order Nidovirales 
Order Family Subfamily Genus Species 
Nidovirales 
Arteriviridae  Arterivirus 
Equine arteritis virus 
Lactate dehydrogenase-elevating virus 
Porcine reproductive and respiratory syndrome virus 
Simian hemorrhagic fever virus 
Coronaviridae 
Coronavirinae 
Alphacoronavirus 
Alphacoronavirus 1 
Human coronavirus 229E 
Human coronavirus NL63 
Miniopterus bat coronavirus 1 
Miniopterus bat coronavirus HKU8 
Porcine epidemic diarrhea virus 
Rhinolophus bat coronavirus HKU2 
Scotophilus bat coronavirus 512 
Betacoronavirus 
Betacoronavirus 1 
Human coronavirus HKU1 
Murine coronavirus 
Pipistrellus bat coronavirus HKU5 
Rousettus bat coronavirus HKU9 
Severe acute respiratory syndrome-related coronavirus 
Tylonycteris bat coronavirus HKU4 
Gammacoronavirus Avian coronavirus Beluga whale coronavirus SW1 
Torovirinae 
Bafinivirus White bream virus 
Torovirus 
Bovine torovirus 
Equine torovirus 
Human torovirus 
Porcine torovirus 
Roniviridae  Okavirus Gill-associated virus 
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1.2.  ORDER NIDOVIRALES 
The order Nidovirales is comprised of the families Coronaviridae, Arteriviridae, 
and Roniviridae [7,8,9] (Table 1.1).  The family Arteriviridae is comprised of the single 
genus Arterivirus.  Recently, the family Coronaviridae has been reorganized and now 
consists of two subfamilies, Coronavirinae and Torovirinae.  The subfamily 
Coronavirinae is subdivided into three genera, Alphacoronavirus, Betacoronavirus and 
Gammacoronavirus; and Torovirinae is subdivided into two genera, Bafinivirus and 
Torovirus. The family Roniviridae has a single genus Okavirus.  Although nidoviruses 
are significantly different in virion morphology, genome length and host specificity, they 
belong to the same order based on similarities in their genome organization, gene 
expression mechanisms, and in sharing common ancestry of the key replicase gene 
[10,11,12,13].   
Nidoviruses infect a wide range of hosts, including invertebrates, avian, human 
and many other mammalian species [14].  Porcine reproductive and respiratory syndrome 
virus (PRRSV), a member of the Arteriviridae family, is associated with significant 
economic losses in the swine industry [15].  Coronaviruses (CoV) are well-known agents 
of respiratory, enteric, and neurologic disease in humans and domestic animals 
(alphacoronaviruses and betacoronaviruses: mammals; gammacoronaviruses: avian 
species) and are the only nidovirus group that has been reported to cause disease in 
humans (http://www.ictvonline.org/virusTaxonomy.asp?version=2009).  In 2003, SARS 
emerged from China as a potentially fatal and untreatable human respiratory disease 
which was caused by a previously unknown CoV strain [16,17,18,19].  Discovery of 
SARS-CoV triggered a search for the reservoir species.  After extensive investigative 
studies over a number of years certain species of bats were inflicted as reservoir hosts of 
the virus.  This finding led to the discovery of many novel bat coronaviruses [20].  In 
2008, a highly divergent coronavirus was identified from a deceased captive beluga 
whale and grouped as a gammacoronavirus [21].  The ronivirus yellow head virus (YHV) 
infects black tiger shrimp causing high mortality and resulting in severe economic losses 
for shrimp farms [22].  Except for SARS-CoV, which infects a broad range of mammals, 
the majority of nidoviruses have restricted host specificity, infecting one or a narrow 
range of closely related species.  In 2011, the first insect-associated nidovirus, tentatively 
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named Cavally virus (CAVV), was reported in association with the tropical rainforest. It 
shares genetic features in common with members of the order Nidovirales [23].  These 
findings indicate that the virus has evolved and resultant genomic changes have likely 
facilitated cross-species transmission.  
Nidoviruses are enveloped, positive-sense, single-stranded RNA viruses and 
include mammalian, avian and invertebrate viruses [14].  Arterivirus particles are 
spherical with smaller envelope projections.  In contrast, virions of coronaviruses and 
toroviruses are spherical and disk-shaped, respectively, that contain tubular helical 
nucleocapsids with large surface projections on the envelope formed by membrane-
spanning viral proteins.  Bafinivirus and ronivirus particles are rod-shaped and contain 
tubular nucleocapsids with helical symmetry (Figure 1.1) [14].  
 
Figure 1.1.  Schematic diagram of order Nidovirales.  The tree represents known 
members of order Nidovirales based on the virion architecture representative of five main 
nidovirus genera: arterivirus, coronavirus, torovirus, bafinivirus and okavirus. Schematic 
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representations and electron micrograph pictures were adapted from Enjuanes et al. [24] 
and Snijder et al. [14] with permission.  
 
The size and the number of genes encoded in the genome vary considerably 
among families of the order Nidovirales.  Members of the Arteriviridae family have 
smaller genomes (12.7-15.7 kb) compared to other nidoviruses.  In contrast, the 
Coronaviridae and Roniviridae families possess the largest RNA genomes (26.2-31.3 kb) 
[8]. Despite the wide genome size differences, sequence analysis has shown that all 
nidoviruses share a similar genomic organization (Figure 1.2.).   
 
 
 
Figure 1.2.  Comparison of genome organization of representative nidoviruses. The 
genomic RNA of representative viruses of the families Arteriviridae, Coronaviridae and 
Roniviridae are shown to the same scale.  The open reading frames (ORFs) encoding 
replicase proteins and viral structural proteins are depicted.  The ribosomal frame shift 
(RFS) of the ORF1a/1b and the 3’ poly A tail (An) are indicated.  The newly identified 
ORF5a in arteriviruses is depicted with a red box. EAV, equine arteritis virus; SARS-
CoV, severe acute respiratory syndrome coronavirus; EToV, equine torovirus; GAV, gill-
associated virus.  Modified figure from Nidoviruses book chapter [5] with permission.   
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Arteriviruses have 9 to 12 open reading frames (ORFs), coronaviruses encode 9 to 
14 ORFs, toroviruses have six ORFs and roniviruses have only four ORFs.   The genome 
carries a 5’-capped structure and a 3’-polyadenylated (poly A) tail.  It also contains 
untranslated regions (UTR) at the 5’- and 3’-ends of the genome.  At the 5’-proximal 
two-thirds to three-quarters of the genome, the nonstructural proteins (nsps) are encoded 
by the two largest ORFs, ORF1a and ORF1b connected by a -1 ribosomal frameshift site 
(RFS) [25].  The translation of genomic RNA starts at the start codon of ORF1a resulting 
in the production of a polyprotein, pp1a.  In some cases, specific RNA signals promote 
ribosomal frameshifting at a -1 RFS or “slippery” sequence between ORF1a and ORF1b 
which results in the C-terminal extension of pp1a with the ORF1b-encoded polypeptide, 
pp1ab.  The pp1a and pp1ab are co- and post-translationally processed by two to four 
virus-encoded proteases to produce 13-16 nsps [26].  These products of the large 
replicase protein, possibly with other viral and cellular proteins, assemble into a 
replication/transcription complex (RTC) bound to modified intracellular membranes.  
The different groups of nidoviruses encode different sets of structural proteins that result 
in distinctive virion morphology for each group.  The genes encoding viral structural 
proteins and, in the case of coronaviruses, “accessory or niche-specific” proteins are 
located at the remaining 3’-proximal thirds of the genome downstream of the replicase 
gene.  The structural and accessory proteins are expressed from a 3’ co-terminal nested 
set of sg mRNAs [27,28,29,30].  
 
1.3.  FAMILY ARTERIVIRIDAE 
EAV was first isolated in 1953, LDV in 1960 and SHFV in 1968; the porcine 
arterivirus, PRRSV, was not isolated until the late 1980s [15].  Initially, equine arteritis 
virus (EAV) was classified as a non-arthropod-borne togavirus along with pestiviruses 
and rubiviruses, lactate dehydrogenase-elevating virus (LDV), simian hemorrhagic fever 
virus (SHFV), and cell fusion virus [31].  Although structural proteins of LDV and EAV 
differed from those of togaviruses, EAV, LDV and SHFV were assigned to a new genus 
Arterivirus within the family Togaviridae [32] in 1984.  Subsequently, molecular 
characterization studies have shown that genomic organization and replication strategy of 
EAV resemble those of corona- and toroviruses suggesting that it is evolutionally related 
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to the coronavirus-like superfamily [10,33].  In 1996, the family Arteriviridae was 
established comprising four viruses: EAV, PRRSV, SHFV and LDV of mice [7,34]. 
Arterivirus particles are spherical with a diameter of 40 to 60 nm.  The buoyant density of 
arteriviruses is 1.13 to 1.17 g/cm3 in sucrose, and their sedimentation coefficient ranges 
from 214S to 230S [35,36,37,38].  The icosahedral core, 25 to 35 nm in diameter, is 
surrounded by a relatively smooth envelope that lacks large projections. 
The natural host range of arteriviruses is highly restricted.  Arterivirus infection 
can vary from acute symptomatic or asymptomatic infection, abortion or lethal 
hemorrhagic fever and persistent infection.  Interestingly, all four arteriviruses have the 
ability to give rise to long-term persistent infection in their respective hosts.  The severity 
of disease can vary greatly and seems to be influenced by the strain of the virus, the 
condition and age of the infected animal and various environmental factors.  
Macrophages appear to be the primary target cell for all arteriviruses [15]. 
PRRSV was first recognized in the United States in 1987 and independently in 
Germany in 1990,; it was identified as the cause of a “mystery swine disease” [39,40].  
At present, PRRSV is globally disseminated.  The early PRRSV isolates from North 
America and Europe, PRRSV-NA and PRRSV-EU, were genetically distinct from each 
other with the genotypes sharing only ~63% nucleotide homology [41,42].  Since its 
initial discovery, the virus has continued to evolve.  A new strain of PRRSV has been 
identified in the US [43,44], and a highly virulent strain has appeared in China [45,46,47] 
which subsequently spread to neighboring countries [48,49].  PRRSV is transmitted 
primarily via the respiratory route; however, venereal transmission is an important 
secondary route of spread of PRRSV, as well as for EAV, due to constant shedding of 
virus in semen of infected males. 
The natural host of LDV is the house mouse, Mus musculus domesticus [50].  
LDV is characterized by an increased level of lactate dehydrogenase in the blood of 
infected mice, hence the derivation for the name of the virus [51].  The virus infects a 
renewable subpopulation of macrophages and is able to escape immune surveillance [15].  
Although most cases of persistent infection caused by LDV are asymptomatic, 
neurovirulent LDV variants can cause fatal age-dependent poliomyelitis in certain inbred 
mouse strains [52]. 
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SHFV was isolated after devastating outbreaks of hemorrhagic fever in colonies 
of captive macaque monkeys [53,54].  The virus causes an asymptomatic persistent 
infection among several different species of African monkeys and remains endemic in 
affected populations.  Different strains of SHFV vary considerably in their cellular 
tropism, virulence and immunogenicity based on infection studies in African monkeys.  
Transmission of SHFV from African to Asian monkeys results in hemorrhagic fever with 
a high case-fatality rate.  Vascular damage and disseminated intravascular coagulation are 
principal to the pathogenesis of simian hemorrhagic fever (SHF) [55].  
The size of the arterivirus replicase gene, in particular ORF1a, varies widely 
among arteriviruses, encoding between 1,727 amino acids (aa) in EAV and 2,500 aa in 
PRRSV, while the ORF1b region is more conserved.  Seven to ten small genes encoding 
structural proteins are located downstream of the replicase gene and most of them have 
both 5’- and 3’- terminal sequence regions overlapping with neighboring genes.  With the 
exception of SHFV, the organization of structural proteins is generally well conserved in 
the arterivirus genome except for. Downstream of the SHFV replicase gene are three 
additional ORFs, comprising about 1.6 kb, which may have arisen from the duplication of 
ORFs 2 to 4.   
 
1.4.  EQUINE ARTERITIS VIRUS 
EAV, the causative agent of equine viral arteritis (EVA), is the prototype virus of 
the family Arteriviridae.  The virion of EAV is spherical with a diameter of 40 to 60 nm. 
The isometric core particle (25 to 35 nm in diameter) is surrounded by a relatively 
smooth envelope that lacks large projections. EAV genome is encapsidated by the 
nucleocapsid (N) protein (14 kDa) encoded by ORF7 which forms an icosahedral core 
structure (Figure 1.1) [10,34,56].  The lipid bilayer that surrounds the nucleocapsid 
contains six envelope proteins (E, GP2, GP3, GP4, GP5 and M) encoded by ORFs 2a, 2b, 
3-6, respectively, that are located at the 3’ proximal quarter of the genome 
[34,56,57,58,59].  
EAV is stable at -70°C for years without significant loss of infectivity.  Virus 
infectivity is lost within six months at room temperature, and after a month at 37°C [60].  
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It has been reported that tissue culture fluid containing the experimentally derived 
virulent Bucyrus strain (VBS) of EAV survived ≥75 days at 4°C, 2~3 days at 37°C, and 
20~30 min at 56°C [61].  Lyophilized virus is highly stable at -20°C and moderately 
stable at 4°C [62]. 
 
1.4.1.  Genome properties and organization 
EAV genome length varies between 12,704 to 12,731 bp among different strains 
[7,34,63].  The EAV genome includes a 5’ leader sequence and at least nine ORFs [10,64] 
(Figure 1.3).  The two most 5’-proximal ORFs (1a and 1b) occupy approximately three-
quarters of the genome and encode two replicase polyproteins (pp1a and pp1ab).  The 
two precursor proteins are extensively processed after translation into at least 13 nsps 
(nsp1-12, including nsp7 α/β) by three viral proteases (nsp1, nsp2 and nsp4) [34,65,66].  
The structural proteins of EAV are expressed from a 3’-coterminal nested set of sg 
mRNAs and not from the genomic RNA.  Three of the minor envelope proteins (GP2, 
GP3 and GP4) form a heterotrimer in the EAV particle.  The two major envelope proteins 
(M and GP5) form a disulfide-linked heterodimer in the EAV virion [59,67,68].  The 
GP5 protein expresses the known major neutralization determinants of EAV 
[69,70,71,72,73,74,75].  Although there is considerable variation in the sequence of the 
GP5 protein of field strains of the virus, there is only one known major serotype of EAV 
and all strains evaluated thus far are neutralized by polyclonal equine antiserum raised 
against the Bucyrus strain of EAV [76,77].  However, field strains differ both in their 
neutralization and virulence phenotypes and not all strains are neutralized to the same 
degree [63,74,78,79,80]. 
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Figure 1.3.  The genome organization and polycistronic nature of EAV genome.  The 
leader sequence and leader TRS (transcription regulating sequence) located at the 5’-end 
of genome are indicated as a purple circle and a yellow box, respectively.  Translation of 
E and GP2 genes occurs by leaky scanning of the 5’-proximal end of sg mRNA2 [58].  
The red square indicates the newly identified open reading frame, ORF5a and the protein 
is likely to be expressed from the same sg mRNA [81];  see chapter 7.  
 
 
1.5.  EQUINE ARTERITIS VIRUS LIFE CYCLE 
Enveloped viruses typically have surface molecules that bind to cell surface 
receptors which mediate the process of cell attachment and membrane fusion with the 
host cell membrane.  While receptors for EAV have not yet been identified, it has been 
suggested that EAV is taken up via clathrin-dependent endocytosis and is delivered to 
acidic endosomal compartments [82].  Following entry and release into the cytosol, the 
plus-stranded RNA genome is uncoated and translated into two replicase polyproteins 
(pp1a and pp1ab) from which at least 13 nsps are released by autoproteolytic processing 
mediated by the virus proteases [66,83].  The nsps assemble into a membrane-bound 
RTC [84,85,86,87].  The RTC generates minus-stranded RNA genomes that are used as 
templates for genome replication and subgenomic mRNA transcription.   The 
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subgenomic mRNAs are translated into the viral structural proteins.  The newly 
synthesized genome is encapsidated into the N proteins forming the nucleocapsid (NC), 
which becomes enveloped by budding through the ER-Golgi intermediate compartment 
(ERGIC) that contains membranes with viral envelope proteins.  Newly formed virions 
mature in the golgi complex during their exocytic pathway and are ultimately released 
from infected cells (Figure 1.4). 
 
 
Figure 1.4.  Schematic overview of EAV life cycle.  ER: endoplasmic reticulum; 
ERGIC: ER-Golgi intermediate compartment; NC: nucleocapsid.  Red square represents 
newly identified ORF5a protein.  
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1.5.1.  Genome replication and transcription  
The EAV genome is an RNA polycistronic molecule with a 5’ cap and 3’ poly A 
structure [34].  The 5’ UTR (leader), comprising approximately 208 nucleotides (nt), 
functions as a template for the host translation machinery and as a protective element 
against degradation by exonucleases [88].  Among nidoviruses, replication and 
transcription are processed through different minus-strand intermediates: a full-length 
minus-strand template is used for replication, while subgenome-sized minus strands 
produced during a process of discontinuous RNA synthesis are used to synthesize sg 
mRNAs [89,90,91,92].  The initiation of full-length minus-strand RNA (or anti-genome) 
synthesis, which is also used as template for new genome RNA replication, occurs after 
recognition of RNA signals near the 3’ end of the viral genome by the RNA-dependent 
RNA polymerase (RdRp) complex [93].  For production of new genomic RNA, 
recognition of signals present close to the 3’ end of the anti-genome must be used [4,94].  
During viral RNA synthesis, more plus strands are produced than minus-strand RNAs 
[95].  There are two widely considered but conflicting models of arterivirus transcription: 
leader-primed transcription and discontinuous extension of minus-strand RNA synthesis 
(Figure 1.5).  In both models, the TRS elements play a critical role.  The TRSs are short 
and conserved sequence elements (5’-UCAAC-3’) that determine a base-pairing 
interaction between positive and nascent minus-strand RNA and are essential for leader-
to-body joining [92,96,97].  In the “leader-primed transcription model”, transcription is 
initiated from the 3’ end of the minus-strand genome to produce a leader primer from 
which the 3’-terminal leader TRS base pairs with the anti-TRS in the minus-strand 
genome.  The leader transcript is extended to complete the sg mRNA.  This model 
proposes that the discontinuous step occurs during the plus-strand synthesis and the body 
TRS complementary to the minus-strand genome acts as promoter for transcription 
[27,29,30]. On the other hand, according to the nidovirus transcription model proposed 
by Sawicki and Sawicki [90] which is the widely accepted model, sg mRNAs are 
produced by a discontinuous transcription mechanism controlled by the transcription 
regulation sequence (TRS).  The EAV sg mRNAs contain a common 5’ sequence of 208 
nt, called “leader”, identical to the 5’ end of viral genomic RNA [34].  The leader TRS is 
located in a hairpin loop structure at the 3’ end of the leader [98] and the body TRSs are 
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present upstream of every structural protein gene [28,99].  The EAV genome contains 
multiple UCAAC sequences that could be transcriptionally silent.  For example, the 
RNA3 uses three alternative leader-body junction sites, TRSs 3.1, 3.2, and 3.3 among 
which TRSs 3.1 and 3.3 are noncanonical junction sites.  There are two UCAAC boxes 
upstream of ORF4, -5 and -7 whereas three UCAAC sequences are found upstream of 
ORF2 and -2b [100].  However, only a single TRS has been identified as an active site 
for each of these sg mRNAs.  Moreover, a number of 5’ UCAAC 3’ sequences were also 
identified in the replicase gene [99].  The TRSs are thought to regulate transcription of 
the genome template and to serve as signals for either attenuation or termination of 
minus-strand RNA synthesis in all nidoviruses, thus producing subgenome-sized minus 
strands that are utilized later as templates for sg mRNA synthesis [95].  Minus-strand 
RNA synthesis, initiated at the 3’-end of the viral genome, is attenuated at one of the 
body TRS regions [89,91].  Subsequently, the nascent minus strand carrying the body 
TRS complement at its 3’ end is translocated to the 5’ end of the genomic template.  In 
EAV, the genomic leader TRS serves as a base-pairing target for the 3’ end of the nascent 
minus strand that is facilitated by its presence in the loop of an RNA hairpin.  When 
minus-strand synthesis resumes, nascent strands are extended with the complement of the 
genomic leader sequence, yielding a nested set of subgenome-length minus-strand 
templates that are used for the subsequent synthesis of the various sg mRNAs.  If 
attenuation does not occur, minus-strand RNA synthesis proceeds to yield a full-length 
complement of the genome, the intermediate required for its replication. During the 
discontinuous transcription mechanism, the TRS at the 3’ end of the leader transcript base 
pairs with the complement of the body TRS in the negative-stranded template allowing 
extension of the complement of the genomic leader sequence in the nascent negative 
strand [90].  The resulting sg negative-stranded RNA serves as template for the synthesis 
of the corresponding sg mRNA.  With the exception of the last one, each sg mRNA, is 
structurally polycistronic, although they are functionally monocistronic. With some 
exceptions, only the 5’-proximal ORF is translated from each sg mRNA; therefore, the 
number of sg mRNA produced is proportional to the number of ORFs located 
downstream of ORF1b.   
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Figure 1.5.  Illustration of two transcription models in nidoviruses: “leader-primed 
transcription” [27,29,30] and “discontinuous extension of minus-strand RNA” [90] 
models.  (A) The “leader-primed transcription” proposes that the discontinuous step of 
viral sg mRNA synthesis occurs during the plus-strand synthesis.  After transcription of a 
leader primer (+L) from the 3’ end of minus-strand full-length genome, the leader TRS in 
this primer joins to the anti-body TRS in the minus-strand genome and is extended to 
generate sg mRNA.  (B) The alternative model, “discontinuous extension of minus-strand 
RNA model” proposes that sg-length negative strand is produced that functions as a 
template for generation of sg mRNA.  The anti-body TRS may serve as a “jump” signal 
of the nascent minus strand to leader TRS located at the 5’-end of the plus-strand full-
length genome.  After the anti-leader (-L) is added to the nascent minus strand, the sg-
length minus strand functions as template for transcription.  The later model has gained 
stronger experimental support from biochemical and genetic studies.  Modified from 
Pasternak et al. (2006) [89] with permission.   
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1.5.2.  EAV replication/transcription complex  
Formation of paired membranes and double-membrane vesicles (DMVs) at 3-6 h 
post-infection is a typical feature of arterivirus replication [101,102,103,104,105].  
Frequently, RTCs of positive-strand RNA viruses are found to be associated with 
modified intracellular membranes.  The transmembrane nsps are incorporated into 
cellular organelles, particularly the ER, where early viral RNA synthesis occurs and 
results in increased expression of replicase proteins.  Interaction of accumulated nsps 
with membranes results in membrane pairing and vesiculation [84].  It is supposed that 
formation of DMVs is based on interactions between luminal domains of transmembrane 
proteins of either virus and/or cellular origin to bring opposite membranes together.  In 
nidovirus-infected cells, newly synthesized viral RNA and many replicase subunits were 
found in the perinuclear region together with a large number of DMVs [84,106,107].  
Immunoelectron microscopy revealed that viral nsps that are part of RTC and nascent 
viral RNA are associated with DMVs [84,107,108,109].  Therefore, DMVs are presumed 
to carry the enzyme complex responsible for virus replication and sg mRNA synthesis.  
Expression of EAV nsp2-3 is critical in inducing formation of DMVs [84,85].   Among 
the EAV replicase subunits, the nsp2, nsp3, and nsp5 encode a considerably large portion 
of hydrophobic regions that are presumed to have a structural function by inducing DMV 
formation [85] and anchoring the RTC to the membrane [86,110,111].  More recently, 
isolated RTC contained replicase subunits that were involved in DMV formation (nsp2 
and nsp3) or viral replication (nsp9 and nsp10) and were cosedimented with newly 
synthesized viral RNA in a heavy membrane fraction [112] which confirmed their 
association with DMV and their essential role in RTC function. 
 
1.6.  NONSTRUCTURAL PROTEINS OF EAV 
The replicase gene, ORF1a and ORF1b, occupies 75% of the 5’ end of the EAV 
genome,.  Translation of genomic RNA results in two large polyproteins, 187-kDa pp1a 
(1728 aa) and 345-kDa pp1ab (3175 aa).  Expression of pp1ab occurs through a -1 
ribosomal frameshift mechanism in the overlapping region of ORF1a and ORF1b [10].  
The polyproteins undergo an extensive proteolytic processing by three virus-encoded 
proteases (nsp1, nsp2, and nsp4) resulting in 13 nsps [66,113] (Figure 1.6; Table 1.2).  
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The mature nsps are involved in the formation of a membrane-anchored RTC that directs 
viral genome replication and synthesis of a nested set of sg mRNAs [89,91].  The 
structural proteins are expressed from sg mRNAs whose genes are located downstream of 
the replicase gene.  The ORF1a encodes two papain-like cysteine protease domains 
(“accessory proteases” located in nsp1 and nsp2) and a chymotrypsin-like serine protease 
(“main protease”) in nsp4.  The ORF1a protein is cleaved at seven sites resulting in eight 
cleaved end products, nsp1 to nsp8, plus a number of processing intermediates 
[110,111,114].  The ORF1b is processed into four major end products by nsp4 protease, 
including RNA-dependent RNA polymerase and NTPase/RNA Hel domains essential for 
viral RNA replication and mRNA transcription [10,11].  Immunofluorescence studies 
have shown that the ORF1b-encoded replicase subunits are localized in the perinuclear 
region of the EAV-infected cells suggesting that they may be associated with intracellular 
membranous compartments [87], most likely the ER.    
 
 
Figure 1.6.  Schematic representation of EAV replicase polyproteins.  The numbers 
of nsps are indicated above corresponding nsps.  The predicted PCPβ and CP cleavage 
sites are indicated by black arrows.  The 3CLSP cleavage sites are indicated by open 
arrowheads.  The genes encoding structural proteins are depicted in grey.  PCP, papain-
like cysteine protease; CP, cysteine protease; 3CLSP, 3chymotrypsin-like serine protease; 
ZF, predicted zinc finger; C/H, cysteine/histidine-rich clusters; TM, predicted 
transmembrane domains; P, protease domain; Z, zinc-binding domain; N, NendoU.  
Figure modified from Nidoviruses book chapter [26] with permission. 
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Table 1.2. Nonstructural proteins of EAV.   
ORF Nucleotide 
position (bp)a 
Protein Protein 
length (aa) 
Predicted 
M.W. (kDa) 
ORF1a 225-5399 (5175) 1a polyprotein 1728 190 
ORF1b 5405-9751 (4347) - - - 
ORF1ab 225-9751 (9527) 1ab polyprotein 3176 349.3 
Nonstructural 
proteins 
225-1004 (780) nsp1 260 28.6 
1005-2717 (1713) nsp2 571 61.4 
 2718-3416 (699) nsp3 233 25 
 3417-4028 (612) nsp4 204 21 
 4029-4514 (486) nsp5 162 18.1 
 4515-4580 (66) nsp6 22 2.3 
 4581-5255 (675) nsp7 225 25.2 
 5256-5405 (150) nsp8 50 5.5 
 5256-7333 (2078) nsp9 693 76.8 
 7334-8734 (1401) nsp10 467 50.5 
 8735-9391 (657) nsp11 219 24.2 
 9392-9748 (357) nsp12 119 12.5 
a The nucleotide positions are based on the sequence of the experimentally derived EAV 
VBS strain (GenBank accession number: DQ846750). 
 
1.6.1.  Nsp1 
The 29-kDa nsp1 (260 aa) is the first viral protein expressed and is the most N-
terminal replicase cleavage product produced. It contains an “accessory protease” which 
is not involved directly in proteolytic processing of RdRp and helicase.  Three domains 
have been identified in the nsp1 region: predicted zinc finger (ZF) domain, papain-like 
cysteine protease (PCP) α and PCPβ.  The predicted ZF domain present near the N 
terminus of nsp1 contains four Cys and His residues [26].  ZFs found in many cellular 
transcription factors are involved in protein-nucleic acid and protein-protein interactions 
[115].  The nsp1 is released from the replicase polyprotein by the autocatalytic activity of 
PCPβ, which is responsible for cleavage of nsp1/2, located in its C-terminal domain 
[110,116].  The cleavage and release of nsp1 from the replicase polyprotein was found to 
be essential for viral RNA synthesis [117].  In EAV, the PCPα is functionally inactive 
due to its loss of an active Cys site during virus evolution [118].  However, PCPα may 
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possess RNA-binding and/or protein-binding activities (along with PCPβ), serving as a 
platform for the ZF during transcription.  Therefore, the structural integrity of nsp1 is 
essential since all three domains are required for trans-activation of sg RNA synthesis 
[119].  It has been reported that nsp1 is essential for sg RNA transcription but dispensable 
for genome replication [119].  The nsp1 not only plays a crucial role in processing of 
replicase polyprotein and production of sg mRNA but it is also important for virion 
biogenesis [119] [117].  Nsp1 is the only EAV replicase subunit that localizes both in the 
nucleus and cytoplasm where it associates with modified cytoplasmic membranes of the 
replication complex [84,120].  During the early stages of infection, nsp1 is primarily 
located in the nucleus while its cytoplasmic localization, especially in the perinuclear 
region, becomes evident later in infection [120].   
 
1.6.2.  Nsp2 
The 61-kDa nsp2 serves as a cofactor in the processing of the downstream part of 
the polyprotein directed by the nsp4 protease [85].  The nsp2 contains two hydrophobic 
regions around aa 450 and 490 and a main hydrophobic region between aa 520 and 640, 
large enough to span the lipid bilayer several times.  However, the exact topology of this 
protein needs further characterization [85].  The N-terminal domain of nsp2 contains 
cysteine protease activity responsible for cleavage of the nsp2/3 site [121].  Therefore, 
nsp2 is released from the polyprotein by internal cysteine autoprotease activity [110].  In 
the major processing pathway, the mature nsp2 acts as cofactor for the processing of the 
nsp4/5 site by the nsp4 serine protease (SP).  The nsp2 interacts strongly with nsp3 or 
nsp3- containing precursors (e.g. nsp3-8), a property that may be required for processing 
the nsp4/5 site by the nsp4 SP (Figure 1.7).   When there is no interaction between nsp2 
and nsp3-8, its internal site nsp4/5 cannot be cleaved and further processing of the 
replicase subunits occurs via the minor processing pathway (Figure 1.7). 
 
1.6.3.  Nsp3 
The 22-kDa nsp3 is highly hydrophobic and is presumed to be a tetra-spanning 
transmembrane molecule [122].  It contains four conserved cysteine residues in the 
predicted first luminal domain (aa 853 to 902) that are likely to be involved in membrane 
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pairing and DMV formation [122].  Due to the multiple spanning nature of the protein, 
nsp3 is considered to play a key role in the interaction between the EAV RTC and host 
cell membranes.  Site-directed mutagenesis studies have shown that mutation of nsp3 
impairs the interaction of the protein with the ER, disrupts the formation of DMVs, 
affects replicase polyprotein processing and inhibits viral RNA synthesis [85,122].  It is 
possible that the N-terminal domain (aa 833 to 993) of nsp3 could function as a signal 
sequence for membrane insertion of nsp2/3 polyprotein before its cleavage by nsp2 [122].  
However, the mechanism of interaction between nsp3 and the membranes or with other 
replicase subunits involved in DMV formation remains poorly understood. 
 
1.6.4.  Nsp4 
The 33-kDa nsp4 contains chymotrypsin-like SP activity at the N-terminal 
domain.  As the protease name indicates, the main catalytic residue of this C-like protease 
in arteriviruses is Ser.  Nsp4 is the “main protease” which controls the production of the 
viral RNA-dependent RNA polymerase and RNA helicase [66,123].  It is responsible for 
processing the polypeptides (nsp3-8 and nsp3-12) that remain after nsp1 and nsp2 have 
been autocatalytically released from pp1a and pp1ab [65,110,111,114,116,121].  The 
nsp4 SP cleaves at five sites in the ORF1a protein [114] and three sites in the ORF1b 
protein [111]. The nsp4 SP processes the C-terminal half of the ORF1a (nsp3-8) protein 
via two alternative pathways (Figure 1.7).  In the major processing pathway, nsp2 
associates with nsp3-8 (96 kDa) as a cofactor which triggers nsp4 SP to cleave the 
majority of nsp3-8 precursors at the nsp4/5 site resulting in nsp3-4 (50 kDa) and nsp5-8 
(44 kDa) intermediates.  Subsequently, the nsp5-8 is cleaved at the nsp7/8 site while the 
nsp5/6 and nsp6/7 are inaccessible to the protease [111].  In the minor processing 
pathway, the nsp4/5 site remains intact while the nsp5/6 and nsp6/7 sites are cleaved 
(Figure 1.7) [111].    
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Figure 1.7.  Proteolytic processing of EAV replicase polyprotein pp1a through the 
major and minor pathways.  The proteases involved in processing are depicted in a 
black box with “P”.  The PCPβ and CP cleavage sites are indicated with black 
arrowheads.  The 3CLSP nsp4 cleavage site is indicated by open arrowheads. PCP, 
papain-like cysteine protease; CP, cysteine protease; 3CLSP, 3chymotrypsin-like serine 
protease; TM, predicted transmembrane domains.  Figure modified from Nidoviruses 
book chapter [26] with permission. 
 
1.6.5.  Nsp5, nsp6, nsp7α/β and nsp8  
The processing intermediate nsp5/6/7/8 is a result of cleavage of the nsp4/5 
junction upon association of nsp2 as a cofactor with nsp3-8.  In the major pathway, 
nsp3/4 and nsp7/8 junctions are cleaved, but not the nsp5/6 and nsp6/7; therefore, cleaved 
nsp6 and 7 are not generated.  In the minor pathway, nsp4/5 is not cleaved; instead, nsp4 
cleaves the nsp3/4, nsp5/6, nsp6/7, and nsp7/8 junctions of the nsp3-8 intermediate 
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producing cleaved nsp6 and nsp7 [111].  Fully processed nsp5, nsp6, nsp7, and nsp8 are 
approximately 41, 3, 25, and 5.5 kDa, respectively [110].    
The nsp5 contains a significant portion of the highly hydrophobic domain 
suggesting a role in the membrane association of the EAV replication complex [86,110].  
Moreover, the presence of hydrophobic nsp5 in the N-terminus of processing 
intermediates, like nsp5-8, nsp5-7 and even larger intermediates such as nsp5-12, 
supports its probably association with the intracellular membrane [86].   
Little is known about the nsp6 and nsp8 proteins [110].  Currently, there are no 
references to either protein in the literature.  
An internal cleavage site (nsp7α/β) has been identified in mature nsp7 which is 
cleaved by nsp4 protease and produces nsp7α (123 aa; ~13.5 kDa) and nsp7β fragments 
corresponding to the N- and C-terminal regions of nsp7, respectively [113].  Most 
recently, the solution structure of nsp7α, the most conserved region of nsp7, has been 
determined by Nuclear Magnetic Resonance (NMR) [124].  The nsp7α contains four 
hydrophobic regions needed for correct folding of the proteins; it has a unique 
conformation consisting of three α-helices packed against a mixed β-sheet [124].  
Although this study did not reach a definite conclusion about the function of nsp7, it 
confirmed that nsp7α is critical for arterivirus RNA synthesis [124].  
 
1.6.6.  Nsp9  
The 80-kDa EAV nsp9 (aa 1678 to 2370 of pp1ab) contains the RdRp domain 
which functions as the catalytic subunit of the viral RTC and directs viral RNA synthesis 
in conjunction with other viral proteins and host cellular proteins.   The EAV nsp9/RdRp 
initiates RNA synthesis by a de novo mechanism involving homopolymeric templates in 
a template-specific manner.  Increased intracellular concentration of Zn2+ can block the 
initial step of viral RNA replication carried out by nsp9/RdRp [125].  
 
1.6.7.  Nsp10 
The 51-kDa EAV nsp10 contains a predicted zinc-binding domain (ZBD) in its N-
terminus and the nucleoside triphosphate-binding/helicase (Hel) motif in its C-terminal 
domain [10,11,126].  The nsp10 is the most conserved replicase subunit of the viral RNA 
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synthesis machinery [127,128,129].  The nsp10 has ATPase and nucleic acid duplex-
unwinding activities that require the presence of 5’ single-stranded regions indicating 5’-
3’ polarity of the reaction [130].  The ZBD region, especially the 13 conserved Cys and 
His residues that are most likely to be associated with zinc binding, is critical for ATPase 
and duplex-unwinding activities of the C-proximal helicase domain [10,11,126,131].  
Reverse genetic studies have shown that mutation of conserved Cys/His residues in ZBD 
disrupted interactions between the ZF and enzymatic domains, thus completely blocking 
viral RNA synthesis and virion biogenesis [126,131].  Taken together, the nsp10-
associated ZF domain has multiple functions specifically involved in viral RNA 
replication, sg mRNA transcription and virion biogenesis [126]. 
 
1.6.8.  Nsp11 
The 26-kDa nsp11 is considered as a multifunctional protein with a crucial role in 
viral RNA synthesis.  The nsp11 contains a highly conserved endoribonuclease (NendoU; 
nidoviral-endonuclease specific for U) domain which is not present in other RNA viruses 
and is therefore considered a unique genetic marker of the order Nidovirales [132,133].  
The NendoU possesses pyrimidine (uridylates in particular)-specific endoribonuclease 
activity independent of divalent cations (e.g. Mn2+) in vitro [134].  Studies using reverse 
genetics have shown the importance of NendoU activity for viral RNA synthesis 
[132,134].  However, identification of substrate and molecular characterization of 
NendoU still remain unclear.  
 
1.6.9.  Nsp12  
Little is known about the 12-kDa nsp12 of arteriviruses.  There are no current 
references available in the literature. 
 
1.7.  STRUCTURAL PROTEINS OF EAV 
The ORFs encoding the structural proteins of EAV are located downstream of 
ORF1a and 1b that encode viral replicase proteins.  The ORF2a, 2b and 3 through 7 are 
expressed from a 3’ co-terminal nested set of subgenomic mRNAs.   The viral RNA 
genome is packaged by the N protein, encoded by ORF7, into an icosahedral core 
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surrounded by a lipid-containing envelope with small surface projections [135,136].  Six 
viral proteins, encoded by ORF2 to 6, have been identified in the EAV envelope (Table 
1.3.) [57,58,137].  The envelope (E) protein is the third most abundant protein in the viral 
membrane and is encoded by ORF2a.  The GP2b, GP3, and GP4 proteins, encoded by 
ORF2b, -3 and -4 respectively, are minor envelope glycoproteins that exist in equimolar 
amounts in virus particles [57,137].  The minor envelope proteins are covalently 
associated and form a heterotrimeric complex on the surface of the virion.  The 
nonglycosylated membrane protein M and glycosylated GP5 protein are the major 
envelope proteins and are the most abundant envelope proteins. These major envelope 
proteins are presented as disulfide-linked heterodimers in virus particles [67].  Wieringa 
et al. [59] has shown that the major envelope proteins (GP5 and M) and the N protein are 
essential for EAV particle formation.  In contrast, neither E protein nor the minor 
envelope proteins are required for production of viral particles since absence of either of 
these proteins did not inhibit incorporation of viral genomic RNA or change buoyant 
density or microscopic appearance of the virus [59].  In contrast, all major and minor 
structural proteins are required for production of infectious progeny virus as has been 
shown by individually knocking out the expression of each structural protein separately 
[59].  
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Table 1.3.  Structural proteins of EAV.   
ORF Nucleotide position 
(bp)* 
Protein Protein length 
(aa) 
Predicted M.W. 
(kDa) 
ORF2a 9751-9954 (204) E 67 7.4 
ORF2b 9824-10507 (684) GP2 227 25.0 
ORF3 10306-10797 (492) GP3 163 17.9 
ORF4 10700-11158 (459) GP4 142 15.6 
ORF5a 11112-11291 (180) ORF5a 59 6.5 
ORF5 11146-11913 (768) GP5 255 28.0 
ORF6 11901-12389 (489) M 162 17.8 
ORF7 12313-12645 (333) N 110 12.1 
* The nucleotide positions are based on the sequence of experimentally derived EAV 
VBS strain (GenBank accession number: DQ846750). 
 
1.7.1.  Minor envelope proteins 
E protein 
The EAV E protein is a small 8 kDa (67 aa) protein encoded by ORF2a [58].  
ORF2a and ORF2b are both expressed from a bicistronic mRNA2.  The E protein lacks 
N-linked oligosaccharide side chains and its single cysteine residue does not form 
intermolecular disulfide bonds.  E protein is stable, highly hydrophobic and is predicted 
to be an integral membrane protein with an uncleaved signal-anchor sequence in the 
central part of the molecule (Figure 1.8).  The E protein could be either a type III integral 
membrane protein or it may span the lipid bilayer twice with both termini located in the 
cytoplcasmic face of the membrane [58].  It contains a conserved site for myristoylation 
in the N-terminal domain followed by a phosphorylation site for casein kinase II [138].  
The E protein is found in intermediate amounts in infected cells [58].  E protein along 
with GP2 protein is essential for production of infectious progeny virus [58].  Data 
suggest that the E protein is noncovalently associated with the GP2, GP3 and GP4 
trimeric complex.  In the absence of the minor envelope protein complex, the amount of 
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E protein in viral particles is diminished by 60 to 80 %.  Similarly, the absence of E 
protein completely blocks the incorporation of the minor envelope proteins (GP2, GP3 
and GP4) into viral particles [59].   
 
GP2 
The GP2 protein is a 25 kDa minor envelope protein encoded by ORF2b (Figure 
1.8).  GP2 is a type I membrane glycoprotein with a single N-glycosylation site at 
position 155 (Asn-155) [139].  It has three amino-terminal (extracellular) cysteine 
residues likely to be important for dimerization and protein function and one in its 
transmembrane anchor domain [139].  The Cys-102 is responsible for the cystine bridge 
with the GP4 protein while Cys-48 and Cys-137 form an intramolecular disulfide bond 
[140].  The GP2 protein occurs in several distinct conformations, as four monomers as a 
result of different disulfide-bonded structures and as a disulfide-linked dimer [139].  
However, only the dimeric form of GP2, which is associated with GP3 and GP4 proteins 
as a heterotrimeric complex, is assembled into viral particles and the GP2 monomers are 
retained in the endoplasmic reticulum of infected cells [139].  GP2 is abundant in EAV-
infected cells, but is expressed in low amounts in viral particles.  It has been shown that 
GP2 protein is not essential for viral RNA replication and transcription [58,141]. 
Sequence comparison analysis indicated that the GP2 protein is highly conserved 
between EAV isolates [142].  
 
GP3 
The GP3 is encoded by ORF3 and is a membrane-associated protein of 36 to 42 
kDa with six potential N-glycosylation sites, Asn-28, Asn-29, Asn-49, Asn-96, Asn-106 
and Asn-118 [137,143].  The membrane topology of GP3 proteins has still not been 
clearly demonstrated.  The protein could be either a class II protein, anchored into the 
lipid bilayer by its uncleaved amino-terminal signal sequence, or a class IV protein, 
possibly embedded by both sides of the hydrophobic terminal domains (Figure 1.8) 
[137,143].  While the GP3 protein has two putative N-myristoylation sites and three 
casein kinase II phosphorylation motifs, it is unclear whether there are active sites.  Little 
is known about the function of this protein; however, inactivation of ORF3 expression 
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inhibited the production of infectious virus particles indicating that GP3 protein has an 
essential role in the viral replication cycle.    
 
GP4 
The GP4 protein, encoded by ORF4, is a typical class I integral membrane 
glycoprotein with amino-terminal signal sequence and its predicted carboxy-terminal 
hydrophobic membrane anchor (Figure 1.8) [137].  Three of the four predicted N-
glycosylation sites (Asn-33, Asn-55, Asn-65 and Asn-90) are functional and produce a 
fully glycosylated protein with a molecular mass of 28 kDa [137].  However, Wieringa et 
al. [137] reported that N-glycosylation of the GP4 protein is an inefficient process and 
only a few portions of the protein acquire N-linked glycans in EAV-infected cells.  
Moreover, only the fully glycosylated form of GP4 is found in virus particles, which 
indicates that a small fraction of the ORF4 products produced in EAV-infected cells are 
incorporated into virus particles [137].  The function of GP4, as well as the GP3 protein, 
is not well characterized, but both are essential in the viral replication cycle.    
 
Figure 1.8.  Predicted membrane topology of minor envelope proteins: E, GP2, GP3 
and GP4 proteins. Two alternative predictions of E protein and GP3 membrane 
topology are shown.  Putative N-glycosylation sites are indicated in yellow with 
corresponding amino acid positions. 
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GP2/GP3/GP4 heterotrimeric complex 
The GP2, GP3 and GP4 proteins are incorporated into virions as a covalently 
associated heterotrimeric complex and lack of one of the components blocks the 
successful incorporation of the other minor envelope proteins [59].  After the release of 
virus particles from infected cells, GP3 becomes disulfide-linked to the GP2/GP4 
heterodimers which results in a 66-kDa complex consisting of covalently bound GP2, 
GP3 and GP4 [144].  Due to this post-assembly modification, both GP2/GP4 
heterodimers and GP2/GP3/GP4 heterotrimers are detected in EAV particles [144].  The 
cystine bridges play essential roles in the formation and stabilization of the trimeric 
complex.  The cysteine residues at positions 48 and 137 (Cys-48 and Cys-137, 
respectively) of GP2 are linked by an intrachain disulfide bond while the cysteine residue 
at position 102 (Cys-102) of GP2 forms an intermolecular cystine bridge with one of the 
cysteines of the GP4 protein [140].   The covalent association of GP3 with the GP2/GP4 
heterodimer likely occurs through the GP4 protein; however, the precise cysteine residue 
forming the intermolecular disulfide bond between GP4 and GP3 has not yet been 
determined (Figure 1.9).  Similarly, the cysteine residue of GP4 that interacts with Cys-
102 of GP2 has not been identified.  The GP2/GP3/GP4/E heterotrimeric complex is most 
likely involved in the virus entry process into the cell based on the observation that it is 
not required for EAV virus particle formation, but is essential for production of infectious 
progeny virus.   
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Figure 1.9.  Two predicted models of GP2-GP3-GP4 heterotrimer.  The two 
alternative models differ in membrane topology of GP3 that is currently not determined.  
The GP3 protein may be either a class II membrane protein (A) or a class IV membrane 
protein (B).   The intermolecular cystine bridges are depicted arbitrarily with disulfide 
bonds (S-S) since the Cys positions have not yet been determined.  N-glycosylation sites 
are indicated in orange with corresponding amino acid positions.  Modified from 
Wieringa et al. [144] with permission. 
 
A novel structural protein GP5a 
A detailed computational analysis revealed an additional ORF which overlaps the 
5’ end of ORF5, named ORF5a, that is conserved in all arterivirus species [81].  The 
ORF5a protein is 59 aa long and is likely to be expressed from the same subgenomic 
mRNA (sg mRNA5) as the GP5 protein, possibly involving leaky ribosomal scanning.  
The ORF5a protein is predicted to be a type III membrane protein with a short (5-12 aa) 
amino terminal domain into the lumen, a central signal-transmembrane sequence and a 
carboxy-terminal domain into the cytosol (Figures 1.10 and 1.11) [81]. The function of 
this protein is yet to be characterized, but studies using reverse genetics suggested that 
this novel protein may be the eighth structural protein of arteriviruses and is important for 
arterivirus infection [81].   
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Figure 1.10.  Amino acid sequences of ORF5a protein of five representative 
arterivirus sequences.  The ORF5a is predicted to be a type III membrane protein and 
the predicted transmembrane domain is indicated in yellow.  The lengths, variable among 
species, of amino-, caryboxy-terminal and signal-anchor/transmembrane domains are 
indicated. Figure adapted from Firth et al. (2011) with permission [81]. 
 
 
 
Figure 1.11.  Predicted membrane topology of ORF5a protein.  The ORF5a protein is 
predicted to be a class III membrane protein with the carboxy-terminal domain in the 
cytosol and the amino-terminal domain in the lumen.   
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1.7.2.  Major envelope proteins 
GP5 
The 30- to 42-kDa GP5 protein is encoded by ORF5 and contains one or two 
potential N-glycosylation sites (Asn-56 and Asn-81).  It is known that most of the 
laboratory adapted EAV strains contain only the N-linked sugar moiety at position Asn-
56 [74,145,146].  A third potential N-glycosylation site at aa 73 (Asn-73) was observed 
in five EAV isolates from clinical specimens obtained from the 2006-2007 EVA 
occurrence in the USA [63].  GP5 is one of the most abundant proteins in the EAV 
particle.  The GP5 protein is a type IV integral membrane protein with triple-membrane 
spanning domains from aa 116 to 181 (Figure 1.12) [57].  The ectodomain of GP5 is 95 
aa long and contains an N-terminal signal sequence that is cleaved [68].  The smear 
appearance of the GP5 protein after analysis by denaturing SDS-PAGE, is due to the 
addition of poly-N-acetyllactosamine during its transport through the secretory pathway 
[57,67].  However, the function of poly-N-acetyllactosamine modification of the GP5 
protein is unclear.  The GP5/M forms a disulfide-linked heterodimer in the virus particle 
[67].  Proper posttranslational modification and folding of the GP5 protein occurs only in 
the presence of the M protein suggesting that the latter may act as its essential scaffold 
protein [73]. Studies using EAV chimeras have shown that replacement of the GP5 
ectodomain with that of different arterivirus species did not alter the cell tropism of EAV, 
indicating that GP5 is not involved in receptor binding [147].   
Equine neutralizing antibodies and monoclonal antibodies against EAV bind to 
the N-terminal hydrophilic ectodomain (aa 19 to 115) of GP5 [74,145,148,149,150].  
Four distinct neutralization determinants of the virus have been identified: aa 49 (site A), 
61 (site B), 67 to 90 (site C) and 99 to 106 (site D) [74,145,148,149,151,152].  Except for 
site A located in the C1 region, these sites are located in the V1 variable region (aa 61-121) 
within the second half of the N-terminal ectodomain of GP5.  Site D expresses several 
overlapping linear epitopes [145,151] in the protein that may possibly interact with three 
other sites to form conformational epitopes [74].     
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The membrane (M) protein  
The 16-kDa M protein is encoded by ORF6.  The M protein is the most highly 
conserved envelope protein of arteriviruses [57].  The M protein has three internal 
membrane-spanning segments and a short amino terminus exposed at the viral surface 
(10 to 18 aa long) and its carboxy terminus (approximately 72 aa long) is buried within 
the virus interior (Figure 1.12) [34,57].  It lacks N-glycosylation sites and contains five 
methionines and one cysteine.  The M protein forms a disulfide-linked heterodimer with 
the GP5 protein in the virus particle [67].  The M protein also forms covalently linked 
homodimers, but only the GP5/M heterodimers are incorporated into virus particles.  It is 
possibly involved in virus budding.    
 
 
Figure 1.12.  Predicted structure of GP5 and M heterodimer.  The neutralization sites 
A (aa 49), B (aa 61), C (aa 67-90) and D (aa 99-106) are shown. The predicted N-
glycosylation sites (Asn-56 and Asn-81) are depicted with orange circle.  The green circle 
represents the N-glycosylation site (Asn-73) found in isolates of a recent EVA outbreak.  
The GP5 and M proteins are covalently linked by a disulfide bond (S-S) formed between 
Cys-34 in the GP5 protein and Cys-8 in the M protein.  Modified from Balasuriya et al. 
[76] with permission. 
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GP5/M heterodimeric complex 
The GP5 and M proteins form a disulfide-linked heterodimer and occur in 
equimolar amounts in the virion (Figure 1.12).  These proteins associate with each other 
with different kinetics and efficiencies in infected cells.  Newly synthesized GP5 proteins 
rapidly interact with M protein, while newly produced M proteins are incorporated 
slowly into the heterodimer.  Presence of a high concentration of M protein in the ER is a 
prerequisite for efficient recruitment of GP5 protein into the GP5/M heterodimeric 
complex [67].  The interaction between the two major envelope proteins is determined by 
the formation of the disulfide bridge between the cysteine residue at position 8 (Cys-8) of 
M and Cys-34 of GP5 since abolition of either cysteine residue completely inhibited 
heterodimerization of the two proteins [68].   
The GP5/M heterodimeric complex is essential for EAV assembly where the 
interaction between nucleocapsid and viral envelope is most likely to be mediated by the 
disulfide-bonded GP5/M heterodimers since the minor envelope proteins are not required 
for generation of virus particles.  Covalent association of the GP5 and M proteins is 
indispensable for the production of infectious arteriviruses [68,153].  In addition, 
expression of both GP5 and M proteins as a heterodimer is required for induction of 
neutralizing antibodies [154].  Nonetheless, peptides derived from just the GP5 
ectodomain were also able to induce neutralizing antibodies to EAV in horses [148,155].   
 
The nucleocapsid (N) protein 
The 14-kDa (110 aa) N protein, encoded by ORF7, is the most abundant viral 
protein in EAV-infected cells.  The N protein is synthesized in the cytoplasm of EAV-
infected cells and possibly binds to envelope protein domains exposed to the cytoplasm 
during the budding process.  Most of the N protein localizes in the cytoplasm of infected 
cells, while a small fraction resides in the nucleus where it seems to accumulate in 
nucleoli.  This suggests a possible post-translational modification of some molecules of N 
protein, such as phosphorylation.  An important function of the N protein is the 
packaging of the viral genome into a putative icosahedral core.  The N-terminal domain 
(aa 1-47) of the N protein, the least conserved region, is thought to interact with the viral 
genomic RNA during nucleocapsid assembly [120].  The C-terminal (aa 49-110) of the 
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EAV N protein forms a dimer consisting of a β-sheet that is capped and flanked by α-
helices.  In the crystal structure, the N protein forms a dimer-dimer, in other words a 
tetramer, organized via a quasi-twofold axis [156].  The N protein comprises more than 
30% of the protein molecules in an EAV particle.   
 
1.8.  GENETIC VARIATION AND MOLECULAR EPIDEMIOLOGY OF EAV 
Although only one major serotype of EAV has been recognized to date [157], 
there is considerable antigenic variation among EAV field strains.  Genomic variation 
among field strains of EAV has been demonstrated [142,158,159,160,161,162] by 
comparative sequence analysis of ORFs 2 to 7.  ORF5 was found to be a main target due 
to the variable regions within ORF5; it is valuable for tracing the origin of EAV strains 
[80,142,146,158,159,163,164,165,166,167,168].  Phylogenetic analyses based on M and 
N protein genes confirmed EAV strain variation [159].  Distinct geographic groups of 
EAV isolates from Europe and the USA were separated based on sequence analysis of the 
M protein gene [161].  Comprehensive phylogenetic analyses have identified two 
phylogenetic groups:  Group I consists of viruses isolated mainly in North America and 
Group II consists mainly of viruses isolated in Europe [146,158,164,166,169].  In 
addition, several subgroups have been identified within each group.  However, American 
lineage viruses were isolated in Europe and vice versa indicating interchange of viruses 
between the two continents, which is thought to have resulted mainly as an outcome of 
the movement of carrier stallions and/or shipment of virus-infective semen.  The 
nucleotide identity between North American and European isolates of EAV is about 85% 
[158,164].  However, a genetically very diverse strain of EAV has been isolated from the 
semen of a donkey in South Africa which has been reported to have nucleotide identity of 
only 60-70% compared to sequences of EAV strains isolated from North American and 
European horses and donkeys [170].     
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1.9.  EQUINE VIRAL ARTERITIS 
 
1.9.1.  Seroprevalence, world distribution and modes of transmission 
EAV, the causative agent of EVA is distributed throughout the world 
[171,172,173,174,175,176], but the seroprevalence of EAV infection varies between 
countries and horses of various breeds and ages.  There is a marked difference in 
seroprevalence of EAV infection between Standardbred and Thoroughbred horses in 
countries in which this has been studied.  EAV is endemic among adult Standardbred 
horses in the United States, (seroprevalence of 78 to 84%), whereas only 0 to 5% of 
Thoroughbred horses are seropositive [177].  Antibodies against EAV have been found in 
horses, donkeys and mules in South Africa [176,178,179,180] but not in free-ranging or 
captive zebra species in southern Africa [181,182].  EAV-specific neutralizing antibodies 
were detected in 51 zebras (24%) of the Burchell’s zebra population in the Serengeti 
National Park [183].  There is only one report of the detection of EAV nucleic acid from 
aborted alpaca fetal tissue by reverse-transcription polymerase chain reaction (RT-PCR) 
and neutralization antibodies were found in a high percentage of its cohorts [184].  
 Transmission of EAV between horses occurs primarily via either the respiratory 
or venereal route [77,185,186,187,188,189].  Respiratory transmission of EAV occurs by 
dispersal of infectious respiratory tract secretions from acutely infected horses.  This is 
the most important and primary route of dissemination of EAV during outbreaks [187].   
High titers of EAV are present in respiratory secretions for some 7 to 14 days during the 
acute phase of infection [177,187].  Similarly, the virus may be detected in the buffy coat 
for up to 28 days after exposure with some strains of EAV [177,190].  The second most 
important mode of transmission of EAV is venereal, from acutely or chronically infected 
stallions. Venereal transmission of EAV occurs during natural breeding or by artificial 
insemination with infective semen from persistently infected stallions [188,189]. 
Persistently infected stallions shed virus solely by the venereal route and up to 85 to 100% 
of seronegative mares bred to long-term carrier stallions seroconvert within 28 days after 
breeding.  Persistence of virus in semen of carrier stallions does not appear to cause any 
short- or long-term virus-related fertility problems [177,188].  Persistently infected 
stallions are the primary natural reservoir of EAV; they disseminate and perpetuate the 
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virus in equine populations.  Recent study by Broaddus et al. (2011) demonstrated that 
there could also be a risk of EAV transmission resulting from in vivo embryo transfer 
from a donor mare inseminated with EAV infective semen [191].  Dissemination of EAV 
by indirect contact through contaminated fomites (e.g. personnel, vehicles, twitches, 
apparel and shanks) is believed to play a minor role; however, its significance varies 
between outbreaks [77,192,193].  Other sources of EAV can be an infected teaser stallion 
or nurse mare [77].  It has recently been reported that exposure of pregnant mares to EAV 
very late in gestation can result in transplacental transmission of the virus and congenital 
infection of the fetus [194].  
 
1.9.2.  Clinical signs  
Equine viral arteritis is a contagious infectious disease of equids caused by EAV.  
The virus was first isolated during an outbreak of abortion and respiratory illness on a 
Standardbred breeding farm near Bucyrus, Ohio in 1953 [185,195].  The disease was 
named after the distinctive vascular lesions present in acutely infected horses [196].  
Many years earlier, EVA was commonly referred to as “epizootic cellulitis-pinkeye” or 
as “equine influenza” [197,198]. EAV is present in equine populations in many countries 
throughout the world [77,177,199,200].  The outcome of EAV infection in horses ranges 
from subclinical infection to an influenza-like illness in adult horses, abortion in pregnant 
mares, and interstitial pneumonia or pneumoenteritis in young foals [77,194,201,202,203].  
Development of clinical signs depend on a variety of factors including strain of virus, 
challenge dose, route of infection, age and physical condition of the horse(s) and 
environmental conditions [77,204].  The incubation period can range from 3 to 14 days 
(usually 6 to 8 days following venereal exposure) followed by development of pyrexia of 
up to 41°C (39-41°C) which may persist for 2 to 9 days.  In addition to pyrexia, typical 
cases of the disease may exhibit all or any combination of the following signs: depression, 
anorexia, nasal and/or ocular discharge, conjunctivitis, rhinitis, leukopenia, periorbital or 
supraorbital edema, edema of the limbs, edema involving the scrotum and prepuce of the 
stallion and mammary glands of the mare, urticaria around the head, sides of neck and/or 
body, and abortion of pregnant mares [77,192,195,204,205,206].  The most consistent 
clinical features of EVA are pyrexia and leukopenia.  Regardless of clinical severity, 
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most naturally infected horses recover spontaneously from EVA.  However, the virus can 
cause a rapidly progressive pneumoenteric syndrome and severe fulminating interstitial 
pneumonia in neonatal foals [194,207] and foals up to a few months of age [208]. 
Abortion in pregnant mares may occur late in the acute phase or early in the convalescent 
phase of EAV infection [77,195,209,210].  Abortions have been documented anywhere 
from 3 to over 10 months of gestation following natural or experimental infection 
[77,210,211].  It has been shown that it is safe to vaccinate healthy pregnant mares up to 
3 months before foaling and during the immediate postpartum period with a commercial 
modified live virus vaccine (MLV, ARVAC®, Pfizer Animal Health) but not during the 
last 2 months of gestation due to an increased risk of abortion [212].  In natural outbreaks 
of EVA, abortion rates have varied from less than 10% to between 50 to 60% [77].  
Although mortality is very low in natural outbreaks of EVA, experimental inoculation 
with the experimentally derived EAV VBS strain can cause up to 60% case-fatality in 
adult horses [77,213].  
 
1.9.3.  Persistent infection  
Persistence of virus in the semen of infected stallions is a unique feature of EAV 
infection.  Frequency of the carrier state can vary from less than 25% to 65% in stallions 
exposed to EAV via the respiratory route [188,190,214,215].  The virus appears to be 
restricted to the male reproductive tract and is localized mainly in the ampulla of the vas 
deferens [77].  Not withstanding high neutralizing antibody titers in serum, carrier 
stallions continuously shed infectious virus in their semen.  The virus is associated with 
the sperm-rich and not the pre-ejaculatory fluid fraction of semen.  Duration of virus 
persistence can vary; carrier stallions can stop shedding virus in their semen weeks to 
years after infection with no evidence of reversion to a shedding status later.  However, 
the mechanism of spontaneous viral clearance in persistently infected stallions has not yet 
been identified [77]. Many outbreaks are initiated following venereal transmission of 
infection to a susceptible mare by a carrier stallion.  Subsequent spread of virus to 
seronegative cohorts occurs via the respiratory transmission route [78,79].  The carrier 
stallion is mainly responsible for maintenance and dissemination of EAV in the equine 
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population; thus, they are clearly central to the epidemiology of EAV infection 
[78,79,216].    
 Although the detailed mechanism of establishment of the carrier state in stallions 
is still unidentified, Little et al. [217] have reported that shedding of EAV in the semen of 
persistently infected stallions is testosterone-dependent [217,218].  Surgical castration of 
carrier stallions resulted in either viral clearance or significant reduction of virus 
shedding in their semen [218] has been convincing.  The effects of testosterone on 
reproductive tissues, such as immunosuppressive activities or maintenance of susceptible 
host cell population, that could maintain EAV persistence have also been considered 
[219,220].  Other studies have related persistence to the interaction between the host 
immune response and EAV in the reproductive tract [190,221,222].  It was suggested that 
high levels of circulating testosterone is essential for long-term persistence but not for 
viral replication or persistence of intermediate duration [223].  Experimental infection of 
prepubertal and peripubertal colts with EAV have shown that the virus can replicate in 
the male reproductive tract for a variable period of time (intermediate duration) even in 
the absence of circulating concentration of testosterone similar to those of sexually 
mature stallions after clinical recovery [223].  However, none of the prepubertal colts 
maintained long-term virus persistence comparable to that of experimentally or naturally 
infected stallions [223].  Therefore, long-term persistent EAV infection does not occur 
either in colts exposed to the virus before the onset of puberty or mares, geldings or 
fetuses [177,189,218].    
It is assumed that virus persists by continuously re-infecting susceptible tissues in 
the reproductive tract together with constant evolution of antigenic variants of the virus 
[79,80,164].  In contrast to the relative genetic stability of EAV during infection 
associated with respiratory transmission, significant evolution and genetic heterogeneity 
of EAV quasispecies occur during persistent infection of individual carrier stallions 
[78,79,80].  Sequence analyses of EAV isolated from semen of carrier stallions have 
demonstrated that there is a significant evolution of EAV quasispecies during long-term 
persistence that results in emergence of novel variants with divergent phenotypes 
responsible for major EVA outbreaks [79,80,224].  High rates of nonsynonymous 
changes occur in regions of GP3 and GP5 proteins [80,164] indicating that these viral 
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proteins are under strong selective pressure during establishment and maintenance of 
persistent EAV infection [74,80].  Particularly, amino acid changes in the GP5 protein 
that occur during persistent infection of stallions are found to be restricted to the critical 
V1 neutralization region [74,224].  It has also been observed that development of clinical 
signs of EVA was more common in susceptible mares bred to certain carrier stallions 
than others [189].  Thus, genetic variation of EAV during persistent infection results in 
both altered neutralization phenotype and emergence of variants of variable virulence 
phenotypes [80,164].   
Persistent infection of cell cultures has been reported previously for numerous 
viruses including certain nidoviruses 
[101,225,226,227,228,229,230,231,232,233,234,235].  Since there is no information 
available about host and viral factors, other than testosterone, involved in establishment 
and maintenance of persistent EAV infection, Zhang et al. [236] developed an in vitro 
model system in an attempt to elucidate the mechanism of EAV persistence.   This study 
showed that viral determinants are also critical in mediating persistent infection of EAV 
in vitro.  Reverse genetic studies using an EAV infectious cDNA clone clearly 
demonstrated that amino acid changes in the structural proteins were responsible for the 
persistence in HeLa cells, indicating a multigenic effect on EAV persistence [236].  This 
in vitro model system could serve as a suitable method to determine viral and/or host 
factors involved in EAV persistence as well as possibly help to define the mechanisms of 
EAV persistence in vivo.    
 
1.9.4.  Pathogenesis  
Most of the information on the pathology and pathogenesis of EVA is derived 
from experimental studies in horses inoculated with the experimentally derived Bucyrus 
strain of EAV [187,195,210,213,237,238,239].  The most frequently observed gross 
necropsy findings in horses inoculated with the Bucyrus strain of EAV are edema, 
congestion, and hemorrhage in subcutaneous tissues, lymph nodes, and viscera of the 
thoracic and abdominal cavities [195,206,213,239].  There is considerable variation in the 
quantitative distribution of EAV between experimental studies, which may reflect 
differences in the route of infection, virus dose, strain of virus, and quality of the 
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specimens and cell culture systems used for virus isolation.  Apart from its incidental 
recovery from buffy coat cells [240,241], and with the possible exception of the 
reproductive tract of stallions and colts, EAV is not generally isolated after 28 days 
following infection.    
The exact mechanism of EVA pathogenesis remains to be determined.  The 
vascular lesions are likely caused by the direct effect of viral replication on vascular 
endothelium.  EAV replicates in pulmonary macrophages and endothelial cells following 
respiratory infection and rapidly spreads first to the draining lymph nodes and then 
systematically by a cell-associated viremia [51,187,213,242].  Although endothelial cells 
and macrophages are the principal sites of virus replication, selected epithelia, 
mesothelium, and smooth muscle cells of the tunica media of smaller arteries, venules, 
and the myometrium may also be infected [76,242].  Increased vascular permeability and 
leukocyte infiltration resulting from generation of chemotactic factors leads to 
hemorrhage and edema around affected vessels [238].  The clinical manifestations of 
EVA likely reflect endothelial cell injury and increased vascular permeability; however, 
the relative roles and importance of direct virus-mediated endothelial cell injury and 
virus-induced vasoactive and inflammatory cytokines in the pathogenesis of EAV-
induced vascular injury have not yet been clearly defined [76]. 
The pathogenesis of EAV-induced abortion is still controversial.  Fetuses aborted 
after natural or experimental infection with EAV frequently do not show any gross or 
histopathological lesions [195,206,210,243,244].  Fetuses are usually partially autolyzed 
at the time of expulsion and may have increased peritoneal and pleural fluid, and 
petechial hemorrhages in the mucosal linings of the respiratory and digestive tracts and 
on the serosal lining of peritoneal and pleural cavities [195,206,210].  The placenta 
typically is grossly unremarkable and expelled with the fetus.  Doll et al.[210] concluded 
that fetal expulsion is the result of a lethal fetal infection and not maternal factors such as 
fever, toxemia, or debilitation.  However, Jones et al.[245] suggested that abortions result 
from an impaired uterine and placental blood supply due to systemic vascular necrosis in 
the mare. Coignoul and Cheville [243] also suggested that abortion may result from 
myometritis of the mare rather than fetal infection with the virus, based upon light and 
electron microscopic studies of tissues from the genital tracts, placentae and fetuses of 
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mares experimentally infected with experimentally derived Bucyrus strain of EAV.  In 
contrast, MacLachlan et al., [213] suggested that abortion likely results from direct 
infection of the fetus by EAV.  Fetal stress and subsequent activation of the fetal 
hypothalamic-pituitary axis due to viral infection of the developing fetus likely contribute 
significantly to the pathogenesis of EAV-induced abortion.  
 
1.10.  IMMUNE RESPONSE TO EAV INFECTION 
  The immune response to viruses can be considered under two categories.  The 
innate immune response, the first line of defense, plays an important role in the detection 
of invading pathogens and in limiting their spread.  The second category is the adaptive 
immune response, the second line of defense, is responsible for total clearance of 
pathogens.  While the innate immunity is activated immediately, the adaptive immunity 
takes longer to develop.  While antibodies are clearly important in preventing reinfection 
with viruses, removal of virus-infected cells during acute infection typically is mediated 
by the cellular arm of the immune system. 
 
1.10.1.  Innate immune response  
Natural EAV infection of horses primarily occurs via either the respiratory tract 
following exposure to infective secretions/excretions or the reproductive tract following 
venereal exposure [77,246].  Thus, it is the innate immune response of the mucosal lining 
of the respiratory and genital tracts that constitutes the first line of defense that EAV 
encounters in cases of natural exposure.  There are few detailed studies that describe the 
innate immune response of horses to EAV or other viruses, thus information pertaining to 
innate antiviral immunity is largely derived from the study of other viruses of order 
Nidovirales.   
The innate immune response is the first line of the host’s defense against a virus infection; 
it also plays an important role in activation of the adaptive immune response.  Type I 
IFNs (IFN-α and IFN-β) are major players in the innate immune response and are 
expressed in response to most intracellular infectious agents, especially viruses [247].  
They induce expression of genes encoding antiviral proteins and also function as an 
important link between innate and adaptive immune responses.  There is mounting 
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evidence that PRRSV circumvents the host innate response, resulting from inadequate 
induction of type I IFNs [248,249,250].  As a consequence, there is a delayed production 
of IFN-γ, cellular immunity and neutralizing antibodies [76,251], and in consequence, 
delayed viral clearance [250,252,253].  Additionally, it has been shown that PRRSV 
infection of alveolar macrophages fails to elicit any significant expression of genes 
encoding proinflammatory cytokines, including TNF-α [254,255].  Furthermore, the 
sensitivity and induction of IFN-α in porcine alveolar macrophages (PAMs) differ 
significantly among different strains of PRRSV [256].  Some of the North American 
PRRSV strains strongly down regulate the induction of IFN-α in PAMs [256].    
Viral components are recognized by specific host pathogen recognition receptors 
(PRRs) that trigger the activation of IRF3, NF-kB and AP-1, three regulators of IFN-β 
expression. IFN-β is responsible for the induction of interferon stimulated genes (ISGs) 
that encode antiviral effectors important in limiting viral spread and in establishing an 
antiviral state in the infected cells as well in the neighboring non-infected cells.   
In previous studies, it has been shown that EAV infects alveolar macrophages 
(AMΦ) after respiratory infection of horses, but recent in vitro studies using cultured 
equine AMΦ confirmed that although these cells were susceptible to infection, they were 
refractory to productive replication of EAV [257].  In contrast, productive replication 
occurred following EAV infection of cultured blood-derived equine macrophages (BMΦ) 
[257].  EAV infection of both equine AMΦ and BMΦ resulted in increased transcription 
of genes encoding proinflammatory mediators, including IL-1β, IL-6, IL-8 and TNF-α, 
with the release of substantial quantities of TNF-α into the culture medium [257].   
Furthermore, virulent and avirulent strains of EAV induced different quantities of TNF-α 
and other proinflammatory cytokines (IL-1β, IL-6, IL-8), and the magnitude of the 
cytokine response of equine AMΦ and BMΦ to EAV infection reflected the virulence of 
the infecting virus strain [257].  These studies clearly show that cytokine mediators are 
produced by EAV infected equine cells and, presumably, these play an important role in 
determining the nature and severity of the outcome of infection.  However, a more 
specific and detailed investigation into innate and adaptive immune responses to EAV 
has not been carried out. 
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1.10.2.  Humoral immune response  
The humoral immune response to EAV is characterized by the development of 
both complement-fixing (CF) and virus-specific neutralizing (VN) antibodies [157,258].  
The CF antibodies appear between 1-2 weeks and peak 2-3 weeks after EAV infection in 
adult horses and ponies [157].  Interestingly, avirulent strains of EAV (e.g. MLV) 
stimulate a stronger CF antibody response than that elicited by virulent strains, such as 
the VBS of EAV [157].  The mechanism of EAV neutralization by specific antisera is not 
clear.  Several in vitro studies indicate that neutralization of EAV is complement-
dependent [259,260,261,262].  These studies have shown that EAV neutralizing activity 
of horse, hamster, guinea pig and rabbit antisera was decreased following heat 
inactivation, and restored by addition of fresh complement.  Homologous complement 
appeared to be more efficient in neutralizing the sensitized virus than heterologous 
complement [157,263].  Complement dependent EAV neutralizing antibody activity is 
associated with the IgG fraction of late antiserum, but not with early antisera or their IgM 
and IgG fractions [261].  The requirement of complement for efficient virus 
neutralization is also dependent on the virus strain [176,263].   
EAV infection in horses induces long-lasting immunity that protects against 
reinfection with all strains of the virus [76,196,264,265,266].  Appearance of neutralizing 
antibodies (7-14 days post infection) coincides with the disappearance of virus from the 
circulation of infected horses [240,267].  However, virus does persist in the reproductive 
tract of the carrier stallion for a variable period despite the presence of high titers of VN 
antibodies in serum [77].  The humoral immune response to structural EAV proteins in 
naturally or experimentally infected horses varies widely with the infecting EAV strain, 
the interval after infection, and the individual horse [150,221,268].  The variation in the 
antibody response to EAV structural proteins was also observed in horses immunized 
with the modified live EAV vaccine [221,268].  Vaccination of horses with either live 
attenuated virus strains or inactivated virus vaccines also induce long-term VN antibodies 
in horses [266,269,270].  In addition, horses immunized with recombinant GP5 protein 
(residues 55 to 98) or synthetic oligopeptides (residues 75 to 97) also developed 
neutralizing antibodies to EAV [148].  Foals acquire EAV-specific antibodies from the 
colostrum of seropositive (immune) dams and these antibody levels decrease with time.  
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Furthermore, passively acquired antibodies protect young foals that received colostrum 
from EAV seropositive mares against EAV infection confirming the importance of 
antibodies in protection against the disease [271,272].  However, VN antibodies are not 
detected in sera from foals prior to nursing suggesting that the passive immunity does not 
occur through the placenta in utero [271].  The maternally acquired antibody titer is high 
at 1 week of age and declines until no longer detectable after 2-6 months.  The mean 
biological half-life of maternal antibodies in serum from foals was 32 days [272]. Foals 
that received colostrum should be vaccinated after maternal antibodies disappear since 
these antibodies in their serum are able to neutralize the vaccine virus [271].  The time to 
implement vaccination of foals is dependent on the duration of passively acquired 
immunity to EAV [272]. 
The humoral immune response to EAV is mainly directed to the major envelope 
proteins, GP5, M and N proteins [148,221,268,273,274,275,276].  Early studies on 
characterization of antigenicity and function of viral proteins using monoclonal 
antibodies (MAbs) have identified that neutralization determinants of EAV are located in 
the GP5 protein [149,151,152].  Different neutralization abilities of MAbs suggested that 
while they recognize different epitopes, they all recognized the GP5 protein. To induce 
neutralizing antibodies in mice, co-expression of GP5 and M in eukaryotic cells is 
required [73].  In contrast, non-neutralizing MAbs were directed to either the GP5 or N 
protein [74,145,149,151,152,273,277,278].  Initially, Balasuriya et al. [151] identified a 
critical neutralizing epitope present between residues 99 to 104 using MAbs, 
neutralization-resistant mutants and recombinant proteins of individual viral proteins.  
Amino acid mutations within this region were found in neutralization-resistant mutants 
[151,152].  Similarly, Chirnside et al. identified a linear epitope between residues 55 and 
98 of the GP5 protein using the expression vector pGEX system [148].  Additionally, 
Glaser et al. [145] recognized that resistance to VN is associated with mutations around 
positions 99 and 100 based on testing different EAV isolates.  Taken together, the 
dominant neutralizing domain was recognized as between aa residues 75 and 104 within 
the GP5 protein [145].  The study conducted by Balasuriya et al. [74] further 
characterized at least four potential neutralization sites on the N-terminal hydrophilic 
ectodomain of the GP5 protein, including aa 49 (site A), 61 (site B), 67-90 (site C), and 
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99-106 (site D).  Most of the neutralization epitopes, except for aa 49, are located in the 
variable region V1 (aa 61-121) of the GP5 protein [74].  Studies using MAbs and reverse 
genetics have shown that aa changes at aa 61 (site B) and 67-90 (site C) of the GP5 
protein influence the expression of conformational neutralizing epitopes and similar 
changes could also be responsible for antigenic variation among EAV field strains 
[69,74].   Therefore, it is likely that aa changes in the GP5 N-terminal ectodomain, 
especially if they occur during persistent infection in carrier stallions, contribute to the 
emergence of EAV strains with different neutralization phenotypes [69].  Besides 
neutralizing antibodies recognizing GP5 protein, horses also produce non-neutralizing 
anti-GP5 antibodies in response to EAV infection or immunization with an inactivated 
whole-virus vaccine [274,279].   
Non-neutralizing antibodies which recognized N and M proteins [221,268,279] 
were detected as early as 14 days post-infection (dpi) and lasted at least 145 days in 
sequential sera from horses experimentally infected with EAV [276].  The M protein is 
the most consistently recognized among the EAV structural proteins by convalescent sera 
from EAV-infected horses [221,268] while response to the N and GP5 proteins was 
variable.  The GP2 protein was poorly recognized by equine antisera [268].  The C-
terminal domain of the M protein (aa 88-162) contains linear epitopes and is recognized 
by all EAV-specific horse antisera [280].  The ORF7 encoding the N protein is highly 
conserved among strains [159].  The portion between aa 1-69 of the N protein has been 
identified as the most immunoreactive region.  Sera from persistently infected stallions 
consistently recognized GP5, N and M proteins [268].  In contrast, most convalescent 
sera from mares, geldings and stallions that did not become carriers after exposure to 
EAV recognized the carboxy-terminal region of the M protein [268].   
Until now, characterization of the humoral immune response to EAV has been 
mainly focused on the structural proteins of EAV.  The nonstructural proteins of EAV are 
the first viral proteins synthesized in cells infected with EAV and are essential to the viral 
replication cycle.  Based on their expression levels and immunogenicity, it is reasonable 
to think that antibodies to nsps are generated during early infection.  However, little is 
known about the equine humoral immune response to the nonstructural proteins.  In 
response to this need, chapter 9 of the dissertation is focused on determining the humoral 
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immune response of EAV-infected horses to each of the nsps encoded by the ORF1a and 
ORF1b region of the viral genome. 
 
1.10.3.  Cell mediated immune response 
  Both innate and adaptive immunological responses are mediated by leukocytes, 
and among these cells, lymphocytes are the pivotal population [281].  Castillo-Olivares et 
al. [282] described EAV-specific cytotoxic T-lymphocyte (CTL) responses using 
peripheral blood mononuclear cells (PBMCs) from convalescent EAV-infected 
(experimental) ponies.  The data showed that cytotoxicity induced by EAV-stimulated 
PBMCs was virus-specific, genetically-restricted, and mediated by CD8+ T cells, and that 
EAV-specific CTL precursors persist for at least 1 year after infection in ponies [282].  
Other than this study, there are no comprehensive studies that describe either the innate 
or cell-mediated immune (CMI) response to the MLV vaccine or to any other strains of 
EAV in horses.   
  In contrast to EAV, CMI responses to two other arteriviruses (PRRSV and LDV) 
have been characterized in detail [15,76,250,283,284].  PRRSV-specific T cell responses 
(both CD4+ and CD8+) in infected pigs occur between 4 and 12 weeks after infection and 
it is suggested that the unglycosylated M envelope protein may be an important target of 
the CMI response [283,284].  
  The murine arterivirus LDV causes lifelong persistent infection in mice and 
evades both humoral and cell mediated immune responses. The virus escapes the 
neutralizing antibodies by generating neutralizing-escape variants.  Furthermore, during 
the acute phase of LDV infection, mice mount a strong CTL immune response that 
disappears within 30 days [285].  It has been suggested that this may be due to the clonal 
deletion (exhaustion) of LDV-specific CD8+ T cells in the thymus as well as inhibition of 
IL-4 with suppression of helper T cells [15].   
  In summary, it has been clearly shown that PRRSV and LDV have their own 
mechanisms to evade the host immune response, but nothing is known about immune 
evasion by EAV in horses. 
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1.11.  DIAGNOSIS OF EQUINE VIRAL ARTERITIS 
 
1.11.1.  Virus isolation 
 EAV infects a wide variety of cell types.  The virus can be propagated in a number of 
continuous cell lines such as baby hamster kidney (BHK-21), African green monkey 
kidney (Vero and BSC-1), rhesus monkey kidney (LLC-MK2), rabbit kidney (RK-13 and 
LLC-RK1), equine ovary cells (EO), hamster lung (HmLu), and canine hepatitis virus-
transformed hamster tumor cells (HS and HT-7) [60,103,145,261,265,286,287,288,289].  
The cytopathic effect (CPE) and virus titer can vary significantly among cell lines.  The 
CPE in EAV infected cells is usually characterized by rounding, vacuolation, increased 
optical density, refraction and detachment from culture vessels [60,61,290,291].  
  The presence of EAV in body fluid, tissue samples, blood, semen and placenta 
can usually detected by virus isolation in cell culture.   The most appropriate specimens 
for virus isolation from live animals are nasopharyngeal swabs, conjuctival swabs and 
citrated or EDTA blood samples for separation of buffy coat cells.  Isolation of EAV is 
currently performed using a high passage RK-13 cell line.  Virus isolation (VI) is the 
current gold standard test, approved by World Organization for Animal Health (OIE), for 
the detection of EAV in semen from stallions and is the prescribed test for international 
trade [292].   
 
1.11.2.  Molecular diagnostics 
  Rapid and highly specific diagnostic systems for detection and characterization of 
EAV in diagnostic specimens are critical to ensure proper management of infected 
animals and to provide effective control measures of the disease.  The modern nucleic 
acid-based tests are widely available to test clinical specimens for many infectious 
disease agents.   The molecular diagnostic tests are often more sensitive, faster and less 
expensive.  A number of sensitive standard RT-PCR, RT-nested PCR and real-time RT-
PCR based assays have been developed for the detection of EAV nucleic acid in tissue 
culture fluid, nasal secretions and semen [293,294,295,296,297,298,299,300].  Initially, 
published primer sets were specific to the 3’ end of ORF1b of the viral polymerase gene 
[293,294,297,298].  However, more conserved regions of the viral genome were also 
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used as targets.  Comparative nucleotide and amino acid sequence analysis of ORF7 
(encoding N protein) deduced the aa sequences of ORF7 which are highly conserved and 
less likely to be the subject of antigenic variation.  Therefore, both TaqMan®-based 
[299,300] and TaqMan® minor-groove-binding (MGB) group-based [301] real-time RT-
PCR have been developed targeting ORF7 of the EAV genome.  These assays have been 
compared and validated using a large number of equine semen and tissue culture fluid 
(TCF) samples.  Lu et al. [302] compared specificity and sensitivity of two TaqMan®-
based RT-PCR assays, described by Balasuriya et al. (T1) [299] and Westcott et al. (T2) 
[300].  Both T1 and T2 assays showed high sensitivities, 100% and 95.2%, respectively, 
for detecting EAV RNA in TCF.  However, these assay were less sensitive, 93.4% and 
42.6%, respectively, than the OIE-prescribed VI test (gold standard) for detection of 
EAV RNA in semen.  In an attempt to increase the diagnostic sensitivities of the T1 and 
T2 assays for testing semen samples, Miszczak et al. [303] used three different one-step 
real-time RT-PCR reagents in combination with two different magnetic bead-based RNA 
extraction methods to test 409 semen samples.  The study determined that under strictly 
defined conditions with respect to the nucleic acid extraction method and testing reagents, 
the T1 assay provides sensitivity equal to or slightly higher than virus isolation for the 
detection of EAV in semen.  Taken altogether, the real-time RT-PCR can reliably detect 
EAV nucleic acid when the reagents for nucleic acid extraction and amplification 
methods are optimized.  Therefore, this assay has the potential to provide a faster, 
convenient and more economical test for detection of EAV nucleic acid in TCF and 
equine semen and be an alternative to VI. 
 
1.11.3.  Serological diagnosis  
The virus neutralization test (VNT) is considered the “gold standard” for 
detection and determination of antibodies to EAV [292].  Currently, the VNT is the only 
validated test accepted for international trade.  Although, the VNT is highly sensitive and 
accurate, it has several disadvantages: it is expensive, labor-intensive and time-
consuming to perform.  In addition, results can vary among laboratories when adequate 
attention is not paid to standardization of both test reagents and procedure.  Moreover, 
serum cytotoxicity caused by anti-cellular antibodies directed against RK-13 cells can to 
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the inexperienced, be mistaken for viral CPE and can give rise to difficulties in test 
interpretation at lower serum dilutions.  Also, the VNT cannot differentiate the antibody 
response of vaccinated from naturally infected horses.  To overcome these disadvantages, 
several enzyme-linked immunoassays (ELISA) have been described using whole virions, 
recombinant GP5, M and/or N proteins expressed from bacterial- or baculovirus systems 
with ovalbumin-conjugated synthetic oligopeptides of GP5 protein as antigen 
[150,221,254,274,275,304,305,306].  Given the importance of the GP5 protein to virus 
neutralization, it was the logical target as an antigenic protein for development of 
serological diagnostic assays.  An ELISA using a recombinant fusion protein expressing 
GP5 55-98 had a sensitivity and specificity of 99.6% and 90.1%, respectively [274].  An 
ELISA based on a cocktail of recombinant GP5, M and N proteins expressed in 
baculoviruses had 100% specificity and 92.3% sensitivity when tested with sera from 
naturally or experimentally infected horses.  However, the test was not reliable in 
detecting antibodies in sera of vaccinated horses [221].  A blocking ELISA using 
partially purified EAV and MAb against the GP5 protein with 99.4% sensitivity and 97.7% 
specificity was developed [254].  Another ELISA based on GP5 protein, the ovalbumin-
conjugated synthetic peptide containing amino acids 81-106 of GP5 (GL-OVA) had a 
sensitivity and specificity of 96.7% and 95.6%, respectively [150].  Due to the conserved 
nature of the nucleotide sequence of M and N proteins among different EAV strains and 
isolates, they are considered appropriate candidates for diagnostic purposes as well [159].  
Jeronimo and Archambault (2002) demonstrated that the carboxy terminus of the M 
protein (aa 88-162) is consistently recognized by EAV-specific horse sera, thus 
suggesting this region be used as the antigen for serology tests such as ELISA [280].  
However, none of the above mentioned assays were sensitive and specific enough to 
replace the current VNT.  Currently, there is a commercially available ELISA, Ingezim 
Arteritis ELISA (Ingenasa, Madrid, Spain); however, sensitivity and specificity of the 
assay was considerably lower compared to VNT making this commercially available 
ELISA unsuitable for screening of samples [307].  As discussed in chapter 8, a new 
immunological assay to detect antibodies to EAV in horses was developed using the 
microsphere assay system.  This particle array using microspheres (microbeads) 
incorporates three well-developed technologies: bioassays, solution-phase microspheres 
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and flow cytometry.  The microsphere immunoassay (MIA) has several advantages over 
traditional ELISAs: accuracy, high sensitivity and specificity, reproducibility, high-
throughput sample analysis and multiplex capability.  In our study, the assay was based 
on recombinant structural proteins with putative antigenic regions.  Among tested 
recombinant structural proteins, either full-length or partial, GP555-98 MIA showed the 
highest sensitivity and specificity of 92.6% and 92.9%, respectively.  Currently, we are in 
the process of maximizing the sensitivity of this assay by incorporating a cocktail of 
recombinant EAV proteins including structural and nonstructural proteins.  Hopefully, 
the new strategy will improve the sensitivity and specificity of the assay and it can be 
used as a reliable serological diagnostic test to detect antibodies to EAV. 
 
1.12.  PREVENTION AND TREATMENT OF EQUINE VIRAL ARTERITIS  
 
1.12.1.  Vaccine 
The development of a safe and effective vaccine against an infectious disease is 
always of paramount importance in preventing a disease outbreak and minimizing 
economic losses.  The modified live virus (MLV) vaccine against EVA was developed 
many years ago following serial passage (P266) of the experimentally derived Bucyrus 
strain of EAV in horse kidney (HK), rabbit kidney (RK) and equine dermal (ED) cells 
[62,308].  This attenuated strain of virus did not show any reversion to virulence after 
five consecutive passages in horses [264,267].  Experimental vaccination studies have 
been performed to ensure the safety of the vaccine for use in stallions [309,310].  
However, vaccination of pregnant mares is not recommended especially in the last 
trimester of pregnancy.  The commercial modified live virus vaccine, ARVAC® (passage 
history HK-131, RK-111 and ED-24), and the strains of earlier passage history were 
shown to be effective for protection against disease [264,266,267,309].  Vaccination 
studies using the MLV showed that a single dose of vaccine stimulates only low, 
transient levels of VN antibodies; however, additional doses boost antibody levels with 
titers maintained for at least 9-12 months [193,310,311].  Similarly, formalin-inactivated 
virus vaccine without adjuvant was shown to induce high titers of VN antibodies after 
repeated doses [269,270,312,313].  The modified live virus vaccine, ARVAC® is 
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currently in use in North America, while the adjuvanted killed virus vaccine, 
ARTERVAC®, is approved for use in several European countries.  
Current serological tests cannot discriminate between naturally infected and 
vaccinated horses.  Therefore, an effort was undertaken to develop vaccines that might 
make such discrimination possible e.g. sub-unit vaccine.  
DNA vaccination using GP5 and N proteins of EAV has been tested using mice 
[314].  The highest VN antibodies were induced when animals were vaccinated with 
plasmid DNA encoding ORF5 [314].  Later, a DNA vaccine expressing ORFs 2, 5, and 7 
in combination with equine interleukin-2 was tested in horses [315].  After the initial 
immunization, three boosters were administered at two-week intervals.  All vaccinated 
horses developed high VN antibody titers regardless of age and VN antibodies were still 
detectable over a year later [315].  The N-terminal ectodomain (aa 18-122) of GP5 
expressed in bacterial cells induced higher neutralizing antibody titers compared to other 
GP5 polypeptides in ponies [155].   
Balasuriya et al. [154] explored the possibility of using alphavirus replicon 
particles (VRP) co-expressing GP5/M as a vaccine and of inducing protective immunity 
in horses.  Previously, they established that VRP expressing GP5/M heterodimer can 
induce neutralizing antibodies in mice.  This study showed that the VRP system could be 
used as a strategy for developing a vaccine against EAV and other viral pathogens.    
 
1.12.2.  Antivirals 
Antiviral potentials of phosphorodiamidate morpholino oligomers (PMOs) 
directed against EAV have been studied [316,317].  PMOs are single-stranded DNA 
analogues [318], usually 20-25 bases in length, water-soluble and nuclease-resistant [319].   
PMOs can base pair with a complementary RNA target sequence and form a steric 
blockade to interfere with gene expression, particularly with translation of the genome 
[319,320].  Peptide-conjugation to the PMO (P-PMO) greatly improves delivery of PMO 
into cells [321].  The 5’ UTR of the EAV genome was found to contain the most sensitive 
targets for inhibition with P-PMOs [317].  Treatment with an antisense P-PMO targeting 
the EAV 5’-terminus at a concentration of 5-10 µM eliminated the virus from persistently 
infected HeLa cells [316].  However, the efficacy of P-PMO against EAV in vivo remains 
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to be evaluated.  Moreover, several carbohydrate-binding agents such as plant and non-
plant lectins have been shown to have antiviral activities against nidoviruses [322].  It has 
also been reported that EAV could not be propagated in 100 U/ml recombinant equine 
IFN-γ when 100 TCID50 of infectious virus was inoculated into horse cells [323].  
Furthermore, horse cells transfected with small interfering RNA (siRNAs) targeting the 
ORF1ab prior to infection with EAV drastically reduced virus titers in cell culture [324].  
Although the antiviral effects shown in vitro are promising, in vivo application of the 
above mentioned antiviral agents may be limited due to the large body weight of horses 
and  the costs involved. 
 
1.13.  RECENT ADVANCES IN EAV RESEARCH AND FUTURE DIRECTIONS 
 
1.13.1.  Reverse genetics 
The naked genome of a positive-strand RNA virus is infectious: it serves as an 
mRNA for translation of viral replicase, thus, infection starts by a simple transfection of 
the genome into the host cell.  Construction of full-length cDNA clones has greatly 
enhanced our understanding of RNA virus replication and gene expression by 
manipulating the genetic information. They can serve as potential tools for fundamental 
studies of virus replication and pathogenesis.  
To date, the first two cDNA clones of the original Bucyrus strain were derived 
from a highly cell culture adapted strain [325,326] and one of these clones, pEAV030 
(GenBank accession number: Y07862) was found to be attenuated in horses [327].  The 
third clone was derived from a horse adapted, experimentally derived VBS strain of EAV 
[328].  The recombinant virus generated from this infectious cDNA clone (rVBS) causes 
severe disease in experimentally infected horses [328].  Recently, a full-length cDNA 
clone of MLV has been constructed [329].  Infectious RNAs can be produced in vitro 
from full-length EAV cDNA clones using T7 RNA polymerase.  
Availabililty of EAV cDNA clones have greatly increased our knowledge of 
molecular characterization of genetic expression and replication of EAV using reverse 
genetics technology.  Balasuriya et al. (2004) employed an infectious cDNA clone and 
reverse genetics technology to generate a panel of chimeric and mutant viruses by means 
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of site-directed mutagenesis and to characterize neutralization determinants of EAV [69]. 
However, manipulation of the genome of arteriviruses is complicated due to the compact 
and overlapping gene arrangement.  de Vries et al. (2000) investigated the importance of 
the overlapping gene organization in the virus life-cycle by constructing a series of 
mutant full-length cDNA clones in which EAV ORFs 4/5 or ORFs 5/6 or ORFs 4/5/6 
were separated [325].  RNA transcribed from each of these plasmids was infectious, 
indicating that the overlapping gene arrangement is not crucial for viability of the virus.  
The fact that small changes in the spacing between ORFs 4/5 and ORFs 5/6 mutant 
viruses have only a limited effect on virus yields, was a big advantage for generation of 
recombinant chimeric viruses between virulent and attenuated strains of EAV.  Genes 
encoding structural and nonstructural proteins are often interchanged between strains of 
EAV of differing virulence and are used to study virulence determinants, mechanisms of 
pathogenesis and persistent infection [236,330,331].  Assessment of viral proteins 
involved in T lymphocyte tropism is described in this dissertation (chapter 2). 
EAV cDNA clones have also been used as a vector for heterologous gene 
expression, such as enhanced green fluorescence protein (eGFP) [332].   The infectious 
recombinant EAV expressing GFP (EAV-GFP2) from its replicase had similar growth 
characteristics to those of the wild-type virus.  The recombinant virus EAV-GFP2 is a 
convenient tool for basic and applied research.  The same approach, namely insertion of a 
foreign gene in the arterivirus replicase gene for intracellular expression, could be used 
for vaccine development. 
It is clear that infectious clones and reverse genetics are valuable and powerful 
tools that can increase our understanding of many aspects of the viral infection process 
and life cycle, as well as virulence.  Specifically, it offers possibilities for exploring 
vaccine production as well as vector development.  
 
1.14.  HOST-VIRUS INTERACTION AND GENOMIC STUDIES 
Viruses constantly adapt to and modulate the host environment to their advantage 
during replication and propagation.  Therefore, virus interaction with host target cells is 
complex and it is possible that almost every step of the virus infection cycle may rely on 
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the recruitment of cellular proteins and basic machineries by viral proteins.  Moreover, as 
a virus that induces persistent infection, EAV could have developed strategies to 
overcome the antiviral activity of the host factors, possibly through its own set of viral 
proteins by modulating the cellular environment.  Therefore, dissecting the molecular 
interaction between the host and EAV is key to understanding the pathogenesis of EAV 
and to develop strategies to control EAV replication.  
For initial host cell attachment and entry, the virus uses attachment factors and 
cellular receptors as yet to be identified for EAV.  Subsequently, EAV penetrates into the 
cell by a clathrin-dependent endocytosis and low pH is required in the endocytic 
compartments [82].  Similarly, PRRSV also utilizes a low pH-dependent endocytic 
pathway to enter cells, most likely clathrin-dependent endocytosis [333].  It is not clear 
whether there are other means of entry for EAV; however, the clathrin-mediated pathway 
is the only mechanism of EAV entry that has been reported so far.  Still remaining to be 
identified are the factors required for fusion of endosomal membrane and viral envelope 
and the subsequent uncoating step that are both essential steps for releasing the viral 
genome into the cytoplasm.  Following uncoating, the genome is translated and following 
proteolytic processing of the replicase polyprotein, viral RNAs are synthesized and are 
used as templates for genome replication.  In addition, transcription of subgenomic 
mRNAs that encode the structural proteins occurs.  Arteriviruses acquire their envelope 
by budding preformed nucleocapsids into the smooth endoplasmic reticulum and/or the 
Golgi complex [101,102,136].  After budding, virions accumulate in intracellular vesicles 
which are transported to the plasma membrane for release of progeny virus.  However, 
our knowledge about viral proteins that interact with the cytoplasmic molecules during 
this process is very limited.    
In addition to regulating cellular factors to support efficient replication of the 
virus itself, viruses have also evolved with a view to counteracting the host innate and 
adaptive immune responses. In the last several years, it has been increasingly clear that 
viruses have evolved multiple strategies to escape the IFN system, which is the first line 
of defense to virus infection.  They either inhibit IFN synthesis, bind and inactivate 
secreted IFN molecules, block IFN-activated signaling, or disturb the action of IFN-
induced antiviral proteins.  
  55 
With the advent of genomic tools, it became possible to study virus-host 
interactions at the molecular level.  Many new methodologies have been developed in 
genomic and proteomic fields of research to identify host molecules that closely interact 
during the virus life cycle. Thus, the “genomics revolution” offers high-throughput tools 
to study the complex virus-host interaction.  Microarray technology has been extended 
inter alia to genotyping of the host (SNP analysis).  Therefore, genetic and genomic 
technologies offer ample opportunities to discover the mechanisms of virus infections 
and virus interaction with the host, which will have great implications for vaccine 
development and drug design.    
Over the past few years, autoimmune disease and human infectious diseases have 
been investigated extensively in genome-wide association studies (GWAS).  Researchers 
have used a variety of approaches to investigate how the genes identified in GWAS relate 
to disease pathogenesis.  Studies revealed links between disease developments to regions 
of the host genome that are involved in host-virus interactions.  The field of interaction 
between EAV with host factors is discussed in chapter 3.  We believe that some of host 
factors found during the study directly or indirectly interact with EAV to influence its 
replication.  
 
1.15.  SCOPE AND OUTLINE OF DISSERTATION 
 
A virus is a small infectious agent that can replicate only inside of living cells of 
organisms; in other words, it depends solely on the host/cellular machinery to make new 
products.  Therefore, successful infection depends on the interaction between the host and 
virus that are complex and multifactorial.  At the molecular level, interactions that occur 
between cellular and viral gene products determine host susceptibility to infection. The 
series of events that occur during viral infection in a host may result in a disease that is 
the outcome of the effects of virus replication in the host and the host defense system.  
Thus, elucidating the genetic and functional roles that viral proteins play during 
productive viral infection as well as studying the host immune response to combat the 
viral infection are critical to preventing and treating viral diseases. 
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The objective of this study was to characterize the virus-host interactions in EAV 
infection by combining contemporary molecular biology techniques and host genomic 
analysis using GWAS.   The interaction between the virus and the host is important for 
viral replication, virulence and pathogenesis.  The availability of full-length infectious 
cDNA clones and reverse genetic systems greatly facilitates the functional analysis of 
viral proteins in relation to cellular tropism and the immune response.  The interactions of 
viral structural proteins that determine the host cell tropism is discussed first, and 
possible genetic and host cell factors that determine susceptibility/resistance of equine 
PBMCs to EAV infection are then addressed.  The recent availability of the equine 
genome sequence and development of genome-wide screening technologies offer 
unparalleled opportunities to identify variants associated with increased 
susceptibility/resistance to infectious disease agents such as EAV.  Understanding how 
cellular proteins interact with viral RNA or viral proteins, as well as their role in viral 
infection, will allow for better characterization of the mechanisms of EAV pathogenesis 
and persistent infection in stallions.   Furthermore, the findings from this study should 
allow the design of novel antiviral agents based on these interactions and appropriate 
preventive measures. 
Chapter 1, literature review, provides a broad perspective on the molecular 
biology of EAV and EVA in horses.   
Chapter 2 investigates the altered tropism of EAV VBS during extensive cell 
culture passage that resulted in the modified live virus vaccine strain for equine CD3+ T 
lymphocytes and CD14+ monocytes.  Evaluation of chimeric viruses demonstrates that 
cellular tropism in PBMCs is determined by the amino acid sequence of viral envelope 
proteins.  Combined interactions of both major (GP5 and M) and minor (GP2, GP3 and 
GP4) envelope proteins of the EAV VBS are needed for efficient infection of CD3+ T 
lymphocytes (predominantly CD4+ T lymphocytes) and CD14+ monocytes. 
Chapter 3 describes the identification of a distinct phenotypic trait that can be 
used as a marker to divide equine populations, regardless of breed, into susceptible and 
resistant groups based on dual color flow cytometric analysis of CD3+ T cells infected 
with EAV.  The GWAS demonstrates the putative candidate genes associated with 
susceptibility/resistance of CD3+ T lymphocytes to EAV are located on horse 
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chromosome 11.  Biological pathways analysis reveals several cellular genes within this 
region encoding proteins associated with virus attachment and entry, cytoskeletal 
organization and NFκB pathways that may be associated with the trait responsible for the 
in vitro susceptibility/resistance of CD3+ T lymphocytes to EAV infection. The data 
presented in this study demonstrate a strong association of certain genetic markers with 
de facto proof that the trait is under genetic control. 
Chapter 4 addresses whether the differences in the susceptibility or resistance of 
CD3+ T cells in vitro correlate with development and severity of clinical signs in vivo.  
Horses were divided into two groups based on their in vitro CD3+ T cell susceptible or 
resistant phenotype and challenged with the recombinant EAV VBS.  The data show that 
there was a significant difference between the two groups of horses in terms of cytokine 
mRNA expression and increased clinical signs in horses possessing the in vitro CD3+ T 
cell resistant phenotype.  Thus, there was an inverse correlation between the in vitro 
susceptibility or resistance phenotype of CD3+ T lymphocytes and the variable 
clinical/cytokine expression responses observed in horses following infection with EAV.  
This study provides further insight into the variation in clinical signs seen among horses 
after infection with virulent strains of EAV. 
Chapter 5 establishes a correlation between susceptibility of CD3+ T lymphocytes 
to EAV infection and establishment of persistent infection in stallions.  The data suggest 
that carrier stallions that have the phenotype of susceptible CD3+ T lymphocytes to EAV 
infection may represent those at higher risk of becoming persistently infected compared 
to stallions that do not possess this phenotype.  The in vitro assay described is currently 
the most precise method for determining the phenotype. Findings from this study will 
allow us to develop diagnostic tools to predict possible carrier stallions of EAV and 
prevent further spread of the virus. 
Chapter 6 investigates the effect of EAV on type I IFN production and signaling.  
IFN-β mRNA level in equine endothelial cells (EECs) infected with EAV VBS strain was 
not increased compared to that in mock-infected cells; whereas Sendai virus infection 
strongly induced production of IFN-β mRNA.  Protein levels determined by IFN bioassay 
provided additional confirmation of this finding.  Among 12 nonstructural proteins, nsp1 
exhibited the strongest inhibitory effect, namely the ability to inhibit both IFN synthesis 
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and signaling.  Based on these findings, we propose that failure to induce type I IFN in 
infected cells may allow the virus to subvert the equine innate immune response, and 
nsp1 may play a critical role in inducing this effect. 
Chapter 7 addresses discovery of a novel short coding sequence in the 3’-
proximal end of the EAV genome, named ORF5a.  Its biological significance in the EAV 
life cycle was investigated using EAV reverse genetics systems.  The effect of ORF5a 
knockout mutant was independently confirmed using two molecular clones, the 
pEAV515 and pEAVrVBS of the EAV VBS.  This study suggest that the ORF5a protein 
may be the eighth structural protein of EAV, although further studies are needed to obtain 
more detailed information into its yet unknown function. 
Chapter 8 describes development and validation of an MIA to detect equine 
antibodies to the major structural proteins of EAV.  Of the eight recombinant proteins, 
the partial GP555-98 protein showed the highest concordance with the VNT.  The 
sensitivity and specificity of the MIA were 92.6% and 92.9%, respectively. The GP555-98 
MIA and VNT test outcomes correlated significantly (r =0.84; p-value <0.0001). 
Although the GP555-98 MIA is less sensitive than the standard VNT, it has the potential to 
provide a rapid, convenient and more economical test for screening equine sera for the 
presence of antibodies to EAV with the VNT used as a confirmatory assay. 
Chapter 9 describes evaluation of the humoral immune response of horses to each 
of the nonstructural proteins (nsps) of EAV by ORFs 1a and 1b of the viral genome.  To 
characterize the humoral immune response to EAV nsps, serum samples from horses that 
were seropositive to EAV were reacted with recombinant proteins in 
immunoprecipitation assays.  The data showed that nsp2, nsp5 and nsp12 were the most 
immunogenic proteins of the nsps.  Information from this study will be used in ongoing 
efforts to develop improved methods for the serologic diagnosis of EAV infection in 
horses. 
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CHAPTER TWO 
 
Complex Interactions Between the Major and Minor Envelope Proteins of Equine 
Arteritis Virus Determine its Tropism for Equine CD3+ T Lymphocytes and CD14+ 
Monocytes 
J. Virol. 2010, 84(10): 4898-911 
Reprinted with permission 
 
2.1.  SUMMARY 
Extensive cell culture passage of the virulent Bucyrus (VB) strain of equine 
arteritis virus (EAV) to produce the modified live virus (MLV) vaccine strain has altered 
its tropism for equine CD3+ T lymphocytes and CD14+ monocytes.  The VB strain 
primarily infects CD14+ monocytes and a small subpopulation of CD3+ T lymphocytes 
(predominantly CD4+ T) as determined by dual-color flow cytometry.  In contrast, the 
MLV vaccine strain has significantly reduced ability to infect CD14+ monocytes and has 
lost its capability to infect CD3+ T lymphocytes.  Using a panel of five recombinant 
chimeric viruses, we demonstrated that interactions between GP2, GP3, GP4, GP5 and M 
envelope proteins play a major role in determining the CD14+ monocyte tropism while 
the tropism of CD3+ T lymphocytes is determined by GP2, GP4, GP5 and M envelope 
proteins but not the GP3 protein.  The data clearly suggest that there are intricate 
interactions among these envelope proteins that affect binding of EAV to different cell 
receptors on CD3+ T lymphocytes and CD14+ monocytes.  This study shows for the first 
time that CD3+ T lymphocytes may play an important role in the pathogenesis of equine 
viral arteritis when horses are infected with the virulent strains of EAV.   
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2.2.  INTRODUCTION 
Equine arteritis virus (EAV) is a small enveloped virus with a positive-sense, 
single-stranded RNA genome of 12.7 kb that belongs to the family Arteriviridae (genus 
Arterivirus, order Nidovirales), which also includes porcine reproductive and respiratory 
syndrome virus, simian hemorrhagic fever virus, and lactate dehydrogenase-elevating 
virus of mice [7,34].  The EAV genome includes nine known functional open reading 
frames [58].  Open reading frames (ORFs) 1a and 1b encode two replicase polyproteins 
(pp1a and pp1ab) that are post-translationally processed by three ORF1a-encoded 
proteinases (nsp1, 2, and 4) to yield at least 13 nonstructural proteins (nsp1-12, including 
nsp 7α and 7β [34,66,113], and the remaining seven ORFs (2a, 2b and 3-7) encode 
structural proteins of the virus.  These include four minor envelope proteins (E, GP2, 
GP3, and GP4 encoded by ORFs 2a, 2b, 3 and 4, respectively), two major envelope 
proteins (GP5 and M encoded by ORFs 5 and 6) and the highly conserved nucleocapsid 
protein (N encoded by ORF7) [93].  The two major envelope proteins GP5 and M form a 
disulfide-linked heterodimer [67,68] and the three minor envelope proteins GP2, GP3 and 
GP4 form a covalently associated heterotrimeric complex in the virion [140,144].  By 
independently knocking out the expression of each structural protein, it was shown that 
all major and minor structural proteins are required for the production of infectious 
progeny virus [141]. 
EAV is the causative agent of equine viral arteritis (EVA) [185,195].  
Geographically and temporally different strains of EAV vary in the severity of the 
clinical disease they induce and in their abortigenic potential [77,78,216,224].  While 
most EAV infections are asymptomatic, some infected horses can exhibit clinical 
manifestations such as an influenza-like illness, abortion in pregnant mares, and 
pneumonia or pneumoenteritis in neonatal foals [77,194,202,203,208,244,334,335].  
Following experimental infection of horses by the respiratory route, the virus initially 
replicates in both macrophages and endothelial cells in the lung [187,237].  EAV is then 
transported to the draining lymph nodes, where it replicates and is released into the blood 
and lymphatic system for transportation throughout the body.  The virus infects the 
smaller blood vessels, especially the arterioles, causing a panvasculitis [187,213,242].  A 
number of studies have demonstrated that different strains of EAV vary significantly in 
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their pathogenicity, with very different clinical outcomes upon experimental inoculation of 
horses [154,240,327,328,334].  The horse-adapted Bucyrus (VB) strain of EAV is highly 
velogenic and causes severe clinical disease with a case-fatality rate of 50-60% under 
experimental conditions [213,239].  Horses inoculated with virulent strains of EAV (e.g. VB 
and recombinant VB [rVBS] strains, and KY84) develop severe lymphopenia with a high 
titered viremia (6x103-1x105 pfu/ml) [154,213,244,328].  In contrast, horses inoculated with 
the attenuated modified live virus (MLV) vaccine strain, or other avirulent strains of EAV 
(e.g. 030H and CA95G) [224,327] develop a mild, transient lymphopenia with only a very 
low-titer viremia ( ≤1x101 pfu/ml) [61,62,264,265,267,336].   
The modified live virus (MLV) vaccine (ARVAC®, Fort Dodge Animal Health) 
that is in current use in the United States and Canada [61,264,265,267,336], was developed 
by serial passage of the VB strain of EAV in primary horse kidney cells (HK131 passages), 
primary rabbit kidney cells (RK111 passages) and equine dermis cells (ED24 passages) 
which resulted in attenuation of the virus [62].  Previously, it has been shown that the VB 
strain was fully attenuated for horses by 116th passages in primary horse kidney cells 
(EAV HK116) [265,267,291].  Subsequently, EAV HK116 virus was further passaged in 
HK cells for additional 15 times (HK131) and in two other cell lines (RK111 and ED24) 
to obtain the MLV vaccine virus (HK131, RK111, ED24) used in this study.  There are 
23 additional amino acid substitutions that accumulated in GP2, GP3, GP4, GP5 and M 
envelope proteins during cell culture passage of the HK116 virus to generate the current 
MLV strain (ARVAC®; Table 2.1) which may have contributed to further attenuation of 
the vaccine strain of EAV and increased the safety of the vaccine for horses.  Recently, 
using reverse genetics we showed that a chimeric virus containing the nonstructural 
proteins of VB virus and the structural proteins of HK116 (rVBS/HK116 S) [331] strain 
has an attenuated phenotype in horses.  The data showed that critical amino acid 
substitutions in structural protein genes of HK116 virus were responsible for attenuation 
of the VB strain.     
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Table 2.1.  Comparative amino acid analysis of rVBS, HK116 and rMLV envelope proteins 
ORF Protein (aa length) Amino acid difference Position rVBS HK116 rMLV 
ORF2a (9751-9954) E (67) - - - - 
ORF2b (9824-10507) GP2 (227) 62 Tyr Tyr His 
92 Ile Thr Thr 
158 Gly Gly Glu 
223 Arg Pro Pro 
ORF3 (10306-10797) GP3 
(rVBS and HK116: 163; 
rMLV 168) 
80 Leu Leu Val 
123 Leu Leu Ser 
160 Cys Cys Tyr 
164 Stop Stop Gln 
165   Phe 
166   Tyr 
167   Leu 
168   His 
169   Stop 
ORF4 (10700-11158) GP4 (152) 4 Tyr Tyr Ser 
ORF5 (11146-11913) GP5 (255) 69 Leu Leu Pro 
72 Gln Gln Lys 
81 Asn Asp Asp 
100 Ser Gly Gly 
104 Asn Gly Gly 
106 Met Met Val 
170 Ala Ala Ser 
214 Gly Gly Glu 
ORF6 (11901-12389) M (162) 38 Leu Leu Ser 
49 Phe Phe Leu 
71 Val Val Ala 
81 Met Thr Thr 
122 Ile Val Val 
150 Phe Phe Cys 
154 Ala Thr Met 
Note: Amino acid substitutions located in predicted ectodomain on each protein are 
indicated in bold.  All potential N-glycosylation sites are conserved in GP2 (aa 155), GP3 
(aa. 28, 29, 49,96, 106, 118) and GP4 (aa. 33, 55, 90). 
 
 
 To enhance fundamental understanding of the pathobiology of EAV infections it is 
important to identify those peripheral blood mononuclear cells (PBMCs) that are most 
closely associated with the virus during vascular transport and how genetic changes 
associated with an attenuated phenotype alter the dynamics of virus/host-cell relationships in 
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blood.  Thus, we hypothesized that VB and MLV strains differ in their ability to infect 
PBMCs and that the altered tropism of the attenuated MLV strain of EAV in PBMCs is 
associated with amino acid changes in the viral proteins.  To test this hypothesis we used 
three previously described recombinant viruses (rVBS [328], rVBS/HK116 S [331] and 
rMLV [329]), as well as four newly generated chimeric viruses (rVBS/MLV S, rMLV/VBS 
S, rMLV/VBS 234 and rMLV/VBS 56) and infected ex vivo preparations of PBMCs 
collected from horses.  The data suggested that the difference in cellular tropism and 
virulence phenotype of VB and MLV strains is associated with the collective interactions of 
both major (GP5 and M) and minor (GP2, GP3 and GP4) envelope proteins of EAV.  
Furthermore, this study also demonstrated that CD3+ T lymphocyte tropism is primarily 
determined by amino acid substitutions in the GP2, GP4, GP5 and M envelope proteins but 
not the GP3 minor envelope protein.  However, the macrophage tropism is mainly 
determined by intricate interactions among GP2, GP3, GP4, GP5 and M envelope proteins 
of the virus.   
 
2.3.  MATERIALS AND METHODS 
Cell lines   
Equine pulmonary artery endothelial cells (EECs) were maintained in Dulbecco’s 
modified essential medium (Mediatech, Herndon, VA) with sodium pyruvate, 10% fetal 
bovine serum (Hyclone Laboratories, Inc., Logan, UT), 100U/ml of 
penicillin/streptomycin and 200mM L-glutamine [154,213,328].  The rabbit kidney cells 
(RK-13, ATCC CCL-37; American Type Culture Collection, Manassas, VA) were grown 
in Eagle’s minimum essential medium with 10% ferritin supplemented bovine calf serum 
(Hyclone Laboratories, Inc., Logan, UT) and 100U/ml of penicillin/streptomycin (Gibco, 
Carlsbad, CA).   
 
Horses 
A total of 10 horses of different breeds (Thoroughbreds, n=4; Standardbreds, n=2; 
mixed breeds, n=4) were used in this study.  The horses were maintained on pasture at the 
Department of Veterinary Science’s Maine Chance Farm, Lexington, KY.  All horses 
were confirmed seronegative for EAV neutralizing antibodies using previously described 
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protocols [337].  The horses were clinically evaluated prior to collection of blood samples 
for isolation of peripheral blood mononuclear cells.  Furthermore, complete blood counts 
and differential counts were performed to establish that all animals had normal blood cell 
values.  Blood samples were collected according to a protocol approved by Institutional 
Animal Care and Use Committee at University of Kentucky, Lexington, KY. 
 
Antibodies   
To determine the phenotype of EAV infected mononuclear cells, the following 
monoclonal antibodies (MAbs) directed against different cell-type-specific surface 
molecules were used in this study: anti-equine CD3+ T lymphocytes (UC F6G; kindly 
provided by Dr. Jeff Stott, University of California at Davis; [338], anti-equine CD4+ T 
lymphocytes and anti-equine CD8+ T lymphocytes (CVS4 and CVS8, respectively; 
Serotec, Raleigh, NC; [339,340]. A MAb specific for human CD14 (Alexis Biochemicals, 
Lausen, Switzerland) that cross-reacts with equine CD14 [341] was used to identify 
equine monocytes and R-phycoerythrin (R-PE) conjugated anti-human CD21 (B-ly4; BD 
Pharmingen, San Jose, CA) previously shown to cross-react with equine B cells was used 
[342].  R-phycoerythrin (R-PE)-conjugated F(ab’)2 fragment of goat anti-mouse IgG1 
(Southern Biotech, Birmingham, AL) was used as a secondary antibody.    
To detect EAV antigens in infected cells, MAbs against EAV nonstructural 
protein-1 (nsp1; MAb 12A4) and nucleocapsid protein (N; Mab 3E2) were used 
[213,306].  Mouse ascitic fluid containing MAbs 12A4 and 3E2 were purified using a 
Melon™ Gel IgG Spin Purification Kit (Pierce, Rockford, IL).  Purified IgG was directly 
conjugated to Alexa Fluor® 488 (Invitrogen, Carlsbad, CA) following manufacturer’s 
instructions.  Briefly, purified IgG from MAbs 12A4 and 3E2 were diluted with PBS to a 
concentration of 2 mg/ml and 1 M sodium bicarbonate (pH 8.3) was added.  
Subsequently, diluted IgG solution was incubated with Alexa Fluor® 488 reactive dye for 
1 h at room temperature in the dark with slow stirring.  The reaction mixture was loaded 
onto a fine size exclusion purification resin column for separation of labeled antibodies 
from unincorporated dye.  Fractions of Alexa Fluor® 488 labeled antibodies were 
collected and stored at 4°C.  To detect nonspecific binding, mouse IgG1 (MOPC; Sigma, 
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St. Louis, MO) and Alexa Fluor® 488 conjugated mouse IgG1 isotype controls (Invitrogen, 
Carlsbad, CA) were used. 
 
Viruses   
Two strains of EAV, the virulent Bucyrus (VB) strain (ATCC VR-796; [185,195] 
and the modified live virus (MLV) vaccine strain (ARVAC®, Fort Dodge Laboratories, 
Fort Dodge, IA, [62,309], were used for in vitro study of identifying the EAV target cell 
population in PBMCs.  Each virus was propagated once in EECs to prepare high titered 
working stocks as previously described [343,344].  Briefly, EECs infected with each 
virus were frozen at -80°C when 90-100% cytopathic effect (CPE) was observed.  Cell 
lysates were clarified by centrifugation (500 ×g) at 4°C for 15 min, followed by 
ultracentrifugation (Beckman Coulter, Miami, FL) at 121,600 ×g through a 20% sucrose 
cushion in NET buffer (150 mM NaCl, 5 mM EDTA, and 50 mM Tris-HCl, pH 7.5) at 
4°C for 4 h to pellet the virus.  Purified preparations of each strain of EAV were 
resuspended in phosphate buffered saline (PBS; pH 7.4) and frozen at -80°C.  Virus 
stocks were titrated by standard plaque assay in RK-13 cells and titers were expressed as 
PFU/ml [291].   
 
Construction of chimeric cDNA clones of EAV and recovery of recombinant viruses 
Infectious cDNA clones of the virulent VB strain of EAV and modified live virus 
(MLV) vaccine strain of EAV (pEAVrVBS and pEAVrMLV, respectively) were recently 
constructed in our laboratory [328,329].  The in vitro and in vivo characterization of these 
viruses showed that they are phenotypically indistinguishable to that of their respective 
wild-type parental viruses.  Five chimeric infectious cDNA clones, pEAVrVBS/HK116 S, 
pEAVrVBS/MLV S, pEAVrMLV/VBS S, pEAVrMLV/VBS 234 and pEAVrMLV/VBS 
56 were constructed by using standard molecular biological techniques [236,328,331].  
The recombinant chimeric infectious cDNA clone pEAVrVBS/HK116 S was generated 
by substituting the genes (ORFs 2a to 7) encoding the structural proteins of pEAVrVBS 
by the corresponding genes from the HK116 virus [331].  The recombinant chimeric 
infectious cDNA clone pEAVrVBS/MLV S was constructed by replacing the structural 
protein genes (ORFs 2a to 7) of the infectious cDNA clone pEAVrVBS [328], which was 
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derived from the VB strain of EAV, with the corresponding genes of pEAVrMLV clone 
[329].  A similar approach was used to construct the recombinant infectious cDNA clones 
pEAVrMLV/VBS S where the structural protein genes (ORFs 2a to 7) of the infectious 
cDNA clone pEAVrMLV were substituted with the corresponding genes of the 
pEAVrVBS clone; the pEAVrMLV/VBS 234 clone in which the minor envelope protein 
genes (ORFs 2a to 4) of the rMLV were replaced with the corresponding genes of 
pEAVrVBS; and the rMLV/VBS 56 clone in which the major envelope protein genes 
(ORFs 5 and 6) of the pEAVrMLV were replaced with the corresponding genes of 
pEAVrVBS.   
The recombinant viruses, rVBS, rMLV, rVBS/HK116 S, rVBS/MLV S, 
rMLV/VBS S, rMLV/VBS 234 and rMLV/VBS 56, were generated by in vitro 
transcription of infectious viral RNAs from XhoI-linearized full-length infectious cDNA 
clones and electroporated into EECs following previously described protocols [328].  
Virus particles were harvested from cell culture supernatant at 48 to 72 h after 
electroporation when cytopathic effect (CPE) was evident, clarified of cell debris by 
centrifugation, and stored at -80°C in single-use aliquots (passage 0 [P0]).  Recombinant 
viruses (P0) harvested from transfected EECs were used to prepare high titered working 
stocks by passing one more time in EECs (P1) as described above and purified viruses 
were used for in vitro infection studies.  
 
Comparative amino acid sequence analysis and membrane topology prediction of 
EAV envelope proteins   
The published sequences of rVBS, rMLV, HK116 were downloaded from the 
GenBank database (http://www.ncbi.nlm.nih.gov/ Genbank/index.html; accession 
numbers DQ846751 [328], EU586275 [329], and EU586274 [331], respectively).  ORFs 
2a, 2b, 3, 4, 5 and 6 were translated into amino acid sequences and aligned with the 
Vector NTI Advance™ 11 software (Invitrogen, Carlsbad, CA).  Prediction of membrane 
topology for viral envelope proteins was performed using four most commonly used 
topology prediction methods available on the Internet: PSIPRED 
(http://www.psipred.net/psiform.html) [345,346], TMHMM 
(http://www.cbs.dtu.dk/services/TMHMM/) [347], TMPred 
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(http://www.ch.embnet.org/software/TMPRED_form.html), TOPPRED 
(http://www.bioweb.pasteur.fr/seqanal/interfaces/toppred.html) [348]. All user-adjustable 
parameters were left at their default values. 
 
Preparation of peripheral blood mononuclear cell (PBMC) cultures   
Blood (150-200ml) was collected aseptically from each of 10 horses using 
vacutainer tubes containing 15% EDTA solution (Kendall Healthcare, Mansfield, MA).  
Peripheral blood mononuclear cells (PBMC) were isolated from the buffy coat fraction 
by centrifugation through Ficoll-Paque Plus™ (Amersham Biosciences, Piscataway, NJ) 
at 500 ×g for 30 min at 25°C.  The PBMC layer was collected, washed twice with PBS 
(pH 7.4) by centrifuging at 100 ×g for 10 min to eliminate the platelets.  The cells were 
resuspended in complete RPMI (c-RPMI) 1640 medium (Gibco, Carlsbad, CA) 
supplemented with 10% heat-inactivated fetal bovine serum (Hyclone Laboratories, 
Logan, UT), 2 mM glutamine, 100U/ml penicillin/streptomycin and 55 µM 2-
mercaptoethanol and counted using a Vicell Counter-XR (Beckman Coulter, Miami, FL).  
The adherent and non-adherent cell populations were separated by plating out the PBMCs 
in 100 mm tissue culture dishes (Corning, Corning, NY).  Briefly, the cells were 
incubated at 37°C for 4 h to allow adherent cells to attach, and after incubation, the 
unattached cells were removed, centrifuged and resuspended to be counted and plated out 
as a non-adherent cell population in 100 mm tissue culture dishes containing 5ml of c-
RPMI medium.  The adherent cells were washed twice with PBS to remove remaining 
non-adherent cells and replaced with 5 ml of fresh c-RPMI medium.  Both adherent and 
non-adherent cells were incubated at 37°C until infected with EAV.   
 
Sorting of lymphocytes and monocytes   
Positive selection of five different cell populations (CD3+, CD4+, CD8+, CD21+ 
and CD14+ cells) was performed using aseptically obtained horse blood and a MoFlo Cell 
Sorter (Dako Cytomation, Glostrup, Denmark).  Briefly, 5 × 107 PBMCs were incubated 
with specific MAbs against equine CD3, CD4 or CD8 for T lymphocytes and human 
CD14 that cross-react with equine monocytes.  Equine B lymphocytes were sorted by 
two-way sorting using R-PE conjugated anti-human CD21 antibody that cross react with 
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equine B lymphocytes on cells already incubated with anti-equine CD8 MAb.  All 
antibodies were incubated on ice in sorting buffer (1% FBS in Hanks’ Balanced Salt 
Solution, pH 7.4; Gibco, Carlsbad, CA) for 20 min.  After incubation with primary 
antibody, cells were washed and stained with goat anti-mouse IgG1-R-PE (Southern 
Biotechnology Inc., Birmingham, AL) or goat anti-mouse IgG-FITC (Caltag Laboratories, 
Burlingame, CA) on ice for 20 min.   
 
In vitro infection of lymphocytes and monocytes   
Cultures of lymphocytes and monocytes were infected with either wild-type (VBS 
and MLV) or recombinant viruses (rVBS, rMLV, rVBS/HK116 S, rVBS/MLV S, 
rMLV/VBS S, rMLV/VBS 234 and rMLV/VBS 56) of EAV at an m.o.i. of 2.  As 
negative controls, mock infected lymphocytes and monocytes were cultured under 
identical conditions.   
 
Dual-color immunofluorescence staining and flow cytometry   
For two color immunofluorescence staining of wild-type or recombinant virus 
infected cells, lymphocytes (1×106 cells) were incubated on ice for 30 min with MAbs 
specific for equine CD3+, CD4+ or CD8+ T cells and R-PE conjugated anti-human CD21 
antibody for B cells.  Blood-derived monocytes (1×106 cells) were stained with anti-
human CD14 monoclonal antibody.  After washing, cells were incubated with secondary 
R-PE-conjugated goat anti-mouse IgG1 (Southern Biotech, Birmingham, AL) for 30 min 
on ice.  After washing to remove unbound secondary antibody, cells were fixed with 4% 
paraformaldehyde and then washed once in PBS-saponin buffer (PBS [pH 7.4] 
supplemented with 1% FBS, 0.1% saponin and 0.1% sodium azide).  Intracellular 
staining for EAV antigen was performed using an Alexa Fluor® 488 conjugated anti-EAV 
nsp1 MAb 12A4 or anti-EAV N MAb 3E2 in PBS-saponin buffer and incubated on ice 
for 30 min.  After incubation, washed cells were resuspended in PBS containing 0.5% 
paraformaldehyde for two-color cytometric acquisition using a FACSCalibur (Becton 
Dickinson, San Jose, CA).  Lymphocytes and monocytes were gated and selected based 
on forward and side-scatter parameters of analysis.  Cells were evaluated by a two-color 
plot of anti-EAV antigen (FL-1) vs. cell surface antigen (FL-2), and the percentage of 
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CD3+, CD4+, CD8+, CD21+ or CD14+ and EAV antigen positive cells was determined by 
CellQuest™ quadrant statistics.  Results were expressed as the percentage of 
lymphocytes or monocytes infected with EAV, after subtraction of the non-specific 
staining of mock-infected cells.  
 
Virus growth curve and quantitative EAV real-time TaqMan® RT-PCR assay 
Sorted CD3+, CD4+, CD8+ T lymphocytes, CD21+ B lymphocytes and CD14+ 
monocytes were infected with VB or MLV strains of EAV at an m.o.i. of 2.  Tissue 
culture supernatants were collected at 0, 1, 6, 12, 18, 24, 36, 48, 60 and 72 hpi for one-
step growth curve and quantitative EAV real-time TaqMan® RT-PCR assays.  For one-
step growth curve analysis, virus titers in tissue culture supernatants were determined 
according to the method of Reed and Muench [349], and expressed as 50% tissue culture 
infective dose (TCID50)/50 μl.  To detect EAV nucleic acids, a one-tube real-time 
TaqMan® RT-PCR assay was performed using the TaqMan® One-Step RT-PCR Master 
Mix (Applied Biosystems, Foster City, CA) in an Applied Biosystems 7500 Fast Real-
Time PCR System according to a previously published protocol [299,302].  The copy 
numbers of EAV molecules were determined by absolute quantification with an IVT 
ORF7 RNA standard curve as described previously [299,302].   
 
Statistical analysis   
The student’s t-test was used to establish significant difference among infected 
lymphocyte subpopulations and monocytes between group A and B horses.  Statistical 
analysis was performed using Sigma Plot 11 (Systat Inc., Richmond, CA). 
 
Nucleotide sequence accession numbers   
The nucleotide sequences of the rVBS/HK116 S, rVBS/MLV S, rMLV/VBS S, 
rMLV/VBS 56 and rMLV/VBS 234 were deposited in GenBank under the accession 
numbers GU732202, GU732201, GU732200, GU732199 and GU732198, respectively.  
 
 
 
  70 
2.4.  RESULTS 
Differences in susceptibility of equine peripheral blood mononuclear cells (PBMCs) 
to infection with virulent and attenuated strains of EAV  
To investigate the susceptibility of equine PBMCs to virulent and attenuated 
strains of EAV, PBMCs collected from ten randomly selected horses were infected either 
with the VB or MLV strains of the virus.  Dual fluorescent antibody staining of PBMC 
cultures was performed using a panel of leukocyte differentiation antigen-specific 
monoclonal antibodies (MAbs) specific for pan CD3+ T lymphocytes, CD4+ helper T 
lymphocytes, CD8+ cytotoxic T lymphocytes and CD21+ B lymphocytes, as well as a 
MAb specific for the EAV nsp1.  Dual immunofluorescence labeling with CD3 specific 
MAb and antibody against EAV nsp1 indicated that CD3+ T lymphocytes recovered from 
six of the ten tested horses could be infected with the VB strain of EAV (Figure 2.1 A).  
At 12 hpi, the mean percentage of CD3+ T lymphocytes double-labeled with cell surface 
antibody and MAb to EAV nsp1 antigen was 0.5% (± 0.02).  The mean percentage of 
double-labeled CD3+ T lymphocytes increased to 5.5% (± 1.0) by 24 hpi.  The EAV nsp1 
antigen expression peaked with a mean percentage of 6.6% (± 0.8) of double-labeled 
CD3+ T cells at 36 hpi and decreased to 4% (± 0.4) at 48 hpi.  Interestingly, none of the 
CD3+ T lymphocytes from the remaining four horses were infected with the VB strain of 
EAV (Figure 2.1 B).  Based on the phenotype of CD3+ T lymphocyte subpopulations to 
in vitro infection with VB strain of EAV, the ten horses could be divided into susceptible 
(Group A; 6/10) and resistant (Group B; 4/10) groups.  Contrary to infection with the VB 
strain, T lymphocytes from none of the 10 donor horses were susceptible to infection 
with the MLV vaccine strain of EAV (Figures 2.1 A and B). 
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Figure 2.1.  Differences in susceptibility of CD3+ T lymphocytes to infection with VB 
and MLV strains of EAV.  Dual color immunofluorescence flow cytometric analysis 
was performed at various hours post-infection (hpi).  (A) Values represent the mean 
percentage of infected CD3+ T cells (± S.E.M) with VB (black circles) and MLV (white 
circles) for 6 horses with T lymphocytes susceptible to EAV VB infection (Group A).  
Percentages of infected cells at the indicated times (data points on the curve) were 
determined by using dot plots derived from dual fluorescence flow cytometric analyses of 
cells (representative dot plots of VB infection, insets a through d; MLV infection, insets e 
through h).  (B) Values represent the mean percentage of infected CD3+ T cells (± S.E.M) 
with VB (black circles) and MLV (white circles) for 4 horses with T lymphocytes 
resistant to EAV VB infection (Group B) as determined by using dot plots derived from 
dual fluorescence flow cytometric analyses of cells (representative dot plots of VB 
infection, insets a through d; MLV infection, insets e through h).  
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In an attempt to define the T lymphocyte subpopulation susceptible to VB 
infection, lymphocytes from Group A horses were infected with the VB strain and were 
stained with either CD4 or CD8 specific MAb and antibody to EAV nsp1.  Similar to 
CD3+ T lymphocytes, the mean percentage of double-labeled CD4+ T cells increased to 
4.4% (± 0.8) by 24 hpi.  The EAV nsp1 antigen expression peaked at 36 h after 
inoculation with a mean percentage of 5% (± 0.7) of double-labeled CD4+ T cells which 
decreased subsequently to 2.8% (± 0.3) at 48 hpi (Figure 2.2 A).  The mean percentage of 
double-labeled CD8+ T cells ranged from 0.03 to 1.1% ([± 0.03 to 0.2]; Figure 2.2 B) 
through to the completion of the experiment.  These findings indicated that the majority 
of CD3+ T lymphocytes infected with the VB strain were CD4+ T lymphocytes rather 
than CD8+ T lymphocytes.  Not surprisingly, in a similar experiment neither CD4+ nor 
CD8+ T lymphocytes from the four horses in group B could be infected with the VB 
strain of EAV (data not shown).  EAV nsp1 antigen expression was not detected in the 
CD21+ B lymphocyte cultures from either group A or B horses inoculated with either the 
VB or MLV vaccine strains (Figure 2.2 C) indicating that B lymphocytes are not 
susceptible to EAV infection.  In summary, viral antigen could be detected primarily in 
CD4+ T lymphocyte subpopulations from Group A horses infected with VB strain of 
EAV.  These data showed that only CD4+ T lymphocytes from some horses are 
susceptible to infection with the VB strain but none of them are susceptible to infection 
with MLV strain indicating that attenuation of the VB strain has altered its cellular 
tropism.  
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Figure 2.2.  Susceptibility differences between CD4+ and CD8+ T lymphocytes and 
CD21+ B lymphocytes to infection with VB and MLV strains of EAV.  Dual color 
immunofluorescence flow cytometric analysis was performed at various time p.i.  Values 
represent the mean percentage of (A) infected CD4+ T cells, (B) infected CD8+ T cells 
and (C) infected CD21+ B cells (± S.E.M) with VB (black circles) and MLV (white 
circles) strains of EAV.  Percentages of infected cells at the indicated times (data points 
on the curve) were determined by using dot plots derived from dual fluorescence flow 
cytometric analyses of cells (representative dot plots of VB infection, insets a through d; 
MLV infection, insets e through h).   
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To investigate whether monocytes are equally susceptible to infection with VB 
and MLV strains of EAV, dual immunofluorescence staining was performed using MAbs 
specific for CD14+ monocytes and MAb specific for the EAV nsp1.  Using the adherent 
cells obtained from PBMCs derived from two of each group of horses, the percentage of 
CD14+ monocytes ranged from 60 to 75% depending on the preparation.  Double-labeled 
flow cytometric analysis showed that monocytes from all of the tested horses could be 
infected with VB and MLV strains of EAV (Figure 2.3).   
 
Figure 2.3.  Infection of monocytes with the VB and MLV strains of EAV.  (A and B) 
Dual color immunofluorescence flow cytometric analysis was performed at various time 
p.i.  Values represent the mean percentage of infected monocytes (± S.E.M) with VB 
(black circles) and MLV (white circles) for (A) 2 horses with T lymphocytes susceptible 
to EAV VB infection (Group A) and (B) 2 horses with T lymphocytes resistant to EAV 
VB infection (Group B).  Percentages of infected cells at the indicated times (data points 
on the curve) were determined by using dot plots derived from dual fluorescence flow 
cytometric analyses of cells (representative dot plots of VB infection, insets a through d; 
MLV infection, insets e through h).   
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However, the mean percentage of MLV infected cells was significantly lower and 
remained near the lower limit of detection throughout the experimental time course 
compared to those detected in VB infected monocytes (Figures 2.3 A and B) from both 
group of horses.  In the case of cultures infected with the VB strain, the maximum mean 
percentage of cells expressing EAV nsp1 antigen in monocytes from Group A horses 
(n=2) was approximately 31.8% (± 7.2) at 12 hpi, after which it had declined sharply by 
(1.8 ± 0.2%) 48 hpi (Figure 3A; Group A).  Similar patterns were noted for monocytes 
purified from the Group B horses (n=2; Figure 2.3 B; Group B).  However, the overall 
mean percentage of cells expressing EAV antigen was significantly lower in monocytes 
from the Group B horses (14.3% ± 7.3 at 12 hpi and 11.3% ± 4.7 at 24 hpi) compared to 
monocytes from the susceptible horses (Group A) at 12 and 24 hpi (Figures 2.3 A and B).  
The mean percentage of infected monocytes in MLV inoculated cultures was minimal at 
12 hpi after which it gradually increased.  Although similar patterns of infection were 
shown for cells derived from horses in groups A and B, the mean percentage of infected 
cells in the case of the former was significantly higher than in the case of the latter 
(Figures 2.3 A and B).  Furthermore, these findings confirm that not only T lymphocytes 
but also monocytes differ in their susceptibility to infection with VB and MLV strains of 
EAV.   
Expression of the structural proteins of EAV in PBMCs infected with virulent and 
attenuated strains of EAV   
One of the key findings of this study is the susceptibility of CD3+ T 
(predominantly CD4+ T) lymphocytes of Group A horses to VB infection as determined 
by the expression of the nsp1 protein.  To investigate whether viral structural protein 
genes are also expressed in infected cultures, two-color flow cytometric analysis was 
performed using MAbs specific for cell surface markers and MAb specific for the EAV 
nucleocapsid (N) protein.  When T lymphocytes isolated from horses in Group A were 
infected with the VB strain, both nsp1 and N protein expression were detected in CD3+, 
CD4+ and CD8+ T lymphocytes (Figure 2.4, panels a through c [nsp1] and panels d 
through f [N]).   
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Figure 2.4.  Detection of EAV nucleocapsid (N) protein expression in T lymphocytes 
infected with the VB strain.  The CD3+, CD4+ and CD8+ T lymphocytes from Group A 
horses infected with VB and MLV strains of EAV were examined by dual-color 
immunofluorescence flow cytometric analysis using MAbs against EAV nsp1 (MAb 
12A4) and N (MAb 3E2) proteins and MAbs for cell specific cell surface antigens at 24 
hpi.  (Panels a through c) Lymphocytes infected with VB strain were stained with anti-
EAV nsp1 AF488 MAb and one of the specific antibodies for T lymphocytes including 
MAbs to CD3, CD4, and CD8, respectively.  (Panels d through f) Dot plots derived from 
same cultures stained with anti-EAV N AF488 MAb and specific antibodies for CD3+, 
CD4+ and CD8+ T lymphocytes, respectively.  (Panels g through i) Lymphocytes infected 
with MLV strain were stained with anti-EAV nsp1 MAb and specific antibodies for T 
lymphocytes including MAbs to CD3, CD4, and CD8, respectively.  (Panels j through l) 
Dot plots derived from same cultures stained with anti-EAV N AF488 MAb and specific 
antibodies for CD3+, CD4+ and CD8+ T lymphocytes, respectively.   
 
 
In contrast, CD3+, CD4+ and CD8+ T lymphocytes were completely refractory to 
infection with the MLV strain since neither nsp1 nor N protein expression could be 
  77 
observed in inoculated cultures (Figure 2.4, panels g through i [nsp1] and panels j 
through l [N]).  The data indicated that a virus replication cycle, at least up to expression 
of structural proteins, occurred in VB infected T lymphocytes but not in MLV infected T 
lymphocytes of Group A horses.  However, release of progeny virus particles could not 
be detected in VB inoculated cultures of sorted CD3+, CD4+ and CD8+ T lymphocytes 
from any of tested horses based on virus one step growth curve and quantitative real-time 
RT-PCR (qrRT-PCR) results (data not shown).  Furthermore, we also investigated the 
expression of N protein in monocytes infected with the VB and MLV strains of EAV 
(Figure 2.5.A.).  In contrast to T lymphocytes, expression of both nsp1 and N protein 
were detected in monocytes infected with VB and MLV strains.  Not surprisingly, the 
percentage of monocytes expressing nsp1 and N proteins was significantly greater in VB 
infected cultures (24.8% ± 4.4 and 18.3% ± 1.8, respectively [panels a and b]) compared 
to the corresponding percentage of cultures infected with the MLV strain (5.5% ± 1.9 and 
3.7% ± 1.8, respectively; Figure 2.5 A [panels c and d]).  Additionally, viral titers and 
viral nucleic acid copy numbers from sorted CD14+ monocytes inoculated with VB and 
MLV strains of EAV confirmed the findings from double-staining flow cytometric 
analysis (Figures 2.5.B and 2.5.C, respectively).  In monocyte cultures inoculated with 
the VB strain, viral titers increased gradually by 18 hpi reaching a maximum titer of 
approximately 105 TCID50/50 µl at 36 hpi.  After reaching this peak level, titers gradually 
declined to 104 TCID50/50 µl by the final sample collection time at 72 hpi.  Although, 
productive viral replication also occurred in MLV inoculated monocytes, viral titers were 
lower than those detected in VB inoculated cells (Figure 2.5.B).  Interestingly, while 
MLV titers remained low until 48 hpi, they showed a significant increase by 72 hpi.  The 
trends in the viral growth curves were similar to those observed in nucleic acid copy 
numbers quantified by qrRT-PCR (Figure 2.5.C).  Monocytes infected with the VB strain 
had increased viral nucleic acid copy numbers from 18 hpi reaching a maximum after 48 
hpi in both groups of horses.  In contrast to VB infected monocytes, viral nucleic acid 
copy numbers in monocytes infected with the MLV strain remained low throughout the 
time course of the experiment, though they had started to increase at 72 hpi which was 
consistent with the viral growth curve results (Figure 2.5.C).  These data confirmed that 
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the MLV strain replicates slower and to lower titers in monocytes compared to the VB 
strain of EAV in Group A horses. 
 
Figure 2.5.  Replication of VB and MLV strains of EAV in blood-derived monocytes 
of Group A horses. (A) The CD14+ monocytes infected with VB and MLV strains of 
EAV were examined by dual-color immunofluorescence flow cytometric analysis using 
MAbs against EAV nsp1 (12A4) and N (3E2) proteins and MAbs for cell specific cell 
surface antigens at 24 hpi.  (Panels a, b) Monocytes infected with VB strain were stained 
with anti-EAV nsp1 MAb (panel a) or N MAb (panel b) and a specific antibody to cell 
surface antigen, CD14 MAb.  (Panels c, d) Monocytes infected with MLV strain were 
stained with anti-EAV nsp1 MAb (panel c) or N MAb (panel d) and a specific antibody 
to cell surface antigen, CD14.  (B) Replication of VB (black circles) and MLV (white 
circles) strains in purified monocytes.  Tissue culture fluids were collected at indicated 
times and viral titers were determined as log10 50% tissue culture infective dose 
(TCID50)/50µl.  Values shown are the mean viral titers ± S.E.M.  (C) Quantification of 
viral RNA copy number in cell culture fluid from purified monocytes infected with VB 
(black bars) and MLV (white bars) strains using qrRT-PCR.  Results are expressed as 
mean (± S.E.M) values.  
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Infection of CD3+ T lymphocytes and CD14+ monocytes with EAV recombinant 
chimeric viruses   
A marked disparity in the ability of VB and MLV strains to infect subpopulations 
of susceptible CD3+ T lymphocytes and monocytes (Group A horses) suggested that there 
is a clear difference in cellular tropism between the two strains.  In our preliminary 
studies, the recombinant viruses, rVBS and rMLV, had similar growth kinetics in equine 
endothelial cells (EECs; data not shown) and an equivalent capacity for lymphocyte 
infectivity as confirmed by flow cytometry analysis (Figure 2.6; panels a through d 
[rVBS] and i through l [rMLV]) when compared to their respective wild-type parental 
viruses, VB and MLV.  To identify the viral proteins responsible for the differential 
cellular tropism between VB and MLV, we attempted to assess the impact of amino acid 
changes accumulated during cell culture passage of HK116 strain, which is fully 
attenuated for horses as compared to the VB strain.  Therefore, we used the previously 
described rVBS/HK116 S chimeric virus [331] containing the structural proteins of EAV 
HK116 virus in backbone of rVBS genome to infect PBMCs from Group A horses.  
When susceptible T lymphocytes were inoculated with chimeric rVBS/HK116 S, the 
number of T lymphocytes expressing EAV nsp1 antigen decreased significantly 
compared to rVBS (2.3% to 0.2%; Figure 2.6; panels e through g).  In contrast, the 
percentage of infected monocytes was comparable to that using the rVBS virus indicating 
that the tropism of the HK116 strain had changed for lymphocytes but not for monocytes 
following 116 passages in primary horse kidney cells (Figure 2.6; panel h).  In summary, 
these data showed that amino acid substitutions in the structural protein genes of HK116 
strain changed CD3+ T lymphocyte tropism of the virus without any significant effect on 
its CD14+ monocyte tropism.   
In an attempt to further identify the specific viral proteins responsible for the 
differential tropism among VB, HK116 and MLV strains in equine PBMCs, we generated 
a new panel of four recombinant chimeric viruses using the infectious cDNA clones of 
the VB and MLV strains (rVBS and rMLV, respectively).  The panel consisted of 
reciprocal chimeric viruses containing interchanged structural and nonstructural protein 
genes of the VB and MLV strains (Figure 2.6).  When susceptible lymphocytes and 
monocytes were infected with rVBS/MLV S and rMLV/VBS S viruses, rVBS/MLV S 
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did not infect any CD3+ T lymphocytes and only replicated in CD14+ monocytes at a very 
low level which was identical to that observed in rMLV infection (Figure 2.6; panels m 
through p).  In contrast, the rMLV/VBS S infected and replicated in both CD3+ T 
lymphocytes and CD14+ monocytes similar to rVBS but there was a reduction in viral 
protein expression in lymphocytes compared with that observed in cells infected with 
rVBS virus (Figure 2.6; panels q through t).  These results suggest that the structural 
proteins of the VB strain are responsible for determining its tropism for lymphocytes and 
monocytes.  Furthermore, comparison of dual-color flow cytometric data of PBMCs 
infected with rVBS/HK116 S and rVBS/MLV S showed significant differences in CD14+ 
monocyte infectivity, indicating that amino acid substitutions that occurred during further 
cell culture passage of HK116 may have contributed to the change in monocyte tropism.  
Taken together, the data suggest that viral tropism for CD3+ T lymphocyte and CD14+ 
monocyte was altered by amino acid changes in structural proteins of EAV.   
To further investigate the role of minor and major envelope proteins of EAV in 
cellular tropism, additional recombinant viruses, rMLV/VBS 234 and rMLV/VBS 56, 
were generated with the MLV infectious cDNA clone as the viral backbone and used for 
in vitro infection of susceptible lymphocytes and monocytes.  Recombinant rMLV/VBS 
234 virus contained the genome sequence identical to that of the rMLV virus except for 
ORFs 2a, 2b, 3 and 4 (encoding for E, GP2, GP3 and GP4 minor envelope proteins) that 
were replaced by the corresponding regions of the rVBS virus.  In the case of rMLV/VBS 
56 virus, whose ORFs 5 and 6 (encoding for GP5 and M major envelope proteins) were 
replaced with the corresponding genes of rVBS in the rMLV backbone (Figure 2.6).  In 
contrast to expectations, neither rMLV/VBS 234 nor rMLV/VBS 56 chimeras were able 
to infect T lymphocytes (Figure 2.6; panels u through w [rMLV/VBS 234] and panels y 
through z’ [rMLV/VBS 56]).  However, comparisons in monocytes showed that while the 
percentage of cells infected with rMLV/VBS 56 virus was similar to that of rMLV and 
rVBS/MLV S viruses, infection rates for rMLV/VBS 234 virus were significantly lower 
(Figure 2.6; panels z’’ and x, respectively).  Therefore, the higher relative fluorescence 
intensity values observed in monocytes with rMLV/VBS 56 (Figure 2.6; panel z’’) 
compared to rMLV/VBS 234 (Figure 2.6; panel x) suggest GP5 and M amino acid 
sequences may play a more critical role than those of E, GP2, GP3 and GP4 in facilitating 
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monocyte infections.  Taken together, these data demonstrate the minor envelope 
glycoproteins as well as the two major envelope proteins play a critical role in 
determining monocyte tropism.   
 
Figure 2.6.  Infection of lymphocytes and monocytes with recombinant EAV.  The 
genome of the infectious full-length cDNA clone of rVBS (red boxes) and the genome of 
rMLV clone (blue boxes) are depicted.  The genes encoding structural proteins of EAV 
HK116 virus are shown in green.  The four chimeric viruses containing nonstructural and 
structural protein genes of either rVBS, or rMLV virus are also depicted. L, leader; An, 
poly A.  The CD3+, CD4+ and CD8+ T lymphocytes and CD14+ monocytes infected with 
recombinant viruses rVBS (panels a through d), rVBS/HK116 S (panels e through h), 
rMLV (panels i through l), rVBS/MLV S (panels m through p), rMLV/VBS S (panels q 
through t), rMLV/VBS 234 (panels u through x) and rMLV/VBS 56 (panels y through z’’) 
were examined by dual-color immunofluorescence flow cytometric analysis using MAbs 
against EAV nsp1 (12A4) and MAbs for cell specific cell surface antigens at 24 hpi.  
 
  82 
Comparative amino acid sequence analysis of GP2, GP3, GP4, GP5 and M proteins 
of rVBS, HK116 and rMLV viruses  
The reverse genetic studies using recombinant chimeric viruses clearly indicated 
that collective interactions among all EAV envelope proteins are required for efficient 
infection of susceptible subpopulations of CD3+ T lymphocytes and CD14+ monocytes, 
and these interactions were disabled or altered by the amino acid changes which had 
occurred during extensive serial passage of the VB strain resulting in the HK116 and 
MLV vaccine strains of EAV.  Accordingly, the nucleotide sequences of ORFs 2 to 6 
from VB, HK116 and MLV strains have been translated, aligned and analyzed in the 
context of the predicted topography of each viral structural protein.  The E minor 
envelope protein encoded by ORF2a was conserved (100% identity) among VB, HK116 
and MLV strains and therefore it is almost certainly not responsible for the differences in 
tropism among the three EAV strains (Table 2.1).  When compared to the VB strain, the 
GP2, GP4, GP5 and M envelope proteins of HK116 strain had several amino acid 
substitutions (2, 1, 3 and 3 substitutions respectively; Table 2.1).  With the exception of 
amino acid substitutions in the M protein and one amino acid substitution in the GP2 
protein (223R>P) of HK116 virus, all the amino acid changes were located in the 
ectodomain of these proteins (Table 2.1 and Figure 2.7).  Interestingly, in contrast to GP2, 
GP4, GP5 and M envelope proteins, the amino acids of the GP3 protein of HK116 strain 
were identical to the parental VB strain.  The data indicated that loss of CD3+ T 
lymphocyte tropism of HK116 virus is primarily due to substitutions involving the GP2, 
GP4, GP5 and M envelope proteins rather than the GP3 minor envelope protein.  
However, further cell culture passage of this HK116 strain resulted in numerous other 
non-synonymous amino acid substitutions in ORFs 2b, 3-6 (Table 2.1, Figure 2.7).  All of 
these substitutions appear to be non-conservative and therefore are likely to affect 
secondary and tertiary structure, which may change the interactions between these 
envelope proteins (Figure 2.7).  Analysis of ORF3 demonstrated a U→C substitution at 
position 10,795 in rMLV resulting in the removal of the normal stop codon present in 
rVBS and HK116 and permitting the addition of five amino acids to the carboxyl-
terminus of GP3.   
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Figure 2.7.  Predicted membrane topology of minor (GP2, GP3 and GP4) and major 
(GP5 and M) EAV envelope proteins.  Amino acid substitutions occurred during 
extensive cell culture passage of the VB strain of EAV resulting in the HK116 and MLV 
strain of the virus are indicated.  A predicted model for the disulfide-bonded structure of 
covalently linked minor envelope proteins GP2, GP3 and GP4 proteins is depicted based 
on previous experimental studies [137,139,140,143,144].  The major envelope GP5 and 
M proteins are covalently linked by a disulfide bond (S-S) formed between Cys-8 in the 
M protein and the Cys-34 in the GP5 protein [68].   
 
 
Furthermore, there are three other non-synonymous nucleotide substitutions 
between rMLV and rVBS (as well as the intermediate HK116 strain) in ORF3 of which 
leucine to serine at amino acid position 123 and cysteine to tyrosine at position 160 
appear to be non-conservative (Table 2.1, Figure 2.7).  In common with ORF3, all four 
non-synonymous nucleotide substitutions in ORF4 are predicted to occur in the 
ectodomain of GP4, a trend also observed in ORF5 where six of the eight non-
synonymous substitutions occur within the same predicted domain for GP5 (Table 2.1, 
Figure 2.7).  Therefore, it appears as if most of the variation in amino acid content 
between the structural proteins of rVBS and rMLV occurs in those regions that could 
interact directly with host-cell receptor molecules.  An exception to this is in ORF6 
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where all seven non-synonymous nucleotide substitutions between rMLV and rVBS are 
predicted to occur in the endodomain or transmembrane-spanning domain of the M 
protein.  During extensive cell culture passage, the second putative N-linked 
glycosylation site at amino acid position 81 (81N>D) in GP5 was lost leaving the GP5 of 
MLV with only the conserved putative N-linked glycosylation site at amino acid position 
56.  Taken together, these data clearly demonstrate that the failure of MLV to infect 
CD3+ T lymphocytes was determined by the amino acid changes in the GP2, GP4, GP5 
and M proteins but not the GP3 protein.  In contrast, the reduced monocyte tropism of the 
MLV strain appears to be due to the amino acid changes in the GP3 protein.  However, 
additional amino acid substitutions in GP2, GP4, GP5 and M protein may also have 
contributed to the altered monocyte tropism.  Since the nucleocapsid protein (N) encoded 
by ORF7 is not exposed on the virus surface, it is unlikely that this protein has 
contributed to the change in cellular tropism of EAV.  Therefore, it is more likely that 
tropism of CD3+ T lymphocytes and CD14+ monocytes was altered due to the changes in 
major and minor envelope proteins of EAV.   
 
2.5.  DISCUSSION 
In contrast to attenuated strains of EAV, highly pathogenic strains are highly 
cell-associated with PBMCs and cause high titered viremia [154,213,328].  However, 
until now the interaction between EAV and PBMCs has not been fully characterized and 
the specific cell types infected with EAV were not identified.  Therefore, the primary 
objective of this study was to unequivocally establish which components of the PBMC 
population were susceptible to EAV infection and then identify the viral proteins 
responsible for infection of these cells.  Based on dual-color flow cytometric analysis and 
conventional viral titration assay along with qrRT-PCR on infected cell culture fluids, we 
demonstrated that the predominant host cell type susceptible to virulent VB strain of 
EAV are CD14+ cells of the monocyte/macrophage lineage.  Furthermore, under ex-vivo 
culture conditions these cells were permissive for complete productive replication of the 
VB strain.  Although this is an important finding, it is perhaps not surprising in view of 
the fact EAV antigens have been found in alveolar macrophages in infected horses 
[76,257] and that all other members of the Arteriviridae family are 
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monocyte/macrophage tropic [51].  However, the finding that the VB strain can infect 
CD3+ T lymphocytes (predominantly CD4+ T cells) of some but not all horses is the first 
report of a member of this virus family being associated with T lymphocytes.  
Surprisingly, there was a clear difference in the horse population based on the 
susceptibility of their CD3+ T lymphocytes and CD14+ monocytes with in vitro VB 
infection.  As a result, horses were categorized as Group A in which almost one third of 
monocytes along with CD3+ T lymphocyte (mainly CD4+ T cells) subpopulations were 
susceptible to infection with the virulent EAV strain or as Group B in which monocyte 
susceptibility was only half of that observed in Group A horses and all CD3+ T 
lymphocyte subpopulations were resistant to EAV infection.  Based on this finding, we 
assumed that horse’s genetic background may play a significant role in determining the 
clinical outcome of primary infection with EAV as reported in other species [350,351].  
Efforts are underway in our laboratory to investigate if there is a genetic basis for the 
differences between horses in the susceptibility of their monocytes and CD3+ T lymphocytes 
to VB infection by analyzing possible associations with single nucleotide polymorphisms 
(SNP).  Furthermore, an in vivo study is planned in which Group A and B horses are 
infected with rVBS to establish the relationship between PBMCs susceptibility and the 
severity of clinical illness or EVA, respectively.   
Expression of nsp1 and N proteins in CD3+ T lymphocytes demonstrated the VB 
strain undergoes initial replication steps such as binding/entry, uncoating and translation 
of nonstructural and structural proteins.  However, production of progeny virus was not 
evident in sorted CD3+, CD4+ and CD8+ T lymphocytes from any of the tested horses 
based on the virus one-step growth curve results or qrRT-PCR results despite synthesis of 
the full complement of viral proteins.  This indicates that the number of progeny virions 
generated is either below the limit of detection, a possible reflection of the relatively 
small numbers of T lymphocytes infected (about 5%), or there is a blockage at a later 
stage in viral assembly and/or release.  It remains to be determined if these cells represent 
“dead-end” hosts or if they are fully permissive.  In contrast to the VB strain, expression 
of MLV nsp1 or N could not be detected in CD3+ T lymphocytes from any tested horses 
demonstrating that the amino acid substitutions that occurred during the attenuation process 
of the VB strain prevented entry and replication of MLV strain in these cells.  In addition, 
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the number of CD14+ monocytes expressing viral nsp1 or N proteins following infection 
with the attenuated MLV strain was significantly less than observed with VB virus.   
Data derived from this study suggested that the amino acid substitutions in major 
and minor envelope proteins that occurred during cell culture passage of the VB strain 
contributed to the altered tropism of MLV virus for CD3+ T lymphocytes and CD14+ 
monocytes.  In an attempt to identify the viral proteins associated with infection of T 
lymphocytes and greater numbers of monocytes, we generated a panel of recombinant 
chimeric viruses in which the structural and nonstructural protein genes of the parental 
rVBS were replaced with corresponding genes of the rMLV strain.  In vitro evaluation of 
rMLV/VBS S chimeric virus demonstrated conclusively that cell tropism was determined 
by envelope proteins of the virus.  The role of the viral envelope proteins in CD3+ T 
lymphocyte and macrophage tropism was further defined by using recombinant chimeric 
viruses in which sequences encoding the minor envelope glycoproteins (GP2, GP3 and 
GP4) or major envelope proteins (GP5 and M) of the MLV strain were replaced with the 
corresponding genes of rVBS in an rMLV backbone (designated rMLV/VBS 234 and 
rMLV/VBS 56, respectively).  Recombinant chimeric viruses derived from these 
infectious cDNA clones were unable to infect T lymphocytes and numbers of monocytes 
expressing nsp1 were either lower (rMLV/VBS 234) or equivalent (rMLV/VBS 56) to 
those observed when these cells were infected with parental rMLV.  For the first time 
evidence is presented suggesting that infection of T lymphocytes along with the ability to 
infect relatively large numbers of monocytes is dependent on cooperative interactions 
between five out of the six envelope proteins of EAV (GP2, GP3, GP4, GP5 and M).  
This, in turn, suggests that the infection process of these cell types is complex, possibly 
involving multiple receptor and/or receptor accessory molecules.  Furthermore, the data 
also indicated that during extensive sequential cell culture passage, viral envelope protein 
genes have coevolved resulting in a synergistic effect on cellular tropism.  Interestingly, 
based on findings with the rVBS/HK116 S chimeric virus, the GP3 protein is not 
associated with altered tropism for CD3+ T lymphocytes.  Substitutions in the other two 
minor envelope glycoproteins (GP2 and GP4) and the two major envelope proteins (GP5 
and M), however, play a critical role in changing the tropism for these cells.  The dual-
color flow cytometry data clearly demonstrated that the HK116 strain was significantly 
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different from both VB and MLV strains.  By 116th passages of the VB strain in primary 
HK cells, the virus lost its permissiveness for CD3+ T lymphocytes but its ability to infect 
CD14+ monocytes remained similar to the parental VB strain.  Further cell culture 
passage of HK116 virus in different cell lines (HK15, RK111 and ED24) to obtain the 
MLV strain, resulted in significant reduction in its ability to infect macrophages (27% to 
5%; Fig. 6; panels h and l, respectively).  However, it is important to note that the 
attenuated phenotype of EAV HK116 for horses correlates with the loss of 
permissiveness for T lymphocytes while the ability to infect monocytes remains similar 
to that of the parental VB strain.  This suggests that either directly or indirectly tropism 
for T lymphocytes has a significant role in the pathogenesis of VB infections in vivo.  
Therefore, the susceptibility of CD3+ T lymphocytes to virulent and avirulent field strains 
of EAV and their role in the pathogenesis of EVA warrants further in-depth investigation.  
Interestingly, based on comparative amino acid sequence and predicted 
membrane topology of the envelope proteins, the majority of the amino acid variations 
between VB and MLV viruses, as well as HK116, are located within the predicted 
ectodomain of each envelope protein, except for the M protein, in which the changes are 
in the transmembrane and cytoplasmic domains (Figure 2.7).  It is known that GP5 and M 
exist in the virion as a heterodimer while the minor envelope proteins (GP2, GP3 and 
GP4) occur in particles as heterotrimeric complexes constituting a virion-exposed 
structure that is predicted to mediate binding of the virion to the primary receptor [144].  
Formation of the heterotrimeric minor envelope complex is dependent on intramolecular 
cysteine bonding with GP2 and GP3 being linked via interactions with GP4 [140].  The 
existence of these complexes coupled with the fact that most of the amino acid 
substitutions appear to be non-conservative, suggest that the cell tropism of MLV and VB 
strains is determined by conformational differences in structural envelope proteins that 
are manifested at the tertiary and quaternary levels.  Therefore, the amino acid 
substitutions located within the various ectodomains may have direct and indirect effects 
on interactions with host cells as well as associations between the viral structural proteins.  
Consistent with our findings, a recent published study on porcine reproductive and 
respiratory syndrome virus has shown that inter-glycoprotein interactions are critical for 
mediating interactions with the receptor responsible for virus entry into host cells [352].  
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Specifically, it has been demonstrated strong interaction between GP4 and GP5, as well 
as weak interactions among other minor envelope proteins resulting in the formation of 
multiprotein complex.  Furthermore, in a previous study we have also demonstrated that 
change in cellular tropism and establishment of persistent infection in HeLa cells by VB 
strain of EAV was associated with amino acid substitutions in the envelope proteins 
[236].  Reverse genetic studies further confirmed that substitutions in the minor envelope 
proteins E and GP2 or GP3 and GP4 alone were unable to change cellular tropism and 
establishment of persistent infection in HeLa cells but recombinant viruses with 
combined substitutions in the E, GP2, GP3 and GP4 as well as a single amino acid 
substitution in the GP5 were able to alter cellular tropism of VB strain of EAV and favor 
establishment of persistent infection in HeLa cells.  Nevertheless, the situation is further 
complicated by the fact so little is known about the EAV receptor and whether this is 
restricted to a single molecule or if the virus can use multiple alternatives but potentially 
cell-type specific molecules. 
 In summary, for the first time we demonstrate that extensive cell culture passage 
of the VB strain of EAV to produce the MLV vaccine strain has altered its cellular 
tropism for equine PBMCs.  Evaluation of chimeric viruses demonstrated that cellular 
tropism in PBMCs is determined by the amino acid sequence of viral envelope proteins.  
Specifically the data suggest that the GP2, GP4, GP5 and M envelope proteins play a 
critical role in CD3+ T lymphocyte tropism while three minor envelope proteins (GP2, 
GP3 and GP4) as well as the GP5 and M major envelope proteins determine the CD14+ 
monocyte tropism of EAV.   
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CHAPTER THREE 
 
Genome-Wide Association Study Identifies a Common Haplotype in Horses 
Associated with CD3+ T Cell Susceptibility to Equine Arteritis Virus Infection  
J. Virol. 2011, 85 (24):13174-84 
Reprinted with permission 
 
3.1.  SUMMARY 
Equine viral arteritis (EVA) is a reproductive and respiratory disease of horses 
caused by equine arteritis virus (EAV), the prototype virus of the family Arteriviridae.  
Recently, we have shown that horses could be divided into susceptible and resistant 
groups based on an in vitro assay using dual color flow cytometric analysis of CD3+ T 
cells infected with EAV. We hypothesized that the differences in in vitro susceptibility of 
CD3+ T lymphocytes to EAV infection may have a genetic basis.  To investigate the 
possible hereditary basis for this trait, we conducted a genome-wide association study 
(GWAS) using the Illumina Equine SNP50 chip to compare susceptible and resistant 
phenotypes.  Initial testing with Thoroughbred horses (n= 37) implicated an association 
between a region of equine chromosome 11 (ECA11) and the CD3+ T cell 
susceptibility/resistant trait.  The results were extended and confirmed by retesting 267 
horses (Thoroughbred [n=94], American Saddlebred [n=60], Quarter Horse [n=53] and 
Standardbred [n=60]) for additional SNPs in this region, leading to the identification of a 
common, genetically dominant haplotype associated with the susceptible phenotype in 
the region ECA11: 49572804-49643932. The presence of a common haplotype indicates 
that the trait occurred in a common ancestor for all four breeds suggesting that it may be 
segregating among other modern horse breeds.  Biological pathways analysis revealed 
several cellular genes within this region encoding proteins associated with virus 
attachment and entry, cytoskeletal organization and NFκB pathways that may be 
associated with the trait responsible for the in vitro susceptibility/resistance of CD3+ T 
lymphocytes to EAV infection. The data presented in this study demonstrated a strong 
association of genetic markers with de facto proof that the trait is under genetic control.  
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To our knowledge, this is the first GWAS of an equine infectious disease and the first 
GWAS of EVA.  
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3.2.  INTRODUCTION 
Equine arteritis virus (EAV) is a small enveloped virus with a positive-sense, 
single-stranded RNA genome of 12.7 kb that belongs to the family Arteriviridae (genus 
Arterivirus, order Nidovirales) [7,34].  EAV is the causal agent of equine viral arteritis 
(EVA), a disease of equids.  The vast majority of EAV infections are inapparent or 
subclinical [77,353].  However, some acutely infected horses may develop any 
combination of the following clinical signs: pyrexia, depression, anorexia, dependent 
edema (scrotum, ventral trunk, and limbs), conjunctivitis, lacrimation and swelling 
around the eyes (periorbital or supraorbital edema), respiratory distress, urticaria, and 
leukopenia [77,353].  During natural outbreaks of the disease, the virus can cause 
abortion in pregnant mares with abortion rates varying from 10 to 71%, depending on the 
virus strain [77,353].  Following EAV infection, a variable proportion of stallions (30-
70%) can become persistently infected and continuously shed the virus in their semen 
[77,190].  The mechanism of persistence of EAV in the male reproductive tract is not 
clear.  However, studies have established that persistence of EAV in stallions is 
testosterone-dependent [217,218].  Moreover, the prevalence of EAV infection differs 
markedly among different breeds of horses, strengthening the assumption of genetic 
influence on susceptibility to infection [77].  The seroprevalence of EAV infection of 
horses varies between countries and among horses of different breeds and ages, with 
marked disparity between the prevalence of infection among Standardbred (STB) and 
Thoroughbred (TB) horses [175].  EAV infection is considered endemic in STB horses 
but not in TBs in the U.S, with 77.5% to 84.3% of all STBs but only up to 5.4% of TBs 
being seropositive to the virus [175,354,355,356].  Furthermore, the seroprevalence of 
EAV infection among Warmblood stallions is also very high in a number of European 
countries, as about 55 to 93% of Austrian Warmblood stallions are positive for antibodies 
to EAV [357].  Although many of these differences are likely attributable to circulating 
virus strains and environmental or management conditions, inherent genetic differences 
may also play a significant role in determining clinical outcome and influence severity of 
disease following exposure to EAV.   
In a recent study using dual color flow cytometry, we demonstrated that the EAV 
VBS can infect a small population of CD3+ T lymphocytes in vitro from some but not all 
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horses [330].  The data suggested that the CD3+ T lymphocyte subpopulation of 
individual horses varied in their susceptibility to in vitro EAV VBS infection and they 
could be divided into susceptible and resistant groups [330].  The CD3+ T lymphocyte 
susceptible/resistant phenotypes were not associated with age, prior exposure to EAV or 
presence of antibodies to EAV but appeared to show an association with breed in 
preliminary studies.  Therefore, we hypothesized that susceptibility/resistance of equine 
CD3+ T lymphocytes to EAV reflects genetic differences between horses in their 
response to infection with the virus.  The primary objective of this study was to identify 
chromosomal regions and candidate genes associated with susceptibility/resistance of 
CD3+ T lymphocytes to EAV infection in horses by using a genome-wide association 
study (GWAS).  Genetic factors contribute to host susceptibility and progression of 
disease, but the genes responsible for disease development are largely unknown.  Until 
now, there was no evidence to indicate what role genetic factors play in determining the 
susceptibility to and outcome of EAV infection in horses.  Availability of the equine 
genome sequence and development of genome wide screening technologies offer 
unparalleled opportunities to identify variants associated with increased 
susceptibility/resistance to infectious disease agents such as EAV [358].  In this study, we 
describe the identification of a distinct phenotypic trait that can be used as a marker to 
divide equine populations, regardless of breed, into susceptible and resistant groups based 
on an in vitro assay system.  Using GWAS in combination with biological pathways 
analysis, we have identified for the first time several cellular genes that may be 
associated with the trait responsible for in vitro CD3+ T lymphocyte 
susceptibility/resistance to EAV infection.   
 
3.3.  MATERIALS AND METHODS  
Virus and antibodies 
The virulent Bucyrus strain of EAV (EAV VBS; ATCC VR-796, American Type 
Culture Collection, Manassas, VA) was used for in vitro infection of equine PBMCs as 
previously described [330].  The monoclonal antibody (MAb) to equine CD3 surface 
molecule, UC F6G, was kindly provided by Jeff Stott, University of California, Davis.  
The R-PE conjugated F(ab’)2 fragment of goat anti-mouse IgG1 (Southern Biotech, 
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Birmingham, AL) was used as the secondary antibody.  To detect EAV antigen in 
infected cells, Alexa Fluor 488-labeled MAb against nonstructural protein 1 (nsp1; MAb 
12A4) was used [306,330].    
 
Horses 
A total of 310 horses of different breeds, ASB (n=60), STB (n=60), TB (n=137), 
and QH (n=53) were used in the study.  
 
Phenotypic trait 
The susceptible or resistant phenotype of each animal was defined by dual color 
flow cytometric analysis of in vitro EAV infected CD3+ T lymphocytes as described 
previously [330].  The horses were classified into susceptible or resistant groups based on 
their CD3+ T lymphocyte susceptible/resistant phenotype to in vitro EAV infection.   
 
DNA extraction 
Genomic DNA (gDNA) was obtained from PBMCs of each animal using 
Puregene whole blood extraction kit (Qiagen, Valencia, CA) following the 
manufacturer’s instructions.  DNA quality and concentration was assessed using 
Nanodrop® (Thermo Scientific, Wilmington, DE) at absorbance ratio OD260nm/280nm.   
 
Genotyping and quality control 
Samples were genotyped using EquineSNP50 Genotyping BeadChip (Illumina, 
San Diego, CA) at the core facility for the Mayo Clinic in Rochester, MN.  This array 
contains 59,355 SNPs derived from the EquCab2.0 SNP database of the horse genome 
(http://www.broadinstitute.org/mammals/horse) with an average probe spacing of 43.2 kb 
between adjacent variants.  For the initial GWAS analysis (N=37), DNA samples from 16 
TB horses known to be susceptible and 21 TB horses known to be resistant for the in 
vitro EAV infectivity trait were used for the EquineSNP50 Genotyping BeadChip 
(Illumina Inc, San Diego, CA; Figure 3.1).   
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Figure 3.1.  Schematic representation of the study design.  Horses were phenotyped 
first and grouped into susceptible or resistant phenotype based on their CD3+ T cell 
infectivity to EAV.  To identify the region associated with EAV susceptible/resistant 
phenotype, gDNA from 37 TB horses was isolated and analyzed using Illumina 
EquineSNP50.  Results from the initial study were confirmed by genotyping 267 
additional horses, including TBs tested with Illumina Equine SNP50, with 
MassARRAY® system technologies.  TB, Thoroughbreds; STB, Standardbreds; ASB, 
American Saddlebreds; QH, Quarter horses. 
  
 
Subsequently, additional SNPs from the region (Table 3.1) were selected using 
the Broad Institute Equine SNP database 
(http://www.broadinstitute.org/ftp/distribution/horse_snp_release/v2/) for further testing 
along with some of the original SNPs.  The second SNP assay was conducted at 
Geneseek, Inc (Lincoln, NE) using the Sequenom MassARRAY® system (Sequenom 
Inc., San Diego, CA; http://www.sequenom.com).  Horses tested in this second assay 
included a second population of TB horses (n=57) as well as horses of several different 
breeds (60 ASB horses, 60 STB horses, 53 QH) plus the 37 TB horses tested in the 
original Illumina assay.  
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Table 3.1.  ECA11 SNPs selected for the MassARRAY® system 
SNP Position on ECA11 (bp) 
 SNP Position on ECA11 (bp) 
BIEC2-157847 49389493  BIEC2-166028b 49649380 
BIEC2-157867a 49424839  BIEC2-166029 49660962 
BIEC2-157892 49446386  BIEC2-157989 49663560 
BIEC2-157899b 49459247  BIEC2-166033 49665617 
BIEC2-165951b 49473877  BIEC2-166034 49676359 
BIEC2-165967b 49475165  BIEC2-166036 49682023 
BIEC2-157944 49509504  BIEC2-166040 49684089 
BIEC2-157945 49514091  BIEC2-157998 49684299 
BIEC2-165988 49529433  BIEC2-166042b 49688617 
BIEC2-157947 49529680  BIEC2-158000 49691181 
BIEC2-165991 49533085  BIEC2-166044 49693957 
BIEC2-165992 49537432  BIEC2-166047 49696679 
BIEC2-157953b 49541824  BIEC2-166049 49700501 
BIEC2-165997 49545584  BIEC2-166050 49707607 
BIEC2-165998 49549767  BIEC2-166052b 49711761 
BIEC2-165999 49558533  BIEC2-166056 49716340 
BIEC2-166001 49564266  BIEC2-166060 49724419 
BIEC2-166003 49569444  BIEC2-166065 49729958 
BIEC2-166005 49572804  BIEC2-166066 49747467 
BIEC2-166006 49580531  BIEC2-158024b 49757978 
BIEC2-166009 49584513  BIEC2-166449 50863263 
BIEC2-166011 49589952  BIEC2-158587 51188148 
BIEC2-166013b 49594275  BIEC2-159231 52379156 
BIEC2-166014b 49604594    
BIEC2-166015 49613954    
BIEC2-166016 49621050    
BIEC2-166018 49627471    
BIEC2-166020 49634340    
BIEC2-166021 49637772    
BIEC2-166027 49643932    
 
 
Data analyses 
Data from both assays were analyzed using the Golden Helix SNP & Variation 
Suite 7 (Bozeman, MT).  Of the 59,355 SNPs, 53,747 had call rates above 95%.  The rest 
were excluded from the analyses.  Filtering for minor allele frequencies (removing SNPs 
with minor allele frequencies below 55%) and genotyping (excluding SNPs with 
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genotypes involving less than 90% of the horses) 42,506 SNPs were evaluated.  Data 
from both studies were evaluated using the association (chi-square) in the additive model 
and linkage disequilibrium. 
 
Gene ontology clustering and pathway analysis 
Unsupervised analysis was performed using Ingenuity Pathways Analysis (IPA) 
tool (Ingenuity Systems Inc., Redwood City, CA) to investigate biological and molecular 
networks associated with genes identified within the selected region.  The IPA builds 
networks relevant to queried genes based on their functional annotation and known 
molecular interaction which data are supported by peer-reviewed scientific publications 
and stored in Ingenuity Pathways Knowledge Base (IPKB).  A list of interactions 
between genes identified in the GWAS (‘focus genes’) and all other genes stored in the 
IPKB was obtained with a maximum network size of 35 genes.  Networks of direct or 
indirect interactions among genes are displayed graphically.  In addition, IPA computes a 
score for each network, the –log (p-value), which indicates the likelihood of the ‘focus 
genes’ in a network from IPKB being found together due to random chance.  To 
investigate the molecular and biological functions, genes identified within the region 
were categorized using the PANTHER classification system (www.pantherdb.org).  In 
addition to above mentioned database analyses, functional information was also obtained 
from a literature search. 
 
3.4.  RESULTS 
Phenotype analysis based on in vitro susceptibility of CD3+ T lymphocytes to EAV 
infection 
Horses from four different breeds TB, American Saddlebred (ASB), STB and 
Quarter Horse (QH), a total of 310 horses, were randomly selected from farms in central 
Kentucky for this study.  In an attempt to define the CD3+ T lymphocyte susceptible or 
resistant phenotype, blood was collected from each horse and peripheral blood 
mononuclear cells (PBMCs) were isolated.  PBMCs were infected with EAV VBS and 
subsequently subjected to dual-color flow cytometric analysis to identify horses with the 
CD3+ T lymphocyte-susceptible or -resistant phenotype to EAV infection.  Cells from 
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horses with a CD3+ T lymphocyte susceptible phenotype were stained with antibodies to 
both CD3+ T lymphocyte surface molecule and intracellular EAV antigen (nonstructural 
protein 1 [nsp1]).  In contrast, cells from horses with a CD3+ T lymphocyte resistant 
phenotype were stained with antibody to CD3+ T lymphocyte surface molecule but not to 
intracellular EAV antigen.  Consistent with previously reported results, horses were 
divided into two distinct groups, CD3+ T cell susceptible or resistant.  Of the 310 horses, 
167 horses had the CD3+ T lymphocyte susceptible phenotype and 143 horses had the 
CD3+ T lymphocyte resistant phenotype.  Subsequently, data were analyzed by individual 
horse breed.  In the susceptible phenotype group, there was no significant difference in 
the percentage of the EAV infected CD3+ T lymphocyte subpopulation, regardless of 
breed.  The percentage of the CD3+ T cell subpopulation susceptible to EAV was 4.0% ± 
0.95 in TB, 5.4% ± 0.4 in STB, 7.2% ± 0.6 in ASB and 3.9% ± 0.4 in QH (Figure 3.2.A).   
The results confirm that determination of the EAV susceptible/resistant CD3+ T 
cell phenotype is consistent in horses, regardless of breed.  Interestingly, there was a clear 
difference in prevalence of the susceptibility/resistance phenotype among breeds.  
Ninety-five percent of STBs tested in this study were of the susceptible phenotype (57 
out of 60).  Similarly, 53 out of 60 ASBs had the CD3+ T lymphocyte susceptible 
phenotype (~90%).  The lowest prevalence of the susceptible phenotype was in TB, 32 
out of 137 (23%), and QHs had both phenotypes evenly distributed with approximately 
50% prevalence of each phenotype (Figure 3.2.B).   
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Figure 3.2.  Effect of breeds on prevalence of T cell susceptible/resistant phenotype.  
(A) Representative dot plots from flow cytometry analysis for each breed are shown.  The 
mean percentage of CD3+ T cells with intracellular EAV nsp1 antigen is indicated in the 
right upper quadrant for susceptible phenotype. (B) The percentage of susceptible (black) 
and resistant (white) phenotype for each breed is indicated in a bar graph.  
Seroprevalence of each breed (red) is indicated below the bar representing phenotypic 
prevalence where available.  TB, Thoroughbreds (n=137); STB, Standardbreds (n=60); 
ASB, American saddlebreds (n=60); QH, Quarter horses (n=53).     
 
 
Genome-wide association study (GWAS)  
To investigate the possibility of genetic influence on susceptibility/resistance of 
CD3+ T lymphocyte to in vitro infection to EAV, we applied the GWAS to identify the 
genetic element(s) associated with this phenotypic trait.  In order to simplify the process 
of defining any genetic differences between positive and negative groups, we initially 
focused on TB horses since they have less diversity for genetic markers than most other 
breeds of horses.  A group of 80 TB yearlings, serologically negative for EAV were 
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tested for the phenotype described above.  Only 16 out of 80 TB yearlings had the CD3+ 
T lymphocyte susceptible phenotype.  Thus, 37 horses were selected for the GWAS 
including 16 with the susceptible phenotype and 21 with the resistant phenotype.  DNA 
from these horses (Illumina TBs) was genotyped for single nucleotide polymorphisms 
(SNPs) using the EquineSNP50 BeadChip (Illumina Inc., San Diego, CA).  Using the 
option for association studies, the distribution of SNPs was compared between the 
susceptible horses and the resistant horses.  The results from this study are represented 
graphically in a Manhattan plot (Figure 3.3) showing the P-values when comparing the 
distribution of markers for susceptible and resistant horses for each SNP.  The values 
from a region of ECA11 showed a distinctive peak.   
 
 
Figure 3.3.  Manhattan plot.  The distribution of probability values (-log10 transformed) 
for the 42,506 SNPs investigated using the 37 Thoroughbred horses (16 susceptibles and 
21 resistants) is depicted.  Genomic positions are indicated by chromosome with different 
colors. 
 
 
The 10 highest associations that were found included 7 SNPs in one region on 
ECA11 (Table 3.2).  The single highest association was found for SNP marker BIEC2-
157867 from ECA11 which had a statistical significance of P=7.42 × 10-8 (uncorrected) 
and P=0.003 using the Bonferroni correction for the number of assays.  None of the other 
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markers achieved statistical significance when factoring the correction to the probability 
value.  
 
 
Table 3.2.  Results from the GWAS using the Illumina Equine SNP50 Beadchip 
SNP# Chromosome Position Uncorrected P-Value 
BIEC2_157867 11 49424839 7.42 × 10-8 
BIEC2_409206 18 24674961 2.00 × 10-5 
BIEC2_158932 11 51677777 5.42 × 10-5 
BIEC2_409219 18 24736336 9.69 × 10-5 
BIEC2_159231 11 52379156 2.90 × 10-4 
BIEC2_158587 11 51188148 3.06 × 10-4 
BIEC2_158588 11 51188190 3.06 × 10-4 
BIEC2_157160 11 48595739 3.63 × 10-4 
BIEC2_157720 11 49039853 3.98 × 10-4 
BIEC2_1046042 8 40043641 4.47 × 10-4 
Representation of 10 highest associations found using the Ilumina Equine SNP50 
BeadChip based on 37 Thoroughbreds exhibiting the in vitro infection phenotype (N=16 
susceptible) and the in vitro resistance phenotype (N=21 resistant) 
 
 
Study validation and haplotype analysis 
To confirm and extend the results from this initial study, additional SNPs were 
selected from the EquCab2.0 SNP database (Table 3.2) along with some of the original 
SNPs for the region on ECA11 and tested using the Sequenom MassARRAY® system 
(Sequenom Inc., San Diego, CA).  The Illumina TB horses served as controls, being 
tested in both SNP assays, and had identical results for the 12 SNPs in common in the 
two assays.  Table 3.3 provides the results from comparing the distribution of SNPs 
among susceptible and resistant horses for all horses (combined), TB horses alone, QH 
alone, ASB horses alone and STB horses alone.  The SNP showing the strongest 
association in the Illumina study, BIEC2-157867 had a significant and slightly higher P-
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value of 5.84 × 10-5 for this new set of TB horses.  The most significant value was found 
for BIEC2-166050 with the combined set of horses (P=1.77 × 10-22).  For the group of 
TB horses, the most significant P-value was for BIEC2-166057 (P=4.96 × 10-7).  All 
breeds except STB showed statistically significant associations for the trait with SNPs in 
this region.   
Next, linkage disequilibrium (LD) among the SNPs in this region was 
investigated and compared to the distribution of cases and controls in the different 
populations.  A haplotype defined by 8 SNPs, BIEC2- 166005, 166006, 166009, 166011, 
166015, 166018, 166021 and 166027, spanning 71 kb from ECA11: 49572804-49643932 
had the highest association across all breeds.  The SNP BIEC2-166016 did not contribute 
to definition of the haplotype and was therefore not included in the haplotype definition.  
The haplotype associated with the susceptibility phenotype was defined by the presence 
of nucleotides GGGGAGGT at those 8 SNP sites.  Figure 3.4 shows a schematic 
representation of LD for the haplotype among all groups of horses tested.  The schematic 
representations are similar for all groups except the STB, in which this haplotype is 
almost completely fixed in the breed. 
Figure 3.5 provides the frequencies for this haplotype among susceptible and 
resistant horses as well as the statistical significance for the differences in each group.  In 
each breed, including STB, this haplotype was associated with susceptible horses.  The 
haplotype was also present among the resistant horses but at a much lower frequency.  
Among the 13 TB cases, all but one horse were heterozygous for the haplotype, 
possessing one copy of the haplotype; the remaining susceptible TBs did not possess the 
haplotype (data not shown).  Among the 44 resistant TB horses, 8 horses possessed one 
copy of the haplotype while two horses were homozygotes (data not shown).  Similar 
results were found for the distribution of the haplotype in other breeds. 
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Table 3.3.  P-values of case and control groups for the combined set and for the individual breed of horses 
BIEC2-SNP# Position P-Combined P-TB P- QH P-ASB P-STB 
166050 49707607 1.73×10-22 6.11×10-4 3.00×10-3 6.18×10-11 n/a 
166027 49643932 1.49×10-21 4.96 ×10-7 1.62×10-3 1.24×10-5 0.61 
166011 49589952 1.17×10-19 1.46×10-4 1.07×10-3 1.74×10-6 n/a 
165991 49533085 1.70×10-19 7.64×10-5 6.26×10-4 2.00×10-4 0.72 
166065 49729958 3.44×10-19 7.02×10-5 9.40×10-4 9.48×10-5 n/a 
166015 49613954 4.99×10-19 2.74×10-4 9.40×10-4 4.11×10-5 n/a 
166021 49637772 5.97×10-19 1.87×10-4 9.40×10-4 4.11×10-5 n/a 
166009 49584513 6.30×10-19 1.87×10-4 9.40×10-4 3.24×10-5 n/a 
166047 49696679 3.23×10-18 7.02×10-5 9.40×10-4 9.48×10-5 0.61 
166018 49627471 6.03×10-18 3.72×10-4 1.64×10-3 4.11×10-5 n/a 
157944 49509504 5.75×10-17 5.78×10-4 3.02×10-3 2.00×10-4 0.56 
166001 49564266 3.10×10-13 2.69×10-3 0.01 3.89×10-4 0.44 
157867a 49424839 1.12×10-9 5.84×10-5 0.50 1.66×10-5 0.48 
157847 49389493 3.60×10-9 0.01 0.17 2.97×10-6 0.93 
165999 49558533 5.45×10-9 0.10 0.18 0.10 0.34 
165997 49545584 2.28×10-5 0.26 0.23 0.69 0.80 
166056 49716340 6.52×10-5 3.93×10-3 0.07 0.02 0.46 
a The most highly associated SNP in the initial assay.           
n/a represents no variation observed between resistant and susceptible.             
NOTE: The table shows SNPs in ECA 11 with the lowest 17 P-values of combined set of horses (N=267) and the individual groups of Thoroughbred (TB, N=57), 
Quarter Horse (QH, N=53), American Saddlebred (ASB, N=60) and Standardbred (STB, N=60). 
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Figure 3.4.  Linkage disequilibrium (LD) plots.  The shown region represents the 
strongest association with the EVA susceptibility haplotype from ECA11:49572804-
49643932. The haplotype block is highlighted with black line.  
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Figure 3.5.  Frequency of the GGGGAGGT haplotype found for selected SNPs in 
ECA11: 49572804-49643932.  The frequency represented by each section of the pie 
chart is shown on the pie chart in white.  Data are represented for all horses together (All) 
and for the individual breeds (Thoroughbred, American Saddlebred, Quarterhorse and 
Standardbred).  The statistical significance for the frequency differences of the 
GGGGAGGT haplotype between susceptible and resistant horses is shown to the left of 
each set of pie charts (P”GGGGAGGT”). 
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Gene network analysis 
The EAV-associated haplotype is located in a block with strong LD expanding 
~71 kb.  This LD block includes five genes: SPAG7, ENO3, PFN1, CHRNE and MINK1.  
For the purpose of analyzing possible functional relationship among genes using the 
Ingenuity Pathway Analysis (IPA, Ingenuity Systems) and the PANTHER classification 
system, we have included those genes in high LD and genes located outside of this 
particular LD block (500 kb upstream and downstream of the most significantly 
associated gene, KIF1C).  Unsupervised IPA analysis retrieved three top networks that 
were merged into a single interaction network (Figure 3.6.A).  The network contained 22 
genes showing significant correlation with networks implicated in cell morphology and 
cellular movement.  Similarly, genes categorized by biological functions were mostly 
involved in cellular movement (P=1.2 × 10-5), cell death (P=1.45 × 10-3), cell morphology 
(P=1.45 × 10-3), cellular assembly and organization (P=1.45 × 10-3) and cellular function 
and maintenance (P= 1.45 × 10-3).  We also classified the genes from the region by their 
molecular function and biological process categories using the PANTHER classification 
database.  The enriched molecular function categories included binding, catalytic 
activities and receptors suggesting these genes might mediate viral-cellular interaction 
and facilitate viral entry (Figure 3.6.B).  Furthermore, there was a predominance of genes 
regulating metabolic and cellular processes as well as cell communication and immune 
responses (Figure 3.6.C; Table 3.4).   
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Figure 3.6.  Pathway analysis.  (A) Three top networks retrieved using unsupervised 
IPA analysis were merged into a single interaction network.  Red nodes represent 
molecules encoded by genes found in the region of ECA11; white nodes are genes 
identified by IPA with direct or indirect interactions with genes of ECA11.  The blue 
nodes represent molecules/complexes identified by IPA involved in canonical pathways.  
Classification of candidate molecules based on their (B) molecular functions and (C) 
biological processes.  
 
 
3.5.  DISCUSSION 
The data presented in this study demonstrate a very strong association of genetic 
markers with the susceptible phenotype described for in vitro infection of CD3+ T 
lymphocytes with EAV.  Association of genetic markers with a trait is de facto proof that 
the trait is under genetic control.  To our knowledge, this is the first GWAS of an equine 
infectious disease and the first GWAS of EVA.  We have developed an easy and reliable 
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in vitro assay based on dual color flow cytometry to phenotype an equine population.  
The data presented in this study clearly demonstrated that there was a genetic difference 
within and among the horse populations based on the susceptibility of their CD3+ T 
lymphocytes to in vitro infection with the EAV VBS of EAV.  The in vitro assay 
described is currently the most precise method for determining the phenotype.  However, 
it is expensive, time consuming and cumbersome to run on a routine or large-scale basis.  
The association of the ECA11 haplotype with the phenotype will allow us to use the 
molecular test in large-scale studies to determine the impact of this phenotype on the 
consequences of infection. 
Interestingly, distinct phenotypic prevalence of each breed found in this study was 
similar to EAV seroprevalence that has been reported previously (Figure 3.2.B) [175,356].  
Similar distribution in both seroprevalence and CD3+ T lymphocyte susceptible trait 
strengthened our hypothesis that genetic factors might play a role in determining the 
CD3+ T lymphocyte susceptibility/resistance of horses to EAV infection.  The haplotype 
associated with the trait was distributed among horses in a manner characteristic for that 
harboring a gene with a dominant mode of action.  However, the association of the trait 
with the genetic markers was imperfect since several susceptible horses were found 
without the implicated genetic markers implicated for susceptibility and, conversely, 
some resistant horses were found with susceptibility markers.  However, this is not 
surprising since the 53 SNPs under study represented a very small proportion from the 
three million bp long region and the chances of having selected the SNP defining the 
actual mutation defy expectations.  Although additional work is needed to investigate 
candidate genes and re-sequencing of candidate regions, it is clear that a gene or genes 
within the region of ECA11: 49572804-49643932 plays a major role in determining the 
CD3+ T lymphocyte susceptibility phenotype.  In a parallel study, we have 
experimentally inoculated both groups of horses and assessed the severity of clinical 
disease, virus shedding, and production of proinflammatory/immunomodulatory 
cytokines in PBMCs using real-time quantitative RT-PCR (Go et al., in revision).  The 
data showed that there was a significant difference between the two groups of horses in 
terms of cytokine mRNA expression and increased clinical signs in horses possessing the 
in vitro CD3+ T cell resistant phenotype.  Thus, there was a clear correlation between the 
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in vitro susceptibility or resistance phenotype of CD3+ T lymphocytes and the different 
clinical/cytokine expression responses observed in horses following infection with EAV.  
Therefore, further studies on genes located in ECA11 will enhance our understanding of 
the pathogenesis of EAV infection, variation in susceptibility to establishment of the 
carrier state in stallions, and hopefully, lead to identification of putative EAV cell 
receptor(s). 
 The association of the haplotype with CD3+ T lymphocyte susceptibility in all 
four breeds is remarkable.  This implies that the trait first appeared in a common ancestor 
of these breeds.  Although these horses are products of four different breed registries, 
they are known to have common ancestors within the last 100 years [359].  The use of the 
four breeds together also produced the strongest associations for the trait using both the 
haplotype and individual SNPs (Table 3.3).  This was a product of the wide differences 
among the selected horse breeds for the susceptibility/resistance trait.  The choice of TB 
horses for the initial stage of the study was fortuitous since the susceptibility/resistance 
trait is highly polymorphic among TB horses.  Had the initial study been conducted 
among STBs, the association would not have been uncovered because almost all STBs 
have the susceptibility phenotype.  Indeed, STBs appear almost fixed for the genes and 
the trait.  Therefore, the results of this study suggest that preliminary studies of such traits 
might best be conducted using pools of different horse breeds when that trait is 
manifested across breed lines.   
Furthermore, we have identified for first time a significant number of candidate 
genes that might be associated with CD3+ T lymphocyte susceptibility to EAV infection 
and these genes may also play a major role in pathogenesis and persistent infection in the 
stallion.  We used IPA in an unsupervised manner, allowing identification of gene-gene 
relationships without a priori assumptions.  This analysis linked 22 of 28 genes to other 
nodes in a highly significant network (Figure 3.6.A).  These genes might be functionally 
interrelated and may play a direct or indirect role in susceptibility to EAV infection and 
pathogenesis of EVA.  In relation to virus life cycle and host response to virus infections, 
these genes can be broadly classified into several categories based on molecular functions 
and biological processes (Figure 3.6.B and 3.6.C; Table 3.4).  The proteins encoded by 
these genes are involved in virus attachment and entry pathway (putative cellular 
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receptors for viral entry, molecules associated with cytoskeleton and endocytosis), 
various transcription factors, cell-signaling molecules and molecules associated with 
inflammatory response, innate and adaptive immunity.  Interestingly, some of these 
proteins that are already identified, have been associated with other virus infections 
(Table 3.4), may contribute to the pathogenesis of EVA as well.     
We found several proteins, such as CHRNE, CXCL16, RABEP1, ARRB2, and 
PELP1 that may be involved in EAV attachment and entry into the cell.  Although, the 
cellular receptor for EAV is not yet known, it is plausible that some of these molecules 
(e.g. CHRNE, CXCL16 and PELP1) may act as putative EAV receptor(s) or if not 
directly, serve as essential component(s) in viral attachment and entry process.  The 
CXCL16 belongs to the macrophage scavenger receptor family which is the receptor 
family in which the porcine reproductive and respiratory syndrome virus receptor and 
human hepatitis C virus, CD168 and SR-BI, respectively, belong [360].  Recently, it has 
been demonstrated that EAV is taken up via clathrin-dependent endocytosis and is 
delivered to acidic endosomal compartments during entry into the cell [82].  Thus, 
proteins involved in the endocytic pathway may also play a critical role in the resistance 
or susceptibility of cells to EAV.  ARRB2 encodes β-arrestin-2, a multifunctional adaptor 
protein, which is involved in desensitization and endocytosis of cell surface receptors in 
clathrin-coated pits [361,362,363]. Similarly, RABEP1 is indirectly involved in receptor 
internalization and endosome fusion, besides its function of interacting with proteins 
involved in endoplasmic reticulum (ER) to Golgi transport [364].  Interestingly, both 
ASGPR1 and ASGPR2, well-studied endocytic recycling receptor molecules, are located 
in the same chromosome approximately 800 kb downstream of RABEP1, making them 
attractive receptor candidates in line with clathrin-dependent endocytosis [82].   
In relation to the viral life cycle, intracellular trafficking of molecules, cell 
movements, cell-to-cell communication as well as cell-substrate adhesion pattern and cell 
polarization are critical in virus infection in cells and spreading processes.  All these 
processes can be modified by viral infections, contributing to the pathogenesis and 
disease progression.  It has become apparent that numerous viruses interact with 
cytoskeletal components at various stages of their life cycle disrupting or remodeling 
cytoskeletal networks to their own advantage.  Some viruses can directly or indirectly 
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hijack cytoskeletal cell component organization to their own advantage often altering cell 
behavior and cell fate.  In EAV infected cells, cytopathic effect (CPE) is characterized by 
rounding, vacuolation, increased optical density, refraction and detachment from the 
supporting surface indicating viral modulations of the actin cytoskeleton [60,61,290,291].  
In the region of interest identified in this study, several genes have been classified as 
involved in cellular movement function such as ARRB2, PLD2 and PFN1 and are known 
to be involved in actin cytoskeleton reorganization (Figure 3.7) [365].  In addition, some 
molecules such as KIF1C, PELP1, DERL2 are important in cellular trafficking.  Derlins, 
including DERL1 and DERL2, are ER membrane proteins involved in the degradation of 
proteins that misfold in the ER [366,367,368,369,370].  KIF1C, a member of the kinesin 
superfamily, is involved in retrograde vesicle transport from the Golgi-apparatus to the 
ER [371].  It has been suggested that KIF1C associates with the 14-3-3 protein which 
regulates cytokinesis and cell cycle arrest due to DNA damage.   
Interestingly, our network analysis also included some genes encoding proteins 
associated with apoptosis and modulating innate and adaptive immune responses to virus 
infections (Figure 3.7).   
These proteins such as ARRB2 are known to modulate chemotatic responses and 
granule release as well as contribute to anti-apoptotic signaling [372,373,374,375].  In 
recent years, ARRB2 has been increasingly implicated in modulation of nuclear factor 
kappa B (NFκB) signaling and interacting with I kappa B alpha (IκBα) and 
extracellularly-regulated kinases 1 and 2 (ERK1/2) activation by acting as 
scaffold/adaptor proteins for G protein coupled receptor activation of MAP kinases, 
respectively, suggesting that ARRB2 is a regulator of innate immune activation and 
inflammatory gene expression besides its importance as a key component in actin 
cytoskeleton modulation [373,376,377,378,379,380,381,382,383,384,385].  
Phosphatidylcholine-specific phospholipase D (PLD2) produces phosphatidic acid, an 
intracellular signaling lipid involved in vesicular trafficking and regulation of 
cytoskeletal organization.  PLD2 is also involved in downstream activation of MAPK and 
cell signaling primarily associated with leukocyte chemotaxis [386].  Furthermore, some 
genes in the region were associated with the host inflammatory response and innate 
immunity.  CXCL16, also a member of the CXC chemokine family, is expressed as a 
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soluble form and a transmembrane protein that induces chemotaxis of activated T cells 
into a site of inflammation [387,388,389].  While the transmembrane form may have 
receptor activity, the soluble CXCL16 induces inflammatory responses [388,390].  The 
nucleotide binding and oligomerization, leucine-rich repeat (NLR) family of proteins 
senses microbial infections and activates the inflammasome, a multiprotein complex 
critical for activation of caspase-1 and production of proinflammatory cytokines, 
particularly interleukin (IL)-1β and IL-18 [391].  The NUP88, belongs to nucleoporin 
proteins [NUPs] essential for the exchange of macromolecules across the nuclear 
envelope [392].  NUP88 promotes nuclear retention of NFκB and is required for proper 
nuclear accumulation of key animal and plant immune regulators such as Rel-like 
transcription factors [393,394].  Thus, depletion of NUP88 in mammalian cells prevents 
NFκB-dependent target gene expression.  Although EAV replicates in the cytoplasm, the 
EAV nsp1 and N proteins are targeted to the nucleus.  In particular, the N protein 
possibly shuttles between cytoplasm and nucleus and may be engaged in cytoplasmic 
virus assembly [120].  Thus, NUP88 may play an important role in EAV assembly and 
cells that are deficient or have an abnormal form of this protein may not be able to 
produce infectious virus particles.     
 Finally, the network analysis showed (Figure 3.7) that many molecules encoded 
by genes found in ECA11 are directly or indirectly related in the ERK1/2 and NFkB 
signaling pathways.  During EAV infection there is increased production of 
proinflammatory cytokines such as IL-1, IL-6, IL-8 and tumor necrosis factor alpha 
(TNF-α) [257].  Some viruses ensure their survival by blocking the host anti-infective 
apoptotic mechanisms with a variety of viral proteins that modulate various stages of the 
death-signaling pathways.  The transcription factor NFkB is activated following 
stimulation with, for example, the proinflammatory cytokines, TNF-α and IL-1.  Many 
viral proteins disrupt the innate immune responses mediated by NFkB by nullifying 
signaling cascades that activate NFkB.  In this respect, activation of NFkB was shown to 
facilitate some viral infections by promoting viral replication and preventing virus-
induced apoptosis, thus priming the host cell for infection.  EAV may utilize such 
mechanisms to evade the equine immune response and establish persistent infection in 
the cells of the reproductive tract of the stallion.  However, further studies are needed to 
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investigate potential mechanisms that involve the roles of proteins encoded by genes 
located in this region of ECA11 in the virus life cycle and host response to EAV infection, 
as well as to identify the mechanism of establishment of persistent infection in some but 
not all stallions infected with the virus.  The findings from this study can help to develop 
working hypotheses to decipher novel mechanisms of viral immune evasion, 
establishment of persistent infection and viral pathogenesis.   
 
 
 
Figure 3.7.  Subcellular location of candidate genes and EAV life cycle.  The function 
and subcellular location of candidate molecules were manually curated based on 
PANTHER, IPA and published literature search.  Subsequently, molecules were mapped 
along with stages of EAV life cycle at the position most likely to interact with virus life 
cycle.  Green circles, molecules encoded by genes located in the haplotype block; red 
circles, putative molecules encoded by genes found within 500 kb upstream and 
downstream of the haplotype block; blue circles, molecules in the vicinity interacting 
with genes located in the region retrieved in the network analysis; black circles, viral 
proteins.  
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Table 3.4.  List of genes located in the vicinity of the highest associated haplotype block  
Gene symbol§ NCBI gene ID Description Known molecular function Virus  
Receptor Activity 
CHRNE 100146223 Similar to nicotinic acetylcholine receptor epsilon  
Acetylcholine receptor activity, ligand-
gated ion channel activity HIV-1  
ARRB2 100072892 Similar to beta-arrestin 2  Receptor internalization.  Endocytosis HIV-1  
PELP1 100072897 Similar to proline, glutamic acid and leucine rich protein 1  
Estrogen receptor coactivator.  
Receptor activity  
RABEP1 100072805 RAB GTPase binding effector protein 1  
Endocytic pathway. Fusion of early 
endosome and regulation of recycling 
vesicle formation 
 
CXCL16* 100061442 Similar to SR-PSOX  Scavenger receptor family.  NKT cell and MØ activation 
HIV, SARS-CoV, 
KSHV  
Intracellular Vesicle Trafficking 
DERL2 100061027 Derlin-2 (Der1-like protein 2) Removal of misfolded protein from ER Murine polyomavirus  
KIF1C 100072836 Kinesin family member 1C  
Vesicle transport, redistribution of 
Golgi membrane. Microtubule motor 
activity 
 
Actin and 
Cytoskeleton     
SPAG7 100061215 Similar to Sperm associated antigen 7  Nucleic acid binding, cytoskeleton 
Human parvovirus 
B19 
PFN1 100061295 Similar to profilin 1 Actin polymerization. Cytoskeletal signaling pathway  RSV 
Innate and Adaptive Immunity 
NLRP1  NLR family, pyrin containing domain 1 
Regulation of inflammatory response. 
Induction of apoptosis 
KSHV/HHV8, 
Myxoma virus, 
HIV-1  
DHX33 100072797 DEAH (Asp-Glu-Ala-His) box polypeptide 33 Putative RNA helicase HIV-1 
NUP88 100061117 Nucleoporin 88kDa Innate immunity, nuclear export Hepatitis C and B virus  
PSMB6 100072870 Proteasome subunit beta type-6 precursor  
Peptidase activity.  Involved in antigen 
presentation by MHCI  
ALOX12 100072916 Similar to 12-lipoxygenase Oxidoreductase activity.  MØ activation.  B cell mediated immunity  
CXCL16¶ 100061442 Similar to SR-PSOX  Scavenger receptor family.  NKT cell and MØ activation 
HIV, SARS-CoV, 
KSHV 
Transcription Factors 
RPAIN 100061089 RPA interacting protein Nuclear transporter of RPA  
ZFP3 100061153 Zinc finger protein 3 homolog DNA binding. Transcription factor  
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CAMTA2 100072844 Similar to Calmodulin-binding transcription activator 2  
Transcriptional coactivator. DNA 
binding  
MED11 100072890 Similar to HSPC296  
Component of pol II transcription 
machinery. Transcription initiation 
complex stabilization 
Measles virus  
Enzyme Activity 
ENO3 100061187 Hypothetical protein LOC100061187  Lyase activity   
MINK1 100061370 Misshapen-like kinase SAPK/JNK signal pathway. Kinase activity  
PLD2 100072863 Similar to Phospholipase D2  ERK1/2 signaling pathway. Hydrolase activity HIV-1 
Others 
MIS12 100060987 MIND kinetochore complex component Chromosome segregation  
C17orf87  Transmembrane protein C17orf87  Transmembrane protein  
L11_049426896 100072818 Hypothetical protein  -   
L11_049471914  Hypothetical protein  -   
INCA1 100072840 Similar to HSD45  Regulation of cell proliferation. Spermatogenesis  
GLTPD2 100072874 Glycolipid transfer protein domain-containing protein 2 Lipid transport  
VMO1 100072878 Vitelline membrane outer layer protein 1 homolog precursor   -   
TM4SF5 100072881 Transmembrane 4 L6 family member 5   -   
ZMYND15 100061402 Zinc finger MYND domain-containing protein 15   -   
L11_049822588  Hypothetical protein  -   
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CHAPTER FOUR 
 
Assessment of correlation between in vitro CD3+ T cell susceptibility to EAV 
infection and clinical outcome following experimental infection 
Vet Micro. 2011 (accepted for publication) 
 
 
4.1.  SUMMARY 
In a recent study, we demonstrated that the experimentally derived EAV VBS 
could infect in vitro a small population of CD3+ T lymphocytes from some but not all 
horses.  In a subsequent genome-wide association study, we demonstrated the putative 
candidate genes associated with susceptibility/resistance of CD3+ T lymphocytes to EAV 
are located on horse chromosome 11.  In this present study, horses were divided into two 
groups based on their in vitro CD3+ T cell susceptible or resistant phenotype and 
challenged with recombinant EAV VBS.  Following experimental inoculation, both 
groups of horses were assessed for severity of clinical outcome, virus shedding, as well as 
production of proinflammatory and immunomodulatory cytokines in peripheral blood 
mononuclear cells using real-time quantitative RT-PCR.  The data showed that there was 
a significant difference between the two groups of horses in terms of cytokine mRNA 
expression and an increase in clinical signs in horses possessing the in vitro CD3+ T cell 
resistant phenotype.  A correlation was found between the in vitro susceptibility or 
resistance phenotype of CD3+ T lymphocytes and the different clinical/cytokine 
expression responses observed in horses following infection with EAV.  This is the first 
study to provide direct evidence for a correlation between variation in host genotype and 
phenotypic differences in terms of the extent of viral replication, nature and severity of 
clinical signs and cytokine gene expression caused by infection with virulent EAV.    
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4.2.  INTRODUCTION 
Equine arteritis virus (EAV) is a small enveloped virus with a positive-sense, 
single-stranded RNA genome of 12.7 kb that belongs to the family Arteriviridae (genus 
Arterivirus, order Nidovirales) [7,34].  EAV is the causal agent of equine viral arteritis 
(EVA) in equids.  The vast majority of EAV infections are inapparent or subclinical 
[76,77,395].  However, some acutely infected horses may develop any combination of the 
following clinical signs: pyrexia, depression, anorexia, dependent edema (scrotum, 
ventral trunk, and limbs), conjunctivitis, lacrimation and swelling around the eyes 
(periorbital or supraorbital edema), respiratory distress, urticaria, and lymphopenia 
[77,353].  In natural outbreaks of the disease, the virus can cause abortion in pregnant 
mares with abortion rates varying from 10 to 71%, depending on the virus strain and 
other factors [77,353].  Following EAV infection, a variable proportion of stallions (30-
70%) can become persistently infected and continuously shed the virus in their semen 
[77,190].  The mechanism of persistence of EAV in the male reproductive tract is not 
clear.  However, studies have established that persistence of EAV in the stallion is 
testosterone-dependent [217,218].   
The clinical signs observed in natural cases of EVA vary considerably between 
outbreaks and among individual horses.  While many of these differences are almost 
certainly attributable to the virus strain, it is also likely that environmental or 
management conditions and host factors such as age, immune status and nutritional state 
play a significant role in determining clinical outcome following exposure to EAV.  In 
addition, it is probable that host genetics may be particularly important although there are 
no reports linking individual horse genotypes with either susceptibility to EAV or the 
clinical consequences of infection.  However, there are very significant differences in the 
seroprevalence among different breeds.  For example, EAV infections are considered 
endemic in Standardbred (STB) horses but not in Thoroughbred (TB) horses in the U.S, 
with 77.5% to 84.3% of all STBs but only up to 5.4% of TBs testing seropositive for this 
virus [355].  Furthermore, the seroprevalence of EAV infection among Warmblood 
stallions is also very high in many European countries with 55 to 93% of all Austrian 
Warmblood stallions possessing antibodies against to this virus.  Although management 
practices could explain some of these dramatic differences (Timoney and McCollum, 
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1993), it is also possible that certain horse breeds are inherently more susceptible to 
infection with this virus than others. 
In a recent study, we demonstrated that the EAV VBS could infect in vitro CD3+ 
T lymphocytes from some but not all horses [330].  The data suggested that the CD3+ T 
lymphocyte subpopulation of individual horses varied in their susceptibility to in vitro 
EAV infection.  Furthermore, a comprehensive single nucleotide polymorphism analysis 
using Equine SNP50 Genotype Bead Chip (Ilumina, San Diego, CA) and Sequenom 
MassARRAY® system (Sequenom Inc., San Diego, CA) has shown that genes associated 
with susceptibility/resistance of CD3+ T lymphocytes to EAV infection are located on 
horse chromosome 11 (Go et al., unpublished).  As a result of this clearly defined genetic 
basis, we hypothesized that in vitro susceptibility of CD3+ T lymphocytes to EAV 
infection may correlate with the clinical responsiveness of horses to challenge with 
virulent strains of EAV.  To test this hypothesis, we conducted an in vivo study by 
exposing horses possessing either susceptible or resistant CD3+ T lymphocytes with 
recombinant viruses derived from the virulent Bucyrus strain (rVBS) of EAV.  Following 
infection, the two horse groups were monitored for clinical signs, duration plus 
magnitude of virus shedding, and production of proinflammatory/immunomodulatory 
cytokines at the mRNA level.   
 
4.3.  MATERIALS AND METHODS 
Cells and viruses 
Equine pulmonary artery endothelial cells (EECs) were maintained in Dulbecco’s 
modified essential medium (Mediatech, Herndon, VA) with sodium pyruvate, 10% fetal 
bovine serum (Hyclone Laboratories, Inc., Logan, UT), 100U/μg per ml of 
penicillin/streptomycin and 200mM L-glutamine [142].  The high-passage rabbit kidney 
cells (RK-13; passage 399-409) were grown in Eagle’s minimum essential medium 
(EMEM) with 10% ferritin supplemented bovine calf serum (Hyclone Laboratories, Inc., 
Logan, UT) and 100U/μg per ml of penicillin/streptomycin (Gibco, Carlsbad, CA).  The 
EAV VBS (ATCC VR-796; American Type Culture Collection, Manassas, VA) was used 
for in vitro infection of equine peripheral blood mononuclear cells (PBMCs) as 
previously described [330].  The rVBS which has been shown to have similar growth 
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kinetics in EECs and equivalent capacity for lymphocyte infectivity, was used for 
experimental inoculation of horses [328,330].  Furthermore, the in vivo virulence 
phenotype of this virus has been previously demonstrated by experimental inoculation of 
horses [328].  Both viruses were propagated in EECs and tissue culture supernatants were 
stored at -80°C.  Virus titers were determined by plaque assay in high passage RK-13 
cells as previously described [291].  The experimental challenge studies were carried out 
in accordance with an IACUC approved protocol.     
 
Horses 
In order to divide horses into two groups based on the in vitro susceptibility 
phenotype of their CD3+ T lymphocytes to the EAV VBS, a large number of horses 
(n=62) were first screened by dual-color flow cytometry as previously described [330].  
A total of 8 mares were selected, 4 in Group A (susceptible) and 4 in Group B (resistant), 
for use in this study (Table 4.1).  All horses were confirmed seronegative for EAV 
neutralizing antibodies using a previously described protocol [337].  
 
Table 4.1. Horses used in the study. 
Group Horse ID Breed Gender Age 
A 
E7 TBX F 7 
F23 Mix F 6 
F84 TB G 10 
G13 TBX F 5 
B 
F19 Mix F 6 
F64 TB F 8 
F83 TB F 7 
E9 TBX F 7 
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Antibodies 
The equine CD3+ T lymphocyte monoclonal antibody (MAb) UC F6G was kindly 
provided by Dr. Jeff Stott, University of California, Davis.  The R-PE conjugated F(ab’)2 
fragment of goat anti-mouse IgG1 (Southern Biotech, Birmingham, AL) was used as the 
secondary antibody.  To detect EAV antigen in infected cells, the Alexa Fluor 488-
labeled MAb against EAV nonstructural protein 1 (nsp1; MAb 12A4) was used [306,330]. 
 
Dual-color flow cytometry analysis of PBMCs 
The susceptibility of CD3+ T lymphocytes to EAV was determined using dual-
color flow cytometry analysis.  Dual fluorescent antibody staining of PBMC cultures was 
performed using anti-equine CD3 monoclonal antibody (MAb) specific for CD3+ T 
lymphocytes as well as an MAb specific for the EAV nsp1 as previously described [330].  
Double-stained PBMCs were analyzed using a FACSCalibur (Becton Dickinson, San 
Jose, CA).  The percentage of CD3 surface antigen and intracellular EAV antigen positive 
lymphocytes were determined by CellQuest™ quadrant statistics (Becton Dickinson, San 
Jose, CA).   
 
Experimental infection of horses 
Horses (Groups A [susceptible; n=4] and B [resistant; n=4]) used in the study 
were transferred to an experimental facility one week prior to challenge for 
acclimatization purposes. Pre-inoculation blood samples and PAXGENE® RNA tubes 
(PreAnalyticX, Valencia, CA) were collected to determine base-line values for complete 
and differential blood counts and cytokine gene expression in peripheral blood from both 
groups of horses.  All horses were clinically evaluated prior to experimental inoculation 
with the virus.  Both groups of horses were inoculated intranasally with 3 × 106 pfu of the 
EAV rVBS in 4.0 ml of EMEM using a fenestrated catheter inserted into the area of the 
posterior nares and the nasopharynx.  Horses were monitored for the appearance of 
clinical signs (cough, nasal discharge, anorexia, depression, edema and urticaria) twice 
daily (AM and PM) for the first two weeks after inoculation and then once daily for two 
additional weeks (Figure 4.1).   
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Figure 4.1.  Schematic representation of study design and timeline for experimental 
EAV inoculation and sample collections.  Serum, blood for PBMC isolation and 
PAXGENE® blood samples were collected prior and post challenge on the indicated days.  
However, PAXGENE® tubes for cytokine mRNA analysis were collected up to 21 DPI, 
whereas other samples were collected up to 42 DPI.  Clinical examinations and 
nasopharyngeal swab collections were also performed on the same days up to 42 DPI.  
Representative dot plots of dual-color immunofluorescence flow cytometry data of CD3+ 
T lymphoctyes are shown for each group with percentage (%) of infected cells indicated 
on the right hand corner.  X-axis of the plot represents relative fluorescence intensity 
(RFI) of cells stained with EAV nsp1 AF488-conjugated antibody and Y-axis represents 
the RFI of cells stained with antibody to CD3 surface molecule of equine T lymphocytes. 
 
 
Blood samples were collected at 0, 2, 4, 6, 8, 10, 12, 14, 21, 28, 35 and 42 days 
post-inoculation (DPI) for complete blood cell counts.  Approximately 3 ml of whole 
blood was collected on 0, 2, 4, 6, 8, 10, 12, 14 and 21 DPI into PAXGENE® blood RNA 
tubes (PreAnalyticX, Valencia, CA) for total RNA extraction from peripheral blood [396].  
The tubes were equilibrated at room temperature for several hours and then stored at -
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20°C until processed.  Blood samples were collected every other day during the first two 
weeks after virus challenge for immediate PBMC isolation and subsequent staining of 
CD3+ T cells infected with EAV as described above.  Nasal swabs were collected at 0, 2, 
4, 6, 8, 10, 12, 14, 21, 28, 35 and 42 DPI using sterile rayon swabs (1/2” x 1”) with 
plastic shafts (16”).  After collection, the rayon tip of each swab was cut off into 7 ml of 
virus transport medium (Hank’s balanced salt solution with penicillin, streptomycin, 
gentamicin sulfate and amphotericin B; all from Life Technologies, Carlsbad, CA).  
Subsequently in the laboratory, individual nasal swabs in transport medium were 
transferred to the barrel of a 12 ml disposable syringe and expressed through a 0.45 µm 
syringe filter (Millipore, Billerica, MA).   Nasal swab elutes/filtrates were stored at -80°C 
until tested.  The serum neutralizing antibody response to EAV was determined in each 
horse at 0, 2, 4, 6, 8, 10, 12, 14, 21, 28, 35 and 42 DPI following previously described 
protocols [337]. 
 
Virus isolation 
Virus isolation was attempted from PBMCs and nasal swabs as previously 
described [328,331].  Briefly, confluent monolayers of RK-13 cells in 6-well plates were 
inoculated with serial 10-fold dilutions (100-105 in duplicate) and overlaid with RK-13 
growth medium containing 0.75% carboxymethylcellulose.  The cells were incubated at 
37°C in the presence of 5% CO2 for 5 days and plaques were visualized by staining 
monolayers with a solution of buffered formalin-crystal violet.  A second passage was 
performed 4 days after the initial passage.   
 
Microneutralization assay 
Neutralizing antibody titers of the test sera were determined as described by 
Senne et al. [292,337].  Briefly, serial two-fold dilutions of each sample from 1:4 to 
1:512 were made in EMEM (Invitrogen, Carlsbad, CA) containing 10% guinea pig 
complement (Rockland Immunochemicals, Gilbertsville, PA).  Each serum sample was 
tested in duplicate in 96-well plates.  An equal volume of virus dilution containing an 
estimated 200 TCID50 of the modified live virus vaccine strain of EAV (ARVAC®, Pfizer 
Animal Health, New York, NY) was added to each well, except serum and cell controls.  
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The plates were shaken to ensure mixing of the well contents and then incubated for 1h at 
37°C.  A suspension of high passage (P399 to P409) RK-13 cells was added to each well 
in a volume double that of the serum-virus mixtures and the plates were incubated in 5% 
CO2 for 72 h at 37°C until viral cytopathic effect had fully developed in the virus control 
wells.  Antibody titers were recorded as the reciprocal of the highest serum dilution that 
provided at least 50% protection of the RK-13 cell monolayer.   
 
Proinflammatory and immunomodulatory cytokine mRNA expression in peripheral 
blood mononuclear cells after experimental inoculation of EAV 
The frozen PAXGENE® blood RNA tubes (PreAnalyticX, Valencia, CA) were 
thawed and total RNA was extracted using the PAXGENE blood RNA extraction kit 
(Qiagen, Valencia, CA) with an automated QIAcube (Qiagen, Valencia, CA) following 
the manufacturer’s protocol.  The RNA concentration was assessed at OD260nm and purity 
was verified by the OD260/OD280 ratio using NanoDrop (Thermo Scientific, Wilmington, 
DE).  The reverse transcription reaction was performed with 0.5 μg of total RNA using 
random hexamer primers and MultiScribe™ reverse transcriptase enzyme (High Capacity 
cDNA Reverse Transcription kit with RNase inhibitor [Applied Biosystems, Foster City, 
CA]) according to the manufacturer’s instructions.  The reactions were incubated at 25°C 
for 10 min, 37°C for 120 min and 85°C for 5 min.  The cDNA samples were stored at -
20°C until further analysis by quantitative RT-PCR (qRT-PCR).  Cytokine mRNA 
expression was measured using equine specific intron-spanning primers/probe sets, 
except for IFN-α which does not possess introns (Table 4.2)[397,398,399,400,401,402].  
Briefly, PCR amplification was carried out using a 10μl reaction mixture containing 4.5 
μl of diluted cDNA (1:1 dilution with nuclease-free water), 0.5 μl of 20X assay mix for 
the primers/probe set of interest (Applied Biosystems, Foster City, CA) and 5 μl of 
TaqMan® Gene Expression Master Mix (Applied Biosystems, Foster City, CA).  Samples 
were incubated in duplicate wells at 95°C for 10 min followed by 40 cycles at 95°C for 
15 s and 60°C for 60 s using an Applied Biosystems 7500 Fast Real-Time PCR System.  
For each sample, cDNA corresponding to the β-glucuronidase (β-GUS) gene was 
amplified and used as an endogenous control for relative quantification of sample cDNA.  
All PCR efficiency values were determined using LinReg [403].  Results were expressed 
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as relative quantification (RQ) calculated as 2 -ΔΔCt where ΔΔCt = [(Avg. gene of interest 
Ct – Avg. β-GUS Ct) sample – (Avg. gene of interest Ct – Avg. β-GUS Ct) calibrator] [404].  
The calibrator was calculated from the mean ΔCt of pre-inoculation samples of each horse.  
 
Validation of reference genes as internal controls 
To determine the effect of the experimental treatment on the expression of 
candidate internal control genes, four reference genes, β-glucuronidase (β-GUS), equine 
β-2- microglobulin, β-actin and equine GAPDH were evaluated.  PBMC samples were 
prepared and infected as described previously.  The relative amounts of reference genes 
cDNA were determined by TaqMan real-time quantitative PCR.  The relative amounts of 
the endogenous controls were calculated using the 2-ΔC’T equation where ΔC’T = CT,Time x- 
CT,Time 0 [404]. 
 
Statistical analysis 
Two-way repeated measures-analysis of variance (ANOVA) (Holm-Sidak method) 
was used to determine differences in body temperature, absolute lymphocyte counts, 
virus titers from PBMCs and nasopharyngeal swabs and cytokine gene expression within 
Group A and B horses.  Significant differences were determined at the level of p <0.05.  
Statistical analysis was performed using SigmaPlot® 11 (Systat Inc., Richmond, CA).   
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Table 4.2. PCR primers and TaqMan® MGB probes specific for equine cytokines 
Cytokine Namea Primersb and probec  Sequences (5'-3') 
IL-1β [400,401] 
 
EQIL-1B-JN2F CCGACACCAGTGACATGATGA 
EQIL-1B-JN2R ATCCTCCTCAAAGAACAGGTCAT
  EQIL-1B-JN2M2 ATTGCCGCTGCAGTAAG 
IL-6 [400,401] 
 
EQIL-6-IL6F GGATGCTTCCAATCTGGGTTCAA
 EQIL-6-IL6R TCCGAAAGACCAGTGGTGATTTT 
 EQIL-6-IL6M2 ATCAGGCAGGTCTCCTG 
IL-8  EQIL-8IS-JN1F GCCGTCTTCCTGCTTTCTG 
 EQIL-8IS-JN1R CCGAAGCTCTGCAGTAATTCTTG
  EQIL-8IS-JN1M2 CAACCGCAGCTTCAC 
IL-10 [397] EQIL10IS-JN2F AGGACCAGCTGGACAACATG 
 EQIL10IS-JN2F GGTAAAACTGGATCATCTCCGAC
  EQIL10IS-JN2M2 CCAGGTAACCCTTAAAGTC 
TNF-α [400,401] EQTNFAIS-JN2F TTACCGAATGCCTTCCAGTCAAT 
 EQTNFAIS-JN2R GGGCTACAGGCTTGTCACTT 
 EQTNFAIS-JN2M1 CCAGACACTCAGATCAT 
IFN-αd EqIL-IFN-α F TGACCTGCCTCACACCCATA 
 EqIL-IFN-α R TTGTCCCAGGAGCATCAAGAC 
 EqIL-IFN-α Pro CCTGGGCAACACAAG 
IFN-γ [398] EQIFNGIS-JN3F AGCAGCACCAGCAAGCT 
 EQIFNGIS-JN3R TTTGCGCTGGACCTTCAGA 
 EQIFNGIS-JN3M1 ATTCAGATTCCGGTAAATGA 
β-GUS [398,399,402] GUS-GUSF GCTCATCTGGAACTTTGCTGATT
  GUS-GUSR CTGACGAGTGAAGATCCCCTTTT 
 GUS-GUSM2 CTCTCTGCGGTGACTGG 
a References are indicated in parenthesis 
b F-forward primer; R-reverse primer 
c Pro-Minor groove binding (MGB™) probe labeled with 5’ FAM (6-carboxyfluorescein) reporter dye and 3’ non-fluorescent quencher dye (NFQ)  
d New primers and probe were designed and validated for this study 
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4.4.  RESULTS 
In vitro CD3+ T lymphocyte susceptible phenotype of horses 
As a prerequisite to the in vivo infection experiments, PBMCs from horses under 
consideration for inclusion in the study were subjected to a phenotypic analysis to 
determine their CD3+ T cell susceptibility following in vitro infection with EAV.  Based 
on their T cell phenotype, horses were divided into two distinct groups.  Of 62 horses 
screened, 4 horses with CD3+ T cells that could be infected (susceptible) with EAV VBS 
were selected and included in Group A and 4 other horses with CD3+ T cells resistant to 
EAV VBS infection were included in Group B.  Dot plots of flow cytometric analysis 
showing infectivity of CD3+ T cells are shown in Figure 4.2 for each horse included in 
the study.  The percentage of the CD3+ T cell subpopulation susceptible to EAV ranged 
from 2.3% to 10.3% in Group A horses (Figure 4.2).  After assessing the phenotype, 
horses were challenged intranasally with the EAV rVBS. 
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Figure 4.2.  Phenotypic analysis of horses used to identify two experimental groups 
in the study.  Horses were divided into Groups A and B based on their susceptibility of 
CD3+ T lymphocytes to infection with the EAV VBS using dual-color 
immunofluorescence flow cytometric analysis.  Dot plot of VBS infection is shown for 
each horse used in the study.  X-axis of the plot represents relative fluorescence intensity 
(RFI) of cells stained with EAV nsp1 AF488-conjugated antibody and Y-axis represents 
the RFI of cells stained with antibody to CD3 surface molecule of equine T lymphocytes.  
Horse ID and percentage (%) of infected CD3+ T lymphocytes are identified on the right 
hand corner of each dot plot.   
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Clinical disease and virus shedding 
Following experimental infection with EAV rVBS, febrile responses were 
observed in all horses from both groups starting at 3 DPI and persisting (5-6 days) until 8 
or 9 DPI (Figure 4.3.A).  However, there was a consistent trend toward higher body 
temperatures in Group B horses from 3-8 DPI that culminated in statistically significant 
increases (p <0.05) in febrile responses compared to all Group A horses at 7 and 9 DPI.  
The febrile response was also delayed in Group A horses with the peak temperature on 8 
DPI which occurred on 7 DPI in Group B.  In addition to febrile responses, other clinical 
signs commonly associated with exposure to EAV were more pronounced in Group B 
horses.  Three out of 4 members of this group had continuous serous nasal discharge 
lasting 3 to 4 days, with one horse (E9) having particularly severe respiratory distress 
with labored breathing (respiratory rate >30/min) for 2 days.  All Group B horses had 
congestion coupled with petechial hemorrhages on oral mucous membranes (Figure 4.4.A) 
from 7-8 DPI and 3 out of 4 of these animals developed mild to moderate hind leg edema, 
restricted to the fetlocks (Figure 4.4.B).  In contrast, a serous nasal discharge was 
encountered (present for 4 days at 6-9 DPI) in only one horse in Group A (F84).  
Furthermore, petechial hemorrhages on oral mucous membranes were not seen in any 
Group A horse, and only one member of this group (F84) developed hind leg edema 
which was mild compared with that seen in Group B subjects.  However, one Group A 
mare (F23) developed skin eruptions (hives) on the body (Figure 4.4.C), while another 
mare (E7) in the same group had mild mammary gland edema (Figure 4.4.D) that lasted 
for more than 10 days.  Horses in both groups developed severe lymphopenia between 4-
8 DPI (Figure 4.3.B) and although this appeared to be more pronounced in Group B 
horses between 4-8 DPI, this trend was not confirmed by subsequent statistical analysis. 
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Figure 4.3.  The body temperatures, peripheral blood lymphocyte counts, and virus 
titers in nasal secretions and blood.  Rectal temperature (A), peripheral blood 
lymphocyte counts (B), virus isolation from peripheral blood mononuclear cells (C) and 
nasal secretions (D) of both groups of horses inoculated with EAV rVBS.  The mean and 
standard deviation are shown in all panels.  Days when horses developed maximum 
clinical outcomes are boxed in yellow. 
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Figure 4.4.  Representative examples of clinical signs following experimental 
inoculation of EAV rVBS.  (A) Petechial hemorrhages, (B) limb edema, (C) hives and 
(D) mammary edema. 
 
 
Horses from both groups had detectable viremia levels from 4-10 DPI with peak 
titers occurring at 8 DPI (Figure 4.3.C).  As might be predicted from the clear differences 
in clinical signs, viral titers in PBMCs were statistically significantly higher in Group B 
compared to Group A horses at 6 and 8 DPI (p <0.05).  Although these results appeared 
to be contradicted by amounts of virus detected in nasal secretions (Figure 4.3.D), the 
differences between the groups were due entirely to a single horse (F84) in Group A that 
had a 55-fold higher virus titer in nasal swab material on day 6 post-inoculation 
compared to the other members of its cohort.  This subject was the only Group A 
recipient to present with a prolonged nasal discharge and interestingly, compared with the 
other group members, had the lowest percentage of EAV susceptible CD3+ T 
lymphocytes (2.3%; Figure 4.2).  As a result of this one “super-shedder”, the viral titers 
present in nasal swab material were not statistically different between the two groups.   
Attempts to detect EAV infected CD3+ T cells in peripheral blood analogous to those 
observed following in vitro infection of PBMCs were conducted using dual-color flow 
cytometry with antibodies to CD3 surface molecule and EAV nsp1 protein (intracellular 
staining).  Unfortunately, CD3+ T lymphocytes expressing intracellular EAV nsp1 
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antigen were not detected in any of the horses (either group) during the first 2 weeks of 
acute infection. 
Humoral responses following inoculation with the EAV rVBS were identical between the 
horses of both groups with serum neutralizing antibody titers being detectable at 8 DPI 
and increasing to ≥1:512 by 10 DPI (Figure 4.5).  The appearance of neutralizing 
antibodies in peripheral blood was directly correlated with significant decreases in 
viremia and virus shedding in nasal secretions coupled with a return to normal clinical 
values.  
 
 
Figure 4.5.  Serum neutralizing antibody responses in both groups of horses 
inoculated with EAV rVBS.  The mean and standard deviation of reciprocal antibody 
titers are shown.  
 
 
Proinflammatory and immunomodulatory cytokine gene expression in peripheral 
blood 
There were significant differences between Group A and B horses in the level 
and/or kinetics of cytokine mRNA expression as determined by qRT-PCR analysis 
(Figure 4.6).  Although increased amounts of IL-1β mRNA were observed in all 
experimental subjects following infection with EAV rVBS, the kinetics were 
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significantly different between the two groups.  In Group A horses, IL-1β mRNA reached 
maximal levels just 2 days after infection, whereas peak amounts were not observed in 
Group B horses until 6 DPI (Figure 4.6.A).  A very similar kinetic distribution was 
observed for IL-6 with maximum mRNA levels seen at 2 DPI for Group A horses 
compared with 4 DPI for Group B (Figure 4.6.B) recipients.  Although the kinetics of IL-
8 and IFN-γ mRNA expression were broadly similar between groups, with a correlation 
between maximal levels and peak viral burdens, significantly higher amounts (p <0.05) of 
mRNAs encoding these cytokines were produced in Group B horses (Figures 4.6 C, F).  
Of the panel of cytokines investigated, only TNF-α mRNA levels appeared to be similar 
between Group A and B horses both in terms of the time and the duration of increased 
expression levels (Figure 4.6.D).  Although increases in overall TNF-α mRNA amounts 
appeared to be higher in Group B horses consistent with their more severe clinical signs, 
this difference was not confirmed statistically. Somewhat surprisingly, EAV infection did 
not stimulate significant increases in IFN-α expression in any of the Group A recipients.  
In contrast, there was substantial induction of IFN-α mRNA synthesis in Group B horses 
(Figure 4.6.E).  Just as with IFN-α mRNA, EAV infection did not stimulate IL-10 gene 
expression in any of the Group A horses, whereas expression of this gene was up-
regulated in the Group B experimental subjects.  In all Group B horses, there were 
significant (p <0.05) increases in IL-10 mRNA levels at 4 and 8 DPI compared with pre-
infection amounts and the equivalent Group A post-infection time-points (Figure 4.6.G). 
In summary, with the exception of TNF-α, there were significant differences between the 
two groups of horses in expression of both proinflammatory (IL-1β, IL-6 and IL-8) and 
immunomodulatory (IFN-α, IFN-γ, and IL-10) cytokines indicating that they may 
influence the clinical outcome along with innate and cellular immune response to EAV.  
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Figure 4.6.  Relative quantification (RQ) of proinflammatory and 
immunomodulatory cytokine mRNA expression in Group A and Group B horses.  
Mean (±SE) mRNA expression of proinflammatory cytokines (A) IL-1β, (B) IL-6, (C) 
IL-8, (D) TNF-α and mean mRNA expression of immunomodulatory cytokines (E) IFN-
α, (F) IFN-γ and (G) IL-10. Statistically significant difference (p  <0.05) between Group 
A and B horses is indicated with an asterisk (*).  
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4.5.  DISCUSSION 
Previous work in our laboratory using an in vitro dual-color flow cytometry assay 
demonstrated that horses could be grouped into two populations based on the 
susceptibility of CD3+ T lymphocyte subpopulations to infection with EAV [330].  
Although progeny virions were not detected [330] suggesting infection of CD3+ T 
lymphocytes is not fully permissive, it was hypothesized that the presence of virus 
specific structural and/or non-structural proteins could modify functional characteristics 
of these cells.  Therefore, the objective of this study was to determine if the differences in 
the susceptibility or resistance of CD3+ T cells in vitro correlate with clinical outcome to 
exposure in vivo.  These studies were conducted using viruses derived from a virulent 
infectious EAV cDNA clone to minimize, as far as possible, the effects of variation 
occurring within the viral population or quasispecies [328].  To our knowledge, there 
have been no published reports demonstrating an association between clinical outcome 
following exposure to EAV and specific host factors.  The results described here clearly 
demonstrate that while other environmental and/or host factors are likely to be important 
as exemplified by the atypical prolonged nasal discharge coupled with high-titer 
respiratory tract virus shedding seen in the Group A horse (F84), there is a correlation 
between clinical response to EAV infection in vivo and the susceptibility of CD3+ T 
lymphocytes in vitro.  Horses with the CD3+ T lymphocyte resistant phenotype (Group B) 
had higher febrile responses, possessed higher titers of virus in blood, were the only 
experimental subjects to have petechial hemorrhages on oral mucous membranes and 
were more likely to suffer hind leg edema or develop serous nasal discharges than horses 
with the CD3+ T lymphocyte (Group A) susceptible phenotype.  However, the overall 
duration of clinical signs and development of humoral immune responses associated with 
viral clearance were indistinguishable between horses in these two groups.   
In addition to clinical signs, there were significant differences between Group A and 
Group B horses in proinflammatory cytokine gene expression.  At present, the regulatory 
mechanisms controlling these very different cytokine mRNA expression profiles in these 
two groups of horses are unknown.  However, production of TNF-α, IL-1β and IL-8 by 
macrophages has been shown to contribute to the pathogenesis of EVA [257] by 
enhancing macrophage activation and exerting profound effects on endothelial cells 
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leading to increased vascular permeability with subsequent tissue edema producing 
clinical signs that are characteristic of severe EVA.  Furthermore, IL-6 may contribute to 
the overall severity of disease by stimulating prostaglandin E2 (PGE2) synthesis leading 
to increases in febrile responsiveness.  Therefore, by comparison with horses in Group A, 
subjects in Group B have higher levels of mRNA encoding IL-1β, IL-6, IL-8 and 
possibly TNF-α, all inflammatory cytokines with the potential to augment the 
pathogenicity of EAV at times when viral burdens attain their highest levels.  At present, 
it is not known if the early (2 DPI) short pulse of increased IL-1β and IL-6 expression 
seen in Group A horses that is predicted to stimulate for example, the synthesis of acute-
phase proteins, has any limiting effects on EAV replication.  
  Significant differences between Group A and Group B horses following infection 
with the EAV rVBS were also seen in IFN-α mRNA levels and in expression of the 
immunomodulatory cytokines IFN-γ and IL-10.  The failure to mount a strong IFN-α 
induction could affect both innate and adaptive immune responses in Group A horses.  
Specifically, reduced IFN-α production could lead to slow dendritic cell maturation, 
antigen-specific CD8+ T cell maturation, as well as slow IFN-γ and other cytokine 
production.  Furthermore, EAV infection did not stimulate IL-10 expression compared to 
pre-infection levels in any Group A horse.  In contrast, significant increases in IL-10 
mRNA amounts, compared with both pre-infection levels and equivalent time-points for 
Group A animals, were observed in all group B horses at 4 and 8 DPI (Figure 4.6.G).  IL-
10 was originally considered as a cytokine that modulates the balance of Th1/Th2 
response, in favor of the Th2-type response [405].  It inhibits macrophage activation and 
antigen presentation, thereby inhibiting T cell function.  The IL-10 secreted by regulatory 
T (Treg) cells reduces T-cell-mediated immune inflammation by inhibiting cytokine 
production (IL-1, IL-6, IL-12, TNF-α and the chemokine IL-8) in macrophages and Th1 
cells (IFN-γ) [406].  As a result, IL-10 can limit and eventually terminate inflammatory 
responses caused by infectious agents [333].  Therefore, it is likely that IL-10 expression 
is up-regulated in Group B but not in Group A subjects because of the higher levels 
and/or different kinetics of inflammatory cytokine expression observed in horses with 
CD3+ T lymphocytes that are resistant to infection with EAV.  Although increased EAV-
induced IFN-γ expression was present in PBMCs from some Group A horses, 
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significantly higher levels of mRNA encoding this cytokine were observed at 8 DPI in 
Group B horses.  Together, these results demonstrate that EAV induces very different 
cytokine expression profiles in Group A and Group B horses.  At present, the 
mechanism(s) underlying these differences is not known, although the possibility exists 
that it may be a direct effect caused by EAV infecting and then modifying the functional 
and/or regulatory properties of specific T-lymphocyte subsets within the CD3+ T 
lymphocyte population.  The fact that nsp1 expressing CD3+ T lymphocytes were not 
found in peripheral blood samples from EAV infected Group A horses is perhaps not 
surprising considering the blood volume of a typical horse is approximately 45 L.  In 
addition, it is very likely that most infected T cells will be present within the tissue sites 
supporting active viral replication rather than in general circulation. 
Unfortunately, the small subpopulation(s) of CD3+ T lymphocytes that are 
susceptible to infection with EAV in PBMCs of Group A horses is unknown at present.  
During in vitro infection experiments with PBMCs harvested from more than 400 horses, 
the percentage of infected CD3+ T lymphocytes ranged from 2.3 to 20%, depending on 
the individual animal (data not shown).  Previously, we have reported that the majority of 
CD3+ T lymphocytes infected with EAV are CD4+ rather than CD8+ T cells [330].  
Regulatory T cells are a subset of CD4+ T cells with natural immune-suppressive activity 
[407].  In this respect, we hypothesize that the small subpopulation of CD3+ T 
lymphocytes infected with EAV could be Treg lymphocytes.  Unfortunately, there are no 
commercial or published antibodies specific for equine Treg cells, such as the antibodies 
available to the Foxp3 and CD25 Treg markers of other species.  However, it may be 
possible to purify dual labeled nsp1/CD3+ expressing T cells by flow cytometry and 
characterize them by PCR analysis using primers for transcription factors that are specific 
for the different T helper cell types (Horohov, personal communication).   
Although infection coupled with disruption to the functional properties of specific 
T-cell subsets might account for all of the observed differences between Group A and B 
horses following infection with EAV, this could also be just one manifestation of a more 
general mechanism affecting a range of cell types.  In this alternative broad-spectrum 
model, variation in genotype between Group A and B horses is predicted to induce direct 
effects in numerous cell-types that fundamentally alter the way in which horses respond 
  136 
following exposure to EAV in terms of permissiveness for viral replication, clinical 
responses and cytokine production.  Unfortunately, we cannot distinguish between these 
two alternatives at the present time.  The genome-wide analysis reported above has 
shown the susceptibility or resistance of CD3+ T lymphocytes to infection with EAV is 
associated with a genetically dominant haplotype on horse chromosome 11 in the region 
ECA11: 49572804-49643932 (Go et al. unpublished data).  There are a number of 
candidate genes within this region that could influence EAV replication or host responses 
to this virus and that are actively associated with immune (innate and adaptive) and 
inflammatory responses.  As an example, in addition to a role in the chemotatic response, 
ARRB2, encoded by β-arrestin-2, is believed to control NFκB signaling by interacting 
with IκBα.  Furthermore, this protein may also modulate MAP kinase activity.  Another 
example is the gene encoding the nucleoporin protein (NUP88) that promotes retention of 
NFκB in the nucleus and is required for the transport of key immune regulators such as 
the Rel-like transcription factors.  Although considerable additional effort is required to 
fully characterize the structural gene or regulatory sequences involved, there is a very 
clear genetic correlation between both the susceptibility or resistance of CD3+ T 
lymphocytes in vitro and the different clinical/cytokine expression responses observed in 
Group A compared to Group B horses following infection with EAV.  It is hoped 
identifying the role of host factors encoded by genes within ECA11: 49572804-49643932 
will advance our understanding of the molecular interactions between EAV and its host.  
In summary, our findings demonstrate that clinical signs and viremia burdens are 
more severe in horses with CD3+ T lymphocytes that are resistant (Group B) compared 
with those that are susceptible (Group A) to EAV infection in an in vitro experimental 
system.  Furthermore, these separate groups within the horse population have 
significantly different cytokine expression profiles following exposure to EAV.  At this 
stage, it is not clear whether higher viremia levels cause these differences or if they are 
the result of genetically programmed intrinsic responses that for example, in Group B 
horses may actually promote viral replication and facilitate more severe clinical disease.  
Although genetic variability is frequently predicted to account for some of the disparities 
in virus-induced clinical signs observed between individuals, this is the first study to 
provide direct evidence for a correlation between variation in the genotype of horses and 
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phenotypic differences in terms of the extent of viral replication, severity of disease and 
cytokine gene expression caused by exposure to EAV.  Although the nucleotide 
sequences located in ECA11: 49572804-49643932 involved in this phenomenon have yet 
to be determined, this study provides inroads for explaining at least some of the variation 
in clinical signs seen among horses after infection with a virulent strain of EAV.  It is 
anticipated that future genetic characterization experiments will increase our 
understanding of the pathogenesis of EAV, plus contribute towards identification of 
molecules involved in controlling innate and/or adaptive immune responses.  
Furthermore, such studies may enable the mechanisms associated with the ability of EAV 
to persist within certain stallion populations to be elucidated leading to effective 
treatments or the option to preventive measures to prevent establishment of the carrier 
state in particular those at higher risk.   
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CHAPTER FIVE 
 
In vitro susceptibility of CD3+ T lymphocytes to EAV infection reflects genetic 
predisposition of stallions at risk of becoming carriers  
 
 
5.1.  SUMMARY 
Following equine arteritis virus (EAV) infection, a variable proportion of stallions 
(30-70%) can become persistently infected and continuously shed the virus in their semen.  
Carrier stallions are the natural reservoir of EAV and ensure the virus is maintained in 
equine populations between breeding seasons by continuously shedding the virus in their 
semen.  Recent studies in our laboratory have shown that an in vitro assay based on dual 
color flow cytometry analysis of CD3+ T cells could be used to divide the horses into 
susceptible and resistant groups.  In this study, we have extended these previous studies 
and established a possible correlation between susceptibility of CD3+ T lymphocytes to 
EAV infection and establishment of persistent infection in stallions.   The data showed 
that carrier stallions that have the susceptible CD3+ T lymphocyte phenotype to EAV 
infection may represent those at higher risk of becoming persistently infected compared 
to stallions that do not possess this phenotype.   
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5.2. RESULTS AND DISCUSSION 
Equine arteritis virus (EAV) is a small enveloped virus with a positive-sense, 
single-stranded RNA genome that belongs to the family Arteriviridae (genus Arterivirus, 
order Nidovirales) [7,34].  EAV is the causal agent of equine viral arteritis (EVA) which 
is a respiratory and reproductive disease of horses and other equid species [76,77].  The 
vast majority of EAV infections are inapparent or subclinical [76,77,395] in nature, but 
occasional outbreaks occur which are characterized by influenza-like signs in adult 
horses, abortion and pneumonia in young foals [77,353]. Following EAV infection, a 
variable proportion of stallions (30-70%) can become persistently infected and 
continuously shed the virus in their semen [77,190].  Carrier stallions are the natural 
reservoir of EAV; they ensure the virus is maintained in equine populations between 
breeding seasons [77,189]. The continued growth in international trade of horses and 
semen has served as a significant means of dissemination of EAV strains around the 
world [77,78,188,189,356,408]. Therefore, identification of carrier stallions is of critical 
epidemiological importance in the prevention and control of EAV infection 
[76,77,199,354,408]. The mechanism of persistence of EAV in the male reproductive 
tract is not clear.  Studies have established that persistence of EAV in the stallion is 
testosterone-dependent [217,218].  Although multiple factors may contribute to 
development of the carrier state, host genetic variation is assumed to explain the 
individual differences in occurrence of the carrier state as well as virus clearance because 
such variations exist even after exposure to the same virus.  Moreover, the prevalence of 
EAV infection varies markedly among different breeds of horses strengthening the 
assumption of genetic influence [77].  Recently, we demonstrated differences in in vitro 
susceptibility of CD3+ T lymphocytes to EAV infection that have a strong association of 
genetic markers with de facto proof that the trait is under genetic control by conducting a 
genome-wide association study (GWAS; Go et al., in press [chapter 3]).  The objective of 
current study is to establish a correlation between susceptibility of CD3+ T lymphocytes 
to EAV infection and establishment of persistent infection in stallions. We were fortunate 
to find stallions that became EAV carriers after natural exposure and stallions that did not 
became carriers after exposure to EAV (seroconverted by natural exposure and not by 
vaccination against EVA).  To ensure carrier status, isolation of EAV from equine semen 
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samples was attempted in high passage (P399-409) rabbit kidney-13 (RK-13) cell lines 
according to the OIE described protocol [292].  Subsequently, PBMCs were collected 
from carrier (n=7) and non-carrier (n=7) stallions.  The susceptible or resistant phenotype 
of each animal was defined by dual color flow cytometric analysis of in vitro EAV 
infected CD3+ T lymphocytes as described previously [330].  Briefly, 1 × 106 PBMCs 
isolated from peripheral blood by centrifugation through Ficoll-Paque Plus (Amersham 
Biosciences, Piscataway, NJ) were infected with the virulent Bucyrus strain (ATCC VR-
796) of EAV at an m.o.i of 2.  Subsequently, infected PBMCs were incubated with 
monoclonal antibody (MAb) specific for equine CD3+ T cells and with secondary R-PE-
conjugated goat anti-mouse IgG1 (Southern Biotech, Birmingham, AL).  Intracellular 
staining for EAV antigen was performed using Alexa Fluor 488-conjugated anti-EAV 
nps1 (12A4) MAb.  Two-color cytometric acquisition was done using a FACScalibur and 
data was analyzed by CellQuest software (Becton Dickinson, San Jose, CA).  Results 
were expressed as the percentage of CD3+ T lymphocytes infected with EAV after 
subtraction of cells stained with mouse IgG1 (MOPC; Sigma, St. Louis, MO) isotype 
control antibody.  Interestingly, CD3+ T lymphocytes from all EAV carrier stallions were 
susceptible to in vitro EAV infection (Figure 5.1.A).  The percentage of CD3+ T 
lymphocytes susceptible to EAV infection ranged from 4% to 17% among carrier 
stallions.  In contrast, none of the EAV non-carrier stallions had the CD3+ T lymphocyte 
susceptible phenotype (Figure 5.1.B).  The data suggested that carrier stallions that have 
the susceptible CD3+ T lymphocyte phenotype to EAV infection represent those at higher 
risk of becoming persistently infected compared to stallions that do not possess this 
phenotype.   
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Figure 5.1.  Dual-color immunofluorescence flow cytometry analysis of carrier and 
seropositive non-carrier stallions.  (A) Carrier status was confirmed by isolating EAV 
from semen.  (B)Non-carrier stallions are seropositive horses with antibodies specific to 
EAV after natural exposure to EAV and not due to vaccination. Cells double stained with 
anti-CD3 and anti-nsp1 (12A4) MAbs are shown in the upper right quadrant of each dot 
plot.  
 
 
Previously, we have identified a dominant haplotype associated with the 
susceptible phenotype in a region of equine chromosome 11 (ECA11): 49572804-
49643932 by testing four horse breeds (Thoroughbred, Saddlebred, Strandardbred and 
Quarter horses).  The presence of the common haplotype suggested that the trait occurred 
in a common ancestor of all four breeds that might have segregated among modern horse 
breeds (discussed in detail in chapter 3 of the dissertation; Go et al., in press).   To 
evaluate whether the same haplotype is associated with carrier and non-carrier status, 
ECA11: 49572804-49643932 region of stallions included in the study was genotyped 
using Sequenom MassARRAY® system (Sequenom Inc., San Diego, CA).  Briefly, 
genomic DNA (gDNA) was isolated from PBMCs of each animal using Puregene whole 
  142 
blood extraction kit (Qiagen, Valencia, CA) following the manufacturer’s instructions.  
DNA from these horses was genotyped for single nucleotide polymorphisms (SNPs) 
using the EquineSNP50 BeadChip (Illumina, San Diego, CA).  Using the option for 
association studies, the distribution of SNPs was compared between carrier and non-
carrier stallions.  The SNP data (Table 5.1) showed that five out of seven carrier stallions 
with the CD3+ T lymphocyte susceptible phenotype had the “GGAGGT” haplotype 
previously reported to be highly associated with the trait (Go et al., in press [chapter 3]).  
Unfortunately, the association of the trait with the genetic markers was imperfect since 
two carrier stallions (CB and I050) were found without the “GGAGGT” haplotype 
implicated for susceptibility.  This emphasizes once again the limitation of low coverage 
SNPs available for equine and results could be inaccurate.  The possibility that the 
“GGAGGT” haplotype associated with CD3+ T lymphocyte susceptibility is not 
conserved in all horse breeds, such as Dutch Warmblood and Rocky Mountain Paint, 
cannot be excluded (Table 5.1). 
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Table 5.1. Haplotype of carrier and non-carrier stallions for selected SNPs in ECA11: 
49572804-49643932 
Phenotype Status Horse ID HAP1 HAP2 Breed 
Positive  EAV shedder  CB CACATC GGAGGC Dutch Warmblood 
Positive EAV shedder G83 CACATC GGAGGT QH 
Positive EAV shedder H069 GGAGGT GGAGGC Paint 
Positive EAV shedder I050 GGAGGC GGAGGC Rocky Mountain Paint 
Positive EAV shedder I070 GGAGGT GGAGGC TWH 
Positive EAV shedder #18 GGAGGT GGAGGT STB 
Positive EAV shedder NM-MR GGAGGT GGAGGC QH 
Negative Non-shedder I062 GGAGGC GGAGGC Rocky Mountain X 
Negative Non-shedder NM-T   TB 
Negative Non-shedder NM-SR   QH 
Negative Non-shedder NM-CC   QH 
Negative Non-shedder NM-D   TB 
Negative Non-shedder NC-R GGAGGC GGAGGC Dutch Warmblood 
Negative Non-shedder CA-W GGAGGT GGAGGC Hanoverian 
NOTE: The positive and negative phenotype refers to in vitro CD3+ T lymphocyte 
susceptibility and resistance, respectively.  The haplotype “GGAGGT” associated with 
CD3+ T cell susceptibility is highlighted in yellow as described elsewhere (Go et al., in 
press [chapter 3]).  Each haplotype is highlighted with a different color. 
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Larger numbers of carrier and non-carrier stallions (naturally exposed) are needed 
to draw definite conclusions about the link between CD3+ T cell susceptibility to EAV 
infection and the genetic traits of horses at risk to become carrier stallions after exposure 
to EAV.  However, it is a challenge to find a large number of such stallions, especially 
the non-carrier stallions that have seroconverted due to natural exposure to the virus. 
Ultimately, results from this study are being confirmed in an in vivo study with 
experimental infection of stallions with susceptible and resistant CD3+ T lymphocyte 
phenotypes with EAV to see whether stallions with CD3+ T lymphocytes are at higher 
risk of establishing carrier status compared to those with the resistant phenotype. 
The data presented in this study clearly demonstrated that there is a genetic 
difference between stallions that become carriers after exposure to EAV and those that 
are able to clear the virus, non-carrier stallions.  The trait could be determined by 
assessing the susceptibility of their CD3+ T lymphocytes to in vitro VBS EAV infection 
which is likely to be the most precise method.  However, it is expensive, time consuming 
and cumbersome to run on a routine or large-scale basis.  This study provides the 
possibility of development of a genetic test to identify stallions that are predisposed to 
persistent infection.  It would allow us to develop new and improved prevention 
strategies in horses.  Eventually, findings from this study will allow us to develop 
diagnostic tools to predict possible carrier stallions of EAV and prevent further spreading 
of the virus. 
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CHAPTER SIX 
 
Equine arteritis virus does not induce type I interferon α/β production in equine 
endothelial cells: Identification of nonstructural protein 1 as a main interferon 
antagonist 
 
 
6.1.  SUMMARY 
The primary objective of this study was to investigate the effect of equine arteritis 
virus (EAV) on type I IFN production.  Equine endothelial cells (EECs) were infected 
with virulent Bucyrus strain (VBS) of EAV at a multiplicity of infection (m.o.i) of 5 and 
type I IFN (IFN-α/β) expression at mRNA and protein levels were measured by real-time 
RT-PCR and IFN bioassay using vesicular stomatitis virus expressing the green 
fluorescence protein (VSV-GFP), respectively.  Sendai virus (SeV), a well-known 
inducer of type I IFN, was used as the positive control for type I IFN induction.  IFN-α 
and IFN-β mRNA levels in EECs infected with EAV VBS were not increased compared 
to those in mock-infected cells, whereas SeV infection strongly induced production of 
IFN-α and IFN-β mRNA in the same type of cells at both 3 and 6 h.p.i.  Protein levels 
determined by IFN bioassay provided additional confirmation of this finding.  
Subsequently, the potential of each of the 12 nonstructural proteins (nsps) of EAV to 
antagonize type I IFN production was determined by IFN-β promoter luciferase reporter 
system.  The results demonstrated that nsps 1, 2 and 11 had the capability to inhibit type I 
IFN activity.  Of these three nsps, nsp1 exhibited the strongest inhibitory effect by 
inhibiting IFN synthesis.  Collectively, these data demonstrated that failure to induce type 
I IFN in EAV infected cells may allow the virus to subvert the equine innate immune 
response.  EAV nsp1 may play a critical role in producing this effect.   
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6.2.  INTRODUCTION 
Equine arteritis virus (EAV) is the causative agent of equine viral arteritis (EVA), 
a respiratory and reproductive disease of horses [77].  EAV is a small enveloped virus 
with a positive-sense, single-stranded RNA genome of ~12.7 kb which belongs to the 
family Arteriviridae (genus Arterivirus, order Nidovirales), which also includes porcine 
reproductive and respiratory syndrome virus, simian hemorrhagic fever virus, and lactate 
dehydrogenase-elevating virus of mice [7,34].  The EAV genome includes nine known 
functional open reading frames (ORFs 1a, 1b, 2-7) [34,56].  ORFs 1a and 1b are located 
in the 5’-proximal three-quarters of the genome and are translated to produce replicase 
polyproteins pp1a and pp1ab (1,727 and 3,175 amino acids, respectively), with the latter 
being a C-terminally extended version of the former [141].  ORF 1b translation depends 
on a -1 ribosomal frameshift just before termination of ORF 1a translation [10].  The two 
replicase precursor polyproteins are cleaved by three different ORF 1a-encoded proteinases 
yielding at least 13 end products named nonstructural protein (nsp) 1 to 12 (including a 
recently described nsp7α and 7β) [113]).  The three EAV proteinase domains are located in 
nsp1, nsp2 and nsp4 [34,66].  The remaining eight ORFs (2a, 2b and 3, 4, 5a, 5b and 6-7) 
are located in the 3’ quarter of the genome and encode the structural proteins (GP2, E, 
GP3, GP4, ORF5a protein, GP5, M and N, respectively) of the virus [57,58,81,137].     
The type I interferon (IFN-α/β) is a key component of the host innate immune 
response to viral infection.  Recognition of pathogen-associated molecular pattern (PAMPs) 
in double-stranded RNA (ds RNA) by intracellular receptors, such as retinoic acid inducible 
gene I protein (RIG-I) and melanoma differentiation-associated gene product (MDA5) [409] 
activates protein signaling cascades that result in activation of antiviral transcription factors 
such as interferon regulatory factor-3 (IRF-3), nuclear factor-кB (NF-кB) and activating 
protein 1 (AP1) [410].  The IFN-β promoter contains four positive regulatory domains 
(PRDs), including the binding site for three different transcription factors, IRF-3 (PRDs I 
and III), NF-κB (PRDII) and AP1 (PRD IV).  Activation of these transcription factors 
triggers the formation of enhanceosomes in the cell nucleus and induces the expression of 
IFN-α/β . [410,411]. 
Many viruses have evolved strategies to counteract key elements of the IFN 
response and prevent development of an antiviral environment in the host.  The innate 
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immune response to EAV infection is poorly characterized.  Recently, it had been shown 
that porcine reproductive and respiratory syndrome virus (PRRSV), a close relative of 
EAV antagonizes type I IFN production in infected cells [412,413,414,415,416,417].  
Based on this finding, we hypothesized that EAV infection may also down regulate type I 
IFN response in infected cells and that the nsps of the virus may play an important role in 
subverting the host innate immune response.  To test this hypothesis, we investigated the 
ability of EAV to modulate type I IFN response in infected cells.  Specifically, we 
investigated the mechanisms used by EAV to inhibit type I IFN production in infected 
cells and the possible role of EAV nsps as modulators of the innate immune response.  
 
6.3.  MATERIALS AND METHODS 
Virus and cells 
Equine pulmonary artery endothelial cells (EECs), baby hamster kidney 21 
(BHK-21 [ATCC CCL-10]) and HEK293T cells (kindly provided by Dr. Ying Fang, 
South Dakota State University, Brookings, SD) were maintained in Dulbecco’s modified 
essential medium (Mediatech, Herndon, VA) with sodium pyruvate, 10% fetal bovine 
serum (FBS; HyClone Laboratories, Inc., Logan, UT), 100 U/μg per ml penicillin 
streptomycin, and 200 mM L-glutamine.  HeLa (ATCC CCL-2) and MDBK (ATCC 
CCL-22) cells were grown in Eagle’s minimum essential medium with 10% ferritin-
supplemented bovine calf serum (Hyclone Laboratories, Inc., Logan, UT) and 100 U/ μg 
per ml penicillin/streptomycin (Gibco, Carlsbad, CA).  The experimentally derived 
virulent Bucyrus  strain (VBS) of EAV was propagated once in EECs to prepare high 
titered working stocks for the present study as previously described [343,344].  Sendai 
virus (SeV; Cantell strain) was purchased from American Type Culture Collection 
(ATCC VR-907; Manassas, VA), propagated once in embryonated chicken eggs to 
prepare the working virus stock.  The virus titer was determined by hemagglutination 
inhibition assay using chicken red blood cells as described previously [418].  Vesicular 
stomatitis virus expressing green fluorescent protein (VSV-GFP; [419]) was kindly 
provided by Dr. Adolfo Garcia-Sastre (Mt. Sinai School of Medicine, New York, NY). 
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Plasmids 
The construction of plasmids for expression of recombinant EAV nsp1 to nsp12 
in mammalian cells has been previously described [420].  Briefly, the coding regions of 
each of the twelve nsps were PCR-amplified from the EAV rVBS full-length infectious 
cDNA clone [328] and cloned into the pCAGGS eukaryotic expression vector [421].  The 
nsp5, nsp6, nsp10 and nsp12 were constructed as C-terminal FLAG-tagged fusion protein.  
Expression of recombinant EAV nsps was performed in BHK-21 cells transfected with 
individual plasmids containing nsp1 to nsp12 coding regions using Fugene HD (Promega, 
Madison, WI) according to manufacturer’s instructions.  The authenticity of each 
recombinant protein was confirmed by immunofluorescence and Western 
immunoblotting assays.  Reporter plasmids expressing the firefly luciferase under the 
control of either the IFN-β promoter (p125-Luc) or an artificial promoter containing three 
IRF3 binding sites (p55-CIB-Luc) were kindly provided by Dr. Takashi Fujita [422].  
The pNF-кB-Luc or pISRE-Luc reporter plasmids expressing the firefly luciferase under 
the control of a promoter with NF-кB-response element or the interferon-stimulated 
response element (ISRE) was purchased from Stratagene (La Jolla, CA).  The pRL-SV40 
plasmid that expresses a Renilla luciferase under the control of a simian virus (SV40) 
promoter was purchased from Promega (Madison, WI).  The pEFneo-RIG-I, pEFneo-
MDA5, and pEFneo-IKKε were kindly provided by Dr. Bin Gotoh [423].  The pcDNA3-
TRIF was purchased from Addgene (Cambridge, MA).  Construction of pCAGGS-IRF3 
plasmid was described previously [415].  
 
Antibodies 
To detect EAV antigens in infected cells, MAbs against EAV nonstructural 
protein-1 (nsp1; MAb 12A4) and nucleocapsid protein (N; Mab 3E2) were used 
[213,306].  Protein-specific polyclonal rabbit antisera recognizing EAV nsp2 [110], nsp3 
(rabbit 98.E3, [84]), nsp4 (a 1:1 mix of anti-nsp4M and anti-nsp4C; [110]), nsp7-8 [110], 
and nsp10 [87] have been previously described.  In addition, antisera against nsp9 and 
nsp11 were raised by immunizing rabbits with purified full-length recombinant proteins 
expressed in E.coli (J.C. Zevenhoven, D. D. Nedialkova and E. J. Snijder, unpublished 
data).  Commercially available anti-FLAG (Agilent Technologies, Santa Clara, CA) 
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monoclonal antibody was used to detect FLAG-tagged fusion proteins in 
immunofluorescence and Western immunoblotting analyses.  Rabbit polyclonal 
antibodies for human IRF3 (Santa Cruz Biotechnology, Santa Cruz, CA) and anti-β-actin 
(Cell Signaling, Danvers, MA) and monoclonal antibodies for human NF-кB p65 (Santa 
Cruz Biotechnology) were used.  Phosphorylation-specific rabbit polyclonal antibodies 
for phospho-IRF3 (Ser398; Upstate Millipore, Billerica, MA), and phospho-NF-кB p65 
(Ser276; Santa Cruz Biotechnology) were used for immunofluorescence and Western 
immunoblotting analyses.  
 
RNA extraction and quantitative real time RT-PCR 
Total RNA was extracted using MagMAX™-96 Total RNA Isolation kit (Ambion, 
Austin, TX) according to the manufacturer’s recommendations in a MagMAX™ 
Express-96 magnetic particle processor (Applied Biosystems, Foster City, CA).  RNA 
from each culture was treated with DNase to remove any contaminating genomic DNA 
(gDNA).  The RNA concentration was assessed at OD260nm and purity was verified by the 
OD260/OD280 ratio using NanoDrop (Thermo Scientific, Wilmington, DE). The reverse 
transcription reaction was performed with 1 μg of total RNA using RT random primers 
and a MultiScribe™ reverse transcriptase (High Capacity cDNA Reverse Transcription 
kit with RNase inhibitor [Applied Biosystems, Foster City, CA]) according to the 
manufacturer’s instructions.  The following IFN-β primers and probe set were used:  
EqIL-IFN-βF: 5’-AATGGCCCTCCTGCTGTGT-3’, EqIL-IFN-βR: 5’-
CCGAAGCAAGTCATAGTTCACAGA-3’ and EqIL-IFN-β probe FAM-
CTCCACCACGGCTC -NFQ for PCR amplification using an Applied Biosystems 7500 
Fast Real-Time PCR System.  For each sample, cDNA corresponding to the β-
glucuronidase (β-GUS) gene was amplified and used as an endogenous control for 
relative quantification of a sample cDNA.  All PCR efficiency values were determined 
using LinReg.  The relative concentration of target gene mRNA was equal to 2 -ΔΔCt 
where ΔΔCt = [(Avg. gene of interest Ct – Avg. β-GUS Ct) sample – (Avg. gene of interest 
Ct – Avg. β-GUS Ct) calibrator].  The calibrator was calculated from the mean ΔCt of mock-
infected samples for each individual gene.    
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Interferon bioassay 
The interferon bioassay was performed using VSV-GFP as previously described 
[416,424].  Briefly, EEC’s were either infected with EAV or SeV alone or dual infected 
with both EAV/SeV at an m.o.i of 5 and incubated for 24 h at 37°C.  Culture supernatants 
were collected and virus in the supernatants was inactivated by ultraviolet (UV)-
irradiation for 30 min.  Two-fold dilutions of supernatants were made in DMEM and 
used in IFN bioassays.  MDBK cells were grown in 96-well plates to 70% confluency 
and incubated with two-fold dilutions of each of the supernatants.   After 24 h incubation 
at 37°C, cells were infected with VSV-GFP at an m.o.i. of 0.1 and further incubated at 
the same temperature for 16 h.  Cells were fixed with 4% paraformaldehyde and 
expression of green fluorescence protein was examined under an inverted fluorescence 
microscope. 
 
Confocal microscopy 
HEK293 T cells grown on coverslips were transfected with plasmids as indicated 
previously, washed with PBS and fixed with 4% paraformaldehyde in phosphate-buffered 
saline (PBS; pH7.4) for 30 min at RT.  After washing three times with PBS (pH 7.4) 
containing 10mM glycine (glycine/PBS), cells were permeabilized with 0.2% Triton X-
100 in PBS (pH 7.4) for 10 min.  The coverslips were incubated with the appropriate 
primary monoclonal or polyclonal antibody in PBS containing 5% fetal bovine serum 
(FBS) for 1 h at RT.  After three 10mM glycine/PBS washes, coverslips were incubated 
with FITC-conjugated or DyLight 549-conjugated goat anti-mouse or anti-rabbit 
antibody (Southern Biotech, Birmingham, AL and KPL, Gaithersburg, MD, respectively) 
for 1 h at RT.  Coverslips were washed and mounted in 4’, 6’-diamidino-2-phenylindole 
(DAPI) containing aqueous mounting medium (Vector Laboratories, Burlingame, CA) 
and observed under an inverted fluorescence microscope.   
 
Cell transfection and luciferase reporter assay 
HEK293T cells were seeded in 24-well plates and transfected with various 
combinations of plasmid DNA: the pEFneo-RIG-I, pEFneoMDA5, pEFneo-IKKε, 
pcDNA3-TRIF, or pCAGGS-IRF3 was mixed with a plasmid encoding the EAV protein 
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(or empty pCAGGS), luciferase reporter plasmid and SV40-RL.  Transfection was 
performed using HD-FuGENE6 transfection reagent following the manufacturer’s 
instruction (Promega, Madison, WI).  For the Sendai virus or IFN stimulation, HEK293T 
cells were transfected with a plasmid encoding the EAV proteins (or empty pCAGGS, 
pCAGGS-NS1), reporter plasmids and pSV40- RL.  At 20 h post-transfection, cells were 
infected with Sendai virus at 5000 HA unit/0.5 ml/ well for 12-16 h, or induced by 
treatment with 2000 IU/0.5 ml/ well of IFN-α or IFN-β for 16 h.  Cells were harvested at 
the indicated time points.  Cell lysates were prepared and subjected to reporter gene assay 
using the dual luciferase reporter system (Promega, Madison, WI) according to 
manufacturer’s instruction.  Firefly and Renilla luciferase activities were measured in a 
luminometer (Berthold Technologies, Oak Ridge, TN).  Values for each sample were 
normalized using the Renilla luciferase values.  
 
6.4.  RESULTS 
Suppression of type I interferon production by EAV 
To investigate the effect of EAV on type I IFN production, IFN-β mRNA 
expression was analyzed using quantitative real time RT-PCR.  Equine pulmonary 
endothelial cells (EECs) were mock-infected or infected with EAV VBS at an m.o.i of 5 
for 8 h, followed by infection with SeV for 3 or 6 hpi.  Sendai virus (SeV) was used as a 
positive control for type I IFN induction and mock-infected cells were used as a negative 
control.  As shown in Figure 6.1.A, IFN-β mRNA was barely detected in cells infected 
with EAV alone, whereas SeV infection induced a strong expression, approximately 190-
200 fold, of IFN-β mRNA in the same cells.  Moreover, SeV-induced IFN-β mRNA 
expression, at both 3 and 6 hpi, was significantly suppressed in cells previously infected 
with EAV.  In parallel with the quantitative measurement for IFN-β mRNA, suppression 
of IFN production by EAV was confirmed by IFN bioassay using VSV expressing the 
green fluorescence protein (VSV-GFP; Figure 6.1.B).  VSV is IFN sensitive and presence 
of IFN-α/β blocks VSV replication.  EECs were mock-infected, either infected with EAV 
or SeV alone, or dual infected with both EAV/SeV.  Subsequently, MDBK cells were 
incubated with two-fold serial dilutions of virus inactivated cell culture supernatant fluid 
for 24 h followed by infection with VSV-GFP at an m.o.i. of 0.1 for 18 h.  The VSV 
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infectivity was determined by monitoring the levels of GFP expression.  As shown in 
Figure 6.1.B, VSV-GFP replicated normally in cell culture supernatant from mock-
infected cells while VSV replication was effectively inhibited in supernatant from SeV-
infected cells up to a dilution of 1:32.  In contrast, VSV replication was not inhibited in 
cell culture supernatant from cells infected with EAV alone.  Consistent with quantitative 
RT-PCR results, SeV-induced type I IFN production was significantly inhibited by EAV 
exposure since VSV-GFP replication was detected at a lower sample dilution compared 
to that of culture supernatant from SeV-infected cells.  Together, the data suggest that 
EAV has an intrinsic ability to prevent induction of IFN in infected cells and suppress 
IFN production in SeV-infected cells.   
 
 
Figure 6.1.  Inhibition of type I IFN production after EAV infection. A. EECs were 
mock-infected or infected with EAV VBS at an m.o.i. of 5 for 8 or 12 h.  Subsequently, 
cells were infected with Sendai virus (SeV; 100 HAU/ml) for 3 h.  Total RNA was 
isolated and real time RT-PCR was performed for the detection of equine IFN-β.  The 
average IFN-β copy numbers ± standard error of the mean (SEM) from three independent 
experiments is shown.  B. VSV bioassay for IFN production.  EECs were mock-infected 
or infected with EAV VBS at an m.o.i. of 1 for 24 h. SeV was used as an IFN stimulator.  
Cell culture supernatants were collected and UV-irradiated for 30 min prior to use in the 
assay. MDBK cells were grown in 96-well plates and incubated with 2-fold dilution 
series of the supernant up to 1/32.  After 24 h incubation, cells were infected with VSV-
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GFP at an m.o.i. of 0.1, and 18 h after infection, GFP expression was assessed by 
fluorescence microscopy.  Each dilution was tested in duplicate. 
 
 
The EAV nsp1, nsp2 and nsp11 exhibited strong inhibition of IFN-β promoter 
activation 
To investigate the role of EAV viral proteins as IFN antagonists, we focused on 
the nonstructural proteins of EAV. The 12 nonstructural proteins derived from an 
infectious cDNA clone of virulent Bucyrus strain of EAV were cloned individually into a 
pCAGGS mammalian expression vector.  The expression and authenticity of recombinant 
proteins from the plasmids were verified by immunofluorescence and Western blot using 
protein-specific rabbit antisera (nsp1-4, nsp7-9 and nsp11) or anti-FLAG antibody (nsp5, 
nsp6, nsp10, and nsp12; data not shown).  To determine the nsp(s) that has an effect on 
IFN-β activation, we used an IFN-β promoter-luciferase reporter plasmid (p125-Luc) that 
expresses the firefly luciferase under the control of the IFN-β promoter.  HEK293T cells 
were co-transfected with individual nsp-expressing pCAGGS plasmid, p125-Luc, and a 
Renilla luciferase expression plasmid (pRL-SV40) to normalize expression levels of 
samples. As a positive control, swine influenza virus NS1 (sw-ns1) gene was used to co-
transfect the cells with the reporter plasmid; this has been widely reported to inhibit IFN-
β promoter induction.  Twenty-four hours after transfection, cells were infected with SeV 
to induce luciferase production. As shown in Figure 6.2.A, the expression of sw-ns1 
significantly inhibited luciferase expression.  In contrast, a strong reporter signal was 
observed in cells transfected with empty pCAGGS plasmid after infection with SeV.  
IFN-β promoter activation by SeV infection was suppressed to various degrees by 
expression of several EAV nsps, among which nsp1, nsp2 and nsp11 showed the 
strongest inhibition of IFN-β promoter-driven luciferase expression.  In particular, nsp1 
exhibited the strongest inhibitory effect, followed by nsp11 and nsp2.  These results 
suggested that several EAV nsps are capable of suppressing IFN-β promoter activation of 
which nsp1 had the strongest inhibitory effect, indicating that it may play a major role as 
a type I IFN antagonist.  The nsps expression from plasmids was confirmed by IFA 
(Figure 6.2.B) 
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Figure 6.2.  EAV nonstructural proteins (nsps) involved in suppression of IFN-
promoter activation.  A. HEK293T cells were co-transfected with p125-Luc, pRL-SV40 
and pCAGGS expressing nsps or pCAGGS empty vector for 24 h.  Cells were harvested 
and measured for firefly and Renilla luciferase activities.  Relative luciferase activity is 
defined as a ratio of firefly luciferase reporter activity to Renilla luciferase activity.  Each 
data point shown represents a mean value ± standard error of the mean (SEM) from three 
experiments.  B. Expression of nsps in transfected cells detected by indirect 
immunofluorescence assay.   HEK293T cells were transfected with each EAV nsp and 
fixed at 24 h post-transfection.  Cells were stained with EAV protein-specific rabbit 
antisera or anti-FLAG monoclonal antibody.  DyLight 549-conjugated goat anti-rabbit 
antibody was used as secondary antibody.  
 
 
EAV nsp1 interferes with IRF3- and NF-κB-mediated IFN-β activation 
Since the nsp1 of EAV showed the highest type IFN antagonistic activity, it was 
decided to further investigate its effect on the specific signaling pathway(s) using AP-1-, 
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NF-κB- and IRF-3-driven luciferase reporter systems.  Cells were co-transfected with 
control plasmids or with plasmids expressing the EAV nsp1 protein, the plasmid pRL-
SV40 and a plasmid containing a firefly luciferase gene under the control of a promoter 
(pAP-1-Luc) or containing two NF-кB binding sites (pNF-κB-Luc) or with three IRF3 
binding sites (p55-CIB-Luc) (Figure 6.3).  In cells expressing EAV nsp1 and sw-ns1 
proteins (positive control), the level of IRF3-dependent luciferase expression upon SeV 
stimulation was significantly reduced compared to that of the control plasmid (empty 
pCAGGS vector).  Similarly, NF-κB-dependent luciferase expression was blocked in 
cells expressing EAV nsp1.  In contrast, EAV nsp1 did not affect the AP-1-dependent 
reporter gene expression after SeV stimulation, whereas sw-ns1 strongly inhibited 
luciferase expression under control of the promoter containing the AP-1 binding site.  
Based on these findings, it would appear that EAV nsp1 suppresses IFN-β transcription 
by interfering with IRF-3 and NF-κB activity but not AP-1 activity. 
 
 
 
Figure 6.3.  EAV nsp1 inhibits both IRF-3 and NF-κB pathways but not AP-1.  
HEK293T cells were co-transfected with (A) AP-1-Luc, (B) NF-κB-Luc and (C) p55-
CIB-Luc, which contains three IRF-3 binding sites, a plasmid that constitutively 
expresses Renilla luciferase, and plasmids expressing EAV nsps or the indicated control 
plasmids.  Cells were infected with Sendai virus (SeV) 24 hpi.  Cells were harvested and 
analyzed for firefly and Renilla luciferase.  Data were normalized using the Renilla 
luciferase values.  Data are averages ± standard deviation for three experiments.   
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EAV nsp1 blocked expression of IRF3-dependent reporter genes 
We further investigated specific steps that EAV nsp1 could possibly block the 
IRF-3 signaling pathway. The ability of IRF-3 to activate its DNA binding site was 
examined using a plasmid construct containing a firefly luciferase gene under the control 
of a promoter with three IRF-3 binding sites (pCIB-55-Luc).  First, we investigated 
whether the nsp1 was interfering with the mitochondrial antiviral signaling (MAVS) 
complex activity.  Since MDA5 or RIG-1 is associated with the MAVS complex, cells 
were co-transfected with a plasmid expressing MDA5, RIG-1 or MAVS protein, a 
plasmid expressing EAV nsp1, the plasmid pRL-SV40 and the p55-CIB-Luc reporter 
plasmid.  As shown in Figure 6.4.A-C, IRF-3-dependent luciferase expression was 
suppressed in the presence of EAV nsp1.  These results suggested that EAV nsp1 might 
inhibit the MAVS-mediated IFN-β induction or downstream portion of the signaling 
pathway.  Therefore, we further tested the effect of EAV nsp1 on TRIF- and IKKε-
mediated IFN-β induction and the results showed that nsp1 had the ability to suppress 
TBK1 and IKKε mediated reporter gene expression (Figure 6.4.D-E).  Similarly, 
overexpression of IRF3 itself did not activate transcription of the reporter plasmid either 
(Figure 6.4.F) suggesting that nsp1 blocked the IRF-3.  The data suggest that EAV nsp1 
might block processes downstream of IRF-3 activation, possibly in the nucleus.  
Furthermore, we studied the activation of IRF-3 in EAV nsp1 transfected cells by 
Western blot analysis.  Neither expression of EAV nsp1 nor control plasmid increased 
levels of phosphorylated IRF-3 (pIRF-3) in cells in the absence of SeV stimulus.  In 
contrast, infection of SeV induced phosphorylation of IRF-3 (pIRF-3) to a similar level in 
cells transfected with EAV nsp1 and the control plasmid.  Total levels of IRF-3 were 
unaltered by expression of nsp1 and the control plasmid or SeV infection (data not 
shown).  Together with the luciferase assay data, these results suggest that the EAV nsp1 
has the ability to block induction of IFN-β at a point downstream of activation of IRF-3, 
since nsp1 expression inhibits the activation of the IFN-β promoter but does not block the 
activation of IRF-3.  
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Figure 6.4.  EAV nsp1 inhibits the IRF-3 signaling pathway.  Suppression of (A) RIG-
I (B) MDA-5 (C) IRF-3 (D) MAVS (E) TRIF and (F) IKKε induced IRF-3 dependent 
reporter gene expression by EAV nsp1 in HEK293T cells.  (A-F) Cells cultured in 24-
well plates were co-transfected with plasmid pEFneo-RIG-I, pEFneo-MDA-5, pEGFP-
N1-MAVS, pcDNA3-TRIF, pEFneo-IKKε, or pCAGGS-IRF3 along with a plCAGGS 
expressing nsp1 protein or pCAGGS empty vector, pRL-SV40 and a luciferase reporter 
plasmid, p55-CIB-Luc for 24 h. Cells were harvested and measured for firefly and 
Renilla luciferase activities.  Relative luciferase activity is defined as a ratio of firefly 
luciferase reporter activity to Renilla luciferase activity.  Mean value ± SEM from three 
experiments is shown. 
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EAV nsp1 blocked expression of NF-κB-dependent reporter genes 
Next, we investigated the ability of EAV nsp1 to inhibit NF-κB mediated 
transcription.  In the presence of EAV nsp1, NF-κB-dependent reporter gene expression 
was strongly inhibited (Figure 6.5.A) following stimulation with TNF-α, a potent inducer 
of the NF-κB signaling,.  Subsequently, the effect of EAV nsp1 on the MAVS complex, 
TRIF and IKKε mediated IFN-β induction was evaluated.  Interestingly, overexpression 
of any of these proteins induced activation of NF-κB-dependent reporter gene expression 
(Figure 6.5.B-D).  Similarly, overexpression of p65, a subunit of the NF-κB complex, 
itself had no effect on activation of transcription from the NF-κB-driven reporter plasmid 
(Figure 6.5.E).  These data suggested that EAV nsp1 likely blocks processes downstream 
of the activation of NF-κB complex, possibly somewhere in the nucleus. 
 
 
 
Figure 6.5.  EAV nsp1 inhibits the NF-κB signaling pathway.  Suppression of (A) 
TNF-α (B) MAVS (C) TRIF (D) p65 subunit of NF-κB and (E) IKKε induced NF-κB-
dependent reporter gene expression by EAV nsp1 in HEK293T cells. (A) Cells cultured 
in 24-well plates were co-transfected with pNF-κB-Luc, pRL-SV40, and pCAGGS 
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expressing nsp1 or pCAGGS empty vector for 24 h and subsequently stimulated with 
TNF-α (20 ng/ml) for 6 h.  (B-E) Cells were co-transfected with plasmid pEGFP-N1-
MAVS, pcDNA3-TRIF, pEGFP-N1-p65 or pEFneo-IKKε along with a pCAGGS 
expressing nsp1 protein or pCAGGS empty vector, pRL-SV40 and a luciferase reporter 
plasmid, pNF-κB-Luc for 24 h. Cells were harvested and measured for firefly and Renilla 
luciferase activities.  Relative luciferase activity is defined as a ratio of firefly luciferase 
reporter activity to Renilla luciferase activity.  Mean value ± SEM from three 
experiments is shown. 
 
 
EAV nsp1 expression blocked the nuclear accumulation of IRF-3 and NF-κB 
The mechanism by which EAV nsp1 can reduce IRF-3 and NF-κB-dependent 
gene expression was examined by assessing the nuclear localization of IRF-3 and p65, 
respectively, in cells expressing EAV nsp1 by confocal microscopy (Figure 6.6).  In 
mock-infected cells, IRF-3 was localized primarily to the cytoplasm.  On the other hand, 
SeV infection stimulated IRF-3 nuclear translocation in a large number of cells.   
However, IRF-3 remained in the cytoplasm of cells expressing EAV nsp1 after SeV 
infection, while IRF-3 was occasionally observed in the nucleus of cells that did not 
express nsp1.  Similarly, NF-κB remained in the cytoplasm of most of the unstimulated 
cells, whereas TNF-α stimulation induced p65 nuclear accumulation in most cells.   In 
cells expressing EAV nsp1, TNF-α stimulation did not induce complete p65 nuclear 
translocation since p65 was found in both nucleus and cytoplasm, indicating that EAV 
nsp1 partially blocks p65 nuclear translocation.  Taken together, it appears that IFN-β 
transcription activation is blocked through inhibition of both IRF-3 and NF-κB nuclear 
accumulation.   
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Figure 6.6.  Effect of EAV nsp1 in IRF-3 and NF-κB nuclear translocation.  (A) 
HEK293T cells were transfected with EAV nsp1 for 24 h and then infected with Sendai 
SeV for 6 h. Cells were fixed and stained with Alexa 488 conjugated-anti-EAV nsp1 
(12A4) MAb and rabbit anti-IRF3 antibody.  (B) HEK293T cells were co-transfected 
with EAV nsp1 and p65-RFP for 24 h and then stimulated with TNF- α (10 ng/ml) for 2 h. 
Cells were fixed and stained with anti-EAV nsp1 (12A4) MAb.  FITC-conjugated goat 
anti-mouse was used as a secondary antibody.  Cell nuclei were stained with DAPI. 
 
 
6.5.  DISCUSSION 
Viruses use different mechanisms to inhibit interferon response in order to evade 
the host innate immune response.  Synthesis and secretion of type I IFN, such as IFN-α 
and IFN-β with antiviral, anti-proliferative and immunomodulatory functions, are critical 
aspects of the antiviral immune response [410,425,426].  Thus, many viral proteins that 
antagonize multiple components of the interferon pathways have been identified.  In 
addition, many viruses encode more than one protein capable of inhibiting the interferon 
response which act synergistically to ensure complete blocking of interferon activity.  
Highly pathogenic viruses, such as Ebola, Nipah and SARS-CoV, encode multiple viral 
proteins capable of inhibiting interferon activity, suggesting important roles for these 
proteins in pathogenesis and disease outcome [427].  In this study, we investigated 
whether EAV has the ability to interfere with the host’s innate immune response, in 
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particular, type I IFN production.  We showed that EAV infection of equine endothelial 
cells significantly inhibited type I IFN production at both mRNA and protein levels, 
whereas infection with SeV stimulated type I IFN production significantly.  Furthermore, 
EAV infection significantly inhibited SeV-induced type I IFN production as well.  Based 
on reporter-gene experiments, three EAV nonstructural proteins, nsp1, nsp2 and nsp11 
strongly inhibited activation of the IFN-β promoter indicating that they modulate type I 
IFN activity.  Among these proteins, expression of nsp1 had the strongest inhibitory 
effect on IFN-β-responsive promoter activation.  Similar to our findings, previous studies 
on PRRSV also demonstrated that nsp1α, nsp1β, nsp2, nsp4 and nsp11 of PRRSV play a 
role in type I IFN antagonism and inhibit activation of IFN-β promoter [414,415].  The 
two N-terminal PRRSV replicase cleavage products, nsp1α and nsp1β have the ability to 
inhibit both IFN synthesis and signaling, while nsp1α strongly inhibits IFN synthesis only.  
Specifically, nsp1β strongly inhibited IRF-3 dependent gene induction in the signaling 
pathway leading to IFN-β synthesis.  In addition to these nsps, the nuceocapsid protein of 
PRRSV also inhibits type I IFN production [83,424].  
Further examination revealed that EAV nsp1 inhibited two key transcription 
factors that activate the IFN-β promoter, IRF-3 and NF-κB, but not AP-1.  EAV nsp1 
expression strongly inhibited IRF-3- and NF-κB-dependent gene induction in the 
signaling pathway that leads to IFN-β synthesis.  Both IRF-3 and NF-κB activation are 
regulated by MAVS which functions downstream of RIG-I and MDA5 and upstream of 
the IKK complex and TBK1/IFF-I [428,429,430,431].   Among the various factors 
involved in type I IFN production, IRF-3 plays a critical role. IRF-3 is expressed in most 
cell types and resides in the cytoplasm in an inactive form.  When stimulated, IRF-3 
becomes phosphorylated and undergoes conformational changes, leading to dimerization 
with the exposed nuclear localization signal.  In the nucleus, IRF-3 recruits co-activator 
CBP/p300 and forms a complex to bind IRF-3 responsive elements (PRD I/III) of the 
IFN-β promoter [410].  In addition to IRF-3, NF-κB is also a critical regulator of host 
innate and adaptive immunity.  It plays an important role in the regulation of cell 
proliferation as well as cell survival.  Through evolution, viruses can either activate or 
inhibit the NF-κB pathway in order to survive in host cells.   Viruses such as African 
swine fever virus and influenza A virus block NF-κB activation to counter the host innate 
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immune response [432,433].  In contrast, viruses such as hepatitis C virus, reovirus and 
herpes simplex virus have developed mechanisms to directly activate NF-κB to support 
production of progeny viruses and intracellular spreading [434,435,436].  Overexpression 
of components of the pathway by which IRF-3 and NF-κB are activated in response to 
SeV infection and TNF-α, respectively, showed that EAV nsp1 acts downstream of all 
tested steps in both signaling pathways.  Therefore, we postulated that EAV nsp1 may 
have an effect on nuclear accumulation of these transcription factors or formation of the 
transcription enhanceosome on the IFN-β promoter inside the nucleus.  Our results 
showed that nsp1 inhibits nuclear accumulation of both IRF-3 and NF-κB.  Furthermore, 
both IRF-3- and NF-κB-dependent gene expressions were blocked by EAV nsp1.  
Interestingly, IRF-3 and p65 activation by SeV and TNF-α, respectively, were not 
affected, but their nuclear accumulation was inhibited.  However, the exact mechanism 
that EAV nsp1 uses to inhibit IRF-3 and NF-κB nuclear accumulation is unclear at this 
time.  It is possible that EAV nsp1 mediates the sequestration of these activated proteins 
in the cytoplasm and affects enhanceosome assembly in the cell nucleus.  Recent studies 
have shown that PRRSV nsp1 modulates type I IFN response by blocking dsRNA–
induced IRF-3 and IFN promoter activities, but IRF-3 phosphorylation and its nuclear 
translocation occur normally in the presence of the nsp1.  It has been reported that 
PRRSV nsp1 blocks the IRF-3 activation by degrading the CREB (cyclic AMP response 
element binding)-binding protein (CBP) and subsequently inhibiting formation of 
enhanceosomes in the nucleus [416]. 
In summary, EAV proteins with interferon antagonistic activity have been 
identified for first time in this study.  Our data indicated that several EAV replicase 
proteins including nsp1, nsp2 and nsp11 have IFN antagonistic activity and regulate the 
host innate immune response.  Among these proteins, nsp1 may play a key role as 
interferon antagonist by inhibiting nuclear accumulation of activated IRF-3 and NF-κB.  
However, further studies are needed to map the exact step(s) at which EAV nsp1 protein 
acts on the IFN induction pathway.  
 
 
Copyright © Yun Young Go 2011 
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CHAPTER SEVEN 
 
A newly discovered ORF5a protein is critical for virus production in equine arteritis 
virus 
This work was included in Firth et al. J. Gen. Virol. 2011, 92: 1097-1106 
Reprinted with permission 
 
 
7.1.  INTRODUCTION 
The members of the family Arteriviridae (order Nidovirales) include equine 
arteritis virus (EAV), lactate dehydrogenase elevating virus (LDV) of mice, porcine 
respiratory and reproductive syndrome virus (PRRSV) and simian hemorrhagic fever 
virus (SHFV).  The arterivirus genome consists of a positive-sense, single-stranded RNA 
molecule.  The genome organization and expression strategy of arteriviruses share 
similarities with those of coronaviruses and it is presumed that their key replicative 
enzymes have a common ancestry [7,8,9].  Therefore, arteriviruses and coronaviruses 
were united in the order Nidovirales, which was recently expanded by addition of 
roniviruses, toroviruses and bafiniviruses [8].  The arterivirus genome consists of at least 
nine known open reading frames (ORFs).  The 5’-proximal ORFs 1a and 1b encode the 
non-structural polyproteins, pp1a and pp1ab precursors, that are processed into at least 13 
mature non-structural proteins [66,83].  The 3’-proximal end of the genome contains 
overlapping ORFs 2 to 7 that are expressed via synthesis of a set of subgenomic mRNAs 
[89,91].  These ORFs encode seven structural proteins: the nucleocapsid (N) protein and 
six envelope proteins, the glycoproteins (GP) GP2, GP3, GP4 and GP5, and the non-
glycosylated envelope (E) and membrane (M) proteins [34,93].  The genome 
organization of the EAV ORFs2-7 region is extremely compact, where the termini of the 
ORFs are overlapping with neighboring genes and with transcription-regulatory 
sequences (TRS) located upstream of each ORF for sg mRNA synthesis [89,91]. The 
compact EAV genome organization is a result of the strong selective pressure that RNA 
virus genomes are under to encode the maximum amount of information into a limited 
sequence space.   Therefore, overlapping coding sequences can be easily found in RNA 
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viruses, although they can be difficult to detect when they are short.  A recent in-depth 
comparative computational analysis revealed conservation of an additional AUG-initiated 
ORF in the arteriviruses, termed ORF5a, which overlaps the 5’ end of ORF5 [81].  The 
newly identified ORF5a protein, conserved in all arteriviruses, was first detected in a 
comparative alignment of PRRSV-NA sequences.  A similar ORF5a was found in 
PRRSV-EU as well as in LDV, SHFV and EAV.  The new coding sequence has 51 or 46 
codons in PRRSV-NA, 43 codons in PRRSV-EU, 47 codons in LDV, 64 codons in 
SHFV and 59 codons in EAV.  The pattern of substitutions across sequence alignments 
indicated that ORF5a is subject to functional constraints at the amino acid level, while an 
analysis of substitutions at synonymous sites in ORF5 revealed a greatly reduced 
frequency of substitutions in the portion of ORF5 that is overlapped by ORF5a.  The 
ORF5a protein and GP5 are likely expressed from the same subgenomic mRNA, via a 
translation initiation mechanism involving leaky scanning. The objective of this study 
was to confirm the biological relevance of ORF5a in the EAV life cycle using the EAV 
reverse genetics systems.  The effect of ORF5a knockout mutant was independently 
confirmed using two molecular clones, the pEAV515 and pEAVrVBS of the virulent 
Bucyrus strain (VBS) of EAV.  In addition to BHK-21 cells, natural host cells, equine 
pulmonary artery endothelial cells (EECs), were included in the study.  
 
7.2.  MATERIALS AND METHODS 
Cells 
Equine pulmonary artery endothelial cells (EECs) [343] were maintained in 
Dulbecco’s modified essential medium (DMEM, Mediatech, Herndon, VA) with sodium 
pyruvate, 10% fetal bovine serum (Hyclone Laboratories, Inc., Logan, UT), 100U/μg per 
ml of penicillin/streptomycin and 200mM L-glutamine [154,213,328].  The baby hamster 
kidney cells (BHK-21; ATCC CCL10; American Type Culture Collection, Manassas, VA) 
were grown in Eagle’s minimum essential medium with 10% ferritin supplemented 
bovine calf serum (Hyclone Laboratories, Inc., Logan, UT) and 100U/ μg per ml of 
penicillin/streptomycin (Gibco, Carlsbad, CA).   
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Infectious cDNA clones 
The ORFX2b mutant viruses were constructed by introducing site-specific 
mutations into two EAV infectious cDNA clones.  Specifically, the pEAV515 clone was 
derived from a cell culture adapted attenuated strain of EAV (pEAV030; [64]) and the 
pEAVrVBS clone was derived from the EAV VBS [328].   
 
Generation of EAV515/ORFX2b and rVBS/ORFX2b mutant viruses 
Briefly, a shuttle vector (pM92128[rVBS]ORFX2b) containing a BamHI (9,150)-
XhoI (12,726) fragment of the pEAVrVBS infectious cDNA clone was used to mutate the 
putative ORFX2b [328].  Site-specific nucleotide substitutions were introduced into the 
start (UAU > UAC) and stop (UGG >UAG) codons of the ORFX2b in the 
pM92128[rVBS]ORFX2b shuttle vector using a standard site-directed mutagenesis 
protocol described by Landt et al. [437].  The engineered mutations in the 
pM92128[rVBS]ORFX2b shuttle vector were confirmed by sequence analysis and 
subsequently, the BamHI-XhoI fragment was transferred back into the full-length 
pEAVrVBS infectious cDNA clone using BamHI and XhoI restriction sites and 
confirmed by sequencing.   
Run-off RNA transcripts were generated in vitro as previously described from 
each mutant infectious cDNA clones (pEAV515/ORFX2b and prVBS/ORFX2b), as well 
as their respective parental infectious cDNA clones (pEAV515 and prVBS) following 
linearization with restriction enzyme XhoI [64,327].  Briefly, 3 µg of each plasmid DNA 
were digested with XhoI and purified by standard phenol-chloroform extraction and 
ethanol precipitation procedures, and dissolved in nuclease-free water.  The in vitro 
transcription reactions were performed in 50 µl reactions by adding 2 µg of each XhoI-
linearized plasmid DNA, rNTP (10mM each), 1mg/ml BSA, 100mM DTT, 5X T7 
transcription buffer, 10mM cap analog (New England Biolabs, Ipswich, MA), RNAguard 
RNase inhibitor and T7 polymerase (Promega, Madison, WI). The transcription reactions 
were incubated at 37°C for 3 h.  The in vitro transcribed RNA was stored at -80°C until 
further use.  Each of the full-length capped RNA transcripts were transfected into either 
BHK-21 cells or EECs by electroporation as previously described [327].  Briefly, 
subconfluent monolayers of BHK-21 and EEC cells were trypsinized, washed, and 
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resuspended in ice-cold phosphate-buffered saline (PBS; pH 7.4) at a concentration of 
1×107 cells.  Freshly thawed 50 µl (80 µg) aliquots of each IVT RNA were placed into 
cuvettes (0.4 cm, electrode gap; BioRad, Hercules, CA) and 600 µl of 5×106 of BHK-21 
or 1×107 of EEC cells were added.  Two pulses of 850 V, infinite ohms (pulse controller), 
and 25-mF capacitance were given with a Gene Pulser II electroporator unit (BioRad, 
Hercules, CA).  After electroporation was complete, cells were set aside at room 
temperature for a 10 minute “recovery period”.  Subsequently, the BHK-21 and EEC 
cells were resuspended in 10 ml of appropriate complete cell culture medium and seeded 
into T-25cm2 tissue culture flasks (Corning, Corning, NY), and incubated at 37°C in a 5% 
CO2 incubator for 48-120 h until 90-100% cytopathic effect (CPE) was observed.  Cell 
culture supernatant was harvested at 18, 24, 48, 72, 96 and 120 h post-transfection and 
centrifuged at 1,600 ×g for 10 min at 4°C.  The supernatant was stored at –80°C in 
single-use aliquots.    
 
Virus titrations and plaque morphology 
Virus titers and the plaque morphology of the recombinant viruses were 
determined by plaque assays.  Briefly, confluent monolayers of EECs and BHK-21 cells 
in 6-well culture plates were infected with 10-fold serial dilutions of recombinant 
EAV515, EAV515/ORFX2b, rVBS and rVBS/ORFX2b viruses in duplicates.  Following 
a 1 h incubation, 0.75% CMC (caboxymethyl cellulose)-DMEM was added to each well 
and cells were incubated at 37°C for 96 h (McCollum, 1962).  Plaques were stained with 
1% crystal violet solution containing 1% formaldehyde at 96 h post-infection and titers 
were expressed as PFU/ml.   
 
7.3.  RESULTS 
Using reverse genetics systems, mutants from two molecular clones, pEAV515 
and pEAVrVBS, were generated with ORF5a-inactivating nucleotide substitutions.  The 
pEAV515 is a derivative of pEAV030 which was based on an EAV isolate that was 
extensively adapted to cell culture (over 300 passages) [64]. Recombinant EAV derived 
from this clone causes very mild clinical signs upon experimental infection of horses 
[327].  In contrast, pEAVrVBS derived from EAV VBS, can cause severe disease in 
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horses [328].  In both mutants, the ORF5a translation initiation codon (AUG to ACG: U-
11113C) was mutated and a premature termination codon was introduced at the 6th 
codon of ORF5a (G-11128A) (Figure 7.1).  The introduced mutations were carefully 
designed to be translationally silent with the overlapping GP4 coding sequence. 
 
 
Figure 7.1.  Schematic representation of ORF5a expression in EAV.  Translated 
ORF5a (blue) is overlapping with both ORFs encoding GP4 (purple) and GP5 (green).  
The start and stop codons of relevant ORFs are boxed.  The “U” and “g” nucleotides 
represent the mutations introduced to knockout ORF5a in the mutant Δ5a-2 viruses.  The 
TRS (grey box) for sg RNA5 synthesis is located far upstream and includes the ORF5a 
start codon and thus, the ORF5a is possibly expressed from the same sg mRNA as GP5 
by leaky ribosomal scanning.  Modified from Firth et al. [81]  
 
 
In vitro-transcribed full-length RNAs were electroporated into both BHK-21 and 
equine pulmonary artery endothelial cells (EECs).  Immunofluorescence staining with 
monoclonal antibody to nsp1 protein was performed to verify transfection efficiency at 
the early phase of virus replication (data not shown).  Virus titers in the medium of 
transfected cells were determined by plaque assay (Figure 7.2). ORF5a knockout mutants 
showed a reduction in virus titer of at least two logs and a tiny plaque size indicating the 
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progeny viruses of ORF5a knockout mutants had severely crippled phenotypes compared 
to the wild-type virus.  Therefore, this comparative study confirmed that the expression 
of ORF5a is critical for efficient EAV amplification irrespective of virus strain where the 
molecular clones are derived and cell lines used for analysis. 
 
Figure 7.2.  Comparison of plaque morphology of wild-type EAV and ORF5a 
knockout mutants.  (A) Plaque morpohology on BHK-21 cells and (B) on equine 
endothelial (EEC) cells.  In both molecular clones, Δ5a-2 plaque sizes and titers are 
severely reduced compared to those of the corresponding parental virus.  Modified from 
Firth et al. [81] 
 
 
7.4.  DISCUSSION 
In this study, we described evidence for the presence, conservation and biological 
significance of a novel short coding sequence in the 3’-proximal end of all arterivirus 
genomes. The ORF5a and the overlapping GP5 gene are likely to be expressed from a 
bicistronic sg mRNA.  The mutational inactivation of ORF5a in EAV has shown that 
ORF5a mutant has severely impaired replication indicating that its expression is 
important for virus life cycle.   To independently confirm the effect of the ORF5a knock 
out, we used two molecular clones derived from EAV strains with different virulence.  
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EAV strains can differ significantly in the severity of the disease they induce [15,328].  
The EAV515 was based on an EAV isolate that was extensively passaged in cell culture 
while the pEAVrVBS was based on EAV isolate, VBS, that causes severe disease in 
horses.   Regardless of the virus backbones used to inactivate ORF5a expression, the 
Δ5a-2 mutants had a severely crippled phenotype with tiny plaque sizes and lower virus 
titers.   In addition to BHK-21 cells, EECs of equine origin were also used to evaluate the 
replication of the mutant viruses in a more natural host cell.  In conclusion, these assays 
have independently confirmed that the expression of ORF5a is required for efficient EAV 
amplification, regardless of the background of the molecular clone and cell type used for 
analysis. 
Discovery of the new ORF5a protein drives arterivirus researchers to question 
whether any previous attempts to engineer EAV-based vectors could have been affected, 
inadvertently, by the presence of ORF5a.  For example, in a construct created by de Vries 
et al. [325] the overlap between ORF4 and ORF5 was removed and 24 nt were inserted to 
create an insertion site for foreign sequences.  Fortunately, the insertion site is in-frame 
with ORF5a and the change appears to be tolerated. Similarly, spontaneous insertion of 
12 nt into ORF5a of PRRSV-NA after passaging in cell culture 70 times seems to be 
tolerated [438].  In contrast, attempts to insert any other foreign sequences encoding GFP 
[439] or ectodomain of GP5 protein of other arteriviruses [147] into EAV-based vectors 
failed, possibly due to the disruption of ORF5a.   Therefore, the reason for crippled or 
non-viable phenotypes of some of previously reported constructs could be, at least 
partially, attributed to the disruption of ORF5a protein expression.   Thus, it would be 
important to engineer any arterivirus-based vector with care not to disrupt the expression 
of functional ORF5a protein.   
Unfortunately, the function of the ORF5a protein could not been determined in 
this study.  Several attempts to raise polyclonal antisera against the ORF5a using 
synthetic peptides containing the non-hydrophobic domain of this protein were 
unsuccessful.  Therefore, it was not possible either to confirm the presence of the ORF5a 
protein in virus particles or to perform a subcellular localization study in the infected 
cells.  However, in a parallel but independent study performed by Johnson et al. [440], 
the expression of the novel protein in cells infected with PRRSV was confirmed using 
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proteomic analysis.   This paper also described the production of antibodies recognizing 
the PRRSV ORF5a protein in infected pigs [440].  Therefore, both PRRSV-NA and EAV 
studies together strongly suggest that the ORF5a protein is the eighth structural protein of 
the arteriviruses, although further studies are needed to obtain more detailed information 
into its yet unknown function. 
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CHAPTER EIGHT 
 
Development of a fluorescent-microsphere immunoassay for detection of antibodies 
specific to equine arteritis virus and comparison with the virus neutralization test 
Clin Vaccine Immunol. 2008, 15(1): 76-87 
Reprinted with permission. 
 
 
8.1.  SUMMARY  
The development and validation of a microsphere immunoassay (MIA) to detect 
equine antibodies to the major structural proteins of equine arteritis virus (EAV) is 
described. This was based on cloning and expression of full-length individual major 
structural proteins (GP51-255;  M1-162; and N1-110) as well as the partial sequence of each 
structural protein (GP51-116; GP575-112; GP555-98; M88-162; and N1-69) that comprise putative 
antigenic regions of these proteins. Purified recombinant viral proteins expressed in E. 
coli were covalently bound to fluorescent polystyrene microspheres and analyzed with 
the Luminex xMap 100 instrument. Of the eight recombinant proteins, the highest 
concordance with the virus neutralization test (VNT) results was obtained with the partial 
GP555-98 protein. The latter assay was validated by testing a total of 2,500 equine serum 
samples previously characterized in the VNT. With use of an optimal cutoff value of 992 
mean fluorescence intensity (MFI), the sensitivity and specificity of the assay were 92.6% 
and 92.9%, respectively. The GP555-98 MIA and VNT test outcomes correlated 
significantly (r = 0.84; p-value<0.0001). Although the GP555-98 MIA is less sensitive than 
the standard VNT, it has the potential to provide a rapid, convenient, and more 
economical test for screening equine sera for the presence of antibodies to EAV, with the 
VNT then being used as a confirmatory assay. 
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8.2.  INTRODUCTION 
Equine arteritis virus (EAV) is the causative agent of equine viral arteritis (EVA), 
a respiratory and reproductive disease of horses [77]. EAV is a small enveloped virus 
with a positive-sense, single-stranded RNA genome of 12.7 kb and belongs to the family 
Arteriviridae (genus Arterivirus, order Nidovirales), which also includes porcine 
reproductive and respiratory syndrome virus, simian hemorrhagic fever virus, and lactate 
dehydrogenase-elevating virus of mice [7,34]. The EAV genome includes nine functional 
open reading frames [34,56]. Open reading frames (ORF) 1a and 1b encode two replicase 
polyproteins (pp1a and pp1ab) [34,56,100], and the remaining seven ORFs (2a, 2b and 3-
7) encode structural proteins of the virus. These include four membrane glycoproteins 
GP2 (25 kDa), GP3 (36-42 kDa), GP4 (28 kDa) and GP5 (30-44 kDa), respectively 
encoded by ORFs 2b, 3, 4, and 5, two unglycosylated membrane proteins E (8 kDa) and 
M (17 kDa) encoded by ORFs 2a and 6, and the phosphorylated nucleocapsid protein N 
(14 kDa) encoded by ORF7 [57,58,137]. The major envelope glycoprotein GP5 expresses 
the known neutralization determinants of EAV. The two major envelope proteins, GP5 and 
M, form a disulfide-linked heterodimer in the virus particle, and this association is critical 
for their maturation and for the expression of some of the neutralization epitopes in 
authentic form [67,68,73].  
Serological and clinical studies indicate that EAV is widely distributed in equine 
populations around the world [173,175,176]. Although there is considerable variation in 
the sequence of the GP5 protein of field strains of the virus, there is only one known 
serotype of EAV, and all strains evaluated thus far are neutralized by polyclonal antiserum 
raised against the prototype Bucyrus strain of EAV [69,70,71,72,74,75,76,158]. Both 
natural and experimental infections of horses with either virulent or avirulent strains of 
EAV result in long-lasting immunity against all strains of the virus [264,265,266]. Equine 
arteritis virus infection in horses induces antibodies against the three major viral 
structural proteins, GP5, M, and N [76,221,268]. Virus neutralizing (VN) antibodies are 
detectable between 1 to 2 weeks after primary infection, and their appearance usually 
coincides with the onset of clearance of virus from the circulation [240,441]. However, 
virus does persist in the male reproductive tract of certain stallions for long periods of 
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time despite the presence of high titers of virus-specific neutralizing antibodies in their 
serum.  
Serologic diagnosis of acute EAV infection of horses is based on demonstration of 
seroconversion or a ≥ 4 -fold increase in neutralizing antibody titer to the virus in paired 
(acute and convalescent) serum samples using the virus neutralization test (VNT). The VNT 
is the principal serological assay used to detect evidence of EAV infection by most 
laboratories around the world, and it continues to be the current World Organisation for 
Animal Health (OIE) prescribed standard test for EVA [77,292,442,443,444]. The assay is 
used for diagnostic, epidemiological surveillance, international trade, and vaccination 
monitoring purposes. The number of equine sera tested annually by a diagnostic laboratory 
can vary considerably, from several hundred to thousands of samples per year [443,444,445]. 
Although the VNT is currently the most highly sensitive and specific serodiagnostic test 
for this infection, it is expensive, labor-intensive, and time-consuming to perform. In 
addition, results tend to vary among laboratories, when adequate attention is not paid to 
standardization of both test reagents and procedure. Moreover, serum cytotoxicity caused 
by anti-cellular antibodies directed against rabbit kidney-13 (RK-13) cells can be 
mistaken for viral cytopathic effect and can give rise to difficulties in test interpretation at 
lower serum dilutions. To overcome these disadvantages, several laboratories have 
developed and evaluated enzyme-linked immunosorbent assays (ELISAs) to detect 
antibodies to EAV using whole virus, synthetic peptides, or recombinant viral proteins 
(e.g., GP5, M, and N) as antigens [70,75,254,274,275,304,305,306,446]. The various 
studies have shown that the source of antigen as well as the sera evaluated can markedly 
influence the results obtained with EAV protein specific ELISAs and competitive ELISA 
[76,80]. None of these ELISAs has yet been shown to be of equivalent sensitivity and 
specificity to the VNT. 
Recent developments in particle array technology have made it possible to perform 
immunoassays using microspheres (microbeads). The best-established microsphere assay 
system is the Luminex xMap system (Luminex Corp., Austin, TX), which incorporates 
three well-developed technologies: bioassays, solution phase microspheres, and flow 
cytometry. The microsphere assay technology developed by Luminex is ideally suited to 
a wide range of applications in drug discovery and diagnostics, as well as basic research. 
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Immunoassays based on this particle array technology can overcome the problems 
associated with the traditional VNT and ELISAs. Some of the distinct advantages of 
microsphere immunoassay (MIA) over traditional ELISAs include accuracy; high 
sensitivity, specificity, and reproducibility; high-throughput sample analysis; and 
multiplexing capability. MIAs are becoming increasingly popular for the serologic 
diagnosis of autoimmune and infectious diseases of humans and animals 
[447,448,449,450,451].  The primary objective of the present study was to develop a 
reliable immunological assay to detect antibodies to EAV in horses, using Luminex 
xMap technology, and to compare its performance with that of the VNT. The MIA could 
be suitable to detect antibodies to EAV in equine sera and the specificity and sensitivity 
of this assay should be equivalent to that of the standard VNT.   
 
8.3.  MATERIALS AND METHODS 
Cells  
High-passage (P399 to P409) rabbit kidney-13 (RK-13) cells were propagated and 
maintained in Eagle’s minimum essential medium (EMEM; Mediatech, Herndon, VA) 
supplemented with 10% fetal calf serum (FCS; Hyclone, Logan, UT), 100U/ml penicillin, 
100μg/ml streptomycin, 1μg/ml amphotericin B and 0.06% sodium bicarbonate at 37°C 
[452]. 
 
Equine sera 
A total of 2,500 diagnostic equine serum samples were evaluated for the presence 
of anti-EAV antibodies by the MIA and VNT. The sera used in the study were selected 
randomly from those submitted for serological testing to the OIE EVA Reference 
Laboratory, Gluck Equine Research Center (n = 1,500) and the Livestock Disease 
Diagnostic Center (n = 1,000), University of Kentucky, Lexington, Kentucky. Panels of 
EAV antibody-positive and antibody-negative sera from the Gluck Equine Research 
Center were selected and used to establish normal MIA ranges for negative and positive 
samples. In addition to these sera, archived sequential serum samples collected from 18 
experimentally infected horses were evaluated with respect to the EAV specific antibody 
response by both VNT and MIA. The horses were divided into four groups and each 
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group was inoculated with a different strain of EAV (rVBS: n = 4; 030H: n = 2; KY84: n 
= 7; and CA95G: n = 5) [154,224,327,453]. Blood samples were collected at 0, 2, 4, 6, 8, 
10, 12, 14, 21, 28, 35, and at 42 days post infection (dpi) for the EAV rVBS-inoculated 
horses; at 0, 2, 4, 6, 8, 10, 12, 14, and 21 dpi for the EAV 030H-inoculated horses; at 0, 2, 
4, 6, 8, 10, 12, 14, 21, and 28 dpi for the EAV KY84-inoculated horses, and at 0, 2, 4, 7, 
9, 14, 21, 28, and 35 dpi for the EAV CA95G-inoculated horses. Sera were aliquoted and 
stored at -20°C.    
 
PCR amplification, cloning, and sequencing of full-length and truncated versions of 
ORFs 5, 6, and 7 of EAV 
The oligonucleotide primers for amplification of the coding sequences of the GP5, 
M, and N proteins (ORFs 5, 6, and 7, respectively) as well as the corresponding partial-
length proteins were designed according to the published sequence of the EAV VBS 
(GenBank accession number: DQ846750) [453]. The nucleotides 5’-CACC-3’ were 
added at the 5’ end of each primer for directional cloning into the pET TOPO® vector 
(Invitrogen, Carlsbad, CA; Table 8.1). The full-length ORFs 5, 6, and 7 (that respectively 
encode full-length GP5, M, and N proteins), as well as the coding region for the amino-
terminal ectodomain (aa 1-116) and two antigenic regions (aa 55-98 and aa 75-112) of 
the GP5 protein [70,274,446], the antigenic carboxyl terminal (aa 88-162) of the M 
protein [280], and the antigenic amino terminal (aa 1-69) region of the N protein [275], 
were PCR-amplified from the plasmid containing the complete genomic sequence of the 
EAV VBS strain (pEAVrVBS; GenBank accession number DQ846751) [453] using Pfu 
DNA polymerase enzyme (La Jolla, Stratagene, CA). PCR amplification was performed 
according to the manufacturer’s instructions. The individual PCR products were 
concentrated using a Centricon (Ultracel YM-30; Millipore, Billerica, MA) and purified 
using a commercial kit (Qiagen, Valencia, CA). The individually amplified cDNA 
fragments encoding EAV ORFs 5, 6, 7 and their respective truncated forms were then 
directly cloned into the pET100 Directional TOPO® vector according to the 
manufacturer’s instructions (ChampionTM pET100/D-TOPO® Expression kit; Invitrogen, 
Carlsbad, CA). The pET100/D-TOPO allows expression of a
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Table 8.1. Primer pairs used for PCR amplification of full-length and partial-length segments of ORFs 5, 6, and 7.  
ORF Protein Sense Sequencea 
Nucleotide 
position 
Size 
(bp) 
Recombinant 
plasmid 
5 
GP51-255 
+ 5'-CACCATGTTATCTATGATTGTATTG-3' 11146-11166 
772 pET-GP51-255 
- 5'-CTATGGCTCCCATACCTCAG-3' 11913-11894 
GP51-116 
+ 5'-CACCATGTTATCTATGATTGTATTG-3' 11146-11166 
355 pET-GP51-116 
- 5'-CTAGAATTCACGGCCATAGTAA-3' 11493-11475 
GP555-98 
+ 5'-CACCTACAATTGTTCCGCCAGTAAAAC-3' 11308-11330 
139 pET-GP555-98 
- 5'-CTACGGTCCATGCGCCTGTTCC-3' 11439-11421 
GP575-112 
+ 5'-CACCACGTTTGGAACCGATTG-3' 11368-11384 
121 pET-GP575-112 
- 5'-CTAATAGTAAATAAAAGGGGGCATGTC-3' 11481-11458 
6 
M1-162 
+ 5'-CACCATGGGAGCCATAGATTC-3' 11901-11917 
493 pET-M1-162 
- 5'-TCATTGTAGCTTGTAGGCTGTCG-3 12389-12367 
M88-162 
+ 5'-CACCATGCCTCGTCTTCGGTCC-3' 12162-12179 
232 pET-M88-162 
- 5'-CTATTGTAGCTTGTAGGCTGTCGCCG-3' 12386-12364 
7 
N1-110 
+ 5'-CACCATGGCGTCAAGACGATCACG-3' 12313-12332 
337 pET-N1-110 
- 5'-TTACGGCCCTGCTGGAGGCGC-3' 12645-12625 
N1-69 
+ 5'-CACCATGGCGTCAAGACGATCACG-3' 12313-12332 
211 pET-N1-69 
- 5'-CTAGTTCGACGAAAGGGTGGCGCG-3' 12519-12499 
a Underline indicates the overhang sequence to enable directional cloning to pET TOPO® vector
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recombinant protein with an XpressTM epitope and a polyhistidine (6×His)-tag at the 
amino terminus of each recombinant protein. Plasmids containing individual ORFs were 
transformed into One Shot® competent E. coli (Invitrogen, Carlsbad, CA). Following 
transformation and purification, individual plasmids were identified and characterized by 
restriction enzyme analysis for correct orientation of the insert. The authenticity of each 
ORF and of each truncated version was confirmed by automatic sequencing as previously 
described [80]. 
 
Expression and purification of full length GP5, M, N and their respective partial-
length recombinant proteins 
Plasmids pET-GP51-255, pET-GP51-116, pET-GP575-112, pET-GP555-98, pET-M1-162, 
pET-M88-162, pET-N1-110 and pET-N1-69 were purified and used to transform the BL21 
StarTM (DE3) strain of E. coli for expression of the recombinant proteins. The E. coli 
strain BL21 StarTM (DE3) is especially designed for expression of genes regulated by the 
T7 promoter. Following transformation with each expression plasmid, a single colony 
was grown for approximately 3 h at 37°C in 2 ml of Luria-Bertani liquid medium 
supplemented with 200 μg/ml of carbenicillin (LBC). Thereafter, 50 μl of the culture was 
plated out on a LBC agar plate and incubated overnight at 37°C. On the next day, 
bacterial colonies on the agar plate were scraped off with a sterile tissue culture scraper 
and added to a 2-L flask containing 500 ml of LBC medium. Cultures were grown to a 
density of 0.5-0.7 at OD600. Protein expression was induced with 0.5mM isopropyl-β-D-
thiogalactopyranoside (IPTG). Bacterial cells were harvested 5 h after induction, by 
centrifugation at 3000 ×g for 15 min at 4°C. Cell pellets were either stored at -80°C or 
immediately used for further processing.  
The recombinant GP51-255, GP51-116, GP575-112 and GP555-98 proteins were 
purified using a Ni-NTA purification system (Invitrogen, Carlsbad, CA) under hybrid 
conditions. Briefly, individual cell pellets were resuspended in guanidinium lysis buffer 
(6M guanidine HCl, 20mM sodium phosphate, 500mM NaCl; pH7.8) containing 
lysozyme (1mg/ml) and proteinase inhibitors (Halt Proteinase Inhibitor Cocktail kit, 
Pierce, Rockford, IL) and slowly mixed on a rocker for 10 min at room temperature. 
After incubation, cell pellets were lysed by sonication with shortwave pulses of 10 sec at 
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high intensity (output 5). Subsequently, the crude lysates were centrifuged at 3000 ×g for 
15 min at 4°C to remove bacterial cellular debris. The supernatant was loaded onto a Ni-
NTA agarose column and allowed to bind for 1 h at room temperature. After binding, the 
agarose containing column was washed twice with denaturing binding buffer (8M urea, 
20mM sodium phosphate, 500mM NaCl; pH7.8) and twice with denaturing wash buffer 
(8M urea, 20mM sodium phosphate, 500mM NaCl; pH6.0), to wash off non-specifically 
bound proteins. Subsequently, protein-bound agarose was washed four times with native 
wash buffer (50mM NaH2PO4, 0.5M NaCl, 10mM imidazole; pH8.0). Finally, each 
recombinant protein was eluted from the column with 2-ml fractions of native elution 
buffer pH8.0 (50mM NaH2PO4, 0.5M NaCl, 250mM imidazole; pH8.0).  
Unlike the GP5 recombinant proteins, the recombinant full-length M1-162, M88-162, 
full-length N1-110, and N1-69 proteins were purified under native conditions. Briefly, 
individual cell pellets were resuspended in native binding buffer (50mM NaH2PO4, 0.5M 
NaCl; pH8.0) containing lysozyme (1mg/ml) and proteinase inhibitors (Halt Proteinase 
Inhibitor Cocktail kit, Pierce, Rockford, IL) and incubated on ice for 30 min. After 
incubation, cell pellets were lysed by sonication with shortwave pulses of 10 sec at high 
intensity (output 5). Subsequently, the crude sonicates were centrifuged at 3000 ×g for 15 
min at 4°C to remove cellular debris. The supernatant was loaded onto a Ni-NTA agarose 
column and allowed to bind for 2 h at 4°C. The recombinant proteins were eluted in 
native elution buffer (pH8.0) as described above.  
Fractions containing the same recombinant protein were pooled together and 
centrifuged at 3,000 ×g for 45 min, with an Amicon® Ultra 5K (Millipore, Billerica, MA) 
centrifugal filter device used to increase recombinant protein concentration. After 
concentration, individual proteins were dialyzed against phosphate-buffered saline (PBS; 
pH=7.4) overnight at 4°C. Final protein concentration was determined using a BCA 
protein assay (Pierce, Rockford, IL), and the proteins were stored at -80°C.  
 
Western immunoblotting assay 
The authenticity of the purified recombinant proteins was confirmed by Western 
immunoblotting assay as previously described [75,151]. Briefly, proteins were mixed 
with an equal volume of 2X Laemmli sample buffer (Bio-Rad, Hercules, CA) containing 
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62.5 mM Tris-HCl, pH 6.8, 2% SDS, 25% glycerol, 0.01% bromophenol blue, and 
200mM of dithiothreitol (Pierce, Rockford, IL) and incubated for 15 min at room 
temperature. Denatured samples were loaded onto sodium dodecyl sulfate-12% 
polyacrylamide resolving gels and a 5% stacking gel. Following electrophoresis, 
recombinant proteins were transferred onto a PVDF membrane (Bio-Rad, Hercules, CA). 
Immunoblotting was performed by using 5% nonfat dried milk powder in Tris-buffered 
saline with 0.05% Tween 20 (pH7.6) as the blocking solution. Expression and 
authenticity of each recombinant protein were confirmed using antibodies against the N-
terminal 6×His tag as well as individual EAV protein-specific monoclonal antibodies 
MAb 6D10 for GP5 [75]; MAb 3E2 for N [213] and rabbit anti-EAV M #7888 for M 
protein [268]. Bound antibodies were detected by enhanced chemiluminescence, as 
previously described [75].   
 
Virus neutralization test (VNT) 
The neutralizing antibody titers of the test sera were determined as described by 
Senne et al. [292,337]. Briefly, serial two-fold dilutions of each sample from 1:2 to 1:256 
were made in MEM (Invitrogen, Carlsbad, CA) containing 10% guinea pig complement 
(Rockland Immunochemicals, Gilbertsville, PA). Each serum sample was tested in 
duplicate in 96-well plates. An equal volume of a working dilution of virus containing an 
estimated 200 TCID50 of the modified live virus strain of EAV (ARVAC®, Ft. Dodge 
Animal Health) was added to each well, except the serum controls. The plates were 
shaken to ensure mixing of the well contents and then incubated for 1h at 37°C. A 
suspension of high passage (P399 to P409) RK-13 cells was added to each well in a 
volume equivalent to that of the serum-virus mixtures and incubated for 72 h at 37°C, 
until viral cytopathic effect had fully developed in the virus control wells. The titer of a 
sample was recorded as the reciprocal of the highest serum dilution that provided at least 
50% neutralization of the reference virus. 
 
Coupling of recombinant proteins to microspheres 
Approximately 50 μg of each recombinant protein were covalently conjugated to 
carboxyl groups on the surface of xMap Multi-Analyte COOH Microspheres according 
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to the manufacturer’s protocol (Luminex Corp, Austin, TX). Each recombinant protein 
was attached to 6.25 X 106 microspheres, and the microspheres were counted with a 
hemocytometer so that equivalent quantities of each specific bead set were incorporated 
into the assay. 
 
Development of microsphere immunoassay 
A 96-well 1.2 μm filter plate was blocked for 2 min with 100 μl of PBS (pH7.4) 
with 1% bovine serum albumin and 0.02% sodium azide (PBN buffer) and then washed 
once with 190 μl of PBS (pH7.4) with 0.05% Tween 20 (PBS-T buffer). Wells were kept 
moist by addition of 20 μl of PBN buffer. Equine sera (50 μl, diluted 1:100 in PBN 
buffer) were added to each well of the filter plate. Approximately 2,500 recombinant 
antigen-conjugated microspheres per protein were added to each well in 50 μl of PBN 
buffer. The plate was incubated on a shaker in the dark for 30 min at 37°C and then 
washed three times with PBS-T using a vacuum manifold. Affinity-purified biotin-
labeled goat anti-equine IgG (50 μl of a 1:1000 dilution in PBN) was added, and the plate 
was incubated on a shaker in the dark for 30 min at 37°C and then washed twice with 
PBS-T. Streptavidin-conjugated with R-phycoerythrin (50 μl of a 1:100 dilution in PBN 
buffer) was added, and the plate was incubated on a shaker in the dark for 30 min at 37°C 
and then washed twice with PBS-T using a vacuum manifold. The microspheres were 
then resuspended in 125 μl of PBN per well, and 75 μl of suspension were transferred to 
a clear polystyrene 96-well plate. Microspheres were aspirated through the flow cell of a 
dual-laser Luminex 100 instrument. The median fluorescence intensity (MFI) of 100 
microspheres of each specific protein was recorded for each well. 
 
Statistical analysis 
A comparison of the diagnostic performance of the tests, VNT and MIA based on 
the GP555-98 and N1-110 proteins, was conducted using nonparametric density estimation 
and receiver operating characteristic (ROC) analysis. An ROC curve provides a graphical 
measure of the accuracy of a continuous diagnostic test.  It represents a plot of the true 
positive fraction (TPF) versus the false positive fraction (FPF) across all possible cutoff 
values that can be used to dichotomize the data into positive or negative outcomes.  In 
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addition to the ROC curve, a related parameter of interest is the area under the curve 
(AUC).  For continuous tests, the AUC equals the probability that a randomly selected 
diseased individual has a test score that is greater than that for a randomly selected non-
diseased individual.  A diagnostic test that perfectly discriminates between non-diseased 
and diseased individuals has an ROC curve that is expressed by the horizontal line 
TPF=1 with the corresponding AUC=1.  Diagnostic tests that are purely random, and 
hence are worthless, have a ROC curve expressed by the 45 degree angle line with a 
corresponding AUC=0.5 [454]. 
Cross-sectional data were obtained from a dual test study design in which both 
tests were carried out on sera from 2,500 horses, and where the true infection status of 
each horse was determined using the definitive gold-standard test, the VNT. The 
Pearson’s correlation coefficient was estimated for the GP555-98 based MIA and VNT. A 
Bayesian bivariate normal analysis of the log transformed joint (GP555-98, N1-110) 
outcomes was used to estimate ROC curves and area under the curve (AUC) based on 
methods developed by Choi et al. [455]. Specifically, data derived using sera from 
infected horses were modeled as a bivariate normal with unknown mean vector, (μGP555-98, 
μN1-110), and an unknown covariance matrix that contained three parameters, namely, the 
(marginal) variances for the GP555-98 test and for the  N1-110 test, and the correlation 
between GP555-98 and N1-110 test values. Independent diffuse normal prior distributions 
with a mean of 0 and variance of 100 were placed on μGP555-98 and  μN1-110, and 
independent inverse gamma priors with a mean of 1 and a variance of 1000 were used for 
the variances. The correlation was assigned a uniform prior ranging from -1 to 1. A 
bivariate normal distribution was also used to model the data for non-infected horses, 
with the same prior specification as used for infected horses.     
Results from the ROC analysis were used to determine an optimal cutoff value for 
the purpose of classifying horses as EAV antibody-positive or –negative, based on the 
outcome of the GP555-98 MIA test. The sensitivity and specificity of the GP555-98 MIA test 
were then estimated at this cutoff value using Bayesian methods. The analysis was 
performed in S-Plus (Insightful Corp., Seattle, WA) and WinBUGS [456]. 
The sensitivity for each recombinant EAV structural protein-based MIA was 
calculated with: (number of true positives/[number of true positives + number of false 
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negatives]) × 100. Test specificities were calculated using the following equation: 
(number of true negatives/[number of true negatives + number of false positives]) × 100.  
 
8.4.  RESULTS 
Cloning, expression, and purification of recombinant proteins 
Following PCR amplification, all major structural protein genes and their 
corresponding partial-length ORFs were individually cloned into the pET100/D-TOPO 
vector. The recombinant protein from each construct was expressed as a bacterial fusion 
protein with an N-terminal tag containing the Xpress epitope and a 6×His tag (Figure 8.1 
A). Various temperatures and IPTG concentrations were evaluated, to optimize the 
conditions for protein expression. With the exception of recombinant GP51-255 and its 
partial-length proteins (GP51-116, GP575-112 and GP555-98), all expressed recombinant 
proteins were present in the soluble fraction of the E. coli lysate. The insoluble GP5 
recombinant proteins had to be purified under hybrid conditions instead of native 
conditions, which were successful for the soluble recombinant proteins (M1-162, M88-162, 
N1-110, and N1-69). 
The expression and authenticity of the recombinant proteins were confirmed by 
Western immunoblotting assays. EAV structural protein-specific antibodies strongly 
reacted with their respective recombinant proteins (Figure 8.1.B). In addition, the 
attachment of a 6×His tag to the expressed proteins was demonstrated by Western 
immunoblotting with HRP-labeled anti-HisG antibody (data not shown). 
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Figure 8.1.  Recombinant EAV structural proteins expressed in E. coli.  (A) 
Schematic representation of various EAV structural proteins expressed in E. coli.  The 
recombinant full-length proteins derived from EAV ORFs 5, 6, 7 and their respective 
truncated versions are depicted. The black bars denote full-length proteins and the open 
bars denote partial-length proteins. The putative major neutralization sites A (aa 49), B 
(aa 61), C (aa 67-90) and D (aa 99-106) located in the N-terminal ectodomain of GP5 
protein are indicated by hatched boxes. (B) Western blot analysis of purified bacterial 
recombinant proteins with EAV protein-specific MAbs and rabbit antisera. Monoclonal 
or rabbit EAV-specific antibodies used to detect each recombinant protein are indicated 
at the bottom of the figure. The MW marker is indicated on the right. The molecular 
masses of recombinant GP51-255, GP51-116, GP575-112, GP555-98, N1-110, N1-69, M1-162 and 
M88-162 proteins were 32, 17, 7, 8, 15.3, 10.6, 20.6 and 11kDa, respectively.  
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Virus neutralization test  
Of the 2,500 equine serum samples tested, 1,750 were negative for VN antibodies 
to EAV (titers <1:4). A total of 750 sera were positive for antibodies to EAV, with titers 
ranging from 1:4 to ≥1:512. 
In addition to the diagnostic samples, a panel of 192 archived sequential sera from 
18 horses experimentally infected with different strains of EAV was evaluated using the 
VNT. The horses experimentally inoculated with EAV rVBS, 030H and KY84 strains 
developed VN antibodies to EAV after 7-10 days post-exposure (Figure 8.2.A, B, and C). 
Sera from horses inoculated with EAV rVBS and KY84 had VN antibody titers ranging 
from 1:128 to 1:1024. The majority of horses in these two groups of horses maintained a 
titer of ≥1:512 throughout the study. Horses infected with EAV 030H laboratory strain 
developed lower antibody titers ranging from 1:32 to 1:64. In contrast, horses inoculated 
with the avirulent CA95G strain developed detectable serum antibody titers from 14 dpi 
to 35 dpi (Figure 8.2.D). Neutralizing antibody titers in sera from the CA95G inoculated 
horses were generally lower than those in horses inoculated with the other 3 virus strains, 
ranging only from 1:4 to 1:16. Only one horse in this group developed a high antibody 
titer (1:256). 
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Figure 8.2.  Comparison of antibody response to EAV as determined by GP555-98 
MIA and VNT using sequential serum samples from experimentally infected horses.  
The reciprocal VN titers and MFI values of horses inoculated with different EAV strains, 
EAV rVBS (A, E), EAV 030H (B, F), EAV KY84 (C, G), and CA95G (D, H) are plotted 
against days post inoculation (dpi). Virus neutralizing antibody response in horse 
experimentally infected with EAV rVBS (n = 4), EAV 030H (n = 2), EAV KY84 (n = 7), 
and EAV CA95G (n = 5) measured by standard VNT (A, B, C and D). Virus antibody 
response in horsed experimentally infected with EAV rVBS (4), EAV 030H (n = 2), 
EAV KY84 (n = 7), and EAV CA95G (n = 5) measured by GP555-98 MIA (E, F, G and 
H).  
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Development of EAV recombinant structural proteins-based MIAs 
Eight expressed recombinant proteins were used to coat polystyrene microbeads 
in development of the MIAs. The optimal dilution of the test sera to be used in the MIAs 
was predetermined by the use of known strong positive titer (≥1:512) and negative (<1:4) 
equine sera. The optimal working dilution was considered the serum dilution with lowest 
background activity from non-specific reactions. At a serum dilution of 1:100, the 
maximal dynamic range was attained for all the recombinant proteins; this was defined as 
the optimal serum dilution in the case of each protein (Figure 8.3).  
 
 
Figure 8.3.  GP555-98 and N1-110 MIA analyses of serially diluted serum samples.  Sera 
from horses with EAV neutralizing antibodies and negative control equine serum were 
serially diluted and evaluated in the GP555-98 and N1-110 MIAs. The median fluorescent 
intensity (MFI) for each dilution of standard was determined. Results are reported as MFI 
per 100 microspheres.  
 
 
To establish cutoff levels for the MIAs specific for each EAV recombinant 
protein, 20 equine sera from known EAV-seronegative horses were used. The MIA 
positive cutoff for each protein was established at three standard deviations above the 
mean microsphere MFI of the known VNT negative sera. The mean MFI for GP51-255 
was 279.5 (SD, 345) with an assay cutoff of 1315; the mean MFI for GP51-116 was 237.9 
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(SD, 321) with a cutoff of 1202; the mean MFI for GP575-112 was 220.8 (SD, 160.4) with 
a cutoff of 702; the mean MFI for GP555-98 was 263.1 (SD, 245) with a cutoff of 998; the 
mean MFI for M1-162 was 344.7 (SD, 209.4) with a cutoff of 973; the mean MFI for M88-
162 was 377.3 (SD, 228.4) with a cutoff of 1063; the mean MFI for N1-110 was 432.1 (SD, 
161.7) with a cutoff of 917; and the mean MFI for N1-69 was 216.6 (SD, 166.5) with a 
cutoff of 716. Samples with MFI values above the cutoff value were designated as 
positive, and those below that value were considered negative. Subsequent analysis of 
125 positive (VNT titers ranging from 1:4 to >1:512) and 125 neutralizing antibody 
negative sera tested in parallel in the VNT allowed evaluation of the performance of each 
recombinant protein (n = 250) in the MIA. MIAs based on recombinant GP5 proteins had 
high specificity. The specificity of GP51-255, GP51-116, and GP575-112 based-MIAs was 
98.4%, with only two false positive results out of 125 VNT antibody-negative samples. 
The GP555-98-based MIA had a slightly lower specificity, 97.6%, than did the other GP5-
based MIAs. The sensitivities of the GP51-255 and GP5 1-116 based MIAs were the lowest 
among all of the proteins (3.2% and 5.6%, respectively), detecting only 4/125 and 7/125 
VNT-positive samples. The sensitivities of the recombinant GP575-112 and GP555-98 based 
MIAs were higher (41.6% and 77.6%, respectively) and with detection of 52/125 and 
97/125 VNT-positive sera, respectively. Both M protein-based MIAs, (M1-162 and partial 
M88-162), had a high specificity (97.6% and 98.4% respectively), and correctly detected 
122/125 and 123/125 VNT seronegative samples. However, both had very low sensitivity 
(6.4%) and only detected anti-EAV antibodies in 8/125 VNT-positive sera. The 
sensitivity of the recombinant N1-69 based MIA was also very poor; it only detected anti-
EAV antibodies in 10/125 (8.0%) VNT-positive sera. In contrast, full-length N1-110 
detected anti-EAV antibodies in 77/125 VNT-positive sera resulting in a significantly 
higher sensitivity (61.6%). In summary, these results confirm that MIAs based on GP51-
255, GP51-116, GP575-112, N1-69, M1-162 and M88-162 were markedly less sensitive than the N1-
110 and GP555-98  MIAs (61.6% and 77.6%, respectively) in detecting anti-EAV antibodies 
in equine sera, as compared to the VNT (Table 8.2). Accordingly, the MIAs based on 
recombinant proteins that showed poor sensitivity were excluded from further study, and 
only GP555-98 and N1-110 protein-based MIAs were selected for further development and 
validation.    
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Table 8.2.  Sensitivities and specificities of MIAs using individual recombinant EAV 
structural proteins 
Recombinant EAV structural 
protein 
Sensitivity (%)a Specificity (%)b 
GP51-255 3.2 98.4 
GP51-116 5.6 98.4 
GP575-112 41.6 98.4 
GP555-98 77.6 97.6 
M1-162 6.4 97.6 
M88-162 6.4 98.4 
N1-110 61.6 91.2 
N1-69 8 97.6 
a,b Based on testing of 125 VNT-positive and 125 VNT-negative serum samples 
 
Validation of the GP555-98 and N1-110 based MIAs 
The same panel of 2,500 diagnostic equine sera evaluated in the VNT was 
analyzed for the presence of EAV-specific antibodies using GP555-98 and N1-110-based 
MIAs. Of the 750 VNT-positive sera, only 698 were determined to be positive by the 
GP555-98 MIA. The GP555-98 MIA failed to detect anti-EAV antibodies in 52 serum 
samples that were confirmed to be seropositive in the VNT (52 false negatives). 
Furthermore, only 1644 of the 1,750 VNT-negative sera gave negative results with the 
GP555-98 MIA assay. This indicated that GP555-98 gave 106 false positive results compared 
to the VNT. The overall sensitivity and specificity of the GP555-98 MIA were 93.1% and 
93.9%, respectively. Similarly, the N1-110 MIA gave 256 false negatives (only 494/750 
were positive) and 374 false positive (1376/1750 were negative) results, as compared to 
the VNT. The sensitivity and specificity of the N1-110 MIA were 65.9% and 78.6%, 
respectively.  
As mentioned previously, the cutoff values were assigned on the basis of three 
standard deviations above the mean MFI of 20 EAV antibody-negative equine sera. 
However, the cutoff value calculated according to this method varied slightly for each of 
the protein-coated bead sets; this could be a factor contributing to the differences in 
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sensitivity observed between the MIA and standard VNT. Moreover, a statistical 
approach using the negative reference population assumes a normal distribution of the 
test variable and does not consider the sensitivity of the assay [457]. Both sensitivity and 
specificity are important parameters when a diagnostic test is applied to a given 
population and an alternative approach to determination of the cutoff value is to consider 
both the negative and positive reference populations [458,459,460]. Such an approach 
was adopted in this study by using nonparametric ROC analysis to define the cutoff value 
with the entire equine serum data set derived from the study. Such an approach to 
tabulation of results is recommended in comparative studies of this type, in order to 
eliminate variability in the day-to-day performance of the assay [461]. By using the ROC 
analysis, a recalculated optimal cutoff value to classify sera as positive or negative was 
992 MFI. With this cutoff, the sensitivity and specificity of GP555-98 MIA were 92.6% 
and 92.9% respectively, as compared to the VNT (Table 8.3). The cutoff value that 
maximizes the tradeoff between sensitivity and specificity of the N 1-110 based MIA was 
1261.43.  At this cutoff, the estimated sensitivity and specificity were 88.3% and 54.7%, 
respectively.   
 
Table 8.3. Sensitivity and specificity of VNT and GP555-98 MIA for determination of 
antibodies to EAV 
Total 
no. of 
samples 
 VNT  GP555-98 
 
Negative Positive 
 
Negativea Positivea 
Sensitivityb % 
(95% CI)c 
Specificityb % 
(95% CI)c 
2500 
 
1750 750 
 
1694 806 
92.6 
(90.1-94.3) 
92.9 
(91.7-94.1) 
a Determined according to the optimal cutoff 992 MFI 
b Sensitivity and specificity calculated using Bayesian analysis. 
c CI, credible interval 
 
 
The results from both recombinant protein-based MIAs were subjected to 
Bayesian analysis. The area under the ROC curve for both GP555-98 and N1-110 MIAs was 
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compared to that for the VNT. The area under curve (AUC) for the GP555-98 MIA was 
higher (AUC=0.983 with a 95% credible interval, the Bayesian analog of a confidence 
interval, of 0.979 to 0.986) than the AUC for the N1-110 MIA (AUC=0.772 with a 95% 
credible interval of 0.751 to 0.793; Fig. 8.4.). This result confirms that the diagnostic 
accuracy of the GP555-98 based MIA is significantly higher than the N1-110 based MIA; it 
can reliably detect anti-EAV antibodies in equine sera.  
 
Figure 8.4.  ROC curves depicting the sensitivity and specificity of the GP555-98 and 
N1-110 MIAs compared to the VNT.  An ROC curve represents a plot of the true positive 
fraction (TPF) versus the false positive fraction (FPF) across all possible cutoff values 
that can be used to dichotomize the data into positive or negative outcomes. In addition to 
the ROC curve, a related parameter of interest is the area under the curve (AUC). 
Estimated ROC curves (solid lines) with pointwise 95% credible bands (dashed lines) for 
the GP555-98 MIA and N1-110 MIA are indicated. 
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A correlation analysis was performed between the GP555-98 MIA and the VNT. 
This indicated that there was a significant correlation between the outcomes of the GP555-
98 MIA and the standard VNT (r = 0.84; p-value<0.0001; Figure 8.5).   
 
Figure 8.5.  Analysis of the correlation analysis between the GP555-98 MIA and the 
VNT for detection of anti-EAV antibodies in equine sera.  GP555-98 MIA scatter plot 
versus VNT using 2,500 equine sera is depicted on the log2 scale.  The VNT data were 
plotted on the X-axis and the MIA data were plotted on the Y-axis. 
 
 
Comparison of the sensitivity of the GP555-98 MIA and VNT using sequential serum 
samples from experimentally inoculated horses 
A panel of 192 archived sequential serum samples from 18 horses comprising 
four groups, each inoculated with a different strain of EAV, was used to compare the 
antibody response detected by the GP555-98 MIA and the VNT [154,327,453]. 
 Analysis of sera collected from EAV rVBS (n = 4) and EAV 030H (n = 2) 
inoculated horses gave a reactive signal in the GP555-98 MIA from day 8 pi. The MFI 
values for sera collected from day 8 to 42 were positive, with values ranging respectively 
for the two strains from 2,541 to 27,736 (Figure 8.2.E) and from 1,295 to 21,874 (Figure 
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8.2.F). Seroconversions detected by the GP555-98 MIA were in full agreement with the 
VNT results, where neutralizing antibodies were also detected from day 8 (Figure 8.2.A 
and 8.2.B). Similarly, reactive signals were detected in sera from horses inoculated with 
EAV KY84 (n = 7) from dpi 7 (two horses) and dpi 10 (other horses). The MFI values in 
sera from horses inoculated with EAV rVBS, 030H and KY84 ranged from 1,648 to 
27,142. The only discrepancy between the results of the GP555-98 MIA and the VNT 
involved serum from one horse (SD7925), which had a threshold neutralizing antibody 
titer (1:4) on day 7 (Figure 8.2.C); this sample was not positive in the MIA (Figure 8.2.G).  
In general, the pattern of antibody development determined with the GP555-98 MIA 
correlated very well with the pattern found using the standard VNT. Both assays detected 
EAV-specific antibodies in samples collected after 10 dpi. If consideration is given to the 
fact that the two tests measure antibodies on different scales, there was greater variability 
in results using the MIA than the VNT. Despite this, the sensitivity of the MIA was not 
affected by this variability. 
 In contrast, when 44 sequential serum samples from 5 horses inoculated with the 
highly attenuated EAV CA95G strain were used to compare the GP555-98 MIA and the 
VNT, the GP555-98 MIA failed to give consistent positive reactive signals (Figure 8.2.H). 
The earliest reactive signal detected by the GP555-98 MIA was on 28 dpi for horse 9624, 
whereas the latter had detectable low levels of neutralizing antibodies from 14 dpi when 
tested by the VNT (Figure 8.2.D). Similarly, horse number 5582 had a threshold 
neutralizing antibody titer (1:4) on day 28 in the VNT; this was not detected by the 
GP555-98 MIA which only had reactive signals from 35 dpi. Horse number 9131 
developed a low neutralizing antibody titer (1:8) by 35 dpi which was detected by the 
GP555-98 MIA. Horses number 9715 and 9649 did not show reactive signals at all whereas 
VN antibodies were detected at low levels from 14 dpi. The MFI values of the antibody-
positive sera from CA95G inoculated horses ranged from 1,055 to 4,688.  
 
8.5.  DISCUSSION 
This study evaluated a newly developed MIA based on GP555-98 as an alternative 
diagnostic procedure for the detection of antibodies to EAV. Evaluation of various forms 
of recombinant viral structural proteins (e.g., full-length proteins, and partial-length 
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proteins containing the antigenic regions) allowed identification of the best recombinant 
protein antigen for use in the MIA. Previous reports have shown that two bacterial fusion 
proteins (aa 1-116 and 55-98) and a synthetic peptide (aa 81-106), both based on GP5 of 
EAV, can be used as effective diagnostic antigens in ELISAs [274,446]. It has been 
previously demonstrated that horses immunized with portions of GP5 expressed either in 
bacteria (aa 55-98) or as a synthetic oligopeptide (aa 75-97) developed EAV-neutralizing 
antibodies [70,446]. Chirnside et al. (1995) used a series of recombinant bacterial fusion 
proteins derived from EAV ORF7 to define the immunoreactive region of the viral 
nucleocapsid (N) protein [275]. These studies indicated that the major N-protein epitope 
that reacts with anti-EAV equine sera is located within the aa residue segment 1-69 in the 
terminal region of the protein. Similarly, it has been demonstrated that only the carboxyl 
terminal sequence (aa 88-162) of the M-protein is necessary to identify equine serum 
antibodies specific to the EAV M protein; it was further suggested that this region should 
be useful for the serodetection of EAV infected horses [280]. On the basis of the 
foregoing, it was decided to express the full-length GP51-255, M1-162 and N1-110 and various 
antigenic regions of the GP5 (aa 1-116, 75-112 and 55-98), M88-162 and N1-69 proteins as 
bacterial fusion proteins to be used in MIAs to detect antibodies to EAV. When the 
sensitivity and specificity of these different MIAs and the VNT were compared, all of the 
MIAs with the exception of the MIA based on GP555-98 bacterial fusion protein, were of a 
very low specificity and sensitivity; accordingly, they were considered unsuitable as sero-
diagnostic assays for EVA.   
The low immunoreactivity of MIAs incorporating three of the GP5 proteins, 
(GP51-255, N-terminal ectodomain GP51-116, and GP575-112), as well as M (M1-162 and M88-
162), and N (N1-110 and N1-69) proteins may result from misfolding and aggregation of the 
E.coli-expressed recombinant proteins. Despite the fact that the GP5 N-terminal 
ectodomain contains the major neutralization epitopes of EAV, the three MIAs 
incorporating GP5, the full-length GP51-255, the N-terminal ectodomain GP51-116, and 
GP575-112 had markedly low sensitivity. It has been reported that in the absence of the M 
protein, the recombinant GP5 protein tends to form large protein aggregates that are 
neither immunogenic nor immunoreactive [76,221]. Similarly, it has been shown that the 
GP5 protein, when expressed by baculovirus or mammalian expression systems, is not 
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processed properly and is easily misfolded [154]. As the length of the recombinant GP5 
was reduced, the sensitivity of the MIA increased significantly; this would indicate that a 
reduction in length allows exposure of some of linear epitopes present in the antigenic 
region of the recombinant GP5 protein.    
There was very good agreement between the results of the GP555-98 based MIA 
and the VNT. However, the GP555-98 MIA was found to have lower sensitivity and 
specificity than the VNT. Many factors could adversely affect the sensitivity of the 
GP555-98 MIA. (i) The short length of the GP5 protein incorporated into the assay could 
have targeted antibodies that are only specific for linear epitopes present in the region of 
aa 55-98, but not for any conformational epitopes. In addition, failure of the GP555-98 
MIA to detect some sera that possessed VN antibodies to EAV could be also due to the 
lack of two major neutralization sites located outside of this region, neutralization sites A 
(aa 49) and D (aa 99-106), and/or lack of conformational interaction of the four 
neutralization sites (A-D) in the N-terminal ectodomain of GP5 as shown previously [69]. 
(ii) Recombinant proteins expressed in E. coli differ from the virion-associated GP5 
protein, due to the lack of secondary structural folding and post translational 
modifications. (iii) The VNT putatively detects antibodies to the GP5 major envelope 
glycoprotein, which carries the known neutralization determinants of EAV [76]. 
Although there is only one known serotype of EAV, the GP5 protein has been shown to 
be the most variable of the EAV structural proteins among field strains of the virus 
[151,158]. Antigenic variation among EAV field strains could reduce sensitivity of the 
assay. It should be noted that the cloned GP5 amino acid sequence (aa 55-98) was 
derived from the EAV VBS, and field strains of EAV have been shown to differ 
significantly in this region; this could result in significant differences in neutralization 
phenotype among viral isolates using polyclonal equine sera. (iv) The lower sensitivity of 
the GP555-98 MIA could also be associated with dilution of the test samples. Previously, it 
has been documented that recombinant proteins expressed by bacteria can exhibit high 
background reactivity with equine serum [274,275,446]. In the present study, we 
determined 1:100 to be the optimal serum dilution for minimization of the non-specific 
binding of antibodies to the bacterial recombinant proteins. At this dilution, the majority 
of sera with low antibody titers (1:4 to 1:8) in the VNT gave false negative results in the 
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GP555-98 MIA (Table 8.4).  It should be emphasized, therefore, that the MIA can only 
reliably detect sera with moderate to high antibody titers (≥ 1:16) to EAV.  
 
Table 8.4.  Distribution of numbers of samples giving false negative results in  
    GP555-98 MIA (n=750) 
Virus 
Neutralizing titer 
No. of false negative in MIA /            
Total no. of VNT positive (%) 
 1:4  5 / 7 (71.4) 
 1:8  4 / 10 (40.0) 
 1:16  6 / 21 (28.6) 
 1:32  10 / 34 (29.4) 
 1:64  11 / 58 (18.9) 
 1:128  4 / 76 (5.3) 
 1:256  5 / 162 (3.1) 
 ≥1:512  6 / 382 (1.6) 
 
 
On testing sera from horses experimentally exposed to rVBS, 030H and KY84 
strains of EAV, there was excellent concordance between the GP555-98 MIA and the VNT 
for detection of the antibody response to the virus. While the EAV 030H and KY84 
strains of EAV had one and four substitutions, respectively, between aa 55 and 98 
compared to the cloned GP555-98, sera from horses exposed to these virus strains did not 
give any false negative reactions in the GP555-98 MIA. In contrast, sera from the EAV 
CA95G strain-inoculated horses failed to give a consistent positive signal in the GP555-98 
MIA. On comparative amino-acid sequence analysis, EAV CA95G virus strain had six aa 
substitutions in this region, five of which were located between aa 79 and 90 (Figure 8.6). 
This would indicate that amino-acid substitutions located in the region of aa 79-90 could 
have a significant effect on the sensitivity of the GP555-98 MIA. Furthermore, comparative 
amino-acid analysis of GP5 showed that some other field strains of EAV (e.g., WA97 
and IL93) had multiple amino acid substitutions between aa 79 and 90 (Figure 8.6). 
Accordingly, horses exposed to EAV strains that have significant number of amino acid 
substitutions in this region may well give false negative results in the GP555-98 MIA.  To 
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maximize sensitivity of a GP5-based MIA, it may be necessary to include a cocktail of 
GP555-98 amino acid sequences comprising multiple sequences representative of known 
phenotypically different strains of EAV rather than depend on a single GP555-98 sequence 
from one strain. 
 
 
Figure 8.6.  Aligned deduced amino acid sequences of GP5 55-98 proteins from 
various laboratory (rVBS and 030H) and field (KY84, CA95G, WA97 and IL93) 
strains of EAV.  Dots indicate the same amino acid as that in the sequence at the top.  
Letters indicate the amino acid substitution at each site.  The predicted N-linked 
glycosylation sites are underlined.  The respective conserved and variable glycosylation 
sites are indicated by * and .Neut., neutralization.  
 
 
ELISA assays targeting whole virus or recombinant GP5, M, and N proteins have 
been investigated for the serological diagnosis of EAV infection 
[221,254,268,274,275,304,305,306,446]. An ELISA procedure incorporating an 
ovalbumin-conjugated synthetic peptide representing aa 81-106 of GP5 has been 
previously described for the detection of anti-EAV antibodies in equine sera [446]. That 
ELISA had a slightly higher sensitivity and specificity (96.75% and 95.6% respectively) 
than the MIA based on GP555-98 used in this study. Similarly, an ELISA based on a 
cocktail of three major structural proteins (GP5, M, and N) expressed by baculovirus was 
able to detect antibodies in most equine sera that were positive in the VNT following 
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natural or experimental infection (92.3% sensitivity and 100% specificity) [221]. It 
should be stressed that the latter two studies [221,446] were undertaken using a limited 
number of EAV VNT antibody-positive (n = 400 and n = 73 respectively) and antibody-
negative (n = 400 and n = 111 respectively) equine sera.  By comparison, the sensitivity 
(92.6%) and specificity (92.9%) of the GP555-98 MIA were evaluated based on testing 
2,500 diagnostic equine sera. 
The MIA based on GP555-98 has several advantages over the VNT as well as over 
various ELISAs. ELISAs that utilize whole viral antigen preparations can give rise to a 
large number of false-positive reactions, when sera are derived from horses vaccinated 
with tissue culture-derived vaccines. Such animals can develop antibodies to cell culture 
proteins remaining in the EAV whole-virus antigen preparation [462]. Furthermore, these 
cell protein-specific antibodies cause cytotoxicity at the lower serum dilutions that in turn 
can interfere with interpretation of the VNT results [463]. The GP555-98 MIA circumvents 
both of these problems, since it utilizes a recombinant protein that represents the 
immunodominant GP5 protein of EAV. Furthermore, the GP555-98 MIA is not subjective 
in interpretation, is less time-consuming, is less expensive, and uses a smaller sample 
volume. Accordingly, the GP555-98 MIA can be considered a more convenient and rapid 
serologic testing procedure for EAV infection, especially for screening large numbers of 
sera. The MIA can be completed within a few hours; in comparison the VNT takes 72 h. 
The MIA does not require the use of live virus and so does not require virus containment 
facilities.  
In summary, we have developed and validated several MIAs that use recombinant 
EAV structural proteins to detect antibodies to EAV in equine serum. Among eight 
recombinant proteins, the highest concordance with the VNT results using selected equine 
sera was obtained with the partial GP5 protein, GP555-98. The GP555-98 MIA and the VNT 
outcomes correlated significantly (r = 0.84; p-value<0.0001). Although the GP555-98 MIA is 
less sensitive than the VNT, it has the potential to provide an accurate, rapid, convenient and 
more economical test for screening equine sera for the presence of antibodies to EAV with 
the VNT used as a confirmatory assay. 
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CHAPTER NINE 
 
Characterization of Equine Humoral Antibody Response to the Nonstructural 
Proteins of Equine Arteritis Virus 
Clin Vaccine Immunol. 2011, 18(2): 268-79 
Reprinted with permission 
 
9.1.  SUMMARY 
Equine arteritis virus (EAV) replicase consists of two polyproteins (pp1a and 
pp1ab) that are encoded by open reading frames (ORFs) 1a and 1b of the viral genome.   
These two replicase polyproteins are post-translationally processed by three ORF1a-
encoded proteinases to yield at least 13 nonstructural proteins (nsp 1-12, including nsp7α 
and 7β).  These nsps are expressed in EAV-infected cells but the equine immune 
response they induce has not been studied.  Therefore, the primary purpose of this study 
was to evaluate the humoral immune response of horses to each of the nsps following 
EAV infection.  Individual nsp-coding regions were cloned and expressed in both 
mammalian and bacterial expression systems.  Each recombinant protein was used in an 
immunoprecipitation assay using equine serum samples from horses (n=3) that were 
experimentally infected with three different EAV strains (VB, KY77 and KY84), 
stallions (n=4) that were persistently infected with EAV, and horses (n=4) that were 
vaccinated with the modified live virus (MLV) vaccine strain.  Subsequently, protein-
antibody complexes were subjected to Western immunoblotting analysis with individual 
nsp-specific rabbit antisera, mouse anti-His antibody, or anti-FLAG-tagged antibody.  
Nsp2, nsp4, nsp5 and nsp12 were immunoprecipitated by most of the sera from 
experimentally or persistently infected horses, while sera from vaccinated horses did not 
react with nsp5 and reacted weakly with nsp4.  However, serum samples from vaccinated 
horses were able to immunoprecipitate nsp2 and nsp12 proteins consistently.  Information 
from this study will assist ongoing efforts to develop improved methods for the serologic 
diagnosis of EAV infection in horses. 
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9.2.  INTRODUCTION 
Equine arteritis virus (EAV) is the causative agent of equine viral arteritis (EVA), 
a respiratory and reproductive disease of horses [77].  EAV is a small (approximately 40-
60 nm in diameter) enveloped virus with a positive-sense, single-stranded RNA genome 
of ~12.7 kb and belongs to the family Arteriviridae (genus Arterivirus, order Nidovirales), 
which also includes porcine reproductive and respiratory syndrome virus, simian 
hemorrhagic fever virus, and lactate dehydrogenase-elevating virus of mice [7,34].  The 
EAV genome includes nine known functional open reading frames (ORFs 1a, 1b, 2-7) 
[34,56].  ORFs 1a and 1b are located in the 5’-proximal three-quarters of the genome and 
are translated to produce replicase polyproteins pp1a and pp1ab (1,727 and 3,175 amino 
acids, respectively), with the latter being a C-terminally extended version of the former 
[141].  ORF 1b translation depends on a -1 ribosomal frameshift just before termination 
of ORF 1a translation [10].  The two replicase precursor polyproteins are cleaved by three 
different ORF 1a-encoded proteinases (see below) yielding at least 13 end products named 
nonstructural protein (nsp) 1 to 12 (including a recently described nsp7α and 7β; [113]).  
The three EAV proteinase domains are located in nsp1, nsp2 and nsp4 [34,66].  The 
remaining seven ORFs (2a, 2b and 3-7) are located in the 3’ quarter of the genome and 
encode the structural proteins (GP2, E, GP3, GP4, GP5, M and N, respectively) of the 
virus.     
EAV infection in horses induces long-lasting immunity that protects against 
reinfection with all strains of the virus [76,195,264,265,266].  Resistance to reinfection is 
assumed to be mediated by neutralizing antibodies directed against glycoprotein 5 (GP5), 
the major envelope protein of the virus [69,74,76,145,148,149,151,152,279,327].  The 
serum neutralization test, which principally detects antibodies to GP5, remains the most 
sensitive assay to detect EAV-specific antibodies in horse serum.  The antibody response 
of horses to individual EAV proteins differs markedly depending on the interval after 
infection, the infecting virus strain, the individual horse, and the specific serological 
assay used [76].  Until now, the characterization of the humoral antibody response of the 
horse to EAV has been mainly based on the structural proteins of the virus 
[143,150,221,254,268,274,275,276,280,304,305,306,462,464].  The serologic response of 
horses to the individual structural proteins of EAV has been extensively characterized by 
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Western immunoblotting, enzyme-linked immunosorbent (ELISA), competitive ELISA 
(cELISA) assays, and microsphere immunoassay (Luminex) using recombinant GP5 and 
membrane (M) proteins and the nucleocapsid (N) protein 
[143,150,221,254,268,274,275,276,280,304,305,306,462,464].  Immunoblotting studies 
confirmed that infected horses respond to a number of viral structural proteins, and that 
sera from horses other than carrier stallions most consistently recognized the conserved 
carboxy-terminal region of the M protein [268].  However, little is known about the 
equine humoral immune response to the non-structural proteins of EAV.   The nsps of 
EAV are the first viral proteins synthesized in cells infected with EAV and are essential 
to the viral replication cycle [26,93].  Thus, it is reasonable to predict the antibodies 
directed against nsps might appear early in the course of EAV infection based on their 
level of abundance and immunogenicity.  Therefore, it is hypothesized that a distinct 
antibody response, similar to the immune response to structural proteins of EAV, may be 
generated to some of the nsps.   The current study aimed to determine the humoral 
immune response of EAV-infected horses to each of the nsps encoded by the ORF 1a and 
ORF 1ab region of the viral genome (the proteolytic cleavage products derived from pp1a 
and pp1ab).  Specifically, in the present study the recombinant nsps expressed in 
mammalian cells and E. coli were utilized in combined immunoprecipitation and Western 
immunoblotting analyses to establish the specificity of the antibody response of EAV-
infected or vaccinated horses to the nsps of EAV.    
 
9.3.  MATERIALS AND METHODS 
Cells   
High-passage (P399 to P409) rabbit kidney-13 (KY RK-13) and baby hamster 
kidney-21 (BHK-21 [ATCC CCL-10]; P61-P80) cells were cultured and maintained in 
Eagle’s minimum essential medium (EMEM; [Mediatech, Herndon, VA]) supplemented 
with 10% fetal calf serum (FCS; Hyclone, Logan, UT), 100U/ml penicillin, 100μg/ml 
streptomycin, 1μg/ml amphotericin B and 0.06% sodium bicarbonate at 37°C.   
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Antibodies   
Monoclonal antibodies specific for nsp1 of EAV (12A4) have been previously 
described [306].  Similarly, mono-specific polyclonal rabbit antisera recognizing EAV 
nsp2 [110], nsp3 (rabbit 98.E3, [84]), nsp4 (a 1:1 mix of anti-nsp4M and anti-nsp4C; 
[110]), nsp7-8 [110], and nsp10 [87] have been previously described.  In addition, we 
used previously unpublished antisera against nsp9 and nsp11 that were both raised by 
immunizing rabbits with full-length expression products purified from E.coli (J.C. 
Zevenhoven, D. D. Nedialkova and E. J. Snijder, unpublished data).  Commercially 
available anti-FLAG (Agilent Technologies, Santa Clara, CA) and anti-His (Invitrogen, 
Carlsbad, CA) monoclonal antibodies were used to detect FLAG and His-tagged fusion 
proteins in Western immunoblotting analyses, respectively.   
 
Equine sera   
Sera from 11 horses that were seropositive for antibodies to EAV by virus 
neutralization assay were used to characterize the equine humoral immune response to 
the EAV nsps (Table 9.1).  The panel consists of three serum samples from horses that 
were experimentally inoculated with virulent Bucyrus (VB) strain or the KY77 and KY84 
strains of EAV, four serum samples from stallions confirmed to be persistently infected 
carriers of EAV (stallions D, E, G and R; [80,224,327]) and four serum samples from 
horses vaccinated with the modified live virus vaccine strain of EAV (ARVAC®; 
formerly Fort Dodge Animal Health Laboratories [now Pfizer Animal Health, New York, 
NY]).  Two equine serum samples negative for neutralizing antibodies to EAV were 
included as controls. 
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Table 9.1.  Serologic response of horses to EAV nsps following experimental infection, vaccination, and in cases of persistent virus 
infection. 
Horse No. §Breed 
Status/ 
PI 
SN⌘ 
titer 
Proteins 
nsp1 nsp2 nsp3 nsp4 nsp5 nsp7 nsp8 nsp9 nsp10 nsp11 nsp12 
Acutely infected horses 
1462 (VB,KY53) TB 2 mo PI ≥1:1024 - + - +w + - - - - - + 
77E853 (KY77) TB 2 mo PI 1:1024 - + - + + - - - - - +* 
198/199 (KY84)  42 DPI 1:1024 - + - + + - - - - - +w 
Persistently infected stallions 
D  Shedder 1:512 - - - +w +w - - - - - +w 
E  Shedder 1:256 - + - + + - - - - - + 
R DWB Shedder ≥1:512 - + - + +w - - - - - +w 
G STB Shedder 1:256 - + - + - - - - - - +w 
Vaccinated horses 
SR-10258 (#800) TB  ≥1:512 - +w - +w - - - - - - + 
94-593 TB 128 DPV 1:512 - +w - +w - - - - - - + 
508 STB 8 mo PV 1:256 - +w - +w - - - - - - + 
478 STB 8 mo PV 1:128 - +w - +w - - - - - - + 
§TB=Thoroughbred; DWB=Dutch Warmblood; STB=Standardbred 
⌘SN=Serum neutralization 
+w Immunoprecipitation protein signal was weaker compared to other positive sera in Western immunoblotting analysis 
+* Protein expressed in both mammalian and bacterial cells were immunoprecipitated with equine sera 
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Virus neutralization (VN) test 
The neutralizing antibody titers of the test sera were determined as described by 
Senne et al. [292,337].  Briefly, serial two-fold dilutions of each sample from 1:4 to 
1:512 were made in MEM (Invitrogen, Carlsbad, CA) containing 10% guinea pig 
complement (Rockland Immunochemicals, Gilbertsville, PA).  Each serum sample was 
tested in duplicate in 96-well plates.  An equal volume of a virus dilution containing an 
estimated 200 TCID50 of the modified live virus vaccine strain of EAV (ARVAC®, Ft. 
Dodge Animal Health) was added to each well, except the serum controls.  The plates 
were shaken to ensure mixing of the well contents and then incubated for 1h at 37°C.  A 
suspension of high passage (P399 to P409) RK-13 cells was added to each well in a 
volume double that of the serum-virus mixtures and the plates were incubated for 72 h at 
37°C, until viral cytopathic effect had fully developed in the virus control wells.  The titer 
of a sample was recorded as the reciprocal of the highest serum dilution that provided at 
least 50% neutralization of the reference virus. 
 
Construction of plasmids for expression of recombinant EAV nsp1 to 12 in 
mammalian cells and E. coli   
The twelve nonstructural proteins (nsp1 to nsp12) of EAV were PCR-amplified 
from the EAV rVBS full-length infectious cDNA clone containing plasmid (pEAVrVBS; 
GenBank accession number DQ846751; [328]) using the primer pairs listed in Table 9.2. 
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Table 9.2.  Primers used to for PCR amplification of individual nsps for cloning into pCAGGS vector 
Protein(aa) 
Nucleotide 
locationc  Primer sequences (5’-3’)
a,b Recombinant plasmid 
Predicted 
MW(kDa) 
nsp1 (260) 255-1004 F ttcGAATTCaccATGGCAACCTTCTCCGCTACTGG pCAGGS-nsp1 28.6 (28.6) 
  R ttcCTCGAGttaGCCGTAGTTGCCAGCAGGCAA   
nsp2 (571) 1005-2717 F ttcGAATTCaccATGGGCTACAATCCACCAGGGGAC pCAGGS-nsp2 61.4 (61.5) 
  R ttcCTCGAGttaACCTATCAGCCGGAACCCCGGA   
nsp3 (233) 2718-3416 F ttcGAATTCaccATGGGATGGATTTATGGGATATGC pCAGGS-nsp3 25 (25.1) 
  R ttcCTCGAGttaTTCAAACACCATCCCGCCCTC   
nsp4 (204) 3417-4028 F ttcGAATTCaccATGGGGCTATTCAGGTCACCGAAGG pCAGGS-nsp4 21 (21.2) 
  R ttcCTCGAGttaCTCTCTATTGGATAAGCCATC   
nsp5 (162) 4029-4514 F ttcGAATTCaccATGAGCAGCCTTTCTGGACCTCAG pCAGGS-nsp5-FLAG 18.1 (19.3) 
  R ttcCTCGAGttaCTTATCGTCGTCATCCTTGTAATCCTCCAGGAAGTATTTCATCATG   
nsp6 (22) 4515-4580 F ttcGAATTCaccATGGGAGGAGTGAAAGAGAGTGTCACC pCAGGS-nsp6-FLAG 2.3 (3.4) 
  R ttcCTCGAGttaCTTATCGTCGTCATCCTTGTAATCCTCCTGGGTAATTGGTTTGC   
nsp7 (225) 4581-5255 F ttcGAATTCaccATGAGTCTCACTGCAACATTAGC pCAGGS-nsp7 25.2 (25.4) 
  R ttcCTCGAGttaTTCATAGCTCCCCTTGCCCAGC   
nsp8 (50) 5256-5405 F ttcGAATTCaccATGGGCCTAGATCAGGACAAAGTG pCAGGS-nsp8 5.5 (5.6) 
  R ttcCTCGAGtcaGTTTAACTGATTCACTGCCTC   
nsp9 (693) 5256-7333 F ttcGAATTCaccATGGGCCTAGATCAGGACAAAGTG pCAGGS-nsp9 76.8 (76.9) 
  R ttcCTCGAGttaCTCATACTGCTTGGTGCGGAAG   
nsp10 (467) 7334-8734 F ttcGAATTCaccATGAGTGCCGTGTGCACAGTTTGTGG pCAGGS-nsp10-FLAG 50.5 (51.6) 
  R ttcCTCGAGttaCTTATCGTCGTCATCCTTGTAATCTTGCTTTTCCCAGCCACAG   
nsp11 (219) 8735-9391 F ttcGAATTCaccATGTCCAACAAAATTTCGTGCCTC pCAGGS-nsp11 24.2 (24.3) 
  R ttcCTCGAGttaCTCTTGGACATAAAAGGTCGC   
nsp12 (119) 9392-9748 F ttcGAATTCaccATGGGTGTTGATGCAGTTACATCAGC pCAGGS-nsp12-FLAG 12.5 (13.6) 
  R ttcCTCGAGttaCTTATCGTCGTCATCCTTGTAATCCACGGGCCCAATGACTGAACC   
a The restriction enzyme sites used for cloning are underlined (EcoRI –GAATTC; XhoI-CTCGAG). 
b The C-terminal FLAG tag in the nsp5, nsp6, nsp10, nsp12 reverse primers are indicated in bold face. 
c The nucleotide positions for the primers are based on GeneBank accession number DQ846751 
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The PCR amplification was performed with high fidelity Pfu DNA polymerase 
enzyme (Agilent; Santa Clara, CA) according to the manufacturer’s protocol.  The nsp5-, 
nsp6-, nsp10-, and nsp12-coding regions were amplified using reverse primers with the 
FLAG-tag coding sequence followed by a downstream stop codon.  Subsequently, the 
individual PCR products were gel purified, digested with restriction enzymes EcoRI and 
XhoI, and cloned into the pCAGGS eukaryotic expression vector (generously donated by 
Dr. Brenda Hogue, Arizona State University, Tempe, AZ [421]).  To remove the 
ORF1a/ORF1b ribosomal frameshift site in the nsp9-coding sequence and allow full-
length nsp9 expression, mutations were introduced into the pCAGGS-nsp9 construct with 
site-directed PCR mutagenesis using the Quick Change® II XL Site-Directed 
Mutagenesis kit (Agilent, Santa Clara, CA) following manufacturer’s instructions.  
Specifically, the ORF1a/ORF1b ribosomal frameshift site had been removed by mutating 
nucleotide A-5404 to C and inserting a C between G-5399 and T-5400 ([65]; numbered 
according to GenBank accession # DQ846751).  Plasmids containing individual nsp-
coding sequences were transformed into E. coli (DH5α) and grown at 37°C overnight.  
Plasmids were purified from overnight cultures of E. coli using the QIAprep Spin 
Miniprep plasmid extraction kit (Qiagen, Valencia, CA).  Following purification, 
individual plasmids were identified and characterized by restriction enzyme analysis for 
correct orientation of the insert.  The nucleotide identity of each construct was confirmed 
by automatic BigDye terminator cycle sequencing (Eurofins MWG-Operon, Huntsville, 
AL).  The plasmids containing individual nsps 1-12 were identified as pCAGGS-nsp1 to 
pCAGGS-nsp12, respectively.   
For generating bacterial expression plasmids for EAV nsp1 to nsp12, each nsp-
coding sequence was amplified from pEAVrVBS using the primers listed in Table 9.3.   
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Table 9.3.  Primers used for PCR amplification of individual nsps for cloning into pQE-TriSystem His-Strep 2 vector. 
Protein (aa) 
Nucleotide 
locationb  Primer sequences (5' - 3')a 
Recombinant 
plasmid 
Predicted MW 
(kDa) 
nsp1 (260) 225-1004 F ttcGAATTCtATGGCAACCTTCTCCGCTACTGG pQE-rVBSnsp1 28.6 (32.5) 
  R ttcCTCGAGGCCGTAGTTGCCAGCAGG   
nsp3 (233) 2718-3416 F ttcGAATTCtGGATGGATTTATGGGATATGC pQE-rVBSnsp3 25 (28.8) 
  R ttcCTCGAGTTCAAACACCATCCCGCCCTC   
nsp4 (204) 3417-4028 F ttcGAATTCtGGGCTATTCAGGTCACCGAAGG pQE-rVBSnsp4 21 (24.9) 
  R ttcCTCGAGCTCTCTATTGGATAAGCCATC   
nsp6 (22) 4515-4580 F ttcGAATTCtGGAGGAGTGAAAGAGAGTGTCACC pQE-rVBSnsp6 2.3 (6.1) 
  R ttcCTCGAGCTCCTGGGTAATTGGTTTGC   
nsp7 (225) 4581-5255 F ttcGAATTCtAGTCTCACTGCAACATTAGC pQE-rVBSnsp7 25.2 (29.1) 
  R ttcCTCGAGTTCATAGCTCCCCTTGCCCAGC   
nsp8 (50) 5256-5405 F ttcGAATTCtGGCCTAGATCAGGACAAAGTG pQE-rVBSnsp8 5.5 (9.6) 
  R ttcCTCGAGGTTTAACTGATTCACTGCCTC   
nsp10 (467) 7334-8734 F ttcGAATTCtAGTGCCGTGTGCACAGTTTGTGG pQE-rVBSnsp10 50.5 (54.4) 
  R ttcCTCGAGTTGCTTTTCCCAGCCACAG   
nsp12 (119) 9392-9748 F ttcGAATTCtGGTGTTGATGCAGTTACATCAGC pQE-rVBSnsp12 12.5 (16.4) 
  R ttcCTCGAGCACGGGCCCAATGACTGAACC   
a The restriction enzyme sites used for cloning are underlined (EcoRI - GAATTC; XhoI - CTCGAG).   
b The nucleotide positions for the primers are based on GenBank accession number DQ846751. 
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Subsequently, PCR products were gel purified, digested with EcoRI and XhoI, and cloned 
into the pQE-TriSystem His·Strep 2 vector (Qiagen, Valencia, CA) which has promoters 
for expression in E. coli, insect cells and mammalian cells, allowing expression of 
His·Strep-tagged proteins from a single vector.  Each construct containing nsp1-12 was 
designated as pQE-rVBSnsp1 through pQE-rVBSnsp12.  Following transformation and 
purification, individual plasmids were identified and characterized by restriction enzyme 
analysis for correct orientation of the insert.  The nucleotide identity of each construct 
was confirmed by automatic BigDye terminator cycle sequencing (Eurofins MWG-
Operon, Huntsville, AL). 
 
Expression of recombinant nsp1 to nsp12 in mammalian cells   
Expression of recombinant EAV nsps was performed in BHK-21 cells transfected 
with individual plasmids containing nsp1-12 coding regions using Fugene® HD (Promega) 
according to manufacturer’s instructions.  Briefly, BHK-21 cells were plated the day 
before transfection at a density of 5 × 105 cells into a 100 mm cell culture dish in 17 ml of 
complete growth medium.  A total of 19 µg of each plasmid was mixed with Fugene® HD 
reagent (Promega) and the complex was incubated for 10 min at room temperature (RT).  
Subsequently, each mixture was added onto confluent monolayers of BHK-21 cells and 
incubated at 37°C in a 5% CO2 incubator.  At 24 h post-transfection, cells were lysed in 
NP40 cell lysis buffer (50mM Tris, [pH 7.4], 250mM NaCl, 5mM EDTA, 50mM NaF, 
1mM Na3VO4, 1% Nonidet P40 [NP40] and 0.02% NaN3) supplemented with 1X 
proteinase inhibitor cocktail (Pierce) and 1mM phenylmethanesulphonyl fluoride (PMSF).  
Insoluble materials were removed by centrifugation at 4°C for 10 min at 13,000 ×g in a 
microcentrifuge.  Cleared cell lysates were stored at -80°C for further use.  The 
expression and validity of each recombinant protein were confirmed by indirect 
immunofluorescence and Western immunoblotting analyses. 
 
Expression and purification of recombinant EAV nsp1 to nsp12 expressed in 
bacterial cells   
Plasmids pQE-rVBSnsp1, nsp3, nsp4, nsp6, nsp7, nsp8, nsp10 and nsp12 were 
transformed in an expression strain of E. coli, M15[pREP4], and a single colony was 
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used to inoculate 10 ml of Luria-Bertani (LB) medium containing both ampicillin (100 
µg/ml) and kanamycin (25 µg/ml).  The culture was grown overnight, diluted 1:20 in 
fresh LB medium with ampicillin and kanamycin, and subsequently grown at 37°C until 
an OD600 of 0.6 was reached.  Recombinant protein expression was induced by addition of 
1mM of isopropyl-β-D-thiogalactopyranoside (IPTG).  Bacterial cells were harvested 4 h 
after induction by centrifugation at 4000 ×g for 20 min at 4°C and stored at -20°C.  
Individual recombinant fusion proteins containing 8× His-tag were purified with the Ni-
NTA (Qiagen, Valencia, CA) agarose-affinity isolation procedure.  Briefly, induced 
bacterial cell pellets were resuspended in buffer B (100mM NaH2PO4, 10mM Tris base 
and 8M urea, pH 8.0) and incubated for 1 h at RT with gentle mixing.  The lysates were 
clarified at 10,000 ×g for 30 min at RT.  The supernatant containing recombinant protein 
was decanted into 50% Ni-NTA slurry and rotated gently for 1 h at RT.  After binding, 
the agarose containing column was washed twice with buffer C (100mM NaH2PO4, 
10mM Tris base and 8M urea, pH 6.3).  Elution was performed in 0.5-ml fractions of 
buffer D (100mM NaH2PO4, 10mM Tris base and 8M urea, pH 5.9) four times followed 
by elution in 0.5-ml fractions of buffer E (100mM NaH2PO4, 10mM Tris base and 8M 
urea, pH 4.5) four times.  Fractions containing the same recombinant protein were pooled 
together and stored at -80°C for further use. 
 
Immunofluorescence assays  
For the indirect immunoflurorescence assay (IFA), BHK-21 cells grown on glass 
cover-slips in 24-well plates were transfected with 0.55 µg of each nsp expression 
plasmid (nsp1 to nsp12) using Fugene® HD (Promega, Madison, WI) according to the 
manufacturer’s instructions.  At 18 h post-transfection, cells were fixed in 4% 
paraformaldehyde in phosphate-buffered saline (PBS; pH7.4) for 30 min at RT and 
washed three times with PBS (pH 7.4) containing 10mM glycine (glycine/PBS).  After 
permeabilization with 0.2% Triton X-100 in PBS (pH 7.4) for 10 min, cover-slips were 
incubated with the appropriate nsp-specific monoclonal or polyclonal antibody, or with 
anti-FLAG tag MAb (1:200), in PBS containing 5% fetal bovine serum (FBS).  After 
three 10mM glycine/PBS washes, coverslips were incubated with FITC-conjugated goat 
anti-mouse or anti-rabbit IgG (Southern Biotech, Birmingham, AL) for 1 h at RT.  Cover-
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slips were washed and mounted in 4’, 6’-diamidino-2-phenylindole (DAPI) containing 
aqueous mounting medium (Vector Laboratories, Burlingame, CA) and observed under 
an inverted fluorescence microscope.   
 
Western immunoblotting   
The solubilized proteins were mixed with 5X reducing sample buffer containing 
100mM dithiothreitol (DTT; Pierce, Rockford, IL) and incubated for 10 min at RT.  
Samples were resolved in a SDS-12% polyacrylamide gel (PAGE).   The gel was 
transferred to a PVDF membrane (Bio-Rad, Hercules, CA).  Blocking was performed in 5% 
skim milk powder dissolved in TBS-T (10mM Tris-HCl [pH 7.6], 150mM NaCl, 0.05% 
Tween 20).  Blots were incubated with primary antibody for 1 h at RT followed by 
biotinylated goat anti-mouse or anti-rabbit antibodies (Invitrogen, Carlsbad, CA) for 1 h.  
Subsequently, the blots were incubated with streptavidin-horseradish peroxidase tertiary 
antibody (Invitrogen, Carlsbad, CA) and detected using an enhanced chemiluminescence 
reaction (ECL, Amersham, Piscataway, NJ). 
 
Immunoprecipitation   
Immunoprecipitation of individual EAV nsps was performed using Dynabeads® 
Protein G (Invitrogen, Carlsbad, CA) Immunoprecipitation kit following manufacturer’s 
instructions.  Briefly, 10 µl of equine antiserum was added to the Dynabeads® Protein G 
and incubated with rotation for 10 min at RT allowing antibody binding to the beads via 
their Fc region.  The bead-bound antibody complex was washed with binding buffer.  
EAV nsp-containing cell lysate was mixed with the bead-bound antisera complex and 
incubated for 30 min at RT with constant rotation.  Then, the bead-antibody-antigen 
complex was washed 3 times with washing buffer.  The immunoprecipitated target 
antigen was eluted in elution buffer and mixed with 5X reducing sample buffer 
containing DTT (Pierce, Rockford, IL) and heated for 5 min at 70°C.  Subsequently, 
denatured samples were resolved by SDS-12% PAGE and subjected to Western 
immunoblotting analysis as described previously.   
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9.4.  RESULTS 
Characterization of EAV nonstructural proteins expressed in mammalian cell 
cDNA fragments corresponding to twelve nonstructural proteins (nsp1-nsp12) of 
the VB strain of EAV were cloned and expressed in BHK-21 cells.  Due to lack of 
protein specific-antisera, recombinant proteins nsp5, nsp6, nsp10 and nsp12 were 
expressed as C-terminal FLAG-tagged fusion proteins from each construct.  The 
expression and validity of each recombinant protein was confirmed by indirect 
immunofluorescence (IFA) and Western immunoblotting analyses with protein-specific 
rabbit antisera and monoclonal anti-FLAG antibody (Figures 9.1.A and 9.1.B).  All 
twelve proteins, except for nsp6 (a very short peptide of 22 amino acids) which was 
expressed only in few cells, were expressed at high levels and detected by IFA (Figure 
9.1.A).  Consistent with the IFA result, nsp6 could not be detected in the Western 
immunoblotting assay indicating that expression of this protein is either insufficient or it 
may be lost during SDS-PAGE and Western immunoblotting due to its extremely small 
size (3.4 kDa after modification).  As shown in Fig. 1B, all of the recombinant proteins 
migrated according to their predicted sizes, listed in Table 9.2. 
 
 
 
Figure 9.1. Expression of EAV nonstructural proteins in mammalian cells.  (A) 
Expression of EAV nonstructural proteins in BHK-21 cells as detected by 
immunofluorescence assay.  For this purpose, BHK-21 cells were transfected with 
plasmids encoding individual nsps and examined at 24 h post-transfection by IFA.  
Protein-specific monoclonal antibody 12A4 (nsp1), protein-specific rabbit anti-peptide 
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sera (nsp2, nsp3, nsp4, nsp7-8, nsp9, and nsp11) or anti-FLAG monoclonal antibody 
(nsp5, nsp6, nsp10 and nsp12) and FITC-conjugated goat anti-mouse or rabbit IgG (H+L) 
were used for detection of each protein.  Each recombinant protein is identified at the 
bottom of each panel.  (B) Western immunoblotting analyses of recombinant EAV nsps 
expressed in mammalian cells, performed with protein-specific monoclonal antibodies as 
specified for panel (A).  Sizes of the molecular weight markers are shown on the left 
hand side of the figure and nsps are identified above each lane.  Arrows indicate the 
position of each recombinant protein.   
 
 
Characterization of EAV nonstructural proteins expressed in E. coli   
As an alternative to the use of a mammalian expression system, we employed a 
bacterial expression system with a C-terminally 8× His-tagged vector as a 
secondary/purification strategy.  This system is more convenient for production of larger 
amounts of protein, which could be used as antigen in future diagnostic tests.  Segments 
of the EAV genome containing the sequences of nsp1, nsp3, nsp4, nsp6, nsp7, nsp8, 
nsp10, and nsp12 were successfully inserted into the pQE-TriSystem His·Strep 2 
expression vector.  When E. coli were transformed with each plasmid expressing 
individual nsp and induced with IPTG, bands migrating at a position corresponding to 
nsp1, nsp4, nsp7, nsp8, nsp10 and nsp12 with a molecular size of approximately 32 kDa, 
26 kDa, 29 kDa, 9 kDa, 55 kDa and 16 kDa respectively, as indicated in Table 9.3, were 
observed on Western blots (Figure 9.2).  Although the predicted molecular mass of nsp4 
is 21 kDa, nsp4 was detected as an approximately 30 kDa product, as documented 
previously [110].  Nsp1 and nsp12 were expressed at high concentrations in both soluble 
and insoluble fractions of cell lysates.  In contrast, larger amounts of nsp3, nsp4, nsp6, 
nsp7, nsp8 and nsp10 could be recovered from insoluble fractions of cell lysates 
compared to soluble fractions.  Therefore, proteins were purified under denaturing 
conditions using an immobilized-metal affinity chromatography procedure with the Ni-
NTA resin column.  Although expression of nsp3 and nsp6 proteins was confirmed in a 
Western immunoblotting analysis before purification, these proteins could not be 
recovered after purification using Ni-NTA resin columns. Accordingly, bacterially 
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expressed nsp3 and nsp6 could not be further evaluated in the study.  Furthermore, nsps 2, 
5, 9 and 11 were toxic and could not be expressed in M15[pREP4] E. coli using pQE-
TriSystem His·Strep 2 vector. 
 
 
 
Figure 9.2.  Western immunoblotting analyses of recombinant nsp4, nsp7, nsp8, 
nsp9 nsp10 and nsp12 of EAV expressed in E. coli.  Samples were total lysates from 
IPTG-induced cultures of E. coli M15[pREP4] cells transformed with pQE-TriSystem 
Strep·His2.  Total bacterial cell lysate was bound to Ni-NTA resin column.  The bound 
individual recombinant proteins were eluted in elution buffer and subjected to Western 
immunoblotting analysis.  Recombinant proteins were detected using anti-His 
monoclonal antibody.  Sizes of the molecular weight markers are shown on the left hand 
side of the figure and nsps are identified above each lane.  Arrows indicate the position of 
the protein.   
 
 
Immunoprecipitation of EAV nsps 1 to 12 expressed in mammalian cells with 
equine serum   
To determine the equine antibody response to nonstructural proteins of EAV, 
recombinant proteins nsp1 to nsp12 expressed in mammalian cells were subjected to 
immunoprecipitation using 11 serum samples containing antibodies to EAV.  The VN 
antibody titers of these serum samples varied between 1:128 and ≥1:1024 (Table 9.1). 
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Individual recombinant nsps expressed in mammalian cells were 
immunoprecipitated using well-characterized equine serum samples from experimentally 
and persistently infected horses plus sera from horses vaccinated with the commercial 
modified live virus vaccine (ARVAC®, Fort Dodge Animal Health Laboratories [now 
Pfizer Animal Health Inc., New York, NY]).  Briefly, total solubilized proteins derived 
from nsp-transfected (nsp1 to nsp12) or pCAGGS-empty vector-transfected BHK-21 
cells were immunoprecipitated with equine sera and the immunoprecipitated proteins 
were subjected to SDS-polyacrylamide gel electrophoresis.  As a control, two equine 
serum samples negative for EAV antibodies were included in these assays.  Individual 
nsps in the immunoprecipitates were then identified with an nsp-specific monoclonal 
antibody (nsp1), a specific rabbit antiserum (nsp2, nsp3, nsp4, nsp7, nsp8, nsp9, nsp11), 
or an anti-FLAG monoclonal antibody (nsp5, nsp6, nsp10 and nsp12) by Western 
immunoblotting analysis.  All three sera from horses that were previously experimentally 
infected with EAV strains VB, KY77, and KY84 precipitated recombinant nsp2 
expressed in mammalian cells.  Also three out of four serum samples from persistently 
infected horses recognized nsp2, although serum from stallion G gave a weak 
precipitation reaction as compared to the others.  In contrast, all four serum samples from 
vaccinated horses weakly immunoprecipitated nsp2 as detected by Western 
immunoblotting assay (Figure 9.3.A).  Similarly, all three sera from horses 
experimentally infected with different EAV strains reacted strongly with recombinant 
nsp5 expressed in mammalian cells.  Interestingly, sera from persistently infected horses 
did not consistently immunoprecipitate nsp5.  Sera from stallion E gave a strong 
immunoprecipitation reaction with nsp5 (comparable to sera from experimentally 
infected horses) while sera from stallions D and R reacted very weakly and serum from 
stallion G did not react at all.  In contrast, none of sera from vaccinated horses were able 
to immunoprecipitate nsp5 (Figure 9.3.B).   
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Figure 9.3.  Immunoprecipitation analyses of (A) nsp2 and (B) nsp5 using sera from 
experimentally infected, vaccinated and persistently infected horses.  Nsp2 and nsp5 
expressed in mammalian cells were immunoprecipitated using equine sera and detected 
by Western immunoblotting analysis with an anti-nsp2 rabbit serum and the anti-FLAG 
tag monoclonal antibody, respectively.  Sizes of the molecular weight markers are shown 
on the left hand side of the figure and serum samples used for immunoprecipitation are 
identified above each lane.  Extreme right hand lanes contain corresponding recombinant 
proteins expressed in mammalian cells as the control.   
 
 
All of the sera from experimentally infected horses gave a very weak 
immunoprecipitation reaction with nsp12 (Figure 9.4).  Equine serum from the horse 
experimentally inoculated with the KY77 strain strongly immunoprecipitated nsp12 
compared to sera from two other horses experimentally inoculated with the VB and 
KY84 strains of EAV.  None of the sera from persistently infected stallions and 
vaccinated horses recognized nsp12 expressed in mammalian cells.  Interestingly, none of 
the 11 equine serum samples evaluated in this study were able to immunoprecipitate nsp1, 
nsp3, nsp4, nsp7, nsp8, nsp9, nsp10, and nsp11 expressed in mammalian cells (Table 9.1).  
Based on these results using recombinant proteins expressed in mammalian cells, only 
nsp2 and nsp5 were consistently recognized by equine antiserum.  As expected, none of 
the proteins were immunoprecipitated by the two negative control sera, confirming the 
specificity of EAV nsp recognition.  Furthermore, none of the equine sera reacted with 
the solubilized cellular proteins from pCAGGS-empty vector-transfected BHK-21 cells 
(data not shown). 
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Figure 9.4.  Immunoprecipitation analysis of nsp12 using sera from experimentally 
infected, vaccinated and persistently infected horses.  Nsp12 expressed in mammalian 
cells was immunoprecipitated using equine sera and detected by Western blot analysis 
with the anti-FLAG tag monoclonal antibody.    
 
 
Immunoprecipitation of EAV nonstructural proteins expressed in E. coli with 
equine serum   
In order to verify whether equine serum from acutely (experimentally) infected, 
persistently infected, and vaccinated horses can react with bacterially expressed antigens 
similar to antigens expressed in mammalian cells, purified nsp1, nsp3, nsp4, nsp7, nsp8, 
nsp10 and nsp12 proteins were subjected to immunoprecipitation analyses with equine 
antisera.  Consistent with the immunoprecipitation results using antigens expressed in 
mammalian cells, none of tested sera recognized nsp1, nsp3, nsp7, nsp8, and nsp10 
antigens.  Interestingly, sera from horses used in this study immunoprecipitated nsp4 and 
nsp12 expressed in bacterial cells although they did not previously immunoprecipitate the 
same proteins expressed in mammalian cells (Figures 9.5.A and 9.5.B).  With the 
exception of serum from one persistently infected stallion, other sera from persistently 
infected stallions and all three experimentally infected horses strongly 
immunoprecipitated nsp4 expressed in E. coli. Serum sample from the persistently 
infected stallion D gave a weak immunoprecipitation reaction as compared to other 
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samples (Figure 9.5.A).  Interestingly, the serum samples from vaccinated horses were 
only able to weakly immunoprecipitate nsp4.  Previously, most tested sera did not react 
or reacted weakly with nsp12 expressed in mammalian cells.  In contrast, most sera 
reacted strongly with bacterially-expressed nsp12 antigen (Figure 9.5.B).  Sera from VB- 
and KY77-inoculated horses and stallion E reacted strongly with the bacterially 
expressed nsp12 antigen, while the rest of the sera (KY84, stallions D, R and G) only 
reacted weakly with this antigen in immunoprecipitation assays.  Additionally, all four 
sera from vaccinated horses were also able to strongly immunoprecipitate nsp12.  Based 
on these results, horses consistently mount an immune response to EAV nsp4 and nsp12.  
Equine antisera from experimentally infected and vaccinated horses, as well as 
persistently infected stallions were unable to immunoprecipitate nsp1, nsp7, nsp8, and 
nsp10 expressed in E. coli.  As expected, none of the proteins were immunoprecipitated 
with negative control sera, confirming the specificity of our approach.   
 
 
Figure 9.5.  Immunoprecipitation analyses of (A) nsp4 and (B) nsp12 using sera 
from experimentally infected, vaccinated and persistently infected horses.  Nsp4 and 
nsp12 expressed in E. coli were immunoprecipitated using equine sera and detected by 
Western immunoblotting analysis with the anti-His monoclonal antibody.  For molecular 
weight markers and controls, see the legend to Figure 9.3.  
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9.5.  DISCUSSION 
In this study, we generated recombinant EAV nsp1 to nsp12 using mammalian 
and E. coli expression systems.  Most of the proteins migrated at the predicted molecular 
size as indicated in Tables 9.2 and 9.3.  However, several nsps expressed in mammalian 
cells showed nonspecific protein bands on the membrane that were also recognized by 
protein-specific rabbit antisera, e.g. nsp2, nsp3, nsp4, nsp9 and nsp11 (Figure 9.1.B).  
This observation was just considered to be background bands or possible 
instability/degradation of expressed proteins.  Previous studies have shown that nsp2, 
nsp3 and nsp5 contain predicted membrane-spanning domains which may serve to anchor 
nsps to the modified intracellular membranes with which the viral replication complex is 
presumed to be associated [87].  Incomplete disassociation of these nsps from cellular 
proteins during SDS-PAGE could have caused some of these extra bands with higher 
molecular weights.  Consistent with previous reports, the recombinant nsp4 (predicted as 
21 kDa and 25 kDa with modifications in mammalian and bacterial expression systems, 
respectively) migrated as a protein of approximately 30 kDa, a phenomenon described as 
aberrant migration of this protein during SDS-PAGE [114,465].  Additionally, the two 
bands of nsp4 visible by Western immunoblotting analysis using nsp4-specific rabbit 
antisera have been reported earlier [465].   
The difficulties encountered during expression of recombinant nsp2, nsp5, nsp9 
and nsp11 and purification of nsp3 and nsp6 in E. coli were likely related to the inherent 
toxicity, codon-usage differences between bacterial and mammalian cells and/or 
misfolding of these proteins when expressed from the pQE-TriSystem vector.  Although 
expression of nsp3 and nsp6 was confirmed in pilot experiments, these proteins could not 
be recovered by Ni-NTA purification.  It is plausible that misfolding of these proteins 
masked their 8× His-tag and prevented binding to the Ni-NTA resin.  Specifically, nsp2 
and nsp5, which showed high immunoreactivity against equine sera when expressed in 
mammalian cells, may need to be expressed using a different expression vector and E. 
coli strain to generate recombinant proteins that could be used in diagnostic assays in the 
future.   
Previous studies on characterization of the equine humoral immune response to 
EAV focused mainly on detection of antibodies to major viral structural proteins, 
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especially GP5, M and N proteins [148,150,221,254,268,274,277,306,462].  To further 
characterize the host immune response to EAV proteins, individual recombinant nsps 
expressed in both mammalian and bacterial cells were immunoprecipitated with EAV 
antibody positive and negative sera and identified with individual protein specific 
monoclonal antibodies or protein-specific rabbit antisera by Western immunoblotting 
analyses.  These viral proteins synthesized during early phase of infection in host cells 
are degraded in the cytoplasm by the proteasome, and the resulting peptides are 
translocated into the endoplasmic reticulum, where they are loaded onto major 
histocompatibilty complex (MHC) class molecules [281].  It has been suggested that 
during antigen processing, antigenic sites buried in native form, such as hydrophobic 
regions are exposed to the immune system and make them more immunogenic [466,467].  
The data showed that nsp2, nsp4, nsp5, and nsp12 are the most immunogenic proteins 
among all twelve nsps (Table 9.1) and that horses tend to mount an immune response to 
these viral proteins.  All three sera from experimentally infected horses consistently 
recognized nsp2, nsp4, nsp5, and nsp12.  In contrast, the antibody response to nsp2, nsp4, 
and nsp12 in persistently infected stallions was somewhat variable.  In addition, nsp5 was 
the only protein which consistently reacted with sera from carrier stallions.  These data 
suggested that the serologic response of horses against nsps which clear the virus 
following acute infection might be different from that of persistently infected horses.  It is 
possible that horses mount a strong immune response to viral nsps in the acute-phase 
(when virus replication is active) which remains until late convalescent-phase but 
decreases over time.  In the presence of high titer neutralizing antibodies in the serum 
during persistent infection, EAV is harbored in the ampulla of the reproductive tract of 
the stallion [188].  Therefore, it could be postulated that virus replicates in 
immunologically privileged cells in the stallion’s reproductive tract preventing (or 
reducing) the exposure of nsps to the host immune system.  However, some of the nsps 
may still be able to induce a limited immune response during prolonged persistent 
infection in the reproductive tract of the stallion.  Moreover, all nsps may not be equally 
immunogenic and this may also vary among different strains of EAV.  This could explain 
the difference between serologic response to nsps in vaccinated animals as compared to 
the horses experimentally inoculated with more virulent field strains (VB, KY77, and 
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KY84 strains).  The response of vaccinated horses with the MLV vaccine strain 
(ARVAC®) was also different from that of experimentally and persistently infected 
horses.  Sera from vaccinated horses recognized nsp2 and nsp12 while nsp4 and nsp5 
reacted very weakly or did not react at all.  Furthermore, different horses may also 
respond differently to EAV nsps during infection.  It has been previously shown that 
immune response to EAV structural proteins differ with the infecting virus strain and 
duration of infection [268].  The M protein was most consistently recognized by various 
serum samples, whereas the response to the N and GP5 proteins was variable [221,268].   
Interestingly, the equine humoral immune response to nsp4 and nsp12 differed 
depending on whether the protein was expressed in mammalian or bacterial cells.  Most 
sera, except for those from vaccinated horses, strongly reacted with nsp4 expressed in 
bacteria.  However, none of the sera immunoprecipitated nsp4 when expressed in 
mammalian cells.  Similarly, the equine sera from experimentally infected horses or 
persistently infected stallions were either only weakly immunoprecipitated or did not 
precipitate the nsp12 expressed in mammalian cells while they strongly reacted and 
immunoprecipitated the nsp12 expressed in E. coli.  The reason for this difference in 
recognition of the same antigen expressed in a different expression system might be due 
to the failure of antigenic epitopes to be presented in their native form to be recognized 
by the equine antibodies.  It is also possible that nsp4 and nsp12 proteins, when expressed 
in a mammalian expression system, are not processed properly or misfolded; this may 
lead to obscuring both the conformational and linear epitopes recognized by equine 
antibodies.  However, the proteins expressed in E.coli are denatured during the 
purification process and this may well expose the linear epitopes recognized by equine 
antibodies and facilitate immunoprecipitation of both nsp4 and nsp12 proteins.   
In porcine reproductive and respiratory syndrome virus (PRRSV) infection in pigs, 
nsp1, nsp2, and nsp7 were found to be the most immunogenic nsps of the virus 
[468,469,470].  Subsequently, PRRSV nsp1 α/β and nsp7, and also nsp2, have been 
explored as potential antigens for the development of serological diagnostic assays.  
However, our data strongly suggest that horses do not mount a strong humoral antibody 
response to EAV nsp1 and nsp7 as compared to pigs infected with PRRSV.  In our hands, 
it appears that EAV nsp1 is toxic in both mammalian and bacterial cells as expression of 
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this protein was not highly efficient as compared to other nsps.  Therefore, suboptimal 
antigen concentration provided for immunoprecipitation assay could have adversely 
affected the result.  As in PRRSV, there is significant variation in EAV nsp2 [63,164].  
However, unlike the PRRSV nsp2, until now, no B cell or T cell epitopes have been 
identified in this protein in the case of EAV [469,471,472].   
The virus neutralization (VN) test is the OIE (World Animal Health Organization) 
prescribed regulatory test for serologic detection of EAV infection of the horse [292].  
However, this assay is expensive, labor-intensive, and time-consuming to perform.  
Results of the assay tend to vary among laboratories when insufficient attention is paid to 
standardization of both test reagents and procedures.  To address this problem, we 
previously developed a microsphere immunoassay (MIA) using recombinant structural 
proteins of EAV.  However, the sensitivity and specificity of the assay was 92.6% and 
92.9%, respectively, compared to the VN test [464].  In this current study, we identified 
the key EAV nsps recognized by horses during acute and persistent infection, as well as 
following vaccination.  Thus, the recombinant nsps (nsp2, nsp4, nsp5, and nsp12) 
identified in this study in combination with the structural proteins could be used in a new 
MIA to further improve the specificity and sensitivity of the assay.  Moreover, nsp5 could 
be a potential candidate to be used as antigen in a companion differential diagnostic test 
to distinguish horses vaccinated with current modified live virus vaccine (ARVAC®) 
from naturally infected horses.  Once we develop this new MIA, it will be used to further 
characterize the antibody response to EAV by testing sequential serum samples from 
experimentally inoculated and vaccinated horses [224,327,328,331].  We also plan to 
evaluate this MIA with a large panel of equine sera determined to be positive and 
negative for EAV antibody by VN test.   
In summary, data presented in this study showed that the equine humoral immune 
response to EAV nsps is directed against the nsp2, nsp4, nsp5, and nsp12.  None of the 
horse sera recognized nsp1, nsp3, and nsp6 through nsp12 when recombinant antigens 
were used in immunoprecipitation assays.  Among these proteins, nsp2 and nsp12 were 
consistently recognized by either experimentally and persistently infected horses or 
vaccinated horses.  In contrast, nsp4 and nsp5 were recognized efficiently only by sera 
from experimentally and persistently infected horses but not by vaccinated horses.  
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Therefore, this study suggests that these antigens can be used for serodiagnostic testing of 
EAV infection.  Incorporation of the immunogenic nsps in a new MIA, along with 
structural proteins as antigen, might greatly improve the sensitivity and specificity of the 
previously developed MIA.  An improved MIA assay is already under development in 
our laboratory.  Thus, a multiplex MIA including the most immunogenic structural and 
nonstructural proteins of EAV could become a potential alternative to the standard VN 
test.  
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SUMMARY OF DISSERTATION 
The nature of the interaction between the virus and the host is cirtical not only for 
viral replication, but also in determining the virulence and pathogenesis of the pathogen 
concerned.  The goal of this study was to better understand how cellular proteins interact 
with viral RNA or viral proteins, and the role they play in viral infection.  Furthermore, it 
was hoped to characterize more clearly the mechanisms of EAV pathogenesis and viral 
persistence in stallions using contemporary molecular biology techniques and host 
genomic analysis via a genome-wide association study (GWAS). 
The viremia that is present in horses acutely infected with EAV is primarily 
associated with the buffy coat cells in the blood (peripheral blood mononuclear cells 
[PBMCs]).  Currently, detailed information of the target cells and the role of viral 
proteins in infection of PBMCs is lacking.  A specific objective was to characterize the 
EAV target cell population in equine PBMCs and the interaction between the targe cell 
population and the virus.  This was accomplished using two strains of EAV, the virulent 
Bucyrus (VB) strain and the attenuated modified live virus (MLV) vaccine strain of EAV.  
The VB strain of EAV primarily infects CD14+ monocytes and a small subpopulation of 
CD3+ T lymphocytes (predominantly CD4+ T) as determined by dual-color flow 
cytometry.  In contrast, the MLV vaccine strain of EAV has significantly reduced ability 
to infect CD14+ monocytes and has lost its capability to infect CD3+ T lymphocytes.  
Using infectious cDNA clones of EAV and reverse genetic systems, it was shown that 
interactions between GP2, GP3, GP4, GP5 and M envelope proteins of the VB strain 
play a major role in determining the CD14+ monocyte tropism while the tropism of 
CD3+ T lymphocytes is determined by GP2, GP4, GP5 and M envelope proteins but 
not the GP3 protein.  This altered tropism correlated with amino acid variations mostly 
located in the ectodomain of major and minor envelope proteins of the virus which 
occurred during extensive cell culture passage of the Bucyrus strain of EAV; this resulted 
in the highly attenuated MLV strain.  This may have direct and/or indirect effects on 
interaction with host cell receptor(s).  Specifically, changes in the MLV genome could 
potentially influence its attachment and entry properties, as well as reducing viral 
replication and production of progeny virus in host lymphocytes.  Infection of CD14+ 
monocytes with EAV is perhaps not surprising in view of the fact that members of the 
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Arteriviridae family are monocyte/macrophage tropic; however, it provided the first 
evidence that CD3+ T lymphocytes may play a role in the pathogenesis of EVA when 
horses are infected with virulent strains of EAV.  During the course of this study, we 
found a clear difference among horses in terms of the susceptibility of their CD3+ T 
lymphocytes to in vitro infection with the VB strain of EAV.  Horses could be 
categorized into two groups, the first arbitrarily designated Group A were those in which 
almost one third of the monocytes along with CD3+ T lymphocyte (mainly CD4+ T cells) 
subpopulations were susceptible to infection with the VB strain of EAV.  The second 
group designated Group B, were those in which monocyte susceptibility was only half 
that observed in Group A horses and all CD3+ T lymphocyte subpopulations were 
resistant to EAV VB strain infection.  Based on this finding, we had to presume that the 
horse’s intrinsic genetic make-up may play a role in determining the clinical outcome of 
infection with EAV.  To investigate the possible hereditary basis of this trait, we 
conducted a genome-wide association study (GWAS) using the Illumina Equine SNP50 
chip to compare horses of susceptible or resistant phenotypes.  This study led to the 
identification of a common, genetically dominant haplotype associated with the 
putative equine susceptible phenotype in the region ECA11: 49572804-49643932.  
The presence of a common haplotype indicates that the trait occurred in a common 
ancestor of all four breeds that were studied, suggesting that it may be segregating 
among other modern horse breeds.  Subsequently, biological pathway analysis 
revealed several cellular genes within this region encoding proteins associated with virus 
attachment and entry, cytoskeletal organization and NF-κB pathways that may be 
associated with the trait responsible for the in vitro susceptibility/resistance of CD3+ T 
lymphocytes to EAV infection.  However, further studies are needed to investigate 
potential mechanisms that involve the roles of proteins encoded by genes located in this 
region of ECA11 in the virus life cycle and the host response to EAV infection.  The 
findings from this study can help in developing working hypotheses to decipher novel 
mechanisms of viral immune evasion, viral pathogenesis, and establishment of persistent 
infection in stallions.  Consistent with these findings, we hypothesized that the in vitro 
susceptibility of CD3+ T lymphocytes to EAV infection correlates with the clinical 
responsiveness of horses following exposure to the virus.  To test this hypothesis, we 
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selected horses that were either susceptible or resistant based on their in vitro CD3+ T cell 
phenotype and challenged them with the recombinant VB strain of EAV.  The study 
findings revealed a difference between the two groups of horses in terms of cytokine 
mRNA expression and evidence of possible increased frequency in clinical signs in 
individuals possessing the in vitro CD3+ T cell resistant phenotype (Group B).  An 
inverse correlation was found between the in vitro susceptibility or resistance 
phenotype of CD3+ T lymphocytes and the different clinical/cytokine expression 
responses observed in horses following infection with EAV.  This was the first study 
to provide direct evidence of a correlation between variation in host genotype and 
phenotypic differences in terms of the extent of viral replication, nature of clinical 
signs and cytokine gene expression following infection with a recombinat virulent 
strain of EAV.  Determining the basis for differences in outcome to virus infection and 
cytokine gene expression in horses may be key in the animals’s control of infection.  We 
extended these studies by investigating the possible correlation between susceptibility of 
CD3+ T lymphocytes to EAV infection and establishment of persistent infection in 
stallions.  Data from this study showed that stallions that possess the susceptible 
CD3+ T lymphocyte phenotype to EAV infection may be at higher risk of becoming 
persistently infected compared to stallions that do not possess this phenotype.  
Identification of specific gene(s) or a chromosome region associated with establishment 
of persistent infection is under investigation.  Hopefully, findings from this study will 
allow us to develop a genetic diagnostic tool to predict stallions at higher risk of EAV 
persistence with the potential to reduce the reservoir of the virus and thereby restrict 
spread of the virus. 
Based on the findings of studies conducted to date, there is evidence that both 
virus and host factors are likely to influence the clinical outcome of EAV infection.  One 
of the major shortcomings of these studies, however, is failure to identify the small 
subpopulation(s) of CD3+ T lymphocytes that are susceptible to infection with VB strain 
of EAV in PBMCs of Group A horses.  Whether susceptibility of T lymphocytes to 
infection with the VB strain of the virus has a determining role in the pathogenesis of 
infection with this strain of EAV remains unknown at this time and warrants further 
investigation.  
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The host immune response facilitates viral clearance and is a key determinant of 
the outcome of infection.  To investigate this in greater detail, a study was undertaken to 
determine the precise effect of EAV on the immune system of horses, innate and humoral 
immunities.  Many viruses have evolved strategies to counteract key elements of the type 
I interferon (IFN) response and successfully prevent development of an antiviral 
environment in the host that would inhibit their persistence in their host.  This strategy of 
evading the host immune system is commonly seen in persistent viral infections.  In vitro 
investigations in an equine endothelial cell line provided evidence that EAV inhibits type 
I IFN production in infected cells.  Among EAV nonstructural (nsps), nsps 1, 2 and 11 
had the capability to inhibit type I IFN activity.  Of these three nsps, nsp1 appeared 
to have the strongest inhibitory effect on IFN synthesis.  Collectively, these data 
demonstrated that failure to induce type I IFN in EAV infected cells may allow the 
virus to subvert the equine innate immune response and facilitate establishment of 
persistent infection in the stallion.  Further studies are needed, however, to map the 
exact step(s) at which EAV nsp1 protein acts on the IFN induction pathway.  
It is a fundamental fact that the host immune system is capable of detecting 
invading foreign pathogens.  Until now, research emphasis has mostly been on the 
humoral immune response to the structural proteins of EAV.  One of the final objectives 
of these studies, therefore, was to evaluate the humoral immune response of horses to 
each of the nsps following EAV infection.  Among 12 nsps, nsp2, nsp4, nsp5 and 
nsp12 were immunoprecipitated by most of the sera from experimentally or 
persistently infected horses, while sera from vaccinated horses did not react with 
nsp5 and only reacted weakly with nsp4.  However, serum samples from vaccinated 
horses were able to immunoprecipitate nsp2 and nsp12 proteins consistently.  
Information from this study hopefully will assist ongoing efforts to develop 
improved methods for the serologic diagnosis of EAV infection in horses.  
The host-virus interaction is in a continuous process of evolution where both entities 
develop strategies to overcome the effects of the other.  The outcome of interaction between 
EAV and the horse have evolved such that the virus can persist in the stallion’s reproductive 
tract despite the presence of high neutralizing antibody titers in its bloodstream.  In the range 
of studies that were carried out, we tried to integrate aspects of the interaction of EAV with 
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its host.  Our focus was initially on the virus and then on those aspects of the host that are 
important for the successful interaction of the virus with the host.  Special attention was paid 
to those aspects that are important for clearance of virus from the host.  The data presented 
in this dissertation suggest new directions for future EAV research using genomic and 
proteomic approaches to study host cell factors involved in EAV attachment and entry and 
establishment of persistent infection in the stallion. 
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APPENDIX 1 
 
List of Abreviations 
 
aa  Amino acid   
AMΦ  Alveolar macrophage 
Asn  Asparagine 
BHK-21  Baby hamster kidney-21 
BMΦ  Blood macrophage  
bp  base pair 
CAVV  Cavally virus 
CD  Cluster of differentiation   
cDNA  Complementary deoxyribonucleic acid 
CF  Complement fixation   
CMI  Cell mediated immunity   
CoV  Coronavirus  
CPE  Cytopathic effect  
CTL  Cytotoxic T lymphocyte 
Cys  Cysteine 
DMV  Double membrane vesicle 
DNA  Deoxyribonucleic acid 
Dpi  Days post infection   
Ds  Double stranded 
E  Envelope protein 
EAV  Equine arteritis virus  
ED  Equine dermal 
EDTA  Ethylenediaminetetraacetic acid 
EEC  Equine endothelial cells  
eGFP  Enhanced green fluorescence protein 
ELISA  Enzyme linked immunosorbent assay 
EPAEC  Equine pulmonary artery endothelial cells 
ER  Endoplasmic reticulum 
ERGIC  ER-Golgi intermediate complex 
EToV  Equine Torovirus 
EU  European 
EVA  Equine viral arteritis 
GAV  Gill-associated virus 
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GFP  Green fluorescent protein 
GP  Glycoprotein 
GWAS  Genome-wide association study 
HEK  Human embryonic kidney 
HK  Horse kidney 
IFN  Interferon 
Ig  Immunoglobulin 
IMP  Immunoprecipitation 
IVT  In vitro transcription 
kDa  kilodalton 
LDV  Lactase dehydrogenase-elevating virus 
M  Membrane protein 
MAb  Monoclonal antibody 
MDBK  Madin-Darby bovine kidney 
MGB  Minor-groove binding 
MIA  Microsphere immunoassay 
MLV  Modified live virus 
Mn  Manganese 
MOI  Multiplicity of infection 
mRNA  Messenger RNA 
MW  Molecular weight 
N  Nucleocapsid protein 
NA   North American 
NC  Nucleocapsid 
NF-κB  Nuclear factor-kappa B 
NMR  Nuclear magnetic resonance 
Nsp  Nonstructural protein 
NTPase  Nucleoside triphosphatase 
OIE  World Organisation for Animal Health 
ORF  Open reading frame 
PAM  Pulmonary alveolar macrophage 
PBMC  Peripheral blood mononuclear cells 
PCP  Papain-like cysteine protease 
PCR  Polymerase chain reaction 
PFU  Plaque forming unit 
PMO  Phosphorodiamidate morpholino oligomers 
pp  Polyprotein  
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PPMO  Peptide-conjugated phosphorodiamidate morpholino oligomers 
PRRS  Porcine reproductive respiratory syndrome 
PRRSV  Porcine reproductive respiratory syndrome virus 
qrRT-PCR quantitative real-time reverse-transcription PCR 
RdRp  RNA-dependent RNA polymerase 
RFS  Ribosomal frameshift 
RK  Rabbit kidney 
RK-13  Rabbit kidney-13 
rMLV  recombinant MLV 
RNA  Ribonucleic acid 
RT-PCR  Reverse transcription-polymerase chain reaction 
rRT-PCR Real time reverse transcription-polymerase chain reaction 
rVBS  recombinant VB strain 
SARS  Severe acute respiratory syndrome 
SARS-CoV Severe acute respiratory syndrome coronavirus 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sg mRNA Subgenomic mRNA 
SHFV  Simian hemorrhagic fever virus 
SNP  Single nucleotide polymorphism   
ss  Single stranded 
T reg  Regulatory T cells  
TCF  Tissue culture fluid  
TCID50  50% tissue culture infective dose 
TRS  Transcription regulation sequence 
UTR  Untranslated region 
VB  Virulent Bucyrus 
VBS  Virulent Bucyrus strain  
VI  Virus isolation 
VN  Virus neutralization 
VNT  Virus neutralization test 
VRP  Venezuelan equine encephalitis virus replicon particle  
YHV  Yellow head virus 
ZBD  Zinc-binding domain  
ZF  Zinc finger 
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APPENDIX 2 
 
Experimental Methods 
 
 
TISSUE CULTURE MEDIA RECIPES 
 
EPAEC (EQUINE PULMONARY ARTERY ENDOTHELIAL CELLS): 
 DMEM (with high glucose [4.5 g/L], without L-glutamine; Cellgro 15-013-CM)  1L 
 Fetal bovine serum (FBS, 10%; Hyclone SH30396.03)    110mL 
 Penicillin and streptomycin (10,000 U/ml and μg/ml; Gibco 15140-122)   11mL 
 0.1 mM Non-essential amino acids (10 mM [100X] Gibco 11140-050)   11mL 
 2 mM L-glutamine (200 mM [100X] Gibco 25030)    10 mL 
 
HEK293T (HUMAN EMBRYONIC KIDNEY 293T CELLS):  
 DMEM (with high glucose [4.5 g/L], without L-glutamine; Cellgro 15-013-CM)  500 mL 
 Fetal bovine serum (FBS, 10%; Hyclone SH30396.03)    50 mL 
 Penicillin and streptomycin (10,000 U/ml and μg/ml; Gibco 15140-122)   5 mL  
 200 mM L-glutamine (200 mM [100X] Gibco 25030)    5 mL 
  
A594 (HUMAN ALVEOLAR BASAL EPITHELIAL CELLS: ATCC CAT. # CCL-185):  
 F-12 Kaighn’s modification (Hyclone SH30526.01)    500 mL 
 Fetal bovine serum (FBS, 10%; Hyclone SH30396.03)    50 mL 
 Penicillin and streptomycin (10,000 U/ml and μg/ml; Gibco 15140-122)   5 mL  
 
PBMC (PERIPHERAL BLOOD MONONUCLEAR CELLS): 
 RPMI 1640 (without L-glutamine; Gibco 21870)    500 ml 
 Fetal bovine serum (FBS, 10%; Hyclone SH30396.03)    50 mL 
 Penicillin and streptomycin (10,000 U/ml and μg/ml; Gibco 15140-122)   5 mL  
 200 mM L-glutamine (200 mM [100X] Gibco 25030)    5 mL 
       55 μM 2-mercaptoethanol (55 mM [1000X]; Gibco 21985-023)    0.5 ml 
 
RABBIT KIDNEY 13 HIGH PASSAGE AND LOW PASSAGE (P207) FROM BILL MCCOLLUM, 
UKY: 
Laboratory Designated Name: RK-13 HP# (High passage), RK-13 LP# (Low passage) 
 
EMEM (With Earle’s salts and L-glutamine; GIBCO 11095-080 500 ml 
Cosmic calf serum 10% (Hyclone SH30087.03)        50 ml 
Penicillin and Streptomycin (GIBCO 15140-122)          5 ml 
 
RABBIT KIDNEY 13 (ATCC CATALOG NO. CCL-37): 
Laboratory Designated Name: CCL-37-RK13 
  
Minimum Essential Medium (EMEM; 
With Earle’s salts and L-glutamine; GIBCO 11095-080     500 ml 
Fetal Bovine Serum 10% (Hyclone SH30396.03)        50 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)             5 ml 
1.0 mM Sodium pyruvate (100 mM [100x] GIBCO 11360-070)         5 ml 
0.1 mM Nonessential amino acids (10 mM [100x] GIBCO 11140-050)       5 ml  
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RABBIT KIDNEY 1 (ATCC CATALOG NO. CCL-106): 
Laboratory Designated Name: LLC-RK1 
 
Medium 199 (GIBCO 11150-059)         500 ml 
Horse serum 10% (Hyclone SH30074.03)      50 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)             5 ml 
 
 VERO 76 (ATCC CATALOG NO. CRL-1587): 
Laboratory Designated Name: VERO 76 
 
DMEM (With high glucose [4.5g/L] and L-glutamine; GIBCO 11965-092)  500 ml 
Fetal Bovine Serum 10% (Hyclone SH30396.03)       50 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)            5 ml 
 
VERO C1008 (ATCC CATALOG NO. CRL-1586): 
Laboratory Designated Name: VERO C1008  
 
EMEM (With Earle’s salts and L-glutamine; GIBCO 11095-080   500 ml 
Fetal Bovine Serum 10% (Hyclone SH30396.03)       50 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)            5 ml 
1.0 mM Sodium pyruvate (100 mM [100x] GIBCO 11360-070)        5 ml 
0.1 mM Nonessential amino acids (10 mM [100x] GIBCO 11140-050)  5 ml  
 
BHK-21 (C-13; ATCC CATALOG NO. CCL-10): 
Laboratory Designated Name: BHK-21 
 
EMEM (With Earle’s salts and L-glutamine; GIBCO 11095-080   500 ml 
Fetal Bovine Serum 10% (Hyclone SH30396.03)       50 ml 
TPB (Tryptose phosphate broth)      50 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)            5 ml 
 
EQUINE DERM CELLS (NBL-6; ATCC CATALOG NO. CCL-57): 
Laboratory Designated Name: ED (Equine derm) 
 
Minimum Essential Medium (EMEM; 
With Earle’s salts and L-glutamine; GIBCO 11095-080    500 ml 
Fetal Bovine Serum 10% (Hyclone SH30396.03)       50 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)            5 ml 
1.0 mM Sodium pyruvate (100 mM [100x] GIBCO 11360-070)        5 ml 
0.1 mM Nonessential amino acids (10 mM [100x] GIBCO 11140-050)     5 ml  
 
MDBK (BOVINE KIDNEY CELLS; ATCC CATALOG NO. CCL-22) 
Laboratory Designated Name: MDBK 
 
EMEM (With Earle’s salts and L-glutamine; GIBCO 11095-080)   500 ml 
Horse Serum 10% (Hyclone SH30396.03)         50 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)            5 ml 
1.0 mM Sodium pyruvate (100 mM [100x] GIBCO 11360-070)        5 ml 
0.1 mM Nonessential amino acids (10 mM [100x] GIBCO 11140-050)  5 ml  
 
FETAL EQUINE KIDNEY PRIMARY CELLS (FEK-XX1) FROM BILL MCCOLLUM, UKY  
Laboratory Designated Name: FEK 
 
EMEM (With Earle’s salts and L-glutamine; GIBCO 11095-080)   500 ml 
Fetal Bovine Serum 10% (Hyclone SH30396.03)       50 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)         5 ml 
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EQUINE PULMONARY ARTERY ENDOTHELIAL CELL MEDIUM (ECMM) 
Laboratory Designated Name: EPAEC 
 
DMEM (With high glucose [4.5g/L], without L-glutamine; Cellgro 15-013-CM)  1 L 
Fetal Bovine Serum 10% (Hyclone SH30396.03)       110 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)            11 ml 
L-glutamine (200 mM; GIBCO       10 ml  
0.1 mM Nonessential amino acids (10 mM [100x] GIBCO 11140-050)        11 ml  
 
 
CELL LINES GROWN WITH EMEM 10% FSCS IN INCUBATOR WITHOUT CO2 
 
BHK-21 (Baby Hamster Kidney 21: C-13; ATCC Cat. # CCL-10); RK-13 (Rabbit Kidney 13 Low passage 
[P194-P204] from Bill McCollum, KY); RK-13 (Rabbit Kidney 13 High passage [P399-P409] from Bill 
McCollum, KY); Vero 76 (African Green Monkey Kidney: ATCC Cat. # CRL-1587); MDBK (Bovine 
Kidney cells: ATCC Cat. # CCL-22); ED (Equine Dermal cells: NBL-6; ATCC Cat. # CCL-57) 
  
   
LARGE SCALE (10 L) CELL CULTURE MEDIA, EMEM 10% FSCS: 
 
Materials 
1. EMEM (NEAA, L-glutamine; Mediatech #50-011-PB; 10L/bt)  10L/bottle    
2. Ferritin supplemented calf serum (FSCS; Hyclone SH30072.03)  1000 mL 
3. Penicillin and streptomycin (10,000 U/ml and μg/ml; Gibco 15140-122) 100 mL 
4. Fungizone (Sigma A-9528, one vial)        10 mL 
Fungizone     50 mg 
Sterile distilled water     50 ml 
Dissolve fungizone in dH2O and dispense in 10 ml aliquots.  Store at -20°C.   
Unreconstituted vial should be stored at 4°C. 
5. Sodium bicarbonate (NaHCO3; Sigma Cat. # S5761-500g)   6 g 
6. Glass fiber prefilter (Millipore Cat. # AP2012450) 
7. Durapore® membrane filters (045 μm; Millipore Cat. # HVLP14250) 
8. 12 L bottle and stir bar 
   Method 
EMEM       96.1g  
NaHCO3         6.0 g 
Penicillin/Streptomycin     100 ml  
Fungizone (Amphotericin 1,000μg/ml)     10 ml  
Serum –ferritin supplemented calf serum (FSCS)     1000 ml 
dH2O (tissue culture grade water)      q.s. to 10,000 ml 
 
1. Add 8 L dH2O to 12 L bottle with stir bar. 
2. Place on stirrer/hotplate and turn stirrer to setting #3. 
3. Add EMEM bottle (rinse twice with water) and mix until dissolved, about 15 min. 
4. Add sodium bicarbonate (color should change from yellow to red), penicillin/streptomycin (p/s), 
fungizone (f), and serum (rinse each container twice with water).  
5. Final concentration of penicillin/streptomycin 100 U/ml and 100μg/ml and fungizone 1 μg/ml. 
6. Add water to 10 L and mix 5 min.  
7. In cell culture room, filter through sterile Millipore filter unit using a prefilter.  Dispense 1 
L/sterile 1 L bottle.   
8. Perform sterility check.  Store at 4°C.   
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CARBOXYMETHYLCELLULOSE (CMC) OVERLAY MEDIA (1.3X EMEM 10% FSCS): 
 
Materials 
1.  Carboxymethylcellulose, medium viscosity (Sigma C-4888)      6.0 g 
2.  Distilled water             140 ml 
 
Method 
1. Add water to a 1 L bottle, swirl while adding 0.75% carboxymethylcellulose (CMC) and then 
shake if necessary. 
2. Let stand overnight at room temperature (shake occasionally). 
3. Autoclave for 20 min at 121°C (liquid setting). 
4. When cooled to approx. 40°C, add 1.3X EMEM 10% FSCS to the 800 ml mark. 
 
1.3X EMEM 10% FSCS: 
 
EMEM       96.1g  
NaHCO3         6.0 g 
Penicillin/Streptomycin     100 ml  
Fungizone (Amphotericin 1,000μg/ml)     10 ml  
Serum –ferritin supplemented calf serum (FSCS)     1000 ml 
dH2O (tissue culture grade water)      q.s. to 7,800 ml 
 
Prepare same as for EMEM 10% FSCS except start with 6 L dH2O and q.s. to 7.8 L. 
 
5. Perform sterility check.  Store at 4°C. 
6. Before using, add 0.8 ml gentamicin/bottle (working concentration – 50 μg/ml). 
 
VIRUS TRANSPORT MEDIUM: 
Hanks's Balanced Salt Solution w/ Phenol Red 1X (Invitrogen; 14170112)   500 ml 
HEPES Buffer (final concentration 25 mM; Invitrogen; 15630080)    20 ml  
Bovine Serum Albumin V (final concetration 0.5%; Sigma: A9647)    2.5 g  
Antibitic-Antimycotic (100X, Peniillin, Steptomycin & Amphotericin B; Invitrogen; 15240112) 5 ml 
Gentamicin Sulfate (final concentration 250 mg/L) Cellgro; 30-005-CR   2.5 ml 
    
 
NET BUFFER (PH 7.5) FOR RESUSPENSION OF VIRUS PELLET: 
 
Materials 
   50 mM Tris hydrochloride (500 ml dH2O)  3.938 g  
   50 mM Tris base (500 ml dH2O)    3.029 g 
   5 mM EDTA     0.95 g 
   150 mM NaCl     4.383 g  
    
Method 
1. Add Tris base to Tris-hydrochloride until the mixture reaches pH 7.5.  (Add about 100ml of 50mM 
Tris-Base to 500ml of 50mM Tris-HCl to get pH 7.5) 
2. Add 5 mM EDTA and 150 mM NaCl to above 50 mM Tris-HCl pH 7.5 
3. Filter and store at 4°C. 
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DULBECCO’S PHOSPHATE-BUFFERED SALINE (PBS): 
PBS (Gibco 21600-069)        95.5 g (1 bottle) 
Sterile distilled water       q.s. to 10,000 ml 
 
1. Add 9 L dH2O to 12 L bottle with stir bar.  Place on stirrer/hotplate and turn stirrer to setting #3. 
2. Add PBS bottle (rinse twice with water) and mix for 10 min.  
3. Add 800 ml to each 1 L bottles.  Autoclave for 20 min at 121°C (liquid setting). 
4. Cool to room temperature before tightening caps and labeling.  Perform sterility check.  Store at 
room temperature. 
 
 
TRYPSIN EDTA SOLUTION: 
  PBS (sterile 1X)        180 ml 
  Trypsin EDTA (no phenol red [10X]; Gibco 15400-054)   20 ml 
 
FREEZING MEDIA:   
Dimethylsulfoxide (DMSO; Sigma D-2650)       10% 
EMEM 10% FSCS          90% 
 
Or 
 
Recovery™ Cell Culture freezing medium (Gibco; 12648-010) 
 
GUINEA PIG COMPLEMENT:  
100 ml/bottle, (Rockland Cat # C300-0100).  Thaw and dispense (on ice) into 1 or 2 ml volumes and store 
at -70°C. 
 
MISCELLANEOUS: 
 
0.5% Trypsin EDTA (no phenol red [10X]; Gibco 15400-054) 
Phosphate buffered saline (PBS, pH 7.4, without calcium chloride/magnesium chloride; Gibco 10010) 
Dulbecco’s Phosphate buffered saline (PBS 10L/bottle, Gibco 10010) 
HEPES buffer solution (1M; Gibco 15630) 
 
 
 
ANTIBIOTICS FOR CELL CULTURE 
 
Gentamicin:  
Gentamicin sulfate, 50 mg/ml, 10 ml/vial (Mediatech 30-005-CR).  Store at 4°C. 
 
Pen-Strep: 
Penicillin and streptomycin (10,000 U/ml and μg/ml; Gibco 15140-122) 
 
Antibiotic-Antimycotic: 
Anti-Anti (100X; Gibco 15240) 
 
Fungizone: 
Amphotericin B Solubilized (Sigma A-9528) 
  235 
BACTERIAL MEDIA RECIPES  
LIQUID MEDIA 
 
LB Medium (Luria-Bertani Medium; 500 ml): 
  Deionized water        500 ml 
  Bacto-tryptone            5 g 
  Bacto-yeast extract       2.5 g 
  NaCl             5 g 
1. Stir until the solutes have dissolved.  Adjust the pH to 7.0 with 5N NaOH.   
2. Sterilize by autoclaving for 20 minutes on liquid cycle. 
 
Psi Broth (500 ml): 
Bacto-tryptone   5.0 g 
Bacto-yeast extract  2.5 g 
NaCl    2.5 g 
4 mM MgSO4  
10 mM KCl  
dH2O    to 500 ml 
1. Autoclave liquid cycle 30 min. 
 
 
MEDIA CONTAINING AGAR 
 
LB Agar Plates: 
Deionized water          500 ml 
  Bacto-tryptone          5 g 
  Bacto-yeast extract       2.5 g 
  NaCl           5 g 
 
1. Prepare LB medium according to the above recipe. Just before autoclaving, add 7.5 g of Bacto 
agar.  Sterilized by autoclaving for 20 minutes on liquid cycle.   
2. When the medium is removed from the autoclave, swirl it gently to distribute the melted agar 
throughout the solution (need to be very careful, the media may boil over when swirled).  Allow 
the medium to cool to 45-500C before adding antibiotics*.   
3. To avoid air bubbles, mix the medium by swirling.  Pour 20-25 ml of medium in a petri dish (use 
the tissue culture hood and fluorescent light should be off).   
4. When medium has hardened completely, invert the plates and wrap in aluminum foil and store 
them at 4°C until needed.  The plates should be removed from storage 1-2 hours before they are 
used and allow them to dry.   
*Antibiotics solutions  
  Antibiotic     Working concentration  
Ampicillin     50 µg / ml 
Streptomycin     50 µg / ml 
Tetracycline     50 µg / ml 
Kanamycin      50 µg / ml 
Carbenicillin     60 µg / ml 
Chloramphenicol     170 µg / ml 
 
Stock solutions should be stored at -200C.  Avoid repeated freeze thawing and exposure to light.  
Magnesium ions are antagonists of tetracycline.  Use media without magnesium salts for selection of 
bacteria resistant to tetracycline.   
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STORAGE MEDIA FOR BACTERIA 
 
Cultures Containing Glycerol: 
1. Aliquot 0.85 ml of bacterial culture in to a freezing vial and add 0.15 ml of sterile glycerol 
(sterilized by autoclaving for 20 minutes on liquid cycle).  Vortex the culture to disperse glycerol 
evenly.  Freeze the culture in ethanol-dry ice or liquid nitrogen, and then transfer the tube to -70°C. 
2. To recover the bacteria, scrape the frozen surface of the culture with a sterile inoculating needle, 
and then immediately streak the bacteria that adhere to the needle onto the surface of an LB agar 
plate containing the appropriate antibiotics.  Incubate the plate at 37°C.  Return the frozen culture 
to storage at -70°C. 
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COMMONLY USED SOLUTIONS AND BUFFERS FOR MOLECULAR BIOLOGY 
 
 
0.5 M EDTA (pH 8.0) 
 Deionized water     115 ml 
 EDTA (di-sodium)    27.918 g 
 5N NaOH     15,825 µl 
 Bring the volume to 150 mls with deionized water 
 
5.0 M Sodium chloride 
 29.22 g of NaCl in 100 mls of distilled water 
 
10% SDS 
 10 g in of SDS in 100 mls of deionized water 
 
3.0 M Sodium acetate (pH 5.2) 
  Dissolve 24.609 g of sodium acetate in 60 mls of deionized water.  Adjust the pH to 5.2 with 
glacial acetic acid (approximately 25.6 mls).  Bring the volume to 100 mls with deionized water. 
 
10 M Ammonium Acetate (50 ml) 
 Ammonium acetate     38.5 g 
 Deionized water to     50 ml  
 
1 M MgCl2 (100 ml): 
 MgCl2  6H20     20.3 g 
 Deionized water to    100 ml 
 
1 M Dithiothreitol (DTT; 10 ml) 
 DTT     1.55 g 
 10 mM Sodium acetate (pH 5.2) to   10 ml 
 Store at -200C 
 
1M Tris HCl (pH 8.0) 
 Tris HCl    Tris base   Molarity 
 4.44 g / l   2.65 g / l   0.05 M 
 88.8 g / l   53.0 g / l   1.0 M 
 8.88 g / 100 mls 5.30 g / 100 mls 1.0 M 
 17.76 g / 200 mls 10.6 g / 200 mls 1.0 M 
 
1M Tris HCl (per liter) 
 Tris Base              121.1g 
 Add deionized water to 800 ml 
  Desired pH     Volume of HCl 
       pH 7.4     70 ml 
       pH 7.6     60 ml 
       pH 8.0     42 ml 
 Add deionized water to 1 liter 
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TE BUFFER 
  
 pH 8.0 
  10 mM Tris HCl (pH 8.0) 
  1 mM EDTA (pH 8.0) 
 
 pH 7.6 
  10 mM Tris HCl (pH 7.6) 
  1 mM EDTA (pH 8.0) 
  
 pH 7.4 
  10 mM Tris HCl (pH 7.4) 
  1 mM EDTA (pH 8.0) 
 
TAE (Tris-acetate; 50X concentrated stock solution [per liter]) 
 Tris base      242 g 
 Glacial acetic acid    57.1 ml 0.5 
 0.5 M EDTA (pH 8.0)   100 ml 
 Deionized water     q.s. 
 
Working concentration 1X (dilute 10 ml in 490 ml of deionized water) 
 
 
Proteinase K 2X Buffer 
Reagent   Final concentration  To make 100 mls of buffer 
Tris HCl (pH 8.0)  0.2 M   20 ml of 1.0 M Tris HCl (pH 8.0) 
NaCl     0.3 M   6.0 ml of 5.0 M NaCl 
EDTA (pH 8.0)   25 mM   5.0 ml of 0.5 M EDTA (pH 8.0) 
SDS    2.0%   20 ml of 10% SDS 
Deionized water      49 ml 
 
 
Ethidium Bromide (EtBr; 10 mg/ml) 
1. Add 1 g of EtBr to 100 ml of deionized water.  
2. Stir on a magnetic stir for several hours to ensure that the dye has dissolved.   
3. Wrap the container in aluminum foil or transfer the solution to a dark bottle and store at room 
temperature.   
4. Final concentration to be used: 0.5 μg/ml 
Method 
1. EtBr in agarose:  5.0 μl of EtBr (10 μg/μl) solution per 100 ml of agarose 
2. EtBr staining solution (1× TAE with 0.5 μg/ml EtBr): 25 μl of EtBr stock solution in 500 ml of 1× 
TAE buffer 
 
Gel Loading Buffer (6X) 
0.25% bromophenol blue (MW 691.9) 
30% glycerol  
Dissolved in 1X TAE solution 
 
To make 40 ml 6X loading buffer: 
 0.25% bromophenol blue (MW 691.9)  0.1 g 
 30% glycerol     12 ml  
 1X TAE solution    to 40 ml  
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Preparation of 25 bp DNA ladder (Invitrogen Cat. # 10597-011) 
100 bp DNA ladder (1 μg/μl)    50μl 
6× loading buffer    100 μl 
Nuclease free water    450 μl 
 
Preparation of 100 bp DNA ladder (Invitrogen Cat. #) 
100 bp DNA ladder (1 μg/μl)    50μl 
6× loading buffer    100 μl 
Nuclease free water    450 μl 
        
Preparation of 1 kb plus DNA ladder (Invitrogen Cat. # 15615-024) 
1 kb plus DNA ladder (1 μg/μl)   50 μl 
6× loading buffer    100 μl 
Nuclease free water     450 μl 
 
Preparation of low DNA mass ladder (Invitrogen Cat. # 10068-013) 
Low DNA mass ladder    100 μl 
6× loading buffer    100 μl 
Nuclease free water    400 μl 
 
Preparation of PCR products 
PCR products      10 μl 
6× loading buffer    2 μl 
 
Preparation of PCR products to estimate concentration 
PCR products      2 μl 
6× loading buffer    2 μl 
Nuclease free water    8 μl 
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 BUFFERS AND REAGENTS FOR WESTERN IMMUNOBLOTTING 
 
10X SDS-PAGE RUNNING BUFFER (4 LITERS) 
 Glycine     580 g 
 Tris base     120 g 
 SDS     40 g 
 Distilled water to     4 liters 
 
TRANSFER BUFFER FOR WESTERN IIMMUNOBLOTTING (FOR PROTEINS <80,000 M.W) 
   1 Liter  4 Liters 
 Tris base 25 mM  2.9 g  11.6 g 
 Glycine 190 mM 14.5 g  58.0 g 
 Methanol 20% 200 ml  800 ml 
 Make up to 1 liter or 4 liters with distilled water (800 or 3200 mls) 
 
WASHING BUFFER FOR WESTERN IMMUNOBLOTTING (TBS-T/ TRIS BUFFERED SALINE 
WITH 0.05% TWEEN 20; pH 7.6) 
   1 Liter  4 Liters 
 Tris base  2.42 g (20 mM)  9.68 g 
 NaCl 8.0 g (137 mM)  32.0 g 
 6N HCl 3.8 ml  10.4 ml 
 Tween 20 (0.05%) 500 µl 2 ml 
       Deionized water to   1 liter   4 liters 
 
ANTIBODY DILUTION BUFFER (ADB) FOR WESTERN IMMUNOBLOTTING 
 Nonfat dry milk 10 g 
 Sodium azide (NaN3) 0.1 g 
 NaCl  9.0 g 
 Na
2
HPO4  4.5 g 
 NaH2PO4  0.5 g  
 PBS (1X)  1 L 
 
AVIDIN-HRP CONJUGATE DILUTION BUFFER IN PBS FOR WESTERN 
IMMUNOBLOTTING 
 PBS (1X) 500 ml 
 1% Nonfat dry milk  5g  
 0.05% Tween 20  250 µl  
 
 
BLOCKING AGENT FOR WESTERN IMMUNOBLOTTING 
5% Nonfat dry milk in TBS-T (25 g for 500 ml) 
(Use nonfat dry milk for horse serum to reduce the high background.  Generally BSA can be used as a 
blocking agent for western immunoblotting). 
 
MOLECULAR WEIGHT MARKERS AND SAMPLE BUFFER 
BenchMark™ Pre-stained protein ladder (Invitrogen; Cat. #10748-010) 
MagicMark™ XP Western protein standard (20-220kDa; Invitrogen; Cat. #LC5602) 
Lane Marker Reducing sample buffer (5X) (Thermo Scientific Pierce; Cat. # 39000) 
Laemmli sample buffer (2X) (BioRad; Cat. # 161-0737) 
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SOLUTIONS AND REAGENTS 
1.5 M Tris HCl, pH 8.8 (BioRad; Cat. # 161-0798) 
0.5 M Tris HCl, pH 6.8 (BioRad; Cat. # 161-0799) 
SDS solution 10% w/v (BioRad; Cat. # 161-0416) 
TEMED (N, N, N’, N’-Tetra-methylethylenediamine) (BioRad; Cat. # 161-0801) 
Blocking grade blocker non-fat dry milk (BioRad; Cat. # 170-6404) 
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COMMONLY USED STAINS 
 
 Crystal violet stain (stock solution): 
  Crystal violet (Mallinckrodt 8839)     12g 
Methanol (Fisher A412-20)        600 ml 
 
Crystal violet stain (working solution): 
1 part of above stock solution 
9 parts 10% buffered formalin (Fisher 23-245-685) 
 
Coomassie Blue R protein stain  
   Brilliant blue R      0.41 g 
   Glacial acetic acid    50 ml 
   95% Ethanol     225 ml 
   Distilled water      225 ml 
 
0.2% Trypan Blue for cell counting 
   Trypan blue  0.2 g 
   PBS  100 ml 
  Sterile filter. 
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ANTIBODIES 
EAV SPECIFIC ANTIBODIES 
 
Specificity Clone Species Origin Specifity 
EAV GP5 6D10 Mouse (MAb) EAV GP5 
EAV GP5 FP55 Rabbit EAV GP5 
EAV M 8887 Rabbit EAV M 
EAV N 3E2 Mouse (MAb) EAV N 
GP2 4033 Rabbit EAV GP2 
GP3 3509 Rabbit EAV GP3 
GP4 7466 Rabbit EAV GP4 
EAV nsp1 12A4 Mouse (MAb) EAV nsp1 
EAV nsp2 L3 Rabbit EAV nsp2 
EAV nsp3 98E Rabbit EAV nsp3 
EAV nsp4 T1 Rabbit EAV nsp4 
Nsp7 and 8 D (M1) Rabbit EAV nsp7 and nsp8 
α-EAV antibody† 11412 Rabbit EAV 
 
CONJUGATED-EAV SPECIFIC ANTIBODIES 
 
Specificity Clone Species Origin Conjugated Form Specifity 
Rabbit 8887 PB IgG Rabbit polyclonal Rabbit Alexa Fluor 488 Prebleed  
EHV-1  Monoclonal Mouse (MAb) Alexa Fluor 488 EHV-1 
EAV anti-nsp1 12A4 Mouse (MAb) Alexa Fluor 488 EAV nsp1 
EAV anti-N 3E2 Mouse (MAb) Alexa Fluor 488 EAV N 
 
 
CELL SURFACE ANTIGEN 
 
Specificity Clone Species 
Origin 
Company Catalog # Species 
Specifity 
Working 
Dilution 
Isoty
pe 
B cells E18A Mouse VMRD E18A Horse 50 μl at 15 
μg/ml 
IgG2a 
B cells  6Dw19 Mouse  Cornell N/A Horse 50 μl/ 5×105 
cells 
IgG1 
CD11a/CD18 CVS9 Mouse Serotec MCA1081 Horse 1:10 IgG1 
CD13 CVS19 Mouse Serotec MCA1084 Horse 1:10 IgG1 
CD14 Big10 Mouse Alexis ALX-804-
496 
Human, 
pig, dog, 
horse 
1:10 IgG1 
CD14-105  Mouse Cornell N/A Horse 1:4 IgG1 
CD172a 
(SWC3) 
DH59B Mouse VMRD DH59B Many 
species  
50 μl at 15 
μg/ml 
IgG1 
CD2 Mac288 Rat Serotec MCA1278 Horse 1:200 IgG2a 
CD3 UC F6G Mouse UCD N/A Horse 1:20 (1×106 
cells/tube) 
IgG1 
CD4 CVS4 Mouse Serotec MCA1078 Horse 1:10 IgG1 
CD4 BH2 Mouse UCD N/A Horse 1:25 to 1:50 
(2×106 cells) 
IgG1 
CD44 CVS18 Mouse Serotec MCA1082 Horse 1:10 IgG1 
CD5 CVS5 Mouse Serotec MCA1079 Horse 1:10 IgG1 
CD8 CVS8 Mouse Serotec MCA2385 Horse 1:10 IgG1 
CD8 KH8 Mouse UCD N/A Horse 1:25 to 1:50 
(2×106 cells) 
IgG1 
CD8α 73/6.9.1 Mouse VMRD 73/6.9.1 Horse 50 μl at 15 IgG3 
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μg/ml 
MHC I N/A Mouse VMRD H58A Horse  IgG2a 
MHC II 
(HLA-DP) 
 Mouse VMRD H42A Horse  IgG2a 
CD163        
 
CELL SURFACE ANTIGEN- CONJUGATED ANTIBODIES 
 
Specificity Clone Species 
Origin 
Company Catalog # Isotype 
CD3-FITC CD3-12 Rat Serotec MCA1477F IgG1 
CD3-DyLight 649  Mouse UCD UC-F6G-
DyLight 
N/A 
CD86 (B70/B7-2)-
R-PE 
IT2.2 Mouse BD 555665 IgG2b, κ 
CD206 (MMR)-PE 3.29B1.10 Mouse Beckman PN IM2741 IgG1 
CD83-PE HB15a Mouse Beckman PN IM2218U IgG2b 
CD21-PE N/A Mouse BD 
Pharmingen 
555422 N/A 
 
ISOTYPE CONTROL ANTIBODIES 
 
Specificity Clone Species 
Origin 
Company Catalog # Species 
Specifity 
Isotype 
IgG1  MOPC-21 Mouse Sigma M5284 Mouse IgG1 
IgG Polyclonal Rabbit BD 550875 Rabbit IgGl 
IgG2a  G155-178 Mouse BD 553454 Mouse IgG2a, κ 
IgG3  A112-3 Mouse BD 553486 Mouse IgG3, κ 
PE-IgG1, κ MOPC-21 Mouse BD 556650 Mouse IgG1, κ 
IgG2a, κ  RTK275 Rat Biolegend 400501  IgG2a, κ 
Rabbit Ig 
Fraction 
N/A Rabbit Dako X0936 Rabbit N/A 
 
SECONDARY CONJUGATED ANTIBODIES 
 
Specificity Conjugate Form Company Catalog # 
Goat F(ab’)2 Anti-mouse IgG1 FITC SouthernBiotech 1072-02 
Goat F(ab’)2 Anti-mouse IgG1 R-PE SouthernBiotech 1072-09 
Goat Anti-mouse IgG (H+L chain 
specific) 
Texas Red® 
(TXRD) 
SouthernBiotech 1031-07 
Goat F(ab’)2  Anti-rat IgG (H+L chain 
specific) 
FITC SouthernBiotech 3052-02 
Goat Anti-horse IgG (H+L chain specific) FITC Jackson 
ImmunoResearch 
108-096-
003 
Goat Anit-guinea Pig IgG (H+L) FITC Vector 
Laboratories 
FI-7000 
Goat Anti-rabbit IgG (H+L) Texas Red® Vector 
Laboratories 
TI-1000 
Goat Anti-horse IgG (H+L) Biotin Vector 
Laboratories 
BA-8000 
Goat Anti-horse IgG (H+L) Peroxidase Jackson 
ImmunoResearch 
108-035-
003 
Donkey F(ab’)2  Anti-goat IgG (H+L 
chain specific) 
Allophycocyanin Jackson 
ImmunoResearch 
705-136-
147 
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Goat Anti-mouse IgG Alexa Fluor 488 Invitrogen A31561 
Goat Anti-rabbit IgG (H+L) DyLight 549 KPL 072-04-15-
16 
Goat F(ab’)2  Anti-mouse IgG (H+L 
chain specific) 
PE-Cy5.5 Caltag 
(Invitrogen) 
M35018 
Goat F(ab’)2  Anti-mouse IgG (H+L 
chain specific) 
R-PE Caltag 
(Invitrogen) 
M35004-1 
Goat F(ab’)2  Anti-rabbit IgG (H+L chain 
specific) 
R-PE Caltag 
(Invitrogen) 
L43001 
Goat F(ab’)2  IgG Unlabeled (UNLB) Southern Biotech 0110-01 
Goat F(ab’)2  Anti-mouse IgG (H+L 
chain specific) 
Alexa Fluor 488 Invitrogen A11017 
Goat F(ab’)2  Anti-mouse IgG (H+L 
chain specific) 
R-PE Invitrogen A10543 
Goat α-rabbit IgG (H+L) Biotin-XX Invitrogen B2770 
Goat α-mouse IgG (H+L) Biotin-XX Invitrogen B2763 
Goat α-rabbit IgG (H+L) HRP Southern Biotech 4050-05 
Goat α-mouse IgG (H+L) HRP Southern Biotech 1031-05 
 
ANTIBODIES FOR INTERFERON PATHWAY ANALYSIS 
Specificity Clone Species 
Origin 
Company Catalog # 
Anti-human interferon alpha MMHA-2 Mouse PBL InterferonSource 21100-1 
Anti-human interferon beta MMHB-3 Mouse PBL Biomedical 
Laboratories 
21400-1 
Anti-human interferon gamma MMHG-2 Mouse PBL Biomedical 
Laboratories 
21550-1 
Anti-STAT1α p91  c-111 Mouse Santa Cruz 
Biotechnology 
Sc-417 
Anti-phospho-STAT1 (Tyr701)   Cell Signaling 9171S 
Anti-STAT2 A-7 Mouse Santa Cruz 
Biotechnology 
Sc-1668 
Anti-phospho-STAT2 (Tyr689)  Rabbit Upstate (Millipore) 07-224 
Anti-NF-κB p65 F-6 Mouse Santa Cruz 
Biotechnology 
Sc-8008 
Anti-phospho-NF-κB p65 
(Ser276) 
 Rabbit Santa Cruz 
Biotechnology 
Sc-101749 
Anti-IRF3 FL-425 Rabbit Santa Cruz 
Biotechnology 
Sc-9082 
Anti-phospho-IRF3 (Ser398)  Rabbit Upstate (Millipore) 07-581 
Anti-human IL-2 Rα (CD25)  Goat R&D AF-223-
NA 
Anti-FLAG M2  Mouse Agilent 200472-21 
Anti-His antibody  Mouse Invitrogen 372900 
β-actin  Rabbit Cell Signaling 4967 
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MITOGENS AND RECOMBINANT CYTOKINES 
MITOGENS 
Name Description Company Catalog # 
ConA Concanavalin A Sigma C5275 
LPS Lipopolysaccharide Sigma L2630 
PWM Pokeweed mitogen Sigma L8777 
PHA-P Phytohemagglutinin Sigma L1168 
PMA Phorbol 12-myristate 13-acetate Sigma P1585 
IL-2 Human Interleukin-2 Sigma I2644 
 
CYTOKINES 
Name Description Company Catalog # 
reIL-2 (Cys141Ser) Recombinant IL-2 R&D  1613-IL 
Human TNF-α Human tumor necrosis factor-α Cell Signaling 8902SF 
Equine IFN-α1 Equine interferon-α1 KingFisher Biotech RP0142E-005 
 
REAGENTS FOR INTRACELLULAR CYTOKINE STAINING USED FOR FLOW 
CYTOMETRY 
Name Description Company Catalog # 
7-AAD 7-Aminoactinomycin D Invitrogen A1310 
PI Propidium Iodide BD Pharmingen 51-66211E 
Ionomycin Ionomycin calcium salt Sigma I3909 
Brefeldin A Brefeldin A Sigma B5936 
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TISSUE CULTURE TECHNIQUES 
 
PROPAGATION OF CONTINUOUS CELL LINES (RK-13, BHK-21 AND VERO CELLS) 
 
Materials 
1. Trypsin EDTA (keep in the water bath for few minutes, at 370C) 
2. Confluent T-75 flask of cells  
3. Appropriate cell culture medium  
 
Method  
1. Cells must be confluent (3-7 days old). 
2. Pour off media. 
3. Rinse cells 2-3 times with PBS (pH 7.4) 
4. Add 1 ml (25 cm2 flask), 2 ml (75 cm2 flask), 4 ml (150 cm2 flask) trypsin-EDTA, and rock gently 
for 30 seconds, then let the flask(s) sit at RT for 1 min 
5. Pour off trypsin-EDTA (optional) and incubate the flask(s) another 7-8 minutes at 37°C. 
6. Add appropriate amount of media EMEM + 10% FSCS + p/s/f for 1:5 split. 
 
Once a week split cells: 1-150 cm2 flask with confluent RK-13 cells is made up to approx. 300-
335 ml EMEM 10% FSCS. 
 10 ml is added to 25 cm2 flask, 
 30 ml to 75 cm2 flask, 
 60 ml to 150 cm2 flask 
Note 
To get a confluent monolayer within 24-36 hours transfer 2 ml of cell suspension into a T-75 flask and add 
20 ml of complete medium to the flask (1:5 split). 
Generally one T-75 flask is sufficient to seed five 96 well plates for neutralization or microtitration assays.  
For specific cell lines: 
  One T-75 flask of BHK-21 cells (confluent) is sufficient for 5-10, 96 well plates.   
  One T-75 flask of Vero cells (confluent) is sufficient for 3-4, 96 well plates. 
  One T-75 flask of RK-13 cells (confluent) is sufficient for 3-4, 96 well plates. 
 
COUNTING OF CELLS  
 
Manual method 
1.  Trypsinize the cells and add 10 ml of complete medium.   
2.  Centrifuge and resuspend the cells in 10 ml of complete medium. 
3.  Make a 1:10 dilution of cell suspension (100 µl in 900 µl of complete medium).  Take 0.5 ml of diluted 
cell suspension into a snap cap tube and add 0.5 ml of 0.2% Trypan blue (1:2 dilution).  Load the 
hemocytometer and count the cells in each of the four large squares.  Some cells will be touching the 
outside borders.  Count only those cells touching two of the outside borders (e.g., the upper and left).  
Determine the average number of cells per 10-4 ml (cells / ml = average number of cells per large 
square × 104 / ml × dilution factor). 
 
Automated method using cell viability analyzer, ViCell XR (Beckman Coulter) 
 
Materials 
 
ViCell XR Quad reagent pak (Beckman Coulter Cat. # 383722) 
4 ml sample cup 120/bag (Beckman Coulter Cat. # 383721) 
 
1. Make 1 ml of 1:10 dilution of cell suspension (100 µl in 900 µl of complete medium) 
2. Place 1 ml in a 4 ml sample cup (Beckman Coulter Cat. # 723908) 
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3. Place the sample cup in the machine (position 1-10) 
4. Log in sample: position, sample ID, cell type, dilution factor.  OK or next sample when done. 
5. Start queue 
6. “Camera image” provides cell image while counting and “Autosample queue” provides average of 
number of counted cells and viability 
 
 
FREEZING CELLS 
 
Materials  
1.  Freezing medium 
2.  Cells in log phase of growth 
3.  Trypsin EDTA (keep in the water bath for few minutes, at 370C) 
4.  Nalgene™ Cryo 1°C freezing container (Nalgene Cat. # 5100-0001) 
 
Method 
1. Pour off the media. 
2. Add 3-4 ml of trypsin EDTA solution and rinse the cells (this is to remove the fetal bovine serum).  
3. Add 3-4 ml of fresh trypsin EDTA solution and leave it for 3-4 min. (preferably at 370C) and bang 
on the flask to detach the cells from the surface. 
4. Add 10-12 mls of complete medium (the medium contain 10% fetal bovine serum and this will 
inhibit trypsin) and pour into a 50 ml conical tube. 
5. Centrifuge at 1100 or 1300 rpm (200 ×g) in a table top centrifuge for 5 minutes at 250C. 
6. Aspirate the supernatant and resuspend the cell pellet in freezing medium at approx. 107 cells / ml.  
Freeze in 2 ml vials (1 ml per vial).  
7. Freeze cells first in Nalgene™ Cryo 1°C freezing container with isopropanol at -80°C for 1 day 
8. Transfer frozen cell vials to liquid nitrogen container 
 
RECOVERY OF FROZEN CELLS 
 
Material 
1. Frozen cells (-70°C) in aliquots. 
2. Growth medium  
 
Method: 
1. Rapid thawing of the cells is necessary.  Thaw the cells in the water bath at 37°C, by swirling the 
tube (do not submerge the lid to avoid contamination of the cells). 
2. Resuspend in 15 ml of growth medium and centrifuge at 1200 or 1300 rpm (200 ×g) in a table top 
centrifuge for 5 minutes at 25°C. 
3. Aspirate the supernatant and resuspend the cells in 10 ml of growth medium.  Transfer the cell 
suspension into a T-75 flask and add 10 ml of medium.  Incubate at 37°C for 2-3 days.   
 
ISOLATION OF EQUINE DERMAL FIBROBLASTS 
 
Materials 
 
Skin biopsy punches (5mm; Miltex Cat. # 33-35)  
Hanks’ balanced salt solution (HBSS; Gibco 14175) 
PBS (pH 7.4) 
Petri dishes and coverslips 
 
Methods (modified from “Isolation and characterization of fibroblasts from diabetic patient with chronic 
vascular disease by Megan Francis, Illinois Institute of Technology [IIT]) 
 
1. Skin biopsy is harversted from chest area of horse 
2. Place tissue in a sterile PBS and gentamicin (200 g/ml) 
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3. Each specimen is washed 3X with sterile HBSS (10mM) in Petri dishes and then turn with the skin 
side to the glass bottom for careful dissection.  Small pieces of dermal connective tissue is harvested 
from the tissue. 
4. The pieces are rinsed with HBSS and transferred to Petri dishes (65 mm × 15 mm). 4-5 pieces per dish.  
A smaller Petri dish (35 mm × 10 mm) is placed on the tissue pieces to keep the tissue in place during 
medium changes. To avoid floating of tissue, place a sterile coverslip on to each piece of tissue until 
fibroblasts get attached on the plate. 
5. Wells are filled with pre-warmed DMEM containing 10% (v/v) FBS, 200 g/ml gentamicin, 1.25 g/ml 
fungizone and 2 mM gluctamine and incubated at 37°C, 5% CO2. 
6. After 2 days of culturing, the medium is replaced DMEM containing 10% (v/v) FBS, 50 g/ml 
gentamicin, and 2 mM glutamine. 
7. Regular medium changes are performed every 2 days. 
8. Cell growth is monitored with an inverted microscope. 
 
ISOLATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS FROM EQUINE BLOOD 
 
Isolation of PBMCs 
 
1. Collect blood via venipuncture into tubes with EDTA. Invert several times to mix and keep on ice at 
farm. Need one 15 ml conical tube w/Ficoll-Paque Plus for two 10 ml EDTA tubes.  
2. Wait approximately 20~30 min. until RBC has settled down, leaving cloudy, yellow plasma layer on 
top of RBC layer. 
3. Using a pipet, carefully aspirate plasma from EDTA tube, stopping aspiration when reach the RBC 
layer. Layer plasma on to 4ml Ficoll-Paque Plus in 15 ml conical tube. Cap tube when finished. Keep 
at room temperature and harvest all plasma layers from tubes collected from same horse. 
4. Centrifuge at 500 g, 30 min, 20°C 
5. Aspirate plasma layer above gradient down to cloudy band of PBMC. Discard into sterile beaker. With 
same pipet, aspirate PBMC at interface and place into 50 ml conical tube. Combine PBMC from 4 
gradient (15 ml conical) tubes into one 50 ml tube for washing. 
6. (For platelets removal) Add at least 3 volumes of PBS to the lymphocytes in the tube. Mix by pipetting. 
7. Centrifuge at 100 g for 10 min at 20°C. Remove the supernatant. 
8. Repeat same washing procedure once more. 
9. Resuspend the pellet in adequate quantity of 10% cRPMI and count cells (Approx. ten of 10 ml EDTA 
tubes give about 3 – 4 × 107 cells per ml) 
 
Separation of adherent and non-adherent PBMCs 
 
1. Count the cells and resuspend them at 1 × 107/ml in complete RPMI (cRPMI). The objective is to get 
at least 2 × 108 PBMC to plate out into one of 150mm culture dish. 
2. Place 20ml PBMC preparation into 1 × 150mm diameter, treated tissue culture dishes (1 × 107 
PBMC/ml; total volume 25ml). Avoid over crowding of the plate to give enough space for the adherent 
cells to attach. 
3. Incubate for 4h at 37°C/ 5% CO2 
4. Gently tilt the dish and aspirate off the supernatant containing non-adherent cells. Pellet non-adherent 
cells by centrifuging at 1900 rpm 15 min. 
5. Wash adherent cells twice with 20ml of PBS (pH7.4). Rinse down the dish in 4 different angles 
(5ml/angle). Aspirate and save the PBS after each wash in a tube and pellet them down for cell 
counting.  
6. Resuspend the cell pellets (non-adherent cells and PBS wash) in 10 ml of plain RPMI for each pellet 
and count cells. 
7. To calculate approx. number of adherent cells, subtract the number of non-adherent cells and cells 
from PBS wash. 
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GENERATION OF MONOCYTE-DERIVED DENDRITIC CELLS 
 
Materials 
1. EDTA (purple top, 15% EDTA liquid, Kendall Cat. #8881 311743) vacutainer tubes 
2. Ficoll-Paque Plus (GE Health Care, Cat. #17-1440-02) 
3. 15ml centrifuge tubes (Corning, Cat. #430052) 
4. Complete RPMI 1640 (Gibco, Cat. #21870) 
5. Plain RPMI 1640 (Gibco, Cat. #21870) 
6. 1× PBS (pH 7.4, Gibco, Cat. #10010)  
7. Corning® treated tissue culture dishes (Corning, 100 mm Cat. # 430167, 150 mm Cat. # 430599)  
8. Differentiation medium 
a. Complete RPMI with GM-CSF (Sigma, Cat. #G5035) and IL-4 (R&D Cat. #1809-EL); see below 
9. Nycoprep (Accurate Chemical, Cat. #AN-223510) 
10. 6-well tissue culture plate (Costar, Cat. #3506) 
 
Collection and processing of blood 
 
1. Collect 300ml of horse blood in 30 EDTA containing vacutainer tubes (10ml × 30). Isolate PBMC by 
layering plasma onto Ficoll-Paque Plus. Plasma from 20ml of blood (2 × 10mls tubes) can be layered 
onto one 15 ml conical tube containing 4 ml of Ficoll.  
 
- This gives approx. 5 × 107/ml viable PBMCs (Total number of cells 1.5 × 109 cells/300ml) 
- It is known that generally 100 ml of blood give 2 × 108 PBMC. Out of these cells 1-2% will be 
monocytes 
 
2. Count the cells and resuspend them at 1 × 107/ml in complete RPMI (cRPMI). The objective is to get 
at least 2 × 108 PBMC to plate out into one of 150mm culture dish. Expect yield of 1.5% DC:PBMC.  
 
Separating blood derived monocytes 
 
8. Place 20ml PBMC preparation into 1 × 150mm diameter, treated tissue culture dishes (1 × 107 
PBMC/ml; total volume 25ml). Avoid over crowding of the plate to give enough space for the adherent 
cells to attach. 
9. Incubate for 4h at 37°C/ 5% CO2 
10. Gently tilt the dish and aspirate off the supernatant containing non-adherent cells 
11. Wash adherent cells twice with 20ml of PBS (pH7.4). Rinse down the dish in 4 different angles 
(5ml/angle). 
12. Aspirate and discard the PBS after each wash. 
13. Add 25ml of differentiation medium to the dish.  
 
 Preparation of stock and working GM-CSF (Sigma; Cat # G5035, Lot 027K1018) 
- Vial contains 5μg of lyophilized GM-CSF 
- Reconstitute with 5ml of sterile pyrogen-free distilled water which will give a stock 
concentration of 1μg/ml. Aliquot in 50μl each tube and store at -20°C. 
- Recommended working concentration is 0.1ng/ml of cRPMI 
 
Working conc. Working vol./ ml 20ml media 
0.1ng 0.1 μl 2 μl 
1ng 1 μl 20 μl 
10ng 10 μl 200 μl 
 
 Preparation of stock and working IL-4 (R&D; Cat #1809-EL, Lot MFM016021) 
- Vial contains 20 μg of lyophilized rEqIL-4 
- Reconstitute with 2 ml of sterile distilled water which will give a stock concentration of 10 
μg/ml. Aliquot in 200μl each tube and store at -20°C. 
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- Working concentration is 100ng/ml 
Working conc. Working vol./ ml 20ml media 
100ng 10 μl 200 μl 
200ng 20 μl 400 μl 
 
14. Incubate the culture dishes in differentiation medium for 4 days at 37°/ 5% CO2. 
 
Collection of cultured cells 
 
1. During differentiation the cells round up and detach, so they are no longer adherent. Harvest the cells 
with a pipette and transfer the entire volume into centrifuge tubes. 
2. Pellet the cells (150 ×g , 10min) and resuspend each pellet in 10ml plain RPMI 
3. Overlay each 10ml aliquot onto 4ml Nycoprep (1.068g/ml) in separate 15 ml centrifuge tubes 
4. Spin at 500 ×g for 15 min with no brake 
5. Harvest and pool the interfaces and wash once with PBS 
6. Count the cells 
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CLASSICAL VIROLOGY TECHNIQUES 
 
PROCESSING OF NASAL SWABS FOR VIRUS ISOLATION 
 
Materials 
10 ml syringes  
Autoclaved plastic forceps 
0.45 µm syringe filter (Corning Cat. # 431220 or Millipore, Millex™ Cat. # SLHA033SB) 
1.7 ml screw cap tubes (Sardstedt Cat. # 72.694.996 [color cap], #72.694.006 [clear cap]) 
15 ml conical tubes  
 
Methods 
1. Thoroughly swab the nasopharyngeal area with a sterile rayon swabs (1/2” x 1”) with plastic shafts 
(16”). 
2. After collection, the rayon tip of each swab is cut off into 7 ml of virus transport medium (Hank’s 
balanced salt solution with penicillin, streptomycin, gentamicin sulfate and amphotericin B; all from 
Life Technologies, Carlsbad, CA).   
3. Squeeze the swab to recover maximum amount of media and centrifuge at 300 ×g for 10 min to 
remove debris. 
4. Transfer individual nasal swabs in transport medium to the barrel of a 12 ml disposable syringe and 
express through 0.45 µm syringe filter (Millipore).   
5. Collect the filtrate into a 15 ml conical tube.  Bring up the sample volume to 7 ml with plain MEM to 
normalize samples (e.g. after filtration usually approx. 6 ml is recovered).  Leave approximately 2.0 ml 
for virus isolation and aliquot the remaining filtrate (approximately 1 ml × 2) into tubes.  Freeze at -
70°C until tested. 
6. Aspirate off media from confluent RK-13 cells in 6-well plates and inoculate 500 μl specimen/well in 
duplicate. 
7. Incubate plates at 37°C in presence of 5% CO2 for 1-2 hours. 
8. Add 10ml CMC overlay to each flask and incubate at 37°C in the presence of 5% CO2 for 5 days.   
9. Do second passage on day 4 using the same cells. Stain cells on day 5 with crystal violet.  Archive the 
TCF at -80°C. 
 
SERUM PROCESSING 
 
Materials 
Vacutainer needles  
Vacutainer adapters (Termuno, Venoject II Cat. # P-1316R) 
15 ml BD Vacutainer tubes (Kendall Monoject [no additive] Cat. # 8881 301819) 
1.7 ml screw cap tubes (Sardstedt Cat. # 72.694.006) 
Transfer disposable pipets for serology (Samco scientific Cat. # 202-1S) 
Methods 
1. Collect blood into vacutainer tubes via jugular venipuncture (about 15 ml blood). 
2. Transport blood tubes to the lab.  Spray tubes with diluted Roccal-D (1:200).  Rinse tubes and dry 
with paper towel.  Let stand at room temperature for 4-5 hours or for 1 hour at 37°C (water bath 
works faster). 
3. Sediment blood cells at 2000 rpm (300 ×g) for 10 min. 
4. Collect serum and aliquot into tubes (1.4 ml × 4).  Freeze at -20°C until tested for virus or 
antibody. 
5. Proceed as in steps 5-8 above for virus isolation. 
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BUFFY COAT PROCESSING FOR VIRUS ISOLATION (WITHOUT GRADIENT 
PURIFICATION) 
 
Methods 
1. Draw blood by venipuncture into vacutainer tubes containing sodium citrate or EDTA and mix 
thoroughly. 
2. Allow blood to stand for 1-2 hours or sediment at 600-700 rpm (100 ×g) for 10 min.  Remove plasma 
layer and sediment at 2000 rpm for 10 min.  The few red blood cells in pellet cause no apparent 
concern. 
3. Aspirate off supernatant; resuspend pellet in 5 ml EMEM 10% FSCS and vortex thoroughly. (If 
desired, pellet can be washed with PBS before resuspending in EMEM media).  Freeze or inoculate. 
4. Proceed as in steps 5-8 above. 
 
PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) PROCESSING FOR VIRUS 
ISOLATION 
 
Materials 
15 ml BD vacutainer tubes w/ACD (Citrate-dextrose solution; Sigma C3821- 50ML) 
Ficoll-Paque Plus (GE Healthcare Cat#17-1440-03) 
15 ml conical tubes  
50 ml conical tubes  
1.7 ml screw cap tubes (Sardstedt Cat. # 72.694.006) 
 
Preparation of Vacutainer tubes with Acid Citrate Dextrose (ACD) 
Using a small gauge needle and a 10 ml syringe, add 1.5 ml ACD to each 15 ml vacutainer tube.  Mark 
tubes to identify that they contain ACD.  Store at 4°C.  
 
Preparation of Ficoll-Paque Plus gradients in 15 ml conical bottom polypropylene tubes 
 
Place 4.0 ml Ficoll-Paque Plus in each tube (will need 15 ml tube per 20 ml vacutainer of collected 
blood).  Centrifuge briefly to pull all of Ficoll-Paque Plus to bottom of the tube.  Store at 4°C but warm 
to room temperature before use.  
 
Methods 
1. Collect blood via venipuncture into tubes with ACD (about 13.5 ml blood and the final volume is 
about 15 ml per tube).  Invert several times to mix.  Keep on ice at farm. 
2. Transport blood tubes to the lab.  Spray tubes with dilute Roccal.  Rinse tubes and dry with paper 
towel.  Invert tubes several times to re-mix blood (prevents PBMC from settling on top of RBC 
too much).  Keep at room temperature. 
3. Wait approximately 20-30 min until RBC has settled again, leaving cloudy, yellow plasma layer 
on top of RBC layer. 
4. Layering plasma onto Ficoll-Paque Plus using transfer disposable pipet. 
5. Using serological pipet, carefully aspirate plasma of one Vacutainer tube, stopping aspiration as 
reach the RBC layer (a few RBCs are OK but try not to pull lost of RBCs into pipet).  Layer 
plasma onto Ficoll-Paque Plus in conical tube.  Plasma from one 20 ml vacutainer of blood should 
approximately fill the Ficoll-Paque Plus tube to 14-15 ml height in tube.  Cap tube when finished.  
Keep at room temperature.  Continue, using the same pipet, and harvest all plasma layers from the 
vacutainers collected from one horse.  
6. Centrifuge at 500 ×g (2800 rpm), 30 min, 25°C. 
7. Harvesting PBMC from gradient: 
 Aspirate plasma layer above gradient down to cloudy band of PBMC.  Discard into 
sterile beaker.  With same pipet, aspirate PBMC at interface (approx. 2-3 ml/15 ml tube) 
and place into 50 ml polypropylene centrifuge tube.  Continue removing plasma, 
harvesting interfaces. Combine PBMC from 4 gradient (15 ml conical) tubes into a 50 ml 
tube for washing. 
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8. Cell washing steps: 
 Add sterile PBS (pH 7.4) to bring the volume to 40 ml.  Cap tube and mix cells by 
inverting tube 5 times (or tapping tube with the index finger). 
 Centrifuge for 15 min at 500 ×g (2800 rpm), 4°C. 
 Aspirate the supernatant without disturbing the cell pellet. 
 Add sterile PBS to bring the volume to 40 ml and cap tube.  Mix cells by tapping the tube 
with the index finger or by vortexing. 
 Centrifuge for 10 min at 500 ×g (2800 rpm), 4°C. 
 Aspirate the supernatant without disturbing the cell pellet. 
 Resuspend the pellet in 8.0 ml of 10% EMEM (this gives about 1.5 × 107 – 3.0 × 107 cells 
per ml).  Leave 2.0 ml of buffy coat cells in the conical tube for virus isolation and 
aliquot the remaining cells (approximately 1.2 ml × 5) into tubes.  
 Freeze the remaining cells at -80°C. 
 
ISOLATION OF EAV FROM SEMEN 
 
1. Thaw 15 ml tube containing semen sample in warm tap water, then place on ice. 
2. Label 8 flasks (25cm2) [4 RK-14 (KY) “high pass” and 4 RK-13 (ATCC-CCL37) “low 
pass”]/semen, 2 ✕ 10-1, 1 ✕ 10-2, 1✕10-3 for high pass, 2 ✕ 10-1, 1 ✕ 10-2, 1✕10-3 for low 
pass. 
3. Sonicate (output 20, #4.5 on dial) samples on ice 3 ✕ 15 sec.; let set on ice for 15 sec. 1 min 
between sonications (dilute small volumes to 5 ml).  Clean sonicator probe with 95% EtOH 2X 
between each sample.  Spin 300 ×g (1900 rpm) for 10 min to remove sperm and debris, save and 
use supernatant (SSP). 
4. Set up 3 tubes (10-1 to 10-3) for each sample, 4.5 ml EMEM 10% FSCS per tube. 
5. Aspirate off media from 25 cm2 (3-6 day old RK-13 monolayers).  Do not rinse! Make 10-1 (0.5 ml 
sample in 4.5 ml diluent), vortex; with new pipet add 0.5 ml of 10-1 to tube #2 (10-2) and 1 ml to 
each of 4 flasks marked 10-1.  Continue the same way with dilutions 10-2 and 10-3 (2 flasks each). 
6. Incubate all flasks at 37°C in air incubator (incubator without CO2) with caps closed for 1 hour (2 
hours maximum). 
7. Add 10 ml of CMC overlay to each flask and incubate at 37°C in air incubator (incubator without 
CO2) with caps closed. 
8. Check for CPE on day 4. 
If bacterial contamination occurs, redo after bacteriological examination and sensitivity testing to 
find out which antibiotics to used in the TC media.  Repeat test as above and also note 
contamination. Specimen may be filtered through a 0.45 μm filter using a 5 or 10 cc syringe, if 
necessary. 
9. If negative, a second passage is performed on day 4. (See 2nd passage) 
10. If sample is toxic this material is passages as is (2nd passage). 
11. If positive, supernatant is usually harvested from a 10-2 flask showing viral activity (store at -
20°C) and a reverse SN-test is performed against known positive and negative sera (See reverse 
SN-test). 
12. After 5 days harvest supernatant from flasks and stain flasks with crystal violet using 2 ml crystal 
violet in buffered formalin.  Stain 1-24 hours, remove stain, rinse flasks with tap water and read.   
13. All semen samples are placed in freezer zip lock storage bags and stored at -70°C. 
14. Permanently store negative SSP at -20°C and positive SSP at -70°C. 
Second passage 
1. Aspirate media from 2 “high pass” and 2 “low pass” confluent 3-5 day old RK-13 cells in 25 cm2 
flasks for each negative semen sample. 
2. From 2 flasks of 10-1 passage #1 take up 0.5 ml from each with same pipet (1ml) and add 1 ml to 1 
new flask for each high and low pass.  Do the same for 10-2 passage #1, taking up 1 ml from each.  
Do 10-1 and 10-2 only.  Close caps and incubate at 37°C for 1-2 hours (minimum 1 hour) in air 
incubator. 
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3. Add 10 ml of CMC overlay to all flasks, close caps, and incubate at 37°C in air incubator (without 
CO2).  
4. Read after 3-4 days. 
5. After 4 days, harvest media and stain flasks (See passage #1). 
 
MAKING WORKING VIRUS STOCKS 
 
Materials 
1.  EAV  
2.  Five confluent monolayers of RK-13 cells in T-150 flasks 
3.  EMEM 
4.  RK-13 medium 
5.  50 ml conical centrifuge tubes 
6.  Freezing vials  
 
Method 
1.  Inoculate monolayers with EAV at an m.o.i. of 1.  Resuspend the virus in approximately 50 ml of 
serum free MEM and add 10 ml per T-150 flask. 
2.  At the same time mock infect one T-75 flask of RK-13 cells. 
3.  Adsorb for 1 hour at 37°C.  . 
4.  Add 40 ml of complete RK -13 medium / T-150 flask.  Incubate at 37°C for 48 hours or until 95% - 
100% CPE. 
5.  Centrifuge at 5000 g (or 3000 rpm in the table top centrifuge) at 4°C for 15 minutes. 
6.  Make 1.8 ml and 0.5 ml aliquots of supernatant and store at -70°C. 
7.  Use one 0.5 ml frozen vial to titrate the virus. 
 
PREPARATION OF HIGH TITER VIRUS STOCKS 
 
Methods 
1. Seed cells into 3, triple-deck flasks and grow until confluency.  
2. Remove the medium and leave approx. 50 ml of complete medium containing 10% fetal bovine 
serum.  Add 500 µl-1 ml of virus per flask.  If the titer of the virus is known use an m.o.i of 1 
(higher m.o.i will may produce deletion mutant). 
3. Adsorb for 1 hour at room temperature on the orbital shaker. 
4. Add 20-40 ml of complete medium containing 10% fetal bovine serum and incubate at 37°C for 3-4 
days.  Check for signs of infection 2 days after the start of infection.   
5. Pellet down the cellular debris (3000 rpm / 4°C / 15 minutes) and aliquot into freezing vials and 
store at 4°C (stable for up to 6 months) and / or -70°C (for long term storage). Virus should be 
stored away from the fluorescent lights since the virus titer appears to decrease when exposed to 
fluorescent light for prolonged period of time.   
6. Determine the virus titer using the plaque assay procedure.   
 
CONCENTRATION OF EQUINE ARTERITIS VIRUS BY USING A 20% SUCROSE CUSHION  
 
Materials 
1. 20% sucrose in NET buffer 
2. SF-MEM 
3. RK-13 Medium 
4. NET buffer 
Method 
1. Five T-150 flasks with 3 days old confluent monolayers of RK-13 cells. 
2. Inoculate EAV PP3 P3 at an m.o.i. of 5.  Use approximately 2 vials (1 ml / vial) / T-150 flask.  10 vials 
of virus for five T-150 flasks. 
3. Dissolve the virus in SF-MEM. 
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1. 10 mls / T-150 × 5 = 50 mls 
2. Take 40 mls of SF-MEM and add 10 ml of virus  
3. Add 10 mls / T-150 flask 
4. At the same time mock infect one T-75 flask of RK-13 cells. 
5. Adsorb for 1 hour at 370C.  . 
6. Add 20 ml of complete RK -13 medium / T-150 flask.  Incubate at 370C for 48 hours or until 95% - 
100% CPE. 
7. Collect the supernatant and centrifuge at 5000 g (or 3000 rpm) / 4°C / 15 minutes to remove cellular 
debris.   
8. Filter the supernatant through 4.5μm bottle-top filter (optional) and overlay on to approx. 3-5 ml of 20% 
sucrose cushion placed in ultracentrifuge clear tubes.  Place each tube into ultracentrifuge bucket and 
balance to equal weight.   
9. Pellet the virus by ultra-centrifugation [36,000 rpm (155,300 g) / 4°C / 4 hours in AH 650 rotor]. 
Remove brake. 
10. Aspirate the supernatant and resuspend the virus pellet in 300-500 μl PBS (pH 7.4).  Sonicate for 15/15 
sec on and off for three times  
11. Store at -80°C.   
12. It is better to collect following samples for micro-titration assay to determine the efficiency of 
purification.   
 
MICROTITRATION ASSAY TO ESTIMATE EQUINE ARTERITIS VIRUS TITERS 
 
Materials: 
1. 96 Wells microtitration plates (Falcon 3072) 
2. Sterile snap cap tubes (Fisher or Falcon 2054) 
3. Multi channel pipette (8 or 12 channels) 
4. Antiserum or ascitic fluid (Monoclonal antibodies) 
5. Negative control serum or control ascitic fluid 
6. EMEM (BioWhittaker) 
7. Complete RK-13 medium  
8. Confluent RK-13 cells (one T-75 flask is sufficient for 5 ninety six well plates) 
9. Equine arteritis virus stock to be titrated 
10. Crystal violet staining / fix solution 
 
Method: 
 
1. Each test virus is done in triplicate.  Label the 96 well plates with cell controls. 
2. Dilute the test virus from 10-1 to 10-8 in EMEM (ten fold serial dilution).  Use 200 µl of virus + 
1800 µl of EMEM.   
3. Add 50 µl of EMEM to all the wells except to control wells (column 10, 11 and 12) where 100 µl 
of EMEM should be added. 
4. Trypsinize a confluent T -75 flask of RK-13 cells and resuspend the pellet in 10 ml of RK-13 
medium.  Take 2 ml of the cell suspension and resuspend in 10 ml (1:5) of RK-13 medium (or 4 
ml in 20 ml would be better.  This gives enough volume to work). 
5. Add 50 µl of diluted virus to test wells in triplicate.  Start with the highest dilution (10-8) and go to 
the lowest dilution (10-1; therefore, can use the same pipet tip) 
6. Add 100µl of resuspended RK-13 cells to each well.  Incubate at 37°C for four days. 
7. Feed the plates with 50 µl of growth media on day 2 and day 3 (if necessary) to maintain 
monolayers. 
8. When CPE occurs (usually 4 days), dump out the media in sink and stain with 1% crystal violet 
solution/fix for 20-30 minutes (it is easy to leave the plate(s) in a bucket containing 1% crystal 
violet/fix solution because the 1% crystal violet/fix solution can be reused.) and then wash gently 
with tap water to remove excess Crystal violet (three times).  Air dry plates and determine EAV 
titer by Reed and Munch method. 
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9. 50% end point values, by Read and Munch Method:  Under lined numbers indicate logarithmic 
characteristic of end point dilution.  Triplicates; 
3 - 2 - 0 - 0 = 0.25  3 - 1 - 2 - 0 = 0.5 
3 - 2 - 1 - 0 = 0.5   3 - 1 - 3 - 0 = 0.2 
3 - 2 - 2 - 0 = 0.0   3 - 0 - 0 - 0 = 0.5 
3 - 2 - 3 - 0 = 0.3   3 - 0 - 1 - 0 = 0.7 
3 - 1 - 0 - 0 = 0.75  3 - 0 - 2 - 0 = 0.8 
3 - 1 - 1 - 0 = 0.0   3 - 0 - 3 - 0 = 0.0 
10. Report virus titers as TCID50 per 50 µl.  
 
 
PLAQUE ASSAY 
 
Materials: 
 6 well plates 
 RK-13 cells  
 Carboxymethylcellulose (CMC) overlay media (1.3X EMEM 10% FSCS) 
 Virus for titration 
 
METHOD: 
1.  Prepare RK-13 in 6-well plates. 
2.  Make virus dilution (10-1 to 10-8) in complete 10% EMEM growth media. 
3.  Aspirate the medium and add 200 µl of diluted virus to each well in duplicate(Start from 10-8  and go to 
10-1).  Mix gently by rocking the plate. 
4.  Incubate the plate at 37°C for 1 hour to allow virus particles to adsorb into cells. 
5.  Following 1 hour incubation period, overlay cells with 4 ml (per well) of CMC overlay media adding 
to the side of the plate.   
6.  Allow plates to sit undisturbed on a leveled surface for 4 days until visible plaques develop. 
7.  After 4 days, discard supernatant and stain with crystal violet staining solution. 
8.  Count >10 to <100 plaques per well.  
9.  PFU/ml = (# of plaques in each well [duplicate]/2) × (highest dilution that gives # of plaques) × 
(dilution factor) 
10.  e.g. [(25 + 30)/2] × 10-5 × 5 (200 μl) = 137.5 × 10-5 = 1.37 × 10-7 pfu/ml 
 
 
 
  258 
SEROLOGY 
 
VIRUS NEUTRALIZATION TEST (VNT) 
 
Methods 
1. Inactivate sera at 56°C for 30 minutes 
2. Put 25μl of serum diluent (10% GP complement in EMEM 10% FSCS [keep on ice until used]) in all 
wells. 
3. Put 25μl of test serum to the first well of two rows (No row for checking toxicity*).  Dilute with 25 μl 
multichannel pipettor. 
4. Add 25 μl of virus (200 TCID50) diluted in EMEM 10% FSCS to all wells except controls (“See 
controls”). 
5. Incubate plates at 37°C (5% CO2 incubator) for one hour. 
6. Add 125 μl of trypsinized cells (prepared as directed below) to every well. 
7. Seal plates and incubate at 37°C (5% CO2 incubator).  Read after 48, read and final at 72 hours. 
Controls: cell controls, known positive and negative sera, and virus titration controls. 
Cell controls: add 50 μl serum diluent to 2 wells. 
Serum controls: add 25 μl serum diluent to 1 well/each test serum, add 25 μl test serum. 
Known positive serum and known negative serum are set up the same way as test sera. 
 
Virus titration: Add 25 μl serum diluent into each of 4 wells for cell controls (Row #1). 
     Add 25 μl of working virus dilution to each of 4 wells (Row #2). 
Add 25 μl of 1:10 dilution of working virus in EMEM 10% FSCS to each of 4 wells 
(Row #3). 
Add 25 μl of 1:100 dilution of working virus in EMEM 10% FSCS to each of 4 wells 
(Row #4). 
Add 25 μl of 1:100 dilution of working virus in EMEM 10% FSCS to each of 4 wells 
(Row #5). 
     Add 125 μl of trypsinized cells to all 20 wells. 
 
*If serum is toxic in serum control well (1:4 dilution), then repeat test with a row to check for toxicity. 
 
 
REVERSE SN-TEST FOR EAV VERIFICATION – confirmation test 
 
Materials 
1. Known positive serum, inactivated and diluted 1:4 in PBS (should come from field sample(s), not from 
vaccinated horses). 
2. Known negative serum inactivated and diluted 1:4 in PBS. 
3. Stock virus (Bucyrus) 
4. Unknown virus isolate 
Methods 
1. Add 0.3 ml of known negative serum to 4 tubes for each virus sample to be tested (including stock 
virus). 
2. Add 0.3 ml of known positive serum to 3 tubes for each virus sample to be tested (including stock 
virus). 
3. Make up 1:10 dilution of guinea pig complement in EMEM + 10% FSCS + antibiotics (10 ml for each 
sample). 
4. Make up 10-1 to 10-5 dilutions of all virus samples to be tested using 1.8 ml of media in #3 and 0.2 ml 
of virus (It may be necessary to dilute stock virus to 10-3 before starting these dilutions). 
5. To positive serum (3 tubes) add 0.3 ml of 10-1, 10-2 and 10-3 virus dilutions. 
6. To negative serum (4 tubes) add 0.3 ml of 10-2, 10-3, 10-4 and 10-5 virus dilutions. 
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7. Incubate serum-virus mixture for 1 hour at 37°C. 
8. 14 flasks 25 cm2 [7 RK-13 (KY) “high pass”, 7 RK-13 (ATCC-CCL37) “low pass”] are used for each 
virus to be tested.  Aspirate off media from 3-5 day RK-13 flasks and add 0.25 ml of above serum-
virus mixture to 2 flasks/dilution. 
9. Incubate for 2 hours at 37°C (closed caps, no CO2), rock flasks after 1hour. 
10. Add 10 ml of CMC overlay/flask.  Incubate for 4-5 days according to development of CPE, remove 
media, and stain with crystal violet plaque stain. 
 
 
TREATMENT OF SERUM WITH TOXICITY DUE TO (DUVAXYN) ANTIBODIES TO RK-13 
CELLS 
 
This procedure has been used successfully to eliminate (or reduce to readable at 1:4) toxicity from serum 
samples demonstrating the vaccine-induced “European” toxicity at 1:4 and greater in the EAV SNT.  These 
horses have been vaccinated with Duvaxyn EHV 1,4 (the EHV-1 component is made in RK-13 cells).  
Always treat a known negative and a known positive serum whenever this treatment is performed on toxic 
serum specimens.  Preferably, use serum that has not been previously inactivated.  Use sterile technique for 
the following steps: 
 
Methods 
1. Decant growth media from as flask of 7-10 day old RK-13 (KY) cells (P399-409).  Wash flask 3X 
with 10 ml Dulbecco’s PBS.  Add 1 ml trypsin EDTA/flask, rotate to spread over cell monolayer, then 
incubate approximately 6-8 min at 37°C. 
2. When cells have detached, add 2 ml EMEM with 10% FSCS/flask.  Mix well with 5 ml pipet, then 
divide between three 1.5 ml microcentrifuge tubes. 
3. Spin tubes at 2,0000 rpm for 15 sec in microcentrifuge.  Use a Pasteur pipet to remove and discard all 
supernatant.  
4. Add 0.5 ml of toxic serum or control serum per tube; mix with pipet until cells are resuspended; label 
tube appropriately.  Incubate for 1 hour at 37°C.  Flick tubes after 30 min to resuspend. 
5. Spin 2,500 rpm for 15 sec.  Use a Pasteur pipet to transfer each serum to a new, labeled 1.5 ml 
microcentrifuge tube. 
6. Inactivate at 56°C for 30 min if serum has not been inactivated previously.  Proceed with EAV SNT 
test, running sera (toxic, negative, positive) as usual and in pre-seeded (planted 18-24 hours prior) 
plates. 
 
ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) 
 
Materials 
1.  Microtiter plates for ELISA  
2.  Coating buffer 
3.  ELISA wash buffer 
4.  Biotinylated anti-mouse IgG 
5.  Enzyme substrate 
6.  Substrate stopping solution 
7.  Blocking solution 
8.  Antibody dilution buffer (ADB) 
9.  Conjugate dilution buffer 
10.  Substrate (e.g., OPD) 
11.  1% SDS 
12.  Test serum or culture supernatant  
13.  Positive control serum 
14.  Negative control serum 
15.  Multichannel pipette 
16.  Wash bottle 
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Method 
1.  Coat the ELISA plates with the antigen as previously described (see antigen preparation for coating 
ELISA plates) and store the plates overnight at 40C.  It is advisable to include negative control antigen 
(e.g., 1% BSA in coating buffer) in the plate. 
2.  Aspirate coating antigen solution and block unbound sites on the plastic by incubation with 150 µl 
blocking solution (1% BSA, gelatin, ovalbumin, casein, milk powder) or with antibody dilution buffer 
(ADB) per well for 30 minutes 
3.  Wash off unbound protein three times with 150 µl ELISA wash buffer (PBS-Tween [0.05%] also 
known as TPBS; add 0.5 ml of Tween 20 to 1 liter of PBS, pH 7.5) per well. 
4.  Add 50 µl of primary antibody diluted in ADB (need to titrate the antibody to find out the best dilution 
to be used).  If tissue culture supernatant is used add 50-100 µl straight.  Include some wells with 
known positive antibody and known negative antibody.  Incubate for one hour at room temperature. 
5.  Wash off unbound antibody three times with 150 µl ELISA wash buffer per well. 
6.  Add 50 µl of Biotinylated secondary antibody (Biotinylated anti mouse IgG 1:2000 dilution in ADB).  
Incubate for one hour at room temperature. 
7.  Wash off unbound secondary antibody three times with 150 µl ELISA wash buffer per well. 
8.  Add 50 µl of 1:2000 dilution of Avidin-HRP in conjugate dilution buffer (PBS pH 7.5, 0.5% BSA, 
0.05% Tween 20).  Incubate for 15 minutes at room temperature. 
9.  Wash off unbound Avidin-HRP three times with 150 µl ELISA wash buffer per well. 
10. Add 100 µl of substrate and let react until BSA control just becomes visible, 1 to 20 minutes (10 mls 
substrate per plate - 0.1M Citrate pH 4.5, 3.3 µl of H2O2, 10 mg OPD substrate).  If needed terminate 
reaction with 50 µl of 1% SDS.   
11. Assess the color intensity visually or quantitatively in a spectrophotometer designed to read microtitre 
plates (ELISA) reader.   
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MOLECULAR BIOLOGY/ RECOMBINANT DNA TECHNIQUES 
 
DESIGNING OF PRIMERS 
 
The approach for designing of specific and efficient primers remains somewhat empirical; there are no hard 
and fast rules.  With experience and by using a good primer designing program (e.g., MacDNASIS v3.5; 
Hitachi) the majority of the primers can be made to work.  Following are some guidelines to design specific 
and efficient primers. 
1.  Where possible, select primers with an average G+C content of around 50%.  
2.  Where possible, select primers with a random base distribution.  Try to avoid primers with stretches of 
polypurines, polypyrimidines, or other unusual sequences. 
3.  Melting temperature (Tm) should be between 55-75°C.   
4.  Increasing the Tm, therefore, the annealing temperature enhances discrimination  against 
incorrectly annealed primers and reduces misextension of incorrect nucleotides at the 3’ end of the 
primers.  Therefore, increasing the annealing temperature will help to increase the specificity.  An 
applicable annealing temperature is 5°C below the true Tm of the amplification primer.  The best 
annealing temperatures is in the range of 55-72°C.  Quick way to calculate annealing temperature is: 
5.  Annealing temp. (°C) = (# of A and T [A+T] × 2  +  # of G and C [G+C] × 4) - 5°C. 
6.  Try to design both positive and negative primers with same Tm (1-20C difference will not matter). 
7.  Make sure the primer ends (3’) with a G or C. 
8.  Primer length should be between 19 and 30 bases (19 to 22 bases are preferred).   
9.  If possible select a unique area of the genome to design the primer. 
10.  Avoid sequences with significant secondary structure (computer programs are very useful for this). 
11.  Check the primers against each other for complementarily.  Avoiding primers with 3’ overlaps will 
reduce the incidence of “primer-dimer” artifacts.   
12.  If possible do a simple homology matching (compare the primers with the whole genome using a 
computer program) and see whether primer(s) have <50% homology in the area closer to be amplified 
(or to the desired area).  This will reduce the number of nonspecific products of same size.   
 
 
AGAROSE GEL ELECTROPHORESIS  
 
Materials 
1. Agarose (SEAKEM LE agarose; FMC Bio Products).   
2. 50X TAE buffer (Tris Acetate EDTA, pH 8.0). 
3. Gel casting plate. 
4. Gel sealing tape 
5. Buffer tank.   
 
Method 
1. Make 1000 ml of 1X TAE, by measuring 20 ml of 50X stock into a 1000 ml graduated cylinder and q.s. 
to 1000 ml mark with deionized distilled water.  
2. Weigh 1.0 g of agarose (for 1% gel) and dissolve it in 100 ml of 1X TAE.  Melt agarose solution in 
microwave until completely dissolved.  Let stand at room temperature (or at 45°C in a water bath) to 
remove air bubbles but not enough to solidify. 
3. Prepare gel-casting plate by taping the ends with gel sealing tape.  Place the sample comb in the proper 
position on the plate.  
4. Pour 100 ml of 1% agarose on to the gel casting plate slowly and allow it to solidify (volume of 
agarose needed depends on the size of the gel casting plate).  The gel should be between 0.3 and 0.5 
cm thick.  After gel has set, final gelling carried out at 4°C for 30 minutes.  There should not be any air 
bubbles in the gel.   
5. Remove the tapes and keep the gel plate in the buffer tank.  Add 1X TAE buffer into the reservoirs 
until it covers the surface of gel at a depth of 3-4 mm. 
6. Slowly remove the sample comb and load the samples into the wells (Mix 1-20µl of RNA or DNA 
with 6X gel loading buffer; loading volume depends on the sample and make sure gel loading buffer 
get diluted to 1X with sample). 
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7. Voltage 70V for 2-3 hours (95V for 45-60 minutes) or until the first band has migrated at least 2.5 
inches away from the wells.  The voltage must never exceed 100V.  For low melt Agarose use low 
voltage (70V).  Always run the gel in constant voltage. 
8. Stain gel in ethidium bromide, letting it sit for 5-10 min.  Destain gel by placing in deionized distilled 
water for 5 min. 
9. Transfer the gel onto a UV light source. Usually a trans illuminator is used to facilitate this step.  Place 
a piece of plastic wrap between the gel and surface of the illuminator.  Use a face shield, gloves, and 
body shield to minimize the UV exposure.  Take a picture for records. 
10. Locate the DNA or RNA bands and excise by using a sharp scalpel blade (e.g. to obtain the desired 
band) 
Note:  Range of separation in gels containing different concentrations of agarose. 
  
 % of agarose (%[w/v])                 Efficient range of separation of linear DNA molecules (Kb) 
  0.3   5-60 
  0.6   1-20 
  0.7   0.8-10 
  0.9   0.5-7 
  1.2   0.4-6 
  1.5   0.2-3 
  2.0   0.1-2 
 
 
 
REAL TIME RT-PCR MEASURING EQUINE CYTOKINE GENE EXPRESSION  
 
Materials 
A. Total RNA extraction 
1. MagMAX  96™ Total RNA isolation kit (Applied Biosystems [ABI];  Cat# 1830) 
2. Isopropanol (Sigma; I9516-500 ml) 
3. Absolute ethanol (Decon Labs Inc.; Cat #2716) 
4. Sterile round bottom 96-well plate (Corning; #3799) 
5. 96-well Magnetic-Ring Stand (ABI; AM10050) 
6. 1.5ml sterile microcentrifuge tubes 
7. AluminaSeal™ (Diversified Biotech; Cat #ALUM-1000) 
8. MagMAX™ Express-96, 96-well Deep Well volume (ABI; Cat# 4400077) 
9. MagMAX Express 96 deep well tip combs (ABI; Cat #4388487) 
10. MagMAX Express 96 standard plates, 200 µl (ABI; Cat #4388475) 
11. MagMAX  Express 96 deep well plates (ABI; Cat #4388476) 
 
B. Reverse Transcription 
1. High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor, 200 reactions (Applied 
Biosystems [ABI] Cat# 4374966) 
2. Twin.tec PCR plate 96, skirted (96 × 150 µl [Eppendorf; Cat# 0030 128.656]) 
3. PCR film (Eppendorf; Cat# 0030 127.480) 
4. Epgradient Master Cycler (Eppendorf thermal cycler) 
5. Nuclease free water (Ambion; Cat #AM9937)  
 
C. Real Time PCR 
1. TaqMan® Gene Expression Master Mix  (Applied Biosystems [ABI], Cat# 4369016) 
2. 20X Gene Expression Assays (Custom designed primers and probe, see below for Order #) 
3. Automated Liquid Handling System (Corbett; CAS-1200) 
4. 50 µl tips, filtered, liquid sensing (Qiagen; Cat #990512) 
5. MicroAmp® Fast Optical 96-Well Reaction Plate with Barcode, 0.1 ml (ABI, Cat# 4346906) 
6. MicroAmp® Optical Adhesive Film (ABI, Cat# 4311971) 
7. Applied Biosystems 7500 Fast Real-Time PCR System 
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Methods 
A. RNA extraction 
1. Extract RNA using MagMAX™-96 Total RNA Isolation Kit.  It lyses up to 2 × 106 cells. Cells can be 
stored in 140μl of Lysis/Binding Solution at -80C until RNA extraction.  
Note: If you stored RNA at -80C, prior to RT heat the sample to 70C for 2 min in a thermal cycler and 
put on ice to denature RNA. 
2. Measure RNA concentration using NanoDrop and adjust to 0.5 µg or 1 µg (in 19.8 µl [final 30 µl 
reaction] or 26.4 µl [final 40 µl reaction]) depending on samples of the study.  
 
B. Reverse Transcription 
1. Prepare 2X reverse transcription master mix, mix and centrifuge briefly.   
 
Final total volume =30 µl 
Components Volume (µl)                
n=1 
Volume (µl)                
(32 samples + 3 extra) 
Volume (µl) 
(28 samples + 3 extra) 
30 µl  40 µl 30 µl 40 µl 30 µl 40 µl 
10X RT buffer 3 4 105 140 93 124 
25X dNTP Mix 
(100mM) 
1.2 1.6 42 56 37.2 49.6 
10X RT Random 
primers  
3 4 105 140 93 124 
MultiScribe RTase 1.5 2 52.5 70 46.5 62 
RNase inhibitor 1.5 2 52.5 70 46.5 62 
Total  10.2 13.6 357 476 316.2 421.6 
(Optional) Water       
 
2. Pipette 10.2 µl of 2X RT master mix into each tube or 96-well plate.  Keep on ice. 
3.  Pipette 19.8 µl of RNA (0.5 µg) sample into each well pipetting up and down two times to mix 
(NOTE: volume can be adjusted with H20 based on the RNA conc.). 
4. Seal plates with PCR film. 
5. Centrifuge briefly to remove bubbles and spin down the contents. 
6. Place the place on ice until ready to load on to the thermal cycler. 
7. Load the reactions into the thermal cycler and start the reverse transcription run (under Yun Young’s 
folder  - High Capacity RT) 
 
Step Temp (°C) Time 
1 25 10 min 
2 37 120 min 
3 85 5 min 
4 4 ∞ 
 
8. Store at -20 or use immediately for PCR amplification. 
9. If you are using -20C/80C frozen cDNA, immediately after thawing, heat the samples to 70C for 2 min 
in a thermal cycler to denature the cDNA and cool on ice. 
10. For real time PCR, dilute cDNA samples 1:1 with RNase free water (pool duplicate cDNA samples in 
one tube and add 60 µl of RNase free water). 
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C. Real Time PCR 
 
Components Volume (µl) 
TaqMan® Gene Expression Master Mix 5 
20X Gene Expression Assays 0.5 
1:1 diluted cDNA template 4.5 
Total 10 
 
1. Use automated pipettor (Corbett) to dispense both reaction mix and cDNA samples. 
2. Turn on the robot and open “1-06-10 YYG.CAS4” program (see Real time plate plan) 
3. Prepare reaction mix in 1.5 ml eppendorf tube. 
- Mix 70 µl of TaqMan Gene Expression Mix + 7 µl of 20X Gene Expression Assays  
- For a 96-well plate I am running 7 cytokines + B-GUS (8 eppendorf tubes) 
- The program is setup to load 5.5 µl of each reagent mix into corresponding well 
4. Place the reagent mix containing tube in the reagent rack and place a new 96-well real time PCR plate 
in the robot.  
5. Press Run (10 minutes). 
NOTE: If cannot proceed to sample loading immediately, wrap the plate with parafilm and store at 4C 
until sample loading. 
6. Meanwhile prepare cDNA samples in a 1.5 ml eppendorf tube for sample loading. 
- Transfer 97 µl of 1:1 diluted cDNA into 1.5 ml eppendorf tube 
- For a 96-well plate, I am running 3 samples + NTC + Positive control 
7. When reaction mix loading is complete, open “1-06-2010 sample load YYG.CAS4” 
8. Place sample tubes on the reagent rack. 
9. Program is setup to load 4.5 µl of cDNA sample into corresponding well and mix twice. 
10. Press Run (20 minutes) 
11. Seal the plate with optical adhesive film 
12. Centrifuge the plate briefly to remove air and bubbles. 
13. Load the plate into the ABI 7500 Fast PCR Cycler (RQ plate – standard mode – 1:30h duration) 
 
Step Temp (°C) Time Cycle 
1 50 2 min 1 
2 95 10 min 2 
3 95 15 sec 40 
4 60 1 min 
 
Applied Biosystems 20X Gene Expression Assay Order Number: 
 
Order Number Order Name*  Order Number Order Name 
1749300  EQIL-1B-JN2   
1918058  EquineIL-2-JN2   
1798106  EQIL4IS-JN2  3065515  EqIL-4 
50414323 EQIL-6   
1833786  EQIL-8IS-JN1   
50442836 EQIL10IS-JN2   
1649196  IL-12   3065515  EqIL-12p40 
1947516  EQIFNA-4-SITER 3053604  EqIFNAlpha 
1947516  EQIFNBETA-SITER 3053604  EqIFNBeta 
50442836 EQIFNGIS-JN3   
1787254  EQTNFAIS-JN2   
1725506 GUS     
*Probe labeled with 5’-FAM and 3’-NFQ 
 
 
  265 
PREPARATION OF COMPETENT BACTERIA CELLS - DH5α 
 
Materials 
1. Large, autoclave tray with ice for the ice/water bath. 
2. 40 sterile microcentrifuge tubes. 
3. Glycerol 
4. LB agar plates without ampicillin. 
5. Autoclave centrifuge bottles, microcentrifuge tubes. Dry cycle. 30 min. 
6. Chill these: centrifuge bottle, 15 ml conical tube, 0.1 M MgCl2 and CaCl2 solutions. 
Perform all procedures using sterile plasticware and solutions. 
Solutions 
1. 100 ml of 0.1 M MgCl2 prepared from 1 M MgCl2 stock. 
2. 100 ml of 0.1 M CaCl2 prepared from 1 M CaCl2 stock. 
3. Stock solutions can be sterilized by autoclaving and stored at room temperature. 0.1M solutions should 
be prepared fresh. 
4. LB (10g Bacto-tryptone, 5g yeast extract, 5g NaCl for 1000 ml LB) supplemented with 1 g/L glucose. 
Autoclave. 
Preparation of solutions 
1.   Glucose-supplemented LB medium (500 ml) 
Bacto-tryptone    5.0 g 
Bacto-yeast extract    2.5 g  
NaCl    2.5 g  
Glucose    0.5 g  
dH2O  to 500 ml 
Autoclave. Liquid cycle 30 min. Store at 4C. 
 
2.   Glycerol 100 ml 
Autoclave. Liquid cycle 30 min. Store at 4C. 
 
3.   1 M MgCl2 stock (100 ml) 
MgCl2·6H2O  (FW 203.30)    20.33 g 
dH2O  to 100 ml 
Autoclave. Liquid cycle 30 min. Store at Room temperature. 
 
4.   1 M CaCl2 stock (100 ml) 
CaCl2·2H2O  (FW 47.02)     14.70 g 
dH2O           to 100 ml 
Autoclave. Liquid cycle 30 min. Store at Room temperature. 
 
5.   0.1 M MgCl2 working solution (100 ml) and 0.1 M CaCl2 working solution (100 ml) 
 
Method 
 
1.   Streak out bacteria (DH5α or other strain) on an LB agar plate (without antibiotics). Allow to grow 
overnight at 37°C. 
2.   The next day, pick a single colony and grow in 2 ml of LB medium (without antibiotics), shaking 
(250 rpm) at 37°C overnight. Best to do this in the late afternoon. 
3.   Take 0.5 ml of the prepared LB medium to use as a blank for the OD. Transfer overnight bacterial 
prep to a 2L flask containing 500 ml of glucose-supplemented LB medium. Incubate at 37°C with 
vigorous shaking. During this time chill all solutions and centrifuge bottles on ice and turn on 
spectrophotometer, set wavelength at 550. After several hours (2.5-3 h), remove 0.5 ml of bacteria 
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using a sterile pipet and check OD550 (use LB/glucose as blank). Continue to check the culture until 
the OD550 reaches 0.5 (bacteria double about every 20 min). As soon as the correct OD is achieved 
immediately transfer the culture flask from the shaker to an ice/water bath. Constantly swirl flask for 
5 min until the whole sample is uniformly chilled. Pour the bacteria into the chilled centrifuge bottle 
and spin at 4000 rpm, 4°C for 20 min. 
4.   Decant supernatant and place bottle with bacteria pellet on ice. Resuspend in 10 ml of ice cold 0.1 M 
MgCl2 using sterile 10 ml pipet. Once resuspended, add the remaining 90 ml of chilled 0.1 M 
MgCl2. Sit on ice for 5 min and spin for 20 min at 4000 rpm 4°C. 
5.   While spinning, transfer 8.6 ml of 0.1 M CaCl2 to a 15 ml conical tube. Add 1.4 ml glycerol. Mix 
well and let sit on ice. 
6.   Decant supernatant and place bottle on ice. Resuspend in 10 ml of ice cold 0.1 M CaCl2 using 
sterile 10 ml pipet. Once resuspended, add the remaining 81.4 ml of ice cold 0.1 M CaCl2. Sit on 
ice for 20 min and spin in the centrifuge for 20 min at 4000 rpm 4°C. 
7.   Decant supernatant well and place bottle on ice. Resuspend bacteria in a chilled solution of 8.6 ml 
0.1 M CaCl2 /1.4 ml glycerol. Mix well and transfer 0.25 ml aliquots to microcentrifuge tubes that 
have been placed in dry ice or drop tubes into liquid nitrogen. Quick freeze and store bacteria at -
80°C until use. Once thawed, the cells should not be frozen  
 
TRANSFORMATION OF DH5α 
 
Materials 
 
1. Water bath at 42°C 
2. Warm SOC medium to RT 
3. Warm 3 LB plates w/ampicillin 
4. Thaw on ice 1 vial of competent cells (DH5α) for each transformation 
 
Methods 
1.  Thaw on ice, one vial of competent cells per transformation. 
2.  Add all ligated product to 100ul of competent cell and mix by stirring gently with the pipette. Do not 
mix by pipetting up and down. 
3.  Incubate on ice for 30 min 
4.  Heat-shock the cells for 45 seconds at 42°C without shaking 
5.  Immediately transfer the tubes on ice 2min 
6.  Add 900ul of RT SOC medium 
7.  Cap the tube tightly and shake the tube horizontally at 37°C for 1 h (240rpm) 
8.  After incubation at 37C for 1h. Transfer the culture to microcentrifuge tube. Decant the supernatant 
leaving about 100ul of media. Resuspend the bacterial pellet. 
9.  Spread 100ul from each transformation on a prewarmed LB agar plate (w/ampicillin) and incubate 
overnight at 37° 
 
 
PREPARATION OF COMPETENT BACTERIA CELLS - M15 [pREP4] 
 
Materials 
1.  M15[pREP4] cells (Qiagen) 
2.  LB medium-kanamycin (25 µg/ml) 
3.  LB agar-kanamycin (25 µg/ml)  
4.  TFB1 
5.  TFB2 
6.  Kanamycin stock solution (25 mg/ml in H2O, sterile filter, store in aliquots at -20°C)  
7.  Large, autoclave tray with ice for ice/water bath 
8.  40 sterile microcentrifuge tubes (Label them and place at -80°C at the beginning of the day) 
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9.  Autoclave centrifuge bottles.  Dry cycle 30 min. Chill centrifuge bottle and 15 ml conical tube and 
TFB1, TFB2 buffers. 
10.  Dry ice 
 
Buffers 
TFB1 (500ml)      MW  500 ml 
100 mM Rubidium Chloride (RbCl)  120.9  6.05 g 
50 mM Manganese Chloride (MnCl2)  197.9  4.95 g 
30 mM Potassium acetate   98.14  1.47 g 
10 mM Calcium Chloride (CaCl2)   147.0  0.735 g 
15% (w/v) Glycerol       75 ml 
Adjust pH to 5.8.  Sterilize by filtration. 
 
TFB2 (100ml)      MW  100 ml 
10 mM MOPS     209.3  0.21 g 
10 mM Rubidium Chloride (RbCl)  120.9  0.12 g 
75 mM Calcium Chloride (CaCl2)   147.0  1.10 
15% (w/v) Glycerol       15 ml 
Adjust pH to 6.8 with KOH.  Sterilize by filtration. 
 
LB Medium-kanamycin (final concentration 25 µg/ml) 
 
Method 
1. Streak out a trace of M15 [pREP4] cells from the vial with a sterile inoculating loop on LB-kanamycin 
agar plate. 
2. Incubate at 37°C overnight. 
3. Pick a single colony and inoculate 10 ml of LB-kanamycin (25 µg/ml).  Grow overnight at 37°C. 
4. Add 2 ml overnight culture to 200 ml prewarmed LB-kan medium in a 500 ml flask, and shake at 37°C 
until an OD600 of 0.5 is reached (approximately 90-120 min). Use LB-kan media as blank.  Turn on the 
centrifuge and keep it cool (4°C). 
5. Cool the culture on ice for 5 min.  Constantly swirl the flask for 5 min until the whole sample is 
uniformly chilled.  Transfer the culture to a sterile, centrifuge bottle. 
6. Collect the cells by centrifugation at low speed (5 min, 4000x g, 4°C). 
7. Discard the supernatant carefully.  Always keep the cells on ice. 
8. Resuspend the cells gently in cold (4°C) TFB1 buffer (30 ml for a 100 ml culture) and keep the 
suspension on ice for an additional 90 min. 
9. Collect the cells by centrifugation (5 min, 4000 x g, 4°C). 
10. Discard the supernatant carefully.  Always keep the cells on ice. 
11. Resuspend the cells carefully in 4 ml ice-cold TFB2 buffer. 
12. Prepare aliquots of 220 µl in sterile microcentrifuge tubes and freeze in liquid nitrogen or a dry-ice.  
Store the competent cells at -80°C. 
 
TRANSFORMATION OF COMPETENT M15 CELLS 
 
Materials 
1. Water bath at 42°C 
2. Psi broth (LB medium, 4 mM MgSO4, 10 mM KCl) 
3. LB-agar plates containing 100 µg/ml ampicillin and 25 µg/ml kanamycin 
Method 
1. Transfer an aliquot of the ligation mix or plasmid (10 µl or less) into a cold sterile 15 ml Falcon tube. 
2. Thaw an aliquot of frozen competent M15[pREP4] cells on ice. 
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3. Gently resuspend the cells and transfer 100 µl of the cell suspension into the tube with the ligation mix 
(or plasmid). 
4. Transfer the tube to a 42°C water bath for 90 sec. 
5. Add 500 µl Psi broth to the cells and incubate for 60-90 min at 37°C in a shaking incubator. 
6. Plate out 100 µl on LB-agar plates containing 25 µg/ml kanamycin and 100 µg/ml ampicillin.  
Incubate the plates at 37°C overnight. 
 
RAPID SCREENING OF SMALL EXPRESSION CULTURES 
 
Method 
1. Pick single colonies of transformants into 1.5 ml of culture media containing both ampicillin (100 
µg/ml) and kanamycin (µg/ml).  Inoculate one extra culture to serve as a noninduced control.  Grow 
the cultures overnight. 
2. Inoculate 10 ml of prewarmed medium (including antibiotics) with 500 µl of the overnight cultures, 
and grow at 37°C for 30 min, with vigorous shaking, until the OD600 is 0.5-0.7. 
3. Induce expression by adding IPTG to a final concentration of 1 mM (do not add IPTG to the culture to 
be used as a noninduced control). 
4. Grow the cultures for an additional 4-5h, and transfer to microcentrifuge tubes.  Harvest the cells by 
centrifugation for 1 min at 15,000 x g, and discard supernatants. 
5. Resuspend cells in Lysis buffer (Use B-PER from Pierce). 
 
Ni-NTA BASED RECOMBINANT PROTEIN PURIFICATION  
 
A. UNDER NATIVE CONDITIONS 
 
Materials  
 
Ni-NTA purification system (Invitrogen, K950-01) 
 
Method 
I. Preparing cell lysates under native conditions 
 
1. Harvest cells from a 50 ml culture by centrifugation (5,000 rpm for 5 min).  Resuspend the cells in 8 
ml of Native binding buffer. 
2. Add 8 mg lysozyme and 1X proteinase inhibitors (Pierce) and incubate on ice for 30 min. 
3. Using a sonicator, sonicate the solution on ice using six 10-sec bursts at high intensity with a 10-sec 
cooling period between each burst. 
4. Centrifuge the lysate at 3,000 × g for 15 min to pellet the cellular debris. Transfer the supernatant to a 
fresh tube. 
5. Remove 5 µl of the lysate for SDS-PAGE analysis.  Store the remaining lysate on ice or freeze at -
20°C. 
 
II.  Preparing Ni-NTA column and purification under native conditions 
1. Resuspend the Ni-NTA agarose in its bottle by inverting and gently tapping the bottle repeatedly. 
2. Pipet 1.5 ml of the resin into a 10 ml purification column. 
Allow the resin to settle completely (5-10 min).  Gently aspirate the supernatant. 
3. Add 6 ml sterile, distilled water and resuspend the resin by alternately inverting and gently tapping the 
column. 
4. Allow the resin to settle using gravity and aspirate the supernatant. 
5. For purification under Native conditions, add 6 ml Native binding buffer. 
6. Resuspend the resin by alternately inverting and gently tapping the column. 
  269 
7. Allow the resin to settle using gravity and gently aspirate the supernatant. Repeat this step one more 
time. 
8. Add 8 ml lysate prepared under native conditions to a prepared purification column. 
9. Bind for 2h at 4°C using gentle agitation to keep the resin suspended in the lysate solution. 
10. Settle the resin by gravity and carefully aspirate the supernatant. Save supernatant at 4°C for SDS-
PAGE analysis. 
11. Wash with 8 ml Native wash buffer.  Settle the resin by gravity and carefully aspirate the supernatant.  
Save supernatant at 4C for SDS-PAGE analysis. 
12. Repeat step 11 three more times. 
13. Clamp the column in a vertical position and snap off the cap on the lower end.  Elute the protein with 
8-12 ml Native elution buffer.  Collect 1 ml fractions and analyze with SDS-PAGE. 
14. Store the eluted fractions at 4C. 
 
B. UNDER HYBRID CONDITIONS 
 
Method 
I. Preparing cell lysates under denaturing conditions 
1. Equilibrate the Guanidium Lysis Buffer, pH 7.8 to 37°C 
2. Harvest cells from a 50 ml culture by centrifugation (5,000 rpm for 5 min) 
3. Resuspend the cell pellet in 8 ml of Guanidium Lysis Buffer from step 1. Add 8mg of lysozyme and 
1X proteinase inhibitor cocktail. 
4. Slowly rock the cells for 10 min at RT to ensure thorough cell lysis 
5. Sonicate the cell lysate on ice with three 5-sec pulses at high intensity 
6. Centrifuge the lysate at 3,000 × g for 15 min to pellet the cellular debris.  Transfer the supernatant to a 
fresh tube. 
7. Remove 5 µl of the lysate for SDS-PAGE analysis.  Store the remaining lysate on ice or at -20°C. 
When ready to use, proceed to the hybrid protocol. 
II. Preparing Ni-NTA column and purification under hybrid conditions 
1. Resuspend the Ni-NTA agarose in its bottle by inverting and gently tapping the bottle repeatedly. 
2. Pipet 2 ml of the resin into a 10 ml purification column supplied with the kit. Allow the resin to settle 
completely by gravity (5-10 min).  Gently aspirate the supernatant. 
3. Add 6 ml of sterile, distilled water and resuspend the resin by alternately inverting and gently tapping 
the column. 
4. Allow the resin to settle using gravity and aspirate the supernatant. 
5. For purification under Denaturing conditions, add 6 ml of Denaturing binding buffer. 
6. Resuspend the resin by alternately inverting and gently tapping the column. 
7. Allow the resin to settle using gravity and gently aspirate the supernatant.  Repeat the step one more 
time. 
8. Add 8 ml lysate to a prepared purification column. 
9. Bind for 1h at RT using gentle agitation to keep the resin msuspended in the lysate solution.  Settle the 
resin by gravity or low speed centrifugation and carefully aspirate the supernatant. 
10. Wash the column with 4 ml Denaturing binding buffer by resuspending the resin and rocking for two 
min.  Settle the resin by gravity and carefully aspirate the supernatant.  Save supernatant at 4°C for 
SDS-PAGE analysis.  Repeat this step one more time. 
11. Wash the column with 4 ml Denaturing wash buffer (pH 6.0) by resuspending the resin and rocking for 
2 minutes.  Settle the resin by gravity and aspirate the supernatant.  Save supernatant at 4°C for SDS-
PAGE analysis. Repeat this step one more time. 
12. Wash the column with 8 ml Native wash buffer by resuspending the resin and rocking for 2 min.  
Settle the resin by gravity and aspirate the supernatant.  Save supernatant at 4°C for SDS-PAGE 
analysis.  Repeat this step 3 more times for a total of 4 native washes. 
13. Clamp the column in a vertical position and snap off the cap on the lower end.  Elute the protein with 8 
ml Native elution buffer.  Collect 2 ml fractions and analyze with SDS-PAGE. 
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PURIFICATION OF RECOMBINANT PROTEINS (pQE-TriSystem - QIAGEN)  
 
PROTEINS UNDER DENATURING CONDITIONS 
 
Methods 
I. Growth of E. coli expression culture (100 ml) 
1. Inoculate 10 ml of culture medium containing both ampicillin (100 ug/ml) and kanamycin (25 ug/ml) 
in a 50 ml flask.  Grow the cultures at 37°C overnight. 
2. Inoculate 100 ml of prewarmed media (with antibiotics) with 5 ml of the overnight cultures and grow 
at 37°C with vigorous shaking until an OD600 of 0.6 is reached (30-60 min). 
3. Take a 1 ml sample immediately before induction. 
4. Induce expression by adding IPTG to a final concentration of 1 mM. 
5. Incubate the cultures for an additional 4-5 h.  Collect a second 1 ml sample. 
6. Harvest the cells by centrifugation at 4000  ×g for 20 min. 
7. Freeze the cells overnight at -20°C. 
 
II.  Preparation of cleared E.coli lyasates under denaturing conditions 
 
1. Thaw the cell pellet for 15 min on ice and resuspend in buffer B at 5 ml per gram wet weight. 
2. Stir cells for 15-60 min at RT or lyse them by gently vortexing, taking care to avoid foaming.  Lysis is 
complete when the solution becomes translucent. 
3. Centrifuge lysate at 10,000  ×g for 20-30 min at RT to pellet the cellular debris.  Save supernatant 
(cleared lysate). 
 
III. Batch purification of 6xHis-tagged proteins from E. coli under denaturing conditions 
Materials  
1. Cleared lysate  
2. Ni-NTA resin 
3. Empty columns 
4. Buffers B-E 
Methods 
1. Add 1 ml of the 50% Ni-NTA slurry to 4 ml lysate and mix gently by shaking (on a rotary shaker) for 
15-60 min at RT. 
2. Load-lysate-resin mixture carefully into an empty column with the bottom cap still attached. 
3. Remove the bottom cap and collect the flow-through. 
4. Wash twice with 4 ml buffer C. 
5. Elute the recombinant protein 4 times with 0.5 ml buffer D, followed by 4 times with 0.5 ml buffer E.  
Collect fractions and analyze by SDS-PAGE. 
Buffers for purification under denaturing conditions (Use molecular grade water) 
Buffer B (Lysis Buffer) 
 
 
 Buffer C (Wash Buffer) 
Components MW 1 L 500 ml 100 ml 
100 mM NaH2PO4 119.96 g/mol 11.9 g  5.99 g 1.19 g 
Components MW 1 L 500 ml 100 ml 
100 mM NaH2PO4 119.96 g/mol 11.9 g  5.99 g 1.19 g 
10 mM Tris Base 121.1 g/mol 1.2 g 0.6 g 0.12 g 
8 M Urea 60.06 g/mol 480.5 g 240.25 g 48.05 g 
Adjust pH to 8.0 using NaOH   
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10 mM Tris Base 121.1 g/mol 1.2 g 0.6 g 0.12 g 
8 M Urea 60.06 g/mol 480.5 g 240.25 g 48.05 g 
Adjust pH to 6.3 using HCl  
 
Buffer D (Elution Buffer) 
Components MW 1 L 500 ml 100 ml 
100 mM NaH2PO4 119.96 g/mol 11.9 g  5.99 g 1.19 g 
10 mM Tris Base 121.1 g/mol 1.2 g 0.6 g 0.12 g 
8 M Urea 60.06 g/mol 480.5 g 240.25 g 48.05 g 
Adjust pH to 5.9 using HCl  
 
Buffer E (Elution Buffer) 
Components MW 1 L 500 ml 100 ml 
100 mM NaH2PO4 119.96 g/mol 11.9 g  5.99 g 1.19 g 
10 mM Tris Base 121.1 g/mol 1.2 g 0.6 g 0.12 g 
8 M Urea 60.06 g/mol 480.5 g 240.25 g 48.05 g 
Adjust pH to 4.5 using HOH  
 
Important Note:  Due to the dissociation of urea, the pH of Buffers B, C, D, and E should be adjusted 
immediately prior to use.  Do not autoclave. 
 
 
PROTEIN ANTIGEN DIALYSIS  
 
Materials 
1. Slide-A-Lyzer MW 3.5K (Pierce; Cat# 66333) 
Methods 
1. Hydrate Membrane 
- Remove the cassette from its pouch and slip into the groove of the buoy 
- Immerse cassette in dialysis buffer 
- Hydrate the 3.5K cassettes for 30sec 
- Remove cassette from buffer and remove excess liquid by tapping the edge of the cassette gently on 
paper towels. 
2. Add sample  * Do NOT allow the needle to contact the membrane 
- Fill the syringe with the sample, leaving a small amount of air in the syringe 
- Insert the tip of the needle through one of the syringe ports located at a top corner of the cassette 
- Inject sample slowly (Avoid foaming) 
- Withdraw air by pulling up on the syringe piston 
- Remove the syringe needle from the cassette while remaining air in the syringe 
3. Dialysis       
- Slip the cassette into the groove of a buoy and float this assembly in the dialysis buffer (Use the 
dialysis buffer at 500 times the volume of the sample 
- Dialyze for 2 hours at 4°C  
- Change the dialysis buffer and dialyze for another 2 hours 
- Change the dialysis buffer and dialyze O/N at 4°C 
4. Sample Removal 
- Fill syringe with a volume of air at least equal to the sample size ( For low volume samples, fill syringe 
with a volume of air approximately equal to two times the sample volume) 
- Penetrate the gasket with the needle through a top, unused syringe guide port. 
- Discharge air into cassette cavity to separate membranes 
- Turn the unit so that needle is on the bottom and allow the sample to collect near the port 
- Withdraw the sample into the syringe 
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BCA PROTEIN ASSAY (adapted for Nanodrop use)  
 
The BCA Assay requires a standard curve to be generated each time it is run 
 
Materials 
BCA protein assay (Pierce; Cat# 23225) 
 
Method 
1.  Prepare diluted albumin (BSA) standards. 
- Dilute the contents of one BSA ampule into several clean vials. Preferably use the same diluent as the 
sample(s). Each 1 ml ampule of 2.0 mg/ml BSA is sufficient to prepare a set of diluted standards. 
 
 Working range = 20-2,000 ug/ml 
Vial Volume of Diluent Volume and Source of BSA Final BSA concentration 
A 0 300ul of Stock 2,000 ug/ml * 
B 125ul 375ul of Stock 1,500 ug/ml * 
C 325ul 325ul of Stock 1,000 ug/ml * 
D 175ul 175ul of vial B dilution 750 ug/ml  
E 325ul 325ul of vial C dilution 500 ug/ml * 
F 325ul 325ul of vial E dilution 250 ug/ml 
G 325ul 325ul of vial F dilution 125 ug/ml * 
H 400ul 100ul of vial G dilution 25 ug/ml 
I 400ul 0 0ug/ml= Blank 
If nanodrop allows only 5 standard points use these concentrations (*) to make the standard curve 
 
2. Prepare the BCA Working Reagent (WR) 
- Use the following formula to determine the total volume of WR required: 
(# standards + # unknowns) × (# replicates) × (volume of WR per sample) = total volume WR required 
 
3. Prepare WR 
- Mix 50 parts of BCA reagent A with 1 part of BCA reagent B (50:1, Reagent A:B) 
 
4.  Regular assay (using a 20:1 reagent/sample volume ratio).  
- Pipet 4 ul of sample in 80 ul of BCA reagent into a 1.7 ml centrifuge tube and mix well. 
- Incubate tubes at 37°C for 30 minutes (working range = 20- 2,000 ug/ml). It is better to use water bath. 
- Cool all tubes to RT. 
 
5.  Measure protein concentration using Nanodrop. 
- A blank must be measured before the standard curve may be generated. 
- Step 1: Measure the blank (BCA reagent – a “0” standard) 
- Step 2: Up to 5 standards can be measured 
- Step 3: Measure samples 
  
 
ANTIBODY PURIFICATION FROM ASCITES 
 
Materials 
 
1. Zeba Desalt Spin Columns (2ml, Thermo Scientific #89889; 5ml #89891) 
2. Melon Gel IgG Spin Purification Kit (Thermo Scientific # 45206) 
3. Ascites Conditioning Reagent (Thermo Scientific #45219) 
4. Variable-speed centrifuge 
5. 15 ml conical tubes 
6. Buffer for exchange 
7. Serum samples 
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8. Pipettes and tips 
 
Methods 
 
A. Ascites Conditioning 
1. Measure the volume of the sample and transfer to a centrifuge tube 
2. Place one half the sample volume of 1 X Gel Purification Buffer into a tube and add 40 μl of the 
Ascites Conditioning Reagent for every 1 ml of original sample volume. Pulse vortex for 10 sec. 
3. While mixing the sample, slowly add the buffer containing the Ascites Conditioning Reagent. 
4. Rock or rotate sample for 10 min at RT. (Mixture appears opaque after conditioning) 
5. Centrifuge sample at 5,000 ×g for 10 min. Take the supernatant and discard the pellet.  
6. Desalt sample using Zeba Desalt Spin Columns pre-equilibrated with 1X Melon Gel Purification 
Buffer. (For best results, use a sample volume less than 10% of the total Zeba Column volume) Follow 
the manufacter’s instructions about “Procedure for Protein Desalting”. 
 
B. IgG Purification from Ascites 
1. Equilibrate the Melon Gel IgG Purification Support and Buffer to RT 
2. Swirl bottle containing the Purification Support (don’t vortex) to obtain an even suspension. Dispense 
500μl of slurry into a Spin Column placed in a microcentrifuge tube. Swirl the bottle of gel slurry 
before pipetting each sample to maintain the gel suspension. 
3. Centrifuge the uncapped column/tube for 1 min at 2,000-6,000 × g, then remove the spin column and 
discard flow-through. 
4. Add 10 μl of 5X Regenerant per 1 ml of sample to the conditioned ascites and mix. Add 100 μl of the 
mixture to the gel, cap column, and incubate for 5 min at RT with end-over-end mixing. 
5. Remove the bottom cap from the column, loosen top cap and re-insert spin column in the collection 
tube. 
6. Centrifuge for 1 min to collect the purified antibody in the microcentrifuge tube. Repeat steps 5-7 for 
the second batch. 
7. The antibody may be directly used or stored at -20°C 
 
NOTE: Discard or regenerate the gel. For gel regeneration, perform the following steps: 
 
1. Add 1.5 times the gel-bed volume of Melon Gel 1X Regenerant, mix for 5 min with end-over-end 
mixing, centrifuge and discard flow-through. Repeat this process a total of three times. 
2. Wash gel with 10 times the gel-bed volume of water. 
3. For storage, wash column with 10 times the gel-bed volume of 1X Melon Gel Purification Buffer. 
For storage longer than 1 week, add a final concentration of 0.02% sodium azide to the buffer used 
to wash the column. 
  
IgG ANTIBODY PURIFICATION FROM SERUM 
Materials 
 
1. Zeba Desalt Spin Columns (2ml, Thermo Scientific #89889; 5ml #89891) 
2. Melon Gel IgG Spin Purification Kit (Thermo Scientific # 45206) 
3. Variable-speed centrifuge 
4. 15 ml conical tubes 
5. Buffer for exchange 
6. Serum samples 
7. Pipettes and tips 
 
Methods 
A. Procedure for buffer exchange 
1. Twist off the column’s bottom closure and loosen cap. Place column in a collection tube. 
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2. Centrifuge column at 1,000 × g for 2 min to remove storage solution. Place a mark on the side of the 
column where the compacted resin is slanted upward. Place column in centrifuge with the mark facing 
outward in all subsequent centrifugation step. 
3. Add 1ml of Melon Gel Purification Buffer to the column. Centrifuge at 1,000 × g for 2 min to remove 
buffer. 
4. Repeat step 3 two additional times, discarding buffer from the collection tube. 
5. Place column in a new collection tube, remove cap and slowly apply 200-700 μl sample to the center 
of the compact resin bed. 
6. To ensure maximal protein recovery from low-volume samples, apply a stacker of ultrapure water or 
buffer to the resin bed after the sample has fully absorbed (40 μl stacker for samples <350μl) 
7. Centrifuge at 1,000 × g for 2 min to collect the sample. Discard column after use. 
 
B. Spin-column procedure for antibody purification 
1. Equilibrate the Melon Gel IgG Purification Support and Purification Buffer to RT (~ 15 min) 
2. Swirl bottle containing the Purification Support (don’t vortex) to obtain an even suspension. Dispense 
500μl of slurry into a Spin Column placed in a microcentrifuge tube. Swirl the bottle of gel slurry 
before pipetting each sample to maintain the gel suspension. 
3. Centrifuge the uncapped column/tube for 1 min at 2,000-6,000 × g, then remove the spin column and 
discard flow-through. 
4. Add 300 μl of Purification Buffer to the column, pulse centrifuge for 10 sec and discard flow-through. 
Repeat this wash once. Place the bottom cap on the column. 
5. Add 10-100 μl of buffer exchanged serum to the column. Cap column and incubate for 5 min at RT 
with end-over-end mixing.  
6. Remove the bottom cap from the column, loosen top cap and re-insert spin column in the collection 
tube. 
7. Centrifuge for 1 min to collect the purified antibody in the microcentrifuge tube. Repeat steps 5-7 for 
the second batch. 
8. The antibody may be directly used or stored at -20°C. 
 
NOTE: Discard the used gel support. If the gel must be used again, it can be regenerated by adding 500μl 
of 5M NaCl or 0.5N NaOH, mix for 5 min, centrifuge, and discard flow-through. Wash gel five times by 
adding 500μl Purification Buffer, centrifuge and discard flow-through. Add 500μl Purification Buffer and 
store at 4°C. The gel may be regenerated three times without significant loss of selectivity. 
 
 
MONOCLONAL ANTIBODY ISOTYPING 
 
Antigen-Independent Protocol 
 
For each antibody sample to be tested, this method uses a set of 10 microplate wells corresponding to one 
negative control, one positive control, and the eight different class/subclass-specific specific primary 
antibodies (rabbit anti-mouse) supplied in the kit.  
 
In the antigen-independent protocol, the first step is coating the microplate with anti-mouse Ig (G+A+M) 
polyclonal antibody; therefore, only the mouse IgG, IgA and IgM subclasses that are recognized by this 
coated antibody are detected. 
 
Materials 
 
1. Monoclonal antibody Isotying kit (Thermo Scientific #37501) 
2. Flat-bottom high binding 96-well ELISA plate 
3. PBS 
4. Coating buffer (10mM sodium bicarbonate, pH 9.4; Cat. #28382) 
5. Coating Antibody working solution: add 1 drop (~50 μl) of Coating Antibody (supplied) to 5 ml of 
Coating Buffer (prepare immediately before use in step 1). 
6. 1X Blocking Solution: add 1 drop (~50 μl) of 50X Blocking Solution (supplied) to 2.5 ml of PBS  
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7. Wash Buffer: add 1 drop (~50 μl) of 50% Tween 20 (supplied) to 50 ml of PBS 
8. HRP-GAR IgG (secondary antibody): add 1 drop (~50 μl) of HRP-Conjugated Goat Anti-Rabbit IgG 
(supplied) to 2.5 ml of wash buffer (prepared immediated before use in step 8) 
9. 1X ABTS Substrate Buffer: add 5 drops (~250 μl) of the 10X ABTS Substrate Buffer concentrate 
(supplied to 2.5 ml of ultrapure water) 
10. 1X ABTS Substrate Solution: add 1 drop (~50 μl) of 50X of ABTS Substrate (supplied) to 2.5 ml of 1X 
 ABTS Substrate Buffer (prepare immediately before to use in step 10 of procedure) 
 
Methods 
 
1. Coat wells of a microplate with Coating Antibdoy by adding 50 μl of Coating Antibody Working 
Solution into 10 wells for each antibody sample to be assayed. Cover and incubate plate at 4°C 
overnight or at RT for 2 hr. 
2. Empty the wells; add 125 μl of 1X Blocking Solution to coated wells; cover and incubate microplate at 
37°C for 1 hr. 
3. Empty wells and wash four times with 125 μl of Wash Buffer. 
4. Add 50 μl of each antibody sample to wells #1 - #9 of each coated plate 10-well set; add 1 drop (50 μl) 
of Positive Control (supplied) to well #10 of each 10-well set; cover and incubate microplate at 37°C 
for 1 hr. 
5. Empty wells and wash four times with 125 μl of Wash Buffer. 
6. Add 1 drop (50 μl) of each specific anti-mouse antibody (8 total) to corresponding wells #1- #8 or each 
10-well set. 
Add 1 drop (50 μl) of Normal Rabbit Serum (negative control) to well #9 of each 10-well set.  
Add 1 drop (50 μl) of the Anti-Mouse IgG1 Antibody to well #10 of each 10-well set. 
Record pattern of these primary antibody additions using the data template.  
Cover and incubate microplate at 37°C for 1hr. 
7. Empty wells and wash four times with 125 μl of Wash Buffer. 
8. Add 50 μl of HRP-GAR IgG (secondary antibody) to each well; cover and incubate microplate at 37°C 
for 1 hr. 
9. Empty wells and wash four times with 125 μl of Wash Buffer. 
10. Add 100 μl of 1X ABTS Substrate Solution to each well; cover and incubate microplate at RT for 
approximately 30 min. until color development is sufficiently complete. 
11. Evaluate results qualitatively by spectrophotometry at 405nm. Positive wells typically have absorbance 
ranging from 0.8 to 1.2. 
 
 
ALEXA FLUOR 488 PROTEIN LABELING (Molecular Probe) 
 
Materials  
 
1. 0.5ml of IgG solution at 2mg/ml 
2. Handheld UV lamp 
3. Ringstand 
4. Alexa Fluor 488 Protein Labeling Kit (Molecular Probe #A10235) – 3 labelings 
5. Autoclaved deionized water 
 
Methods 
 
A. Labeling the protein 
1. Prepare a 1M solution of sodium bicarbonate by adding 1mL of dH20 to the provided vial of sodium 
bicarbonate (component B). Vortex until fully dissolved. It can be stored at 4°C for up to 2 weeks. 
2. If the protein concentration if greater than 2mg/ml, dilute the protein to 2mg/ml in PBS. 
3. To 0.5mL of the 2mg/ml protein solution, add 50μl of 1M bicarbonate. 
4. Allow a vial of reactive dye to warm to RT. Transfer the protein solution from step 3 to the vial of 
reactive dye. This vial contains a magnetic stir bar. Cap the vial and invert a few times to fully dissolve 
the dye. Stir the reaction mixture for 1 hr at RT. 
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B. Purifying the Labeled Protein 
1. Assemble the column and position it upright: attach a funnel to the top of a column. Gently insert the 
column through the X-cut in one of the provided foam holders to avoid damaging the column. Using 
the foam holder, secure the column with a clamp to a ringstand. Carefully remove the cap from the 
bottom of the column. 
2. Prepare the elution buffer by diluting the RT 10X stock (component D) 10-fold in dH2O. Typically, 
less than 10 ml is required for each purification. 
3. Using one of the provided pipets, stir the purification resin (component C) thoroughly to ensure a 
homogeneous suspension. Pipet the resin into the column, allowing excess buffer to drain away into a 
small beaker or other container. Resin should be packed into the column until the resin is ~3cm from 
the top of the column. 
4. Allow the excess buffer to drain into the column bed. Do not worry about the column drying out, since 
the matrix will remain hydrated. Make certain the buffer elutes through the column with a consistently 
even flow prior to adding the reaction mixture. If the flow of buffer is slow or stalled, repack the 
column. Carefully load the reaction mixture from Part A onto the column. Allow the mixture to enter 
the column resin. Rinse the reaction vial with ~100 μl of elution buffer and apply to the column. Allow 
this solution to enter the column. 
5. Slowly add elution buffer, taking care not to disturb the column bed. Continue adding elution buffer 
until the labeled protein has been eluted (about 50 min). 
6. As the column runs, periodically illuminate the column with a handheld UV lamp. You should observe 
two colored bands, which represent the separation of labeled protein from unincorporated dye. Collect 
the first band, which contains the labeled protein, into one of the provided collection tubes. Add 
elution buffer to the column as necessary. Do not collect the slower moving band, which consists of 
unincorporated dye.  
7. Store the labeled protein – which will be in PBS, pH 7.2, containing ~2mM sodium azide- at 2-6°C, 
protected from light. If the final concentration of purified protein conjugate is less than 1mg/ml, add 
BSA or other stabilizing protein to 1-10mg/ml. The conjugate should be stable at 4°C for several 
months. For long-term storage, divide the solution into small aliquots and freeze at ≤ -20°C. 
 
It is good  practice to centrifuge solutions of conjugates in a microcentrifuge before use; only the 
supernatant should then be used in the experiment. This step will remove any aggregates that may have 
formed during storage. 
 
 
BIOTINYLATION OF EAV RECOMBINANT VIRUSES  
 
Materials 
1. Amersham ECL Protein Biotinylation Module (RPN2203) 
2. Orbital shaker 
3. PBS, pH 7.5 
4. PBS containing 1% BSA 
5. Distilled water 
 
Methods 
 
1. Determine the concentration of protein to be biotinylated (see BCA method using nanodrop) 
2. Prepare a 40 mM working concentration of bicarbonate buffer (BB) by diluting 1:20 in distilled water. 
(prepare always fresh) 
3. Place the biotinylation reagent at RT and ensure the vial has equilibrated to RT prior to opening. 
4. Dilute the protein to 1mg/ml in the diluted bicarbonate buffer. The maximum volume suitable for 
loading on to the column is 2.5 ml (the minimum volume is 2.0 ml). Add 40ul of biotinylation reagent 
for each mg of protein. 
5. Incubate at RT for 1 h with constant agitation. 
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6. Discard the buffer at the top of the Sephadex G25 column, and cut 1-2 mm off the tip seal. Equilibrate 
the column with 5 ml of PBS-1% BSA (pH 7.5) followed by 20 ml of PBS. Discard the column 
washings. Do not allow the column to run dry. 
7. Allow the buffer level in the top of the column to fall to the level of the plastic sinter at the top of the 
gel bed. 
8. Apply the protein sample (in 2.0-2.5 ml) to the column. Allow the sample volume to enter the column 
before eluting with PBS and collecting fractions. 
9. Elute the sample in 5 ml of PBS (use 2-3 mls of PBS to wash the tubes containing virus). Collect 1 ml 
fractions (total 5 fractions). Measure protein concentration of 1-5 fractions to determine the eluted 
protein containing fractions. 
10. Measure either protein concentration or UV absorbance at 280nm to verify the fraction number 
containing the eluted protein.  
11. Aliquot in 0.5ml/tube. Make one tube with 110 μl of biotinylated EAV for titration. Store at -80C   
 
VIRUS BINDING ASSAY  
 
Keep everything at 4°C during the whole experiment 
1. See EEC in 6 well plates and wait to grow 100% confluent. 
2. Place cells at 4°C for 30 min to cool down. 
3. Wash cells with cold PBS-2%FBS (PBS-F) 3 times before adding biotinylated VBS into each well. 
4. Incubate the virus and cell mixtures at 4°C on a shaker for 60 min. 
5. Remove the inocula and wash the unbound cells extensively (3X) with cold PBS-F 
6. Add the non-enzymatic cell dissociation solution (Sigma, #C-5914, 1X, 1 ml/25cm2 flask), 
400ul/well and mix on a shaker. 
7. Incubate at 4°C until cells are dissociated form the plates. 
8. Add 1ml PBS-F to each well to the cells and pipet repeatedly to dissociate clumps. Transfer the 
cell suspension in 1.5ml eppendorf tube. Spin at 1000xg for 5 min (in real time PCR room, cool 
centrifuge at 4C prior to the experiment) and wash with 1ml PBS-F once to remove non-enzymatic 
buffer. 
9. Incubate the washed cell pellets with 200ul 1:100 diluted streptavidin-FITC conjugated 
(Amersham, #RPN 1232) in PBS F for 60 min at 4C on a shaker 
10. Wash cells once with ice cold PBS, and resuspend in 500 ul PBS F for immediate flow cytometric 
analysis.  
 
Modified protocol for PBMC (EEC for control) 
1. Prepare PBMC as for conventional flow cytometry staining. Process AD and NAD cells separately. 
Incubate on ice to keep it at 4C. Also resuspend EEC cells to use as control. Count the cells and 
place 106 cells into each well or tube. 
2. Wash cells twice with ice cold PBS-2% FBS (PBS-F) at 4C 
3. Incubate cells with anti-equine CD3 MAb (100ul) and biot-EAV (10ug protein, m.o.i. of 100? I 
am not sure how much difference is between these or which one will work better yet) in facs 
buffer (1% NGS; prepare newly and keep it sterile) for 45 min on ice. 
4. Wash once with PBS-F 
5. Incubate and anti-mouse IgG PE and streptavidin-FITC (total volume 100ul) for 45 min on ice 
6. Wash twice with ice cold PBS-F followed by one wash with ice-cold PBS 
7. Resuspend in 300ul of 2% paraformaldehyde. 
 
 
INDIRECT IMMUNOFLUORESCENT ASSAY 
 
Materials: 
 
1. Chamber slides (Lab-Tek [Chamber Slide™]; Nunc, Inc.) or coverslips for 24-well plate 
2. Cover slips (large). 
3. Confluent monolayer of cells (BHK21, RK13 etc.) 
4. Cell medium (10% BCS-EMEM) 
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5. Fixative: 4% paraformaldehyde 
6. Wash buffer: 10mM glycine in PBS  
7. Permeabilization buffer: PBS w/ 0.2% Triton-X 100  
8. Primary antibody dilution: PBS w/ 5% FBS 
9. Secondary antibody dilution buffer: PBS w/ 5% FBS or 0.02% evans blue in PBS 
10. FITC-conjugated goat anti-mouse IgG F(ab’)2 (Caltag) 
11. Mounting medium (Vector, Vectashield H-1000)  
 
Method: 
 
1. Trypsinize cells (T-75 flask) and resuspend into 60 mls of growth media. Plate 0.3 ml per well on to 8-
well chamber slides (in this case, usually cells in chamber slides will be ready for infection in 24 
hours). Incubate at 37°C. OR T-25 flask of cells were resuspended into 12 ml of growth medium. Plate 
300µl cells per well on to eight chamber slides. Incubate at 37°C 
2. Twenty four hours later or when cells are subconfluent aspirate media and infect with EAV at a m.o.i. 
of 5 (100 µl of diluted VBS53 EAV).  Adsorb for 1 hour at 37°C.  Add 0.3 ml of fresh medium and 
incubate for 24 hours. 
3. Aspirate cell media. 
4. Wash one time with cold PBS (0.6 ml per well). 
5. Fix with 4% paraformaldehyde in PBS for at least 30 min at room temperature.  
6. Rinse 3X in PBS/10mM glycine. 0.5-0.6ml/well. Leave the cells in your last PBS-glycine wash and store 
them at 4°C until labeling 
7. Permeablize with PBS containing 0.2% Triton-X 100, leave at RT 5-10min. 
8. Wash 3X with PBS/10mM glycine with slides on a shaker.  
9. Dilute mouse MAb 12A4 against EAV nsp1  
Make 1:250 dilutions for unconjugated 12A4 (3.5µg/ml) 
Make 1:100 dilutions for AF488 conjugated 12A4 (1mg/ml) 
10. Place 100μl drops of diluted Ab to each well. Incubate at RT for 1 hour. Leave slides on a shaker. 
11. Wash 3X with PBS/10mM glycine 3 times with slides on a shaker. 
12. Dilute secondary Ab [FITC-conjugated goat anti-mouse IgG F(ab’)2 (Cat # 31543, Pierce 
Biotechnology) and FITC-conjugated goat anti-rabbit IgG(H+L) F(ab’)2 (Cat # 31573, Pierce 
Biotechnology)] 
Make 1:100 dilutions 
13. Incubate in dark for 1h at RT with slides on a shaker. 
14. Wash 3X with PBS/10mM glycine with slides on a shaker. 
15. Remove gaskets. Peel off the plastic stickers. Add a drop of mounting medium with DAPI (Vector, 
Vectashield H-1500) on each well of the chamber slides. Then place a coverslip over the stained slide. 
Store at 4°C in dark. 
 
FLOW PROTOCOL FOR SURFACE AND INTRACELLULAR LABELING of AD and NAD 
PBMCs 
 
Materials 
 
1. 4% paraformaldehyde fixation 
2. FACS buffer (DPBS with 0.1% (w/v) sodium azide. Filter 0.2 μm pore membrane. Store at 4°C. 
Add 1% NGS when needed) 
3. Permeabilization buffer: DPBS, 1% heat-inactivated NGS, 0.1% (w/v) sodium azide, 0.1% 
saponin (w/v) and sterile filter (0.2 μm pore membrane) 
4. Antibodies with appropriate dilution (All intracellular antibody dilutions will be performed in 
permeabilization buffer/ surface marker Abs are diluted in FACS buffer) 
5. Secondary antibodies 
6. Blocking solution (Flow buffer with 10% FBS) 
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Methods 
 
Virus infection 
 
1.  Plate cells in each 150 mm culture dish and infect with virus at m.o.i. of 5. Dilute the virus in 
minimum volume of plain media (7 ml of plain RPMI is enough to cover 150 mm dish) Note: 
Include control cells (e.g. equine endothelial cells T-75 has approx. 1.5 × 107 cells)  
2.  Adsorb virus for 1 h and add 18 ml of 10% cRPMI media into each dish. Incubate for 12, 18, 36 h. 
3.  Cell collection. 
4.  Non-adherent cells: collect TCF. Wash twice with PBS (10 ml each time) and pull them together 
with TCF. 
Adherent cells: discard TCF and wash with PBS (10 ml each time) and discard the washed fluid. 
After washing, collect adherent cells using a scrapper and wash the dish with PBS and collect the 
PBS wash. 
5.  Pellet cells and count them. 
 
Surface staining 
 
1. Dilute the surface markers in facs buffer. Dilute cell pellet in facs buffer and equally aliquot ~1.0 x106 
cells into each of V-bottomed 96 well plate. 
2. Label cells with 100ul of cell surface marker. Mix by pipetting and incubate for 30 minutes at 4°C 
(ice-bucket).  
3. Wash once with 200ul facs buffer, centrifuge at 500 g for 5 minutes. 
4. Label cells with 100ul of 2° Ab (goat anti-mouse IgG-PE conjugated diluted 1:200 in facs buffer). 
Incubate for 30 minutes at 4°C covered with aluminum foil 
5. Wash once with 200ul facs buffer, centrifuge at 500 g for 5 min. Flick off excess 
 
E. INTRACELLULAR EAV STAINING 
6. Fix the cells with 200µl 4% paraformaldehyde for 30 minutes at RT in dark. Centrifuge at 500 g for 5 
minutes.  
7. Wash once with 200ul facs buffer.  
8. Permeabilize membrane with permeabilization buffer (200 µl /tube) for 5 minutes. 
9. Centrifuge at 500 g for 5 minutes.  
10. Block Fc receptors with 10% FBS in FACS buffer for 30 minutes at RT in dark. 
11. Dilute the intracellular labeling antibody in permeabilization buffer. 
12. Label with fluorochrome- conjugated intracellular antibody for 30 minutes at RT in dark.  
13. Wash 1X with 200 ul FACS buffer. 
14. Resuspend in 200 ul of 0.5% paraformaldehyde/PBS and store at 4°C for next day acquisition. 
 
 
SDS-PAGE and WESTERN BLOTTING 
A. SDS-PAGE 
Materials  
1.  BIO-RAD minigel apparatus 
2.  Glass plates with 1.5 mm spacers (Bio-Rad Cat #1653312) 
3.  Glass plates (short plates; Bio-Rad Cat#1653308) 
4.  1.5 mm combs, 10 lanes (Bio-Rad Cat #1653365) or 15 lanes (Bio-Rad Cat#1653366)  
5.  Gaskets (Bio-Rad Cat #1653305) 
6.  Casting frames (Bio-Rad Cat#1653304) 
7.  1.5 M Tris HCl pH 8.8, ml (Bio-Rad #161-0798) 
8.  0.5 M Tris HCl pH 6.8, ml (Bio-Rad #161-0799) 
9.  Acrylamide/Bis, 30%/0.8% (Bio-Rad Cat #161-0158) 
10.  10% SDS, µl (Bio-Rad Cat #161-0416) 
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11.  TEMED, µl (Bio-Rad Cat #161-0801) 
12.  10% Ammonium persulfate (APS; Bio-Rad Cat #161-0700)  
13.  Dissolve 1g of APS in 10ml of DW 
14.  Prepare 1 ml aliquots and store at -20°C 
15.  Laemmli sample buffer (Bio-Rad Cat #161-0737) 
16.  No-Weigh™ Dithiothreitol (DTT; Pierce Cat # 20291) 
17.  BenchMark Pre-stained protein ladder (Invitrogen, Cat #10748-010) 
18.  MagicMark XP (Invitrogen, Cat #LC5602) 
19.  Molecular grade water 
 
<Gel Recipes: to make 2 mini-gels of 1.5mm thickness> 
 Resolving (lower) gel Stacking (upper) gel 
 10% 12% 4% 
30% AA 4.9 6 ml 0.675 ml 
1.5 M Tris HCl pH 8.8 3.75 3.75 ml - 
0.5 M Tris HCl pH 6.8 - - 1.25 ml 
dH2O 6 4.95 ml 3 ml 
10% SDS 150 μl 150 ul 50 μl 
10% AP 75 μl 75 μl 30 μl 
TEMED 15 μl 15 μl 5.5 μl 
 
Buffers (See below for buffer recipe) 
1. 1X TGS Running Buffer 
 
Methods 
1.  Assemble the minigel apparatus:  Wash glass plates and spacers with distilled water and detergent.  
Air-dry in a rack.  The glass plates must be absolutely clean.  Just before assembly wipe the glass 
plates with 70% ethanol.   
2.  Preparation of gel solutions using following table:  Make up 12% resolving gels for viral proteins.  
Make up 10% resolving gel if looking for heavy (50,000 kDa) and light (25,000 kDa) of purified 
immunoglobulins.  This will give best separation and resolution of heavy and light chains.  Make up 5% 
stacking gel at the same time.   
3.  Prepare both gel solutions according to the recipe. Do not add TEMED until just before pouring the gel 
into the apparatus.  
4.  Pour the gel solution between the glass plates. Leave enough space for the stacking gel (comb depth + 
1 cm approx). Overlay the gel with dH2O.  
5.  Let the gel to polymerize (approx. 30 min), pour off the overlay and wash the top of gel several times 
with dH2O. Remove any remaining H2O with the edge of a paper towel.  
6.  Add TEMED to the prepared stacking gel solution, mix and immediately pour over top of resolving gel.  
Add close to the top.  Place combs (before placing the combs should be washed with warm water and 
dried) in to the stacking gel (stop 3-5 mm above the inter phase of stacking and resolving gels).  Avoid 
air bubbles.  Allow 15 minutes for polymerization (during this time get the samples ready).  Remove 
combs.  Air bubbles should run in to replace combs.   
7.  Make up one liter of 1X SDS-PAGE running buffer (4X = 232 g glycine, 48 g Tris base, 16 g SDS 
made up to 4 liters) and pour 500 ml into the buffer tank.  
8.  Remove the gels (molds with the plexiglass holders) from the casting stand and lock into the central 
unit with thumbs pushing from the bottom.  Small glass plate goes against the rubber gasket.  Bottom 
clicks into place on base pate of the central unit.  
9.  Drop assemble unit into the buffer tank.  Add running buffer to center compartment until gels get 
submerged.  Do not allow inside buffer and buffer in the tank to communicate (not imperative).  Flush 
out each well with pipette before loading the samples.   
10.  Preparation of Samples and Running the Gel:  Denature protein in sample buffer (with the appropriate 
concentrations of DTT Pierce #20291) for 1-3 minutes.  Can store the samples at -200C or -700C. Mix 
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1 tube of DTT (500mM) with 250ul of sample buffer. Mix with sample 1:1 dilution (e.g. 15ul of DTT 
in sample buffer + 15ul of sample) 
11.  Load 30-35 µl (10 lane combs) or 15 µl (15 lane combs) per lane.  Use long slender pipette tips.  Slip 
into space between two glass plates gently eject the sample into the well made by the comb.  Load 1X 
sample buffer into lane 1 and 10 (or 15; do not load samples into these lanes and this will avoid the 
smiling effect).  Load appropriate molecular weight markers to the second lane.   
12.  Add running buffer to the buffer tank until the level of the top of the gels.  
13.  Cover minigel unit (fits only one way) and fix red to red (positive), black to black (negative).  Proteins 
are negatively charged and they migrate to the anode at the bottom.  Run at 200 V, 30~40 min.  
14.  Stop when the dye front reaches the bottom.  Turn off the power, pull off top and remove central gel 
unit and mark the left side of the glass plates with a “Sharpie” pen (this will indicate the lane one).  
Take apart the plates and cut the corner of the gel with a blade for identification (e.g. top left corner for 
gel).   
15.  Gels are ready for transfer (for western immunoblotting), autoradiography (for immunoprecipitation), 
or staining with Coomassie or silver stains.  Proceed to appropriate protocol.  
 
B. Gel transfer to PVDF membrane 
 
Materials  
1. Immun-Blot® PVDF membrane (7×8.4 cm; Bio-Rad Cat #162-0174) 
2. Extra thick blot paper (cut to same size as blot membranes; Bio-Rad Cat#1703969) 
3. Methanol (Fisher Cat#A412-4) 
4. Clean forceps 
 
Buffers (See below for buffer recipe) 
1. Transfer buffer 
2. TBS-T 
 
Methods 
1. Soak 2 filter papers for each gel in transfer buffer. 
2. Pre-wet PVDF membrane in 100% methanol for 1-2 min and equilibrate the membrane in DW for 2 
min and let it in transfer buffer. 
3. Equilibrate the gel for 10 min in transfer buffer 
4. For transfer, place one filter paper, PVDF membrane, SDS-PAGE and on top the second filter paper. 
5. Assemble the transfer unit.  Run at 15V for 1hr.  
6. Rinse the transferred membrane in TBS-T buffer and proceed to western blotting step. 
 
C. Western Blotting 
Materials 
1. Skim milk (Bio-Rad Cat#170-6404) 
2. Antibody saver trays (Scienceware, small size) 
3. Primary antibody (e.g. anti-EAV nsp1 [12A4] purified IgG) 
4. Biotinylated goat anti-mouse IgG (Zymed Cat #81-6540) or biotinylated goat anti-rabbit IgG (Zymed 
Cat #81-6140) 
5. Streptavidin-HRP (Zymed Cat #43-8323) 
6. ECL™ Western blotting analysis system (GE Healthcare Cat #RPN2109) 
7. Rad Tape (Midsci Cat #RAD-10) 
 
Buffers (See below for buffer recipe)  
1. TBS-T 
2. Antibody dilution buffer (ADB) 
3. 5% nonfat dry milk/PBS blocking buffer 
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Methods 
1. Block the membrane in blocking buffer at 4°C O/N on a shaker or 1-2 hr at RT. 
2. Wash the membrane with TBS-T once. 
3.  Incubate with primary antibody (most of MAb work at 1µg/ml) 1 hr at RT. 
4.  Wash 3 times with TBS-T (10 min/each) 
5.  Incubate with 1:5,000 diluted secondary antibody (Biotin-conjugated anti-Ms or anti-Rb) in ADB 1hr 
at RT. 
6.  Wash 3 times with TBS-T (10 min/each) 
7.  Incubate with 1:2,000 diluted Stv-HRP in Stv-HRP dilution buffer 1hr at RT. 
8.  Wash 3 times with TBS-T (10 min/each) 
9.  Mix 1:1 components of ECL to develop the membrane. 
 
 
COOMASSIE BLUE R PROTEIN STAINING FOR DETECTION OF PROTEIN IN SDS-PAGE 
GELS 
 
1. Place the gels on a glass dish and add 100 ml of Coomassie blue stain and leave on the rocker for 4 
hours or more (can stain over night) to allow staining.   
2. Remove the Coomassie blue stain (save can reuse) and add 200-250 ml of gel destaining buffer (40% 
methanol, 10% acetic acid in distilled water).  Leave on the rocker for 8 hours.  Keep a sponge or 
kimwipes in the glass dish to absorb stain.   
3. Dry the gels on cellophane/perspex frames.  Get two 12’’ x 10’’ cellophane sheets and wet with 
distilled water (wet one at a time).  Lay one wet cellophane sheet on the bottom frame (with center in 
place to support cellophane) and place the gels over that.  Overlay with second wet cellophane, avoid 
air bubbles, make good contact between gels and the cellophane sheets.  Place the top frame (no center 
needed).  Clamp edges together with bulldog clips while pulling cellophane tight.  Make small hole for 
drainage in bottom corner and leave upright.  Allow to dry 8-12 hours and remove the frames and store 
the gels.   
 
NORTHERN BLOT 
 
Materials 
Before starting Northern Blot, check availability of following reagents 
 
Gel Running 
1. 10X Denaturing Gel buffer (Ambion #8676; 4°C) 
2. 1X MOPS Gel Running Buffer (Ambion #8671; 4°C) 
3. Formaldehyde Load Dye (Ambion #8551; -20°C) 
4. Water bath or heat block 65°C 
Transfer RNA to the membrane and hybridization steps (made in the lab) 
1. Depurination solution:  
     0.25M HCl 
2. Denaturation solution:  
     1.5M NaCl   (43.8g for 500 ml or 87.6g for 1L) 
     0.5 M NaOH   (10g for 500 ml or 20g for 1L) 
Add molecular biology grade distilled water to a final volume of 500 ml or 1 L and filter through a 0.45 um 
membrane. 
3. Neutralization solution (pH 7.5):  
     1.0M Tris Base (60.55g for 500 ml or 121.1g for 1L) 
    1.5M NaCl   (43.5g for 500 ml or 87g for 1L) 
Add molecular biology grade distilled water to a volume 400 ml or 800 ml.   
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Adjust to pH 7.5 with HCl.  Make up to a final volume of 500 ml or 1L with distilled water and filter 
through a 0.45um membrane.  
4. Transfer solution 20X SSC [(pH 7.0-7.2)]  
        NaCl            175g 
       Trisodium citrate (Na3C6H5O7.H20)    88.2g 
Add distilled molecular biology grade distilled water to a final volume 1L. 
If necessary, adjust to pH 7.0-7.2 with concentrated citric acid.  Filter through a 0.45um membrane.   
or 
20X SSC ready packs form Ambion (Cat # 9762) 
Dissolve in 1 liter of molecular biology grade water and make it alkaline by adding NaOH to a 10 mM 
concentration (0.4 gram per liter).  This works well for transfer.   
5. DIG Easy Hyb (Roche Biochemicals # 1 603 558) 
6. Water bath 68°C 
7. Hybridization oven 68°C 
8. Boiling water or heat block >95°C 
 
After hybridization 
Low Stringency Buffer (2X SSC containing 0.1% SDS) 
High Stringency Buffer (0.1X SSC containing 0.1% SDS) preheat to 68°C 
 
 
GENERATION RECOMBINANT VIRUS FROM IN VITRO TRANSCRIBED RNA 
 
A. PURIFICATION OF LINEARIZED PLASMID 
 
1. Linearization of plasmid EAV infectious cDNA clone. Digestion of each plasmid DNA with Xho I to 
linearize the plasmid DNA. 
                Plasmid DNA                                   35.0 µl 
           Xho I   (40U/μl, Roche)                    1.0 µl 
              Buffer H (10x) (Roche)                    4.0 µl 
             Total:                                                40.0 µl 
Prepare 1 digestion reaction for each plasmid DNA. Incubate at 37°C for 2 hours. 
 
2. Run 1 µl digested plasmid DNA on 1% agarose gel to make sure that the plasmid DNA is linearized. 
        Digested plasmid DNA         1.0 µl 
        6x loading buffer                   2.0 µl 
        nuclease free water                9.0 µl 
        Total:                                    12.0 µl---------loading amount per well 
Run 12 µl 1 kb DNA ladder (Invitrogen) 
 
3. Add 2 µl of 20 mg/ml Proteinase K (Ambion) and bring the volume to 200 µl with nuclease free water 
and incubate at 37°C for 30 min. 
 
4. 2× phenol chloroform extract and precipitate the DNA with 100% ethanol. 
 -  add 200 µl of phenol : chloroform : isoamyl alcohol (25:24:1) (Cat # P3803, Sigma) and mix until an 
emulsion is formed 
- centrifuge at 13,000 rpm for 4 min at room temperature 
- remove 180 µl of the upper aqueous phase into a new tube 
- add 180 µl of phenol : chloroform : isoamyl alcohol (25:24:1) and repeat the extraction 
- remove 160 µl of the upper aqueous phase into a new tube 
- add 500 µl of 100% ethanol and 16 µl of 3M sodium acetate to the DNA sample 
- mix and centrifuge at 13,000 rpm for 10 min 
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5. Wash with 140 µl of 70% ethanol. Spin at 13,000 rpm for 4 min. Aspirate the 70% ethanol and dry on 
the bench for 4-5 min. 
 
6. Resuspend the pellet in 32 µl of nuclease free water and run 1 µl on gel. 
        Phenol chloroform extracted linearized plasmid DNA     1.0 µl 
        6x loading buffer                                                               2.0 µl 
        nuclease free water                                                            9.0 µl 
        Total                                                                            12.0 µl---------loading amount per well 
 
 
B.  IN VITRO TRANSCRIPTION 
1. Prepare in vitro transcription reactions as follows. For linear DNA, rNTPs, BSA, DTT, 5 x 
transcription buffers, and cap analog, thaw them out at room temperature. Mix well before use. Always 
leave RNA guard RNase inhibitor and T7 RNA polymerase on ice. Use XhoI-linearized and phenol-
chloroform purified plasmid DNA  
 
        Master mix for in vitro transcription 
Linear DNA   15.0 µl 
 rNTPs mix (10mM each)    5.0 µl 
 BSA (1mg/ml)     5.0 µl 
 100 mM DTT     2.5 µl 
 5X T7 Transcription buffer 10.0 µl  
 Cap analog (10mM)    5.0 µl 
RNA guard RNase Inhibitor    2.5 µl 
 T7 RNA polymerase                 2.5 µl 
 Nuclease free water     2.5 µl 
     50.0 µl 
 Incubate at 37ºC for 2 hours. 
 
2. Wash electrophoresis unit (electrophoresis tank, gel cast and running trays, comb) thoroughly with 
detergent. Then rinse thoroughly with dH2O. Spray electrophoresis unit with RNaseZap, then rinse 
thoroughly with dH2O. Let it air dry. 
3. Prepare 1x TAE buffer.  Cast 0.8% agarose gel. 
4. After 1 h of in vitro transcription at 37ºC, run 2 µl of in vitro transcribed RNA on a 0.8% agarose gel.  
  TE Buffer (pH=7.2)  8.0 µl 
  10%SDS   1.0 µl 
  0.5M EDTA (pH=8.0)                    0.25 µl 
  RNA                 2.0 µl 
 
 - place mix at 70ºC for 2 minutes and then place on ice for 2 minutes   
 - add 2.25 µl of 6X gel loading buffer 
- load 13.5 µl mixtures to each well of the gel. Run the gel at 90V. 
 
5. Check the gel under UV light. 
6. Measure RNA concentration with spectrophotometry. 
7. Dilute 2 μl in vitro transcribed RNA into 198 μl nuclease-free water and measure A260. Use nuclease-
free water as blank control. 
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C. TRANSFECTION OF BHK21 CELLS WITH ELECTROPORATION 
 
Preparation of cells 
 
1. Make sure to use cells that are not confluent. Typically a flask of BHK21 cells were split 1:4 two days 
before planning to do the electroporation. One T-150 cm2 flask of BHK21 cells will be used for 2 
electroporations.  
2. Aspirate the medium from T-150 flasks of subconfluent BHK21 (P67) cells. Wash cells twice with 
PBS. Add 4 ml ATV to each T-150 flask. Shake for 30 sec. Let it sit at room temperature for 1 min. 
Then remove the ATV and put the flasks at 37ºC for a few minutes. 
3. After cells slough off, add 10 ml EMEM to each T-150 flask. 
4. Use a pipet with a wide bore to transfer cells to 50 ml conical centrifuge tube. Place immediately on 
ice.  
5. Spin cells at 4ºC, 600 rpm for 5min. Place cells back on ice. 
6. Remove medium and add 25 ml sterile ice cold PBS. Resuspend cell pellet by gentle shaking of tube. 
If you need to use a pipet to resuspend cells, use a wide bore pipet and pipet gently. 
7. Spin cells at 4ºC, 600 rpm for 5min. Place cells back on ice. 
8. Remove media and wash cells by the addition of 25 ml sterile ice cold PBS. At this time take a small 
sample of cells for counting with a hemocytometer. 
9. Spin cells at 4ºC, 600 rpm for 5min. Place cells back on ice. 
10. Remove PBS with a pipet and resuspend cell pellet in ice cold PBS to a final concentration of 1 x 107 
cells/ml.  
 
Electroporation of cells 
 
1. Place 25 μl of freshly thawed in vitro transcribed into each microcentrifuge tube. Set up one tube 
without RNA as negative control. 
2. Add 500 μl of BHK21 cells (5 ×  106 cells) into microcentrifuge tube containing in vitro transcribed 
RNA and mix gently. 
3. Transfer RNA-cells mixture into each electroporation cuvette (0.4 cm electrode gap). Place the cuvette 
into the cuvette holder and pulse cells twice. The following settings are used: 850 volts, capacitance set 
at 25 μF, and the pulse controller set at infinite ohms. When doing pulses, push the two buttons 
together until you hear the beep, then immediately push them again until you hear the second beep. 
4. After electroporation is complete, set cells aside (room temperature) for a 10 min ‘recovery period’. 
5. Do the next sample. 
6. After the recovery period is complete, transfer the cells from the cuvette into 15 ml of room 
temperature growth medium (EMEM) in a T-75 flask. Aliquot 0.15 ml of cells to each well of 8-well 
chamber slides for immunofluorescence assay (2 wells-mock transfected and 2 wells transfected).  
7. Place cells at 37ºC CO2 incubator. Check the development of CPE. When CPE is complete (usually 72-
96 h post transfection), tissue culture fluids were harvested and centrifuged at 1900 rpm for 10 min at 
4ºC.  The tissue culture fluids were titrated in RK13 cells.  
 
ELECTROPORATION USING BTXPRESS ELECTROPORATOR AND ELECTROPORATION 
SOLUTION 
 
Method 
A. PREPARE THE CELLS 
Divide the cells 18-24 hours prior to electroporation as needed and culture overnight. 
 
B. PREPARE FOR ELECTROPORATION 
1. Warm all solutions to RT before use. 
2. Harvest cells for electroporation, and count cells to determine cells/ml. 
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3. Determine the total volume needed for all the electroporations. Multiply the number of 
electroporations needed by 0.1 ml (for 0.2 cm cuvettes) OR by 0.25 ml (for 0.4 cm cuvettes) and add 
10% more for pipetting errors. Total volume needed= ________ ml. 
4. Determine the volume of cells required for each electroporation according to the formula: 
 
5. Volume needed (ml) = (#cells needed/ml [5 x 106 cells/ml]/# counted cells/ml) × Total volume of 
BTXpress Solution from step C 
 
6. Enter the calculated volume needed = ______________ml 
7. Pipette the volume of cells determined in step d into a new tube and centrifuge at 1000 ×g for 5 
minutes. Aspirate the supernatant. 
8. Prepare a culture vessel with pre-warmed complete medium.  
9. Immediately transfer to 60mm petri dish (21 cm2 surface area) containing growth   
 medium. (Each well of 6 well-plate is 10 cm2) I decide to put everything in 6 well plate with 4 
ml growth medium. Then take 500 ul into chamber slides for IFA. 
10. Resuspend the centrifuged cells from step e in ____ ml BTXpress Solution according to the volume 
determined in step c. 
 
C. Add ______ μl IVT RNA (use 20 μg/ml of cells= 5 μg) to the cells. Mix gently. 
i) pEAV-GFP IVT RNA (total 49 μl RNA) 
ii) mock infection 
 
b) Aliquot 100 μl (0.25 cm cuvette) or 250 ul (0.4 cm cuvette) DNA/cell mix to each cuvette. 
c) Eletroporate at RT. Using a square wave system set the voltage and pulse length given for your 
cells as described in Table1.  If using an exponential decay set the capacitance to 950 μF and 
resistance to “None”. Use the voltage given for your cells from Table 1&2 for complete protocol. 
Voltage=____260 V____ 
 
D. Electroporation settings: 
 
Choose Mode:   T 500 V/Capacitance & Resistance (LV)   
Capacitance:    C 950F   
Set Resistance:   R R1 (13ohm) 
Chamber Gap: BTX Disposable Cuvette P/N 640 (4mm gap) 
Set Charging Voltage:      S 260V  
Desired Field Strength:     E 650 V/cm 
Desired Pulse Length:       t Approximately 9 msec (Reality: 10 msec) 
 
a) Immediately mix the cells gently and transfer to the dish prepared in step B-f. 
b) Incubate in complete medium for 12-72 hours or as required. 
c) Harvest cells and perform assay as required. 
 
MAMMALIAN CELL TRANSFECTION USING LIPID-BASED TRANSFECTION REAGENT 
 
Materials 
1. Lipofectamine™ 2000 (Invitrogen, Cat# 11668-027) 
2. Fugene HD (Roche, Cat# E2311) 
Method 
1. Place sterile glass cover slips onto wells to be used for IFA staining. 
2. Trypsinize T-75 flask of Vero 76 (ATCC #CRL-1587) cells and count the cells (One confluent T-75 
contains approx. 1 × 107 Vero cells). 
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3. One day before transfection, plate 2 × 105 cells/well in 500 µl of growth medium so that cells will be 
90-95% confluent at the time of transfection. 
4. For each transfection sample, prepare complexes as follows: 
a. Dilute 0.8 µg of plasmid DNA in 50 µl of Opti-MEM I.  Mix gently. 
b. Mix Lipofectamine™ 2000 gently before use, then dilute 2.0 µl of Lipofectamine in 50 µl of Opti-
MEM I medium.  Incubate for 5 min at RT. 
c. After the 5 min incubation, combine the diluted DNA with diluted Lipofectamine™ 2000 (total 
volume = 100 µl).  Mix gently and incubate for 20 min at RT. 
5. Add the 100 µl of transfection mix to each well containing cells and medium.  Mix gently by rocking 
the plate back and forth. 
6. Incubate cells at 37°C in a CO2 incubator for 4 hr. 
After incubation for 4 hr with the transfection mix, replace the mix with 500 µl of growth media 
(containing FBS).   Incubate at 37°C for 18-48 hours prior to testing for transgene expression. 
 
 
DETECTION OF EAV SUBGENOMIC RNA IN INFECTED CELLS 
Method 
 
A. TOTAL RNA EXTRACTION FROM EAV INFECTED CELLS 
1. Prepare 2 T-25 for infected cells and 2-T25 for uninfected cells. Final number of tubes for each group 
will be 4 (total 8 tubes) 
2. Infect confluent monolayer of EECs in a T-25 flask at an m.o.i of 2 (diluted in 1ml of plain MEM) and 
incubate for 1 h. Add 9 ml of growth media and incubate for 18 h.   
3. Decant the excess media and wash with ice-cold PBS (Gibco) 3 times.  Scrape the cells and pellet 
down in a microcentrifuge tube at 3000g for 15 minutes. 
4. Aspirate the medium and wash 1X in PBS. 
5. Extract RNA using MagMAX™-96 Total RNA Isolation Kit (Ambion, AM1830). According to the 
protocol, it lyses up to 2 × 106 cells in 140μl of Lysis/Binding Solution. So a pellet from 1 T-25 flask 
can be divided into two and extract RNA simultaneously as two different samples. Elute RNA in 50 μl 
of elution buffer. Store RNA at -80°C. 
 
B. REVERSE TRANSCRIPTION  
 
Material 
1.  SuperScript III First-Strand synthesis System for RT-PCR (Invitrogen; Cat# 18080-051) 
 
Method 
3. Prepare the following mixture:  
RNA       2.0 μl 
Reverse primer (20 μM)    1.0 μl 
dNTP mix (10 mM each)   1.0 μl 
RNase-free water   6.0 μl 
2. Mix and briefly centrifuge each component before use. 
3. Prepare RNA/primer mixtures in sterile 0.2 ml tubes as above.  
4. Incubate each sample at 65C for 5 min, then place on ice for at least 1 min. 
5. Prepare the following cDNA Synthesis Mix, adding each component in the indicated order: 
10X RT buffer             2 μl 
25mM MgCl2              4 μl 
0.1M DTT                    2 μl 
Rnase OUT Rnase Inhibitor    1μl 
Superscript III RT          1μl 
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6. Add 10ul of cDNA Synthesis Mix to each RNA/primer mixture, mix gently, and collect by brief 
centrifugation. 
7. Incubate at 50C for 60 min. 
8. Terminate the reactions at 85C for 5 min. Chill on ice. 
9. Collect the reactions by brief centrifugation. Add 1 ul of Rnase H (2 units/ul) to each tube and incubate 
for 20 min at 37C. 
10. The final volume of the product is 21ul. cDNA synthesis reaction can be stored at -20C or used for 
PCR immediately. 
11. For long-term storage, place the reactions at -20C. 
 
C. PCR USING PFU TURBO DNA POLYMERASE (STRATAGENE)  
 
cDNA template    2.0 μl 
Forward primer (20 μM)    0.5 μl 
Reverse primer (20 μM)    0.5 μl 
dNTP mix (25 mM each)  0.2 μl 
10X Pfu Turbo PCR buffer  2.5 μl 
Pfu Turbo DNA polymerase  0.5 μl 
RNase-free water   18.8 μl 
 
D.  PCR CONDITION 
 
Cycles Temp Duration 
1 95C 2 min 
35 95C 45 sec 
 48C 45 sec 
 72C 3 min 
1 72C 10 min 
 
D. PRODUCT SIZE 
 
Product Size (bp) 
gmRNA 12704 
sgmRNA2 3200 
sgmRNA3 2684 
sgmRNA4 2251 
sgmRNA5 1883 
sgmRNA6 1041 
sgmRNA7 659 
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